


NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS AND RISK BEHAVIOUR SURVEY REPORT

2004, 2007, 2010, 2013 AND 2016



Prevalence of
HIV, hepatitis C,
hepatitis B, sexually
transmissible
infections, and risk
behaviours among
Australian prison
entrants



UNSW
SYDNEY





UNSW
SYDNEY



www.kirby.unsw.edu.au

Postal Address:

The Kirby Institute
UNSW Sydney
Wallace Wurth Building
Sydney NSW 2052

Telephone: 02 9385 0900

Facsimile: 02 9385 0920

Email: recpt@kirby.unsw.edu.au

**NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS SURVEY
2004, 2007, 2010, 2013, and 2016**

Prevalence of HIV, HBV, HCV, and risk behaviours
among Australian prison entrants

NATIONAL REPORT
2004, 2007, 2010, 2013, and 2016

Report prepared by Professor Tony Butler and Dr Melanie Simpson

The Kirby Institute for Infection and Immunity in Society (UNSW Sydney)

November 2017



Suggested citation:

Butler, T. and Simpson, M. National Prison Entrants' Blood-borne Virus Survey Report 2004, 2007, 2010, 2013, and 2016. Kirby Institute (UNSW Sydney). 2017. ISBN-13: 978-0-7334-3772-4.

Contents

ACKNOWLEDGEMENTS	3
FOREWORD	5
EXECUTIVE SUMMARY	6
Background	6
Methods	6
Results	7
Implications of the Findings	10
INTRODUCTION	12
METHODS	13
Study Sample	13
Sample Selection	13
Recruitment	13
Survey Sites	14
Screening Procedures	14
Blood Testing	15
Urine Testing	15
Questionnaire	15
Statistical Analysis	15
Interviewers	16
Ethics Approval	16
Reporting of Results	16
RESULTS	17
Response Rate	17
Summary	20
National	26
HIV antibody prevalence	36
HCV antibody prevalence	39
HBV prevalence	50
Chlamydia	63
Gonorrhoea	63
Syphilis	63
Northern Territory	64
HIV antibody prevalence	74
HCV antibody prevalence	74
HBV prevalence	81
Chlamydia	89
Gonorrhoea	90
Syphilis	90
Queensland	91
HIV antibody prevalence	101
HCV antibody prevalence	101
HBV prevalence	111
Chlamydia	124
Gonorrhoea	125
Syphilis	125
South Australia	126
HIV antibody prevalence	136
HCV antibody prevalence	136
HBV prevalence	142
Chlamydia	151
Gonorrhoea	151
Syphilis	152
Tasmania	153
HIV antibody prevalence	163
HCV antibody prevalence	163
HBV prevalence	174
Chlamydia	187
Gonorrhoea	188
Syphilis	188
Victoria	189
HIV antibody prevalence	199
HCV antibody prevalence	199

HBV prevalence.....	207
Chlamydia	217
Gonorrhoea.....	218
Syphilis	218
Methodological Notes.....	219
Appendix 1 – Blood Tests, Test Kits and Testing Laboratories	220
Appendix 2 – Questionnaire.....	221
References	224

ACKNOWLEDGEMENTS

We are grateful to the project steering group, the site co-ordinators and the interviewers:

2016 Project steering group:

Professor Tony Butler and Dr Melanie Simpson (Kirby Institute); **ACT**: Professor Michael Levy (Justice Health Services ACT); **NT**: Jeanette Smith (Top End Health Services, NT); **Qld**: Robert Kemp (QLD Department of Health), Marie Finley (West Moreton HHS); **SA**: Andrew Wiley (SA Prison Health Service); **Tas**: Deborah Siddall and Dr Chris Wake (Correctional Primary Health Services Tasmania); **Vic**: Camilla Preston and Helen Meyer-Tinning (Justice Health Victoria).

2016 State and Territory co-ordinators:

ACT: Professor Michael Levy; **NT**: Jeanette Smith and Julie Pedersen; **Qld**: Marie Finley, David Harris, Anissa Jaros, Rachel Craig and Stephen Joyce; **SA**: Andrew Wiley, Susan O'Neill and Natalie Hewitt; **Tas**: Deborah Siddall; **Vic**: Camilla Preston and David Rodda.

The following individuals conducted the interviews in 2016:

ACT: Stephanie Dakin

Northern Territory: Linda Cullen, Julie Pedersen

Queensland: Jodie Walker, Heydon Manuel, Lorraine Reid, Jacqueline Naves, David Harris, C. Marshall, B. Makoti, V. Lumayno, B. Allen

South Australia: Bridgette Zander, Sharon Hossack, Pauline Johnston, Janice Scott, Louise Pelgrave

Tasmania: Lyndal McManus, Audrey Siberry, Samantha Clifford, Daniel Fassett, Christine Castles, Kiera Marshall, Allie Pickering, Jean Hodgson, Matthew McGillivray

Victoria: Aileen Ampon, Carrie Brander, Cecilia Papdanco, Joanne Folino, Ann Lee

We wish to thank everyone who assisted in the development and conduct of the National Prison Entrants' Blood-borne Virus Survey, including the participants, health professionals at the survey sites, prison managers and prison officers for their cooperation in accommodating the survey teams, laboratory staff, and nursing staff involved in providing the test results to participants.

We would be grateful for the assistance of Nabila Chowdhury, Kirby Institute for checking the data in the report, Leng Boonwaat, NSW Population Health for interpreting the hepatitis B immunity results, and Carla Gorton and Raquel How who assisted with the study in QLD.

Support:

In-kind support was provided by all the jurisdictions to cover the data collection and screening. Financial support for the co-ordination and report writing was provided by the ACT, Queensland, South Australia, Tasmania and Victoria.

FOREWORD

The first National Prison Entrants' Blood-borne Virus Survey (NPEBBVS) was conducted in 2004 and we are pleased to present the fifth iteration of this study, the 2016 national report.

The prevalence of hepatitis C is significantly higher among prisoners than the general community, highlighting the need for ongoing monitoring of blood-borne viruses and risk behaviours in this population. The NPEBBVS fulfils this important role and represents one of the few nationally collaborative multi-jurisdictional prisoner health projects in Australia.

The 2016 NPEBBVS includes data from six Australian jurisdictions and is unique in the world in providing a national snapshot of the prevalence of blood-borne viruses (HIV, hepatitis B, hepatitis C) in this at-risk population. The NPEBBVS is modelled on the Australian Needle and Syringe Program Survey (ANSPS) but also includes those with no histories of injecting drug use who are nonetheless at risk of exposure to blood-borne pathogens from transmission routes such as tattooing, body piercing, fighting, and other blood-to-blood contact.

The NPEBBVS has several unique attributes that add to our knowledge of blood-borne virus epidemiology in Australia, such as the inclusion of a sample of Aboriginal and Torres Strait Islander Australians who are over-represented in prisons (while only 2.8% of Australia's total population, 27% of Australia's prisoners are Indigenous), and testing for hepatitis B immunity in a marginalised and hard-to-access group. The survey uses a venous blood sample, which provides a high degree of test accuracy and permits the test results to be used for diagnostic purposes.

Prisoners are known to engage in sexual risk behaviours and in 2010 the NPEBBVS was expanded to screen for three sexually transmissible infections - syphilis, gonorrhoea and chlamydia. It is reassuring that the 2016 survey findings found very few of these infections among incoming prisoners. It is also reassuring that no cases of HIV were detected in 2016.

Monitoring blood-borne viruses among prisoners is important to the overall community response to preventing the spread of infectious diseases and planning appropriate treatment and prevention strategies. The utility of this survey is highlighted by its use in the Commonwealth Government's national communicable diseases strategies, which recognise prisoners are a key population in communicable disease control in Australia.

EXECUTIVE SUMMARY

Background

Prisoner populations are characterised by engagement in risk behaviours, most notably injecting drug use. Consequently they are at an increased risk of exposure to blood-borne viruses such as hepatitis B, hepatitis C and HIV. Previous Australian research has shown that hepatitis C is between thirty to forty times higher among prisoners compared with the general community. Surveillance of this population is important to monitor trends in the prevalence of blood-borne viruses and changes over time in risk behaviours. This is the fifth NPEBBVS conducted thus far; others have been undertaken triennially since 2004.

Methods

The study represents a consecutive survey of prison entrants conducted over a two week period. In previous years the survey has been conducted over two weeks in October but the 2016 survey varied between jurisdictions (Table 1). Participants in 2016 were 431^a of the 862 consecutive prison entrants in all participating jurisdictions who were offered the survey. Nineteen reception centres across Australia participated in the survey (Table 2). New South Wales and Western Australia did not participate in the 2016 survey.

The survey screened for the following markers: HIV antibody and antigen, hepatitis B surface antibody and antigen, hepatitis B core antibodies (IgM and IgG), hepatitis B e-antigen and antibody, hepatitis C antibody, *Treponema pallidum* antibody, *Chlamydia trachomatis* DNA and *Neisseria gonorrhoea* DNA (see Appendix 1 for test details).

Test results are made available to participants and treatment pathways identified including education and advice, hepatitis B vaccination, treatment for sexually transmissible infections, and referrals for hepatitis C treatment where appropriate.

Risk behaviour and demographic information were collected using a short questionnaire covering injecting drug use, illicit drug consumption, alcohol use, tobacco smoking, body piercing and

^a 42 participants participated in the survey by consenting to provide pathology data only and did not complete a questionnaire. Therefore, these participants are excluded from data tables requiring information that was provided in the questionnaire, but their data has been included where possible.

tattooing, sexual activity, hepatitis C testing and treatment, willingness to be treated for hepatitis C, hepatitis B and cervical cancer immunisation (Appendix 2).

Results

Demographic characteristics

- The final sample consisted of 431 participants. The overall response rate to the survey was 50%.
- Thirty four percent of the sample identified as Aboriginal and/or Torres Strait Islander, which is slightly higher than the national census snapshot proportion of Indigenous prisoners (27%).¹ Similarly, women represented 13% of the sample, which is higher than the proportion of women prisoners in Australia (8%).¹
- Most of those taking part in the 2016 survey (72%) lived in 'highly accessible' and 'accessible' areas prior to prison based on the Accessibility/Remoteness Index of Australia.² Living in 'highly accessible' and 'accessible' areas was more common among people who reported injecting drug use (84%) compared with those who did not (60%).
- Eight out of ten prisoners with a history of injecting drug use reported they had previously been incarcerated and 66% had been in prison in the past year.

Blood-borne viruses

- No cases of HIV were detected among those prisoners screened in 2016.
- In 2016, the overall prevalence of hepatitis C antibody was 22%, a decrease from 31% in 2013. Among jurisdictions with more than thirty prisoners screened for hepatitis C antibodies, the prevalence ranged from 44% in South Australia to 22% in the Australian Capital Territory.
- Hepatitis C antibody prevalence was much higher among those with a history of injecting drug use compared with those who had not injected (50% versus 1%). In 2016, hepatitis C antibody prevalence was higher among men who injected than women who injected (52% versus 45%).
- Among Indigenous people who had a history of injecting drugs, the prevalence of hepatitis C antibody increased from 54% in 2013 to 66% in 2016.

- Nationally, only 10 prisoners (17% of those who self-reported they were hepatitis C positive) stated they had ever received treatment for hepatitis C with two individuals reporting they had received the new direct-acting antiviral medication.
- Only half (57%) of participants who had injected drugs and 20% of those who had never injected drugs were aware that new treatments for hepatitis C existed. The majority of participants were unsure of what the new treatments entailed in regards to treatment length, side effects and mode of administration (injections vs tablets).
- Nationally, 16% of those tested were positive for hepatitis B core-antibody; while 3% tested positive for hepatitis B surface-antigen.
- The prevalence of hepatitis B core-antibody among Indigenous people who had injected drugs remained stable between 2013 and 2016 at 18%. The prevalence of hepatitis B core-antibody among non-Indigenous people who had injected drugs decreased from 20% in 2013 to 7% in 2016.
- Nationally, 46% of those screened in 2016 showed no evidence of immunity against hepatitis B either through past exposure or vaccination and are, therefore, vulnerable to infection.
- Among jurisdictions testing more than thirty prisoners, the highest proportion of prisoners who had been vaccinated against hepatitis B infection was Queensland at 40%.
- Of the 70 prison entrants in 2016 who self-reported they had been vaccinated against hepatitis B, 60% had hepatitis B surface-antibody levels signifying immunity. Conversely, 34 individuals reported that they had not been vaccinated against hepatitis B but the tests revealed that 15% of them had hepatitis B surface-antibody levels considered as conferring immunity.

Sexually transmissible infections

- Among female prisoners eligible for the National HPV Vaccination Program, 53% reported they had not been vaccinated against cervical cancer with 26% unsure of their vaccination status.
- Rates of sexually transmissible infections were no higher than in the general population - chlamydia (4% of men, 7% of women), and gonorrhoea (2% of men, no women). For syphilis,

around 4% of men and 17% of women had markers consistent with past or present infection. While 16% of all those tested had markers indicating possible current infection with syphilis, only 6 individuals (4 men and 2 woman) had serological markers suggesting possible current infection.

Risk behaviours

- Less than half of those screened in 2016 reported they had ever injected drugs (46%), which is similar to 2013 (45%). Of those with a history of injecting, 63% had injected in the past month.
- A history of injecting drug use was most common among prison entrants in South Australia (60%) and least common among those in the Northern Territory (7%).
- Methamphetamine was the most common last drug to be injected (71%); a slight increase from 2013 (68%). Heroin was the second most common drug to be injected at 18%; a slight reduction from 2013 (20%).
- Just over half of those with injecting drug use histories (58%) and almost three-quarters of those who had never injected drugs (70%) reported cannabis use in the month prior to the survey.
- Most injecting drug users had done so for more than 3 years (84%).
- Nine out of ten people who injected drugs reported using clean needles for 'all' or 'most' of their injections in the month prior to coming into prison.
- Tobacco smoking remains alarmingly high among with 87% of prisoners reporting they are current smokers. This is a slight reduction from 2013 (90%). A higher proportion of people who inject drugs were current tobacco smokers (90%) compared with those who had never injected drugs (84%).
- The median age of first tobacco smoking was 13 for those with histories of injecting drug use and 15 for non-injectors.
- Over half (52%) of participants with a history of injecting drug use, and over three quarters of participants who had never injected drugs were at high risk of alcohol-related harm according to the shortened version of the Alcohol Use Disorders Identification Test (AUDIT-C) screening tool.

- A small number of prison entrants (2%) reported they had been paid for sex in the three months prior to the survey.
- Over half of the prison entrants reported never using condoms during casual sex, regardless of with male or female partner.

Implications of the Findings

- Prison provides an important public health opportunity to monitor high-risk populations for exposure to blood-borne infections, other health conditions and risk behaviours, and if appropriate, initiate prevention and treatment measures.
- Given the high prevalence of hepatitis C and hepatitis B in this population compared with the non-incarcerated community, it is important that this survey be regularly conducted to inform policy and health services planning for this at-risk group. The findings from the NPEBBVS are utilised by the Commonwealth Government's national communicable diseases strategies and the Kirby Institute's national surveillance reports, and highlight prisoners as a 'priority population'.
- Prevention initiatives need to target prison entrants, particularly those with a history of injecting drugs and those who are in prison for the first time, to initiate prevention strategies including education, hepatitis B vaccination, hepatitis C treatment, and HPV.
- Nationally, 46% of all prison entrants were vulnerable to hepatitis B infection as they had not been vaccinated or previously exposed to hepatitis B or were hepatitis B carriers. This group should be vaccinated as a matter of priority given this population's engagement in risk behaviours that put them at an increased risk of infection. Accelerated vaccination schedules are effective and should be considered for this population given their mobility inside prison and, in many cases, their inability to complete the recommended six month schedule due to being released back into the community after fairly short periods in detention.
- While the prevalence of HIV has remained low in all jurisdictions across surveys (2004, 2007, 2010 and 2013), the NPEBBVS has an important role to play in monitoring this trend given the prisoner population is comprised of those who engage in practices which put them at an increased risk of HIV infection.

- In 2016, 7% of those who reported they were negative for hepatitis C tested positive for HCV antibodies. Although the proportion of participants incorrectly identifying their status has decreased over time since 2004 (18%), this finding reinforces the benefits of ongoing testing of prisoners for blood-borne pathogens such as hepatitis C to reduce the number who are unaware of their exposure to hepatitis C and prevent further transmission.
- Over half of participants who report ever injecting drugs were aware of the new treatments for hepatitis C, however most were not familiar with what the new treatments involved (e.g. no injections, fewer side-effects and length of treatment).
- In 2016, 10 (14%) prison entrants reported they had received treatment for hepatitis C (up from 11% in 2013). This suggests there is significant potential to increase treatment uptake for hepatitis C in this population.
- Methamphetamine remains the most frequently reported drug last injected by prison entrants. Methamphetamine substitution therapies should be investigated and service providers need to ensure that staff receive training in recognising and managing amphetamine withdrawal on entry to prison.
- Tobacco smoking remains very high among prisoners with almost 9 out of 10 prisoners reporting they currently smoke and no apparent downward trend in the numbers who report they are current smokers. Effective smoking cessation programs that sustain cessation in the community are needed for this population.

INTRODUCTION

Prisoner populations are characterised by engagement in health risk behaviours, most notably injecting drug use.³⁻⁵ Consequently they are at an increased risk of exposure to blood-borne viruses such as HIV and viral hepatitis.⁶⁻¹¹ Australian and overseas studies have consistently shown prisoner populations to have rates of blood-borne viruses many times that of the community. The prison setting has been shown to be a high risk environment for blood-borne virus transmission from sharing contaminated injecting equipment, tattooing, fighting and other blood-to-blood contact.¹²⁻¹⁴

Monitoring blood-borne virus infections among prisoners occurs mostly through ad hoc prevalence surveys rather than systematic surveillance.^{7,8,15} Testing prisoners on reception for HIV was formerly used to monitor this infection but as screening rates dropped and approaches to screening varied between the jurisdictions, this method has become less reliable. In 2009, just under one third of Australian prison entrants were tested for HIV, which ranged from 15% in South Australia to 45% in Western Australia.¹⁶

Since 1995, the Kirby Institute of Infection and Immunity in Society has monitored blood-borne viruses in high-risk groups in the community.¹⁷ For People Who Inject Drugs (PWID) the Australian Needle and Syringe Program Survey (ANSPS) invites NSP attendees to self-complete a risk behaviour questionnaire and to provide a finger-prick sample of blood to test for HIV and hepatitis C.¹⁸ Following discussions with The Kirby Institute in 2003, the ANSPS was adapted and applied to the prison setting in an effort to provide systematic information on blood-borne virus prevalence across Australia. The NPEBBVS presents a rare opportunity for prison medical services to collaborate nationally on a research project.

This report presents the findings from the 2004, 2007, 2010, 2013, and 2016 surveys.

METHODS

Study Sample

The study is a consecutive cross-sectional sample of prison entrants over a two week period. While previous iterations of the survey have collected data in parallel over a two week period in October (the same time as the community ANSPS), the timing of the current survey varied between jurisdictions (Table 1). Participants were 431 of the 862 (50%) prisoners entering Australian correctional centres who were offered the survey. Forty-two participants provided a blood and/or urine specimen but no questionnaire information; this information was included in the tables reporting serology indicators only. The 2016 NPEBBVS reports the findings for the 431 participants for whom sufficient pathology and questionnaire data were available.

Table 1: Survey dates, 2016 NPEBBVS

Jurisdiction	Survey Dates
ACT	5 – 21 December 2016
NT	16 – 29 October 2016 ^a ; 31 October to 13 November 2016 ^b
Qld	16 – 29 October 2016 ^c ; 22 March – 3 April 2016 ^d ; 22 March – 3 April 2017
SA	7 – 20 November 2016 ^e ; 14 – 27 November 2016 ^f
Tas	16 – 29 October 2016
Vic	16 – 29 October 2016

*ACT conducted a longer collection period given low overall prison receptions during this time

^a Darwin Correctional Centre; ^b Alice Springs Correctional Centre; ^c Arthur Gorrie Correctional Centre; ^d Brisbane Correctional Centre and Brisbane Women's Correctional Centre; ^e Lotus Glen Correctional Centre; ^f All sites excluding except City Watch House; ^g City Watch House

Sample Selection

New receptions at 19 sentinel sites were invited to participate in the assessment (Table 2). New receptions were defined as individuals entering prison from the community and did not include remanded inmates returning from court appearances or prisoners transiting through the survey site *en route* to other prisons.

Recruitment

We aimed to minimise any disruption to the prison reception process by conducting the survey immediately after the initial health and welfare assessments which are routinely conducted on all individuals received into prison. However, those unable to be screened at the time of reception were called up within seventy-two hours of entry into the prison and invited to participate in the NPEBBVS.

Potential participants were given an explanation of the project by a member of the survey team. They emphasised the following: involvement was voluntary, the structure of the assessment consisted of a short questionnaire followed by blood testing, there was no obligation to answer any questions deemed intrusive or sensitive, and information would remain confidential. Participants were also informed that every effort would be made to return the blood test results, even if they had been released back to the community, that post-test counselling would be provided, and referrals made to specialist services if necessary. Written consent was obtained from all participants. No payment was made to prisoners for participation.

Confidentiality was maintained on the questionnaires and serology requests through the use of a code comprising the first two letters of each participant's surname and first name, their date of birth and a unique inmate identifier number.

Survey Sites

Nineteen sentinel reception sites in six Australian jurisdictions (excluding NSW and WA) participated in the 2016 survey (Table 2). These centres receive both men and women prisoners directly from the community. In all jurisdictions, prisoners are received into the correctional system through a limited number of reception sites. By targeting these sites we could be certain that we were accessing most of the eligible prison receptions across the participating jurisdictions.

Screening Procedures

Screening was divided into several stages to provide a consistent structure to the survey. Broadly, this involved recruiting participants and obtaining consent, administering the questionnaire, providing a pre-test counselling for those who consented to blood testing, and collecting the blood specimen. The pre-test counselling included psychological assessment of the person's ability to deal with a positive result, provision of information about the possible consequences of infection with blood-borne viruses, transmission risks, confidentiality and notification requirements related to blood tests, and treatment options for those who tested positive. Those who consented to the blood test were also informed that face-to-face post-test counselling would be provided as soon as results became available for both positive and negative test results. In some cases this involved community follow-up.

Blood Testing

Screening for blood-borne viruses included testing for the following pathological markers:

- HIV antibody and antigen
- Hepatitis B surface-antibody
- Hepatitis B surface-antigen
- Hepatitis B core-antibody
- Hepatitis C antibody
- *Treponema pallidum* (syphilis) antibody

Urine Testing

Screening for sexually transmissible infections included testing for the following pathological markers:

- *Chlamydia trachomatis* (chlamydia) DNA
- *Neisseria gonorrhoea* (gonorrhoea) DNA

Details of test kits used for the blood and urine testing by the various laboratories are provided in Appendix 1.

Questionnaire

The questionnaire used in the survey was modelled on the ANSP survey screening instrument that was designed for the community setting to collect behavioural risk factor information on body piercing, tattooing, injecting drug use, sexual activity, and immunisation status. Modifications were made to the questionnaire to adapt it to the correctional setting (Appendix 2). The questionnaire was piloted in each jurisdiction to ensure it was appropriate for the prisoner population, including Aboriginal and Torres Strait Islander detainees. In 2016, questions on alcohol use (AUDIT-C) and knowledge and awareness of hepatitis C questions were added. In 2013, questions were added on willingness to be treated for hepatitis C and intention to be treated for hepatitis C in the near future. Sexual health questions were modified in 2010 to cover the three months prior to the survey and to differentiate between male and female sex partners.

Statistical Analysis

All data were analysed using SPSS version 24. Associations between demographic and behavioural variables and exposure to blood-borne viruses and sexually transmissible infections were assessed using Chi-square tests.

Interviewers

Interviewers were recruited from nursing staff within each State or Territory correctional health system. Training of site co-ordinators was undertaken via a number of teleconferences who in turn trained the local interviewers.

Ethics Approval

Approval for the project was obtained from the health-based human research ethics committees in ACT (also approved for the Queensland site) (ETH.8.16.169), Northern Territory (2010-1437 and HREC-13-181), South Australia (HREC/16/RAH/212), Tasmania (H0016036) and Victoria (CF/16/11424). In addition, approval was obtained from corrective services' committees in the Northern Territory, Queensland, South Australia and Victoria. Approval was also obtained from the Aboriginal Health Ethics Committee in South Australia (04-16-682). The study was also approved by the Human Research Ethics Committee of UNSW Australia (HC16434).

Reporting of Results

The following sections present the findings from the survey stratified by injecting drug user status and other demographic variables, as appropriate. Summary tables include those participants who provided a blood/urine specimen but not a questionnaire. National and state/territory tables exclude those for whom the main classification variables were not available from the questionnaire.

Percentages have been rounded to the nearest whole number.

Due to the small number of prisoners screened in the ACT, findings for this jurisdiction are included in the summary section only.

RESULTS

Response Rate

A number of inmates declined to participate in the survey ('refusers') while others agreed to answer the questionnaire but opted not to provide blood. A small number initially agreed to provide a blood sample but were unable to do so due to poor venous access. Some of the reasons given by the 'refusers' included a perceived lack of personal gain from participation, needle phobia, and feeling fatigued or stressed during the reception process.^b

The response rate was calculated as follows:

$$\frac{\text{Total participants}}{\text{Total receptions offered survey}^*} \times 100$$

*Taken from the running sheets provided by jurisdictions for the two week survey periods.

^b The reception process is often conducted at the end of the day and sometimes in the early hours of the morning. This is because the courts process people during the day and those receiving a custodial sentence or remanded into custody are taken to the reception prison at the end of the day. Once at the prison there is often a waiting period in a holding cell before they are seen by welfare and medical staff. The high response rate seen in this survey reflects the skill of the reception nurses in highlighting the benefits of the survey to prisoners in what is perhaps one of the most stressful and harrowing periods of the participant's life.

Table 2 Reception centre, gender of prison receptions, participants screened, and total number of receptions, 2016 NPEBBVS

State	Reception Site	Gender of prisoners surveyed	Total N ^o receptions*	N ^o valid participants (%)
ACT	Alexander Maconochie Centre	Men	14	9 (64)
NT	Darwin CC	Men & women	28	18
	Alice Springs CC	Men & women	70	59
	<i>Total</i>		98	77 (79)
Qld	Arthur Gorrie CC	Men	48	17
	Brisbane CC	Men	121	93
	Brisbane Women's CC	Women	43	31
	Lotus Glenn CC	Men	31	18
	<i>Total</i>		243	159 (65)
SA	Adelaide Remand Centre	Men	2	1
	Adelaide Women's Prison	Women	7	2
	Yatala Labour Prison	Men	95	25
	Port Augusta Prison	Men & women	16	9
	City Watch House [^]	Men	105	0
	<i>Total</i>		225	37 (16)
Tas	Hobart Reception Prison	Men & women	39	22
	Launceston Reception Prison	Men & women	25	8
	Risdon Prison Complex	Men	1	1
	Mary Hutchinson Women's Prison	Women	2	0
	<i>Total</i>		67	31 (46)
Vic	Dame Phyllis Frost Centre	Women	39	6
	Metropolitan Remand Centre	Men	10	3
	Melbourne Assessment Prison	Men	166	109
	<i>Total</i>		215	118 (55)
Total			862	431 (50)

* Taken from the running sheets provided by jurisdictions for the two week survey periods.

[^] The City Watch House is used for surge capacity for prisoners. While police use this facility, numbers only reflect remandees and not police arrests.

Of those who participated (n=431), 217 (50%) completed all components of the survey (questionnaire, blood and urine test), 109 (25%) completed the questionnaire only, 63 (15%) completed the questionnaire and blood or urine test only, while 42 (10%) completed the blood and/or urine tests only.

Under half (46%) of all respondents reported current or previous injecting drug use (Table 3).

Table 3 Structure of the study sample by gender and injector status, 2016 NPEBBVS*

Gender	Ever Inject Drugs		Total
	No	Yes	
Men	190	148	338
Women	21	29	50
Total	211	177	388

*Table only includes those for whom questionnaire data was available.

Summary 2016

Table 4 Demographic characteristics of prison entrants by jurisdiction (2016)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
Nº of sites	1	n/a	2	4	5	3	3	n/a	18
Nº surveyed	9	n/a	77	159	37	31	118	n/a	431
Nº pathology only	0	n/a	16	7	0	2	17	n/a	42
Nº (%) Male	9 (100)	n/a	69 (90)	127 (80)	33 (89)	26 (84)	112 (95)	n/a	377 (87)
Median age (years)	36	n/a	34	34	33	32	31	n/a	33
Age range	24 – 49	n/a	18 – 58	17 – 70	20 – 55	20 – 48	20 – 68	n/a	17 – 70
Nº (%) Indigenous	2 (22)	n/a	68 (88)	38 (25)	12 (32)	10 (32)	18 (15)	n/a	148 (35)
Nº (%) Aust. born	7 (78)	n/a	61 (100)	137 (91)	37 (100)	29 (100)	88 (87)	n/a	359 (93)

Table 5 Injecting drug use by jurisdiction (2016)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
Nº (%) with IDU history	4 (44)	n/a	4 (7)	84 (55)	22 (60)	15 (52)	49 (49)	n/a	178 (46)
Last drug injected									
Methamphetamine	3 (75)	n/a	3 (75)	63 (75)	19 (86)	11 (79)	26 (53)	n/a	125 (71)
Anabolic steroids [^]	0 (0)	n/a	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	n/a	1 (1)
Cocaine	0 (0)	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	0 (0)
Heroin	1 (25)	n/a	0 (0)	10 (12)	2 (9)	0 (0)	19 (39)	n/a	32 (18)
Methadone	0 (0)	n/a	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	n/a	2 (1)
Morphine	0 (0)	n/a	1 (25)	0 (0)	0 (0)	2 (14)	2 (4)	n/a	5 (3)
Subutex/buprenorphine ^{^^}	0 (0)	n/a	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	n/a	2 (1)
Others	0 (0)	n/a	0 (0)	7 (9)	1 (5)	1 (7)	1 (2)	n/a	7 (4)
Not reported	0 (0)	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	1 (1)
Nº (%) injected last month									
No, did not inject	2 (50)	n/a	4 (100)	28 (33)	5 (23)	6 (40)	19 (39)	n/a	64 (36)
Yes, injected	2 (50)	n/a	0 (0)	56 (67)	17 (77)	7 (47)	30 (61)	n/a	112 (63)
Not reported	0 (0)	n/a	0 (0)	0 (0)	0 (0)	2 (13)	0 (0)	n/a	2 (1)
Places injected last month (%)*									
Prison	0 (0)	n/a	--	2 (4)	0 (0)	0 (0)	1 (3)	n/a	3 (3)
Own home	2 (100)	n/a	--	39 (70)	10 (59)	4 (57)	23 (77)	n/a	78 (70)
Friend's home	0 (0)	n/a	--	24 (43)	7 (41)	1 (14)	17 (57)	n/a	49 (44)
Dealer's home	0 (0)	n/a	--	13 (23)	3 (18)	2 (29)	7 (23)	n/a	25 (22)
Street, park, beach	1 (50)	n/a	--	17 (30)	1 (6)	1 (14)	4 (13)	n/a	24 (21)
Car	0 (0)	n/a	--	14 (25)	3 (18)	2 (29)	8 (27)	n/a	27 (24)
Public toilet	0 (0)	n/a	--	11 (20)	1 (6)	3 (43)	7 (23)	n/a	22 (20)
MSIC ^{^^^}	0 (0)	n/a	--	0 (0)	0 (0)	0 (0)	0 (0)	n/a	0 (0)
Commercial shooting	0 (0)	n/a	--	0 (0)	0 (0)	0 (0)	0 (0)	n/a	0 (0)
Squat	1 (50)	n/a	--	1 (2)	1 (6)	0 (0)	1 (3)	n/a	4 (4)
Other	0 (0)	n/a	--	0 (0)	0 (0)	0 (0)	0 (0)	n/a	0 (0)
Use of sterile needles & syringes last month (%)									
All injections	2 (100)	n/a	--	39 (70)	12 (71)	7 (100)	25 (83)	n/a	85 (76)
Most of the time	0 (0)	n/a	--	13 (23)	3 (18)	0 (0)	1 (3)	n/a	17 (15)
Half of the time	0 (0)	n/a	--	0 (0)	1 (6)	0 (0)	3 (10)	n/a	4 (4)
Some of the time	0 (0)	n/a	--	2 (4)	1 (6)	0 (0)	0 (0)	n/a	3 (3)
None of the time	0 (0)	n/a	--	2 (4)	0 (0)	0 (0)	1 (3)	n/a	3 (3)
Not reported	0 (0)	n/a	--	0 (0)	0 (0)	0 (0)	0 (0)	n/a	0 (0)

IDU=injecting drug user; n/a=not asked; *More than one drug option could be selected.

[^]Also includes hormones and peptides from 2016; ^{^^}Also includes Suboxone; ^{^^^}Medically Supervised Injecting Centre, Sydney.

Table 6 Smoking status, other drug use by jurisdiction (2016)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
Ever smoked a full cigarette (%)									
No	0 (0)	n/a	8 (13)	13 (9)	2 (5)	1 (3)	7 (7)	n/a	31 (8)
Yes	9 (100)	n/a	53 (87)	139 (91)	35 (95)	28 (97)	94 (93)	n/a	358 (92)
Not reported	0 (0)	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	0 (0)
Current smoker (%)									
No	2 (22)	n/a	3 (6)	25 (18)	2 (6)	1 (4)	13 (14)	n/a	46 (13)
Yes	7 (78)	n/a	50 (94)	112 (81)	33 (94)	27 (96)	81 (86)	n/a	310 (87)
Not reported	0 (0)	n/a	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	n/a	2 (<1)
Other drugs used last month (%)*									
No drugs in past month	4 (44)	n/a	38 (62)	39 (26)	5 (14)	6 (21)	23 (23)	n/a	115 (30)
Cannabis	2 (40)	n/a	22 (96)	62 (60)	18 (58)	18 (78)	42 (55)	n/a	164 (63)
Heroin	0 (0)	n/a	0 (0)	14 (14)	3 (10)	1 (4)	20 (26)	n/a	38 (15)
Cocaine	1 (20)	n/a	1 (4)	5 (5)	0 (0)	0 (0)	11 (14)	n/a	18 (7)
Methamphetamine	3 (60)	n/a	3 (13)	67 (64)	24 (77)	16 (70)	53 (70)	n/a	166 (63)
Other's methadone	0 (0)	n/a	0 (0)	3 (3)	0 (0)	3 (13)	3 (4)	n/a	9 (3)
Other opiates	2 (40)	n/a	0 (0)	10 (10)	0 (0)	1 (4)	9 (12)	n/a	22 (8)
Other's buprenorphine	1 (20)	n/a	0 (0)	6 (6)	3 (10)	5 (22)	5 (7)	n/a	20 (8)
Anabolic steroids^	0 (0)	n/a	1 (4)	0 (0)	0 (0)	1 (4)	4 (5)	n/a	6 (2)
Hallucinogens	0 (0)	n/a	0 (0)	2 (2)	1 (3)	0 (0)	4 (5)	n/a	7 (3)
Benzodiazepines	1 (20)	n/a	0 (0)	17 (16)	2 (6)	6 (26)	36 (34)	n/a	52 (20)
Ecstasy/MDA	0 (0)	n/a	1 (4)	11 (11)	1 (3)	4 (17)	13 (17)	n/a	30 (12)
Inhalants	0 (0)	n/a	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	n/a	1 (<1)
Other drug	0 (0)	n/a	0 (0)	5 (5)	1 (3)	4 (17)	4 (5)	n/a	14 (5)
Not reported	0 (0)	n/a	0 (0)	9 (6)	1 (3)	0 (0)	2 (3)	n/a	12 (3)
Risk of alcohol-related harm (%)									
Non-drinker	1 (11)	n/a	7 (11)	45 (30)	14 (38)	4 (14)	27 (27)	n/a	98 (25)
Low risk of harm	5 (56)	n/a	16 (26)	59 (39)	11 (30)	13 (45)	41 (41)	n/a	145 (37)
High risk of harm	3 (33)	n/a	37 (61)	36 (24)	9 (24)	12 (41)	31 (31)	n/a	128 (33)
Not reported	0 (0)	n/a	1 (2)	12 (8)	3 (11)	0 (0)	2 (2)	n/a	18 (5)

*More than one drug option could be selected.

^Also includes hormones and peptides from 2016.

Table 7 HIV antibody prevalence by jurisdiction and gender (2016)†

	Male		Female		Total	
	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV
ACT	9	0 (0)	--	--	9	0
NSW	n/a	n/a	n/a	n/a	n/a	n/a
NT	53	0 (0)	5	0	58	0 (0)
Qld	77	0 (0)	24	0	101	0 (0)
SA	23	0 (0)	1	0	24	0 (0)
Tas	16	0 (0)	4	0	20	0 (0)
Vic	73	0 (0)	4	0	77	0 (0)
WA	n/a	n/a	n/a	n/a	n/a	n/a
Total	251	0 (0)	38	0 (0)	289	0 (0)

† Excludes equivocal test results and missing values.

Table 8 HIV antibody prevalence by jurisdiction, gender and injector status (2016)[†]

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N ^o tested	N ^o (%) with HIV
	N ^o tested	N ^o (%) with HIV	N ^o tested	N ^o (%) with HIV	N ^o tested	N ^o (%) with HIV	N ^o tested	N ^o (%) with HIV		
ACT	4	0 (0)	5	0 (0)	--	--	--	--	9	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	2	0 (0)	39	0 (0)	0	0 (0)	2	0 (0)	43	0 (0)
Qld	34	0 (0)	35	0 (0)	17	0 (0)	7	0 (0)	93	0 (0)
SA	15	0 (0)	8	0 (0)	1	0 (0)	0	0 (0)	24	0 (0)
Tas	8	0 (0)	6	0 (0)	2	0 (0)	2	0 (0)	18	0 (0)
Vic	30	0 (0)	29	0 (0)	1	0 (0)	2	0 (0)	62	0 (0)
WA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total	93	0 (0)	122	0 (0)	21	0 (0)	13	0 (0)	249	0 (0)

[†] Excludes equivocal test results and missing values.

Table 9 Hepatitis C antibody prevalence by jurisdiction and gender (2016)[†]

	Male		Female		Total	
	N ^o tested	N ^o (%) with HCV	N ^o tested	N ^o (%) with HCV	N ^o tested	N ^o (%) with HCV
ACT	9	2 (22)	--	--	9	2 (22)
NSW	n/a	n/a	n/a	n/a	n/a	n/a
NT	48	0 (0)	5	0 (0)	53	0 (0)
Qld	76	19 (25)	22	8 (36)	97	27 (28)
SA	24	11 (46)	1	0 (0)	25	11 (44)
Tas	16	5 (31)	4	0 (0)	20	5 (25)
Vic	80	17 (21)	4	2 (50)	84	19 (23)
WA	n/a	n/a	n/a	n/a	n/a	n/a
Total	252	54 (21)	36	10 (28)	288	64 (22)

[†] Excludes equivocal test results and missing values.

Table 10 Hepatitis C antibody prevalence by jurisdiction, gender and injector status (2016)[†]

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N ^o tested	N ^o (%) with HCV
	N ^o tested	N ^o (%) with HCV	N ^o tested	N ^o (%) with HCV	N ^o tested	N ^o (%) with HCV	N ^o tested	N ^o (%) with HCV		
ACT	4	2 (50)	5	0 (0)	--	--	--	--	9	2 (22)
NSW	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	2	0 (0)	35	0 (0)	0	0 (0)	2	0 (0)	39	0 (0)
Qld	35	18 (51)	34	0 (0)	16	8 (50)	6	0 (0)	91	26 (29)
SA	16	10 (63)	8	1 (13)	1	0 (0)	0	0 (0)	25	11 (44)
Tas	8	5 (63)	6	0 (0)	2	0 (0)	2	0 (0)	18	5 (28)
Vic	32	15 (47)	33	0 (0)	1	1 (100)	2	0 (0)	68	16 (24)
WA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total	97	50 (52)	121	1 (1)	20	9 (45)	12	0 (0)	250	60 (24)

[†] Excludes equivocal test results and missing values.

Table 11 Hepatitis B surface-antigen prevalence by jurisdiction and gender (2016)[†]

	Male		Female		Total	
	N ^o tested	N ^o (%) with Hepatitis B surface-antigen	N ^o tested	N ^o (%) with Hepatitis B surface-antigen	N ^o tested	N ^o (%) with Hepatitis B surface-antigen
ACT	9	0 (0)	--	--	9	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a
NT	47	4 (9)	5	0 (0)	52	4 (8)
Qld	74	2 (3)	22	0 (0)	96	2 (2)
SA	20	0 (0)	1	0 (0)	21	0 (0)
Tas	16	0 (0)	4	0 (0)	20	0 (0)
Vic	58	2 (3)	4	0 (0)	62	2 (3)
WA	n/a	n/a	n/a	n/a	n/a	n/a
Total	224	8 (4)	36	0 (0)	260	8 (3)

[†] Excludes equivocal test results and missing values.

Table 12 Hepatitis B core-antibody prevalence by jurisdiction and gender (2016)[†]

	Male		Female		Total	
	N ^o tested	N ^o (%) with HBV	N ^o tested	N ^o (%) with HBV	N ^o tested	N ^o (%) with HBV
ACT	9	0 (0)	--	--	9	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a
NT	47	20 (43)	5	2 (40)	52	22 (42)
Qld	67	12 (18)	22	1 (5)	89	13 (15)
SA	24	3 (13)	1	0 (0)	25	3 (12)
Tas	16	0 (0)	4	0 (0)	20	0 (0)
Vic	74	7 (9)	4	0 (0)	78	7 (9)
WA	n/a	n/a	n/a	n/a	n/a	n/a
Total	237	42 (18)	36	3 (8)	273	45 (16)

[†] Excludes equivocal test results and missing values.

Table 13 Hepatitis B core-antibody prevalence by jurisdiction, gender and injector status (2016)[†]

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N ^o tested	N ^o (%) with HBV
	N ^o tested	N ^o (%) with HBV	N ^o tested	N ^o (%) with HBV	N ^o tested	N ^o (%) with HBV	N ^o tested	N ^o (%) with HBV		
ACT	4	0 (0)	5	0 (0)	--	--	--	--	9	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	2	0 (0)	34	15 (44)	0	0 (0)	2	0 (0)	38	15 (39)
Qld	29	4 (14)	32	6 (19)	16	1 (6)	6	0 (0)	83	11 (13)
SA	16	2 (13)	8	1 (13)	1	0 (0)	0	0 (0)	25	3 (12)
Tas	8	0 (0)	6	0 (0)	2	0 (0)	2	0 (0)	18	0 (0)
Vic	31	4 (13)	30	3 (10)	1	0 (0)	2	0 (0)	64	7 (11)
WA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total	90	10 (11)	115	25 (22)	20	1 (5)	12	0 (0)	237	36 (15)

[†] Excludes equivocal test results and missing values.

Table 14 Hepatitis B virus immune status by jurisdiction (2016)[†]

	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity
ACT	9	4 (44)	0 (0)	0 (0)	5 (56)
NSW	n/a	n/a	n/a	n/a	n/a
NT	51	19 (37)	18 (35)	3 (6)	11 (22)
Qld	87	39 (45)	11 (13)	2 (2)	35 (40)
SA	9	3 (33)	3 (33)	0 (0)	3 (33)
Tas	12	11 (92)	0 (0)	1 (8)	0 (0)
Vic	60	29 (48)	6 (10)	2 (3)	23 (38)
WA	n/a	n/a	n/a	n/a	n/a
Total	228	105 (46)	38 (17)	8 (4)	77 (34)

[†] Excludes equivocal test results and missing values.

Table 15 Hepatitis B virus immune status - Males (2016)[†]

	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity
ACT	9	4 (44)	0 (0)	0 (0)	5 (56)
NSW	n/a	n/a	n/a	n/a	n/a
NT	46	17 (37)	16 (35)	3 (7)	10 (22)
Qld	65	28 (43)	10 (15)	2 (3)	25 (39)
SA	8	2 (25)	3 (38)	0 (0)	3 (38)
Tas	10	9 (90)	0 (0)	1 (10)	0 (0)
Vic	56	26 (46)	6 (11)	2 (4)	22 (39)
WA	n/a	n/a	n/a	n/a	n/a
Total	194	65 (34)	35 (18)	8 (4)	65 (34)

[†] Excludes equivocal test results and missing values.

Table 16 Hepatitis B virus immune status - Females (2016)[†]

	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity
ACT	--	--	--	--	--
NSW	n/a	n/a	n/a	n/a	n/a
NT	5	2 (40)	2 (40)	0 (0)	1 (20)
Qld	22	11 (50)	1 (5)	0 (0)	10 (46)
SA	1	1 (100)	0 (0)	0 (0)	0 (0)
Tas	2	2 (100)	0 (0)	0 (0)	0 (0)
Vic	4	3 (75)	0 (0)	0 (0)	1 (25)
WA	n/a	n/a	n/a	n/a	n/a
Total	34	19 (56)	3 (9)	0 (0)	12 (35)

[†] Excludes equivocal test results and missing values.

Table 17 Genital chlamydia prevalence by jurisdiction and gender (2016)[†]

	Male		Female		Total	
	N ^o tested	N ^o (%) with chlamydia	N ^o tested	N ^o (%) with chlamydia	N ^o tested	N ^o (%) with chlamydia
ACT	5	0 (0)	--	--	5	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a
NT	46	0 (0)	2	0 (0)	48	0 (0)
Qld	59	4 (7)	17	1 (6)	76	5 (7)
SA	24	1 (4)	1	0 (0)	25	1 (4)
Tas	12	0 (0)	4	0 (0)	16	0 (0)
Vic	81	3 (4)	6	1 (17)	87	4 (5)
WA	n/a	n/a	n/a	n/a	n/a	n/a
Total	227	8 (4)	30	2 (7)	257	10 (4)

[†] Excludes missing values.Table 18 Genital gonorrhoea prevalence by jurisdiction and gender (2016)[†]

	Male		Female		Total	
	N ^o tested	N ^o (%) with gonorrhoea	N ^o tested	N ^o (%) with gonorrhoea	N ^o tested	N ^o (%) with gonorrhoea
ACT	5	0 (0)	--	-	5	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a
NT	51	4 (8)	4	0 (0)	55	4 (7)
Qld	59	0 (0)	17	0 (0)	76	0 (0)
SA	24	0 (0)	1	0 (0)	25	0 (0)
Tas	12	0 (0)	4	0 (0)	16	0 (0)
Vic	82	0 (0)	6	0 (0)	88	0 (0)
WA	n/a	n/a	n/a	n/a	n/a	n/a
Total	233	4 (2)	32	0 (0)	265	4 (2)

[†] Excludes missing values.Table 19 Syphilis markers by jurisdiction and gender (2016)[†]

	Male			Female			Total
	N ^o tested	N ^o (%) with syphilis antibodies	N ^o (%) with reactive RPR	N ^o tested	N ^o (%) with syphilis antibodies	N ^o (%) with reactive RPR	N ^o (%) with any marker for syphilis
ACT	9	0 (0)	0 (0)	--	--	0	0 (0)
NSW	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	52	9 (17)	4 (44)	5	4 (80)	1 (25)	13 (25)
Qld	71	1 (1)	0 (0)	24	2 (8)	1 (50)	3 (4)
SA	23	0 (0)	0 (0)	1	0 (0)	0 (0)	0 (0)
Tas	0	0 (0)	0 (0)	0	0 (0)	0 (0)	0 (0)
Vic	78	0 (0)	0 (0)	4	0 (0)	0 (0)	0 (0)
WA	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total	233	10 (4)	4 (2)	34	6 (18)	2 (33)	16 (7)

[†] Excludes missing values.

National
2004, 2007, 2010, 2013, 2016

Table 20 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 8		N = 17		N = 27		N = 23		N = 18	
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Gender (%)										
Male	307 (86)	228 (92)	354 (87)	315 (94)	310 (88)	424 (93)	283 (83)	382 (90)	148 (83)	190 (90)
Female	49 (14)	19 (8)	52 (13)	19 (6)	43 (12)	34 (7)	59 (17)	43 (10)	29 (16)	21 (10)
Transgender	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Age (years)										
Median age	30	34	32	29	33	28	32	31	33	33
Age range	17 – 58	17 – 75	18 – 54	17 – 77	18 – 79	16 – 80	17 – 68	17 – 72	17 – 55	17 – 70
Age group (%)										
<25 years	95 (27)	69 (28)	70 (17)	120 (36)	71 (20)	160 (35)	67 (20)	118 (28)	33 (18)	40 (19)
25+ years	260 (72)	178 (72)	335 (83)	214 (64)	281 (80)	298 (65)	272 (80)	305 (72)	144 (81)	171 (81)
Not reported	2 (<1)	0 (0)	1 (<1)	0 (0)	1 (<1)	0 (0)	3 (1)	2 (<1)	1 (1)	0 (0)
Aboriginal and/or Torres Strait Islander origin (%)										
No	285 (80)	209 (85)	320 (79)	283 (85)	260 (74)	291 (64)	226 (66)	291 (68)	134 (75)	121 (57)
Yes	64 (18)	36 (15)	78 (19)	50 (15)	93 (26)	167 (36)	115 (34)	134 (32)	42 (24)	90 (43)
Not reported	8 (2)	2 (<1)	8 (2)	1 (<1)	0 (0)	0 (0)	1 (<1)	0 (0)	2 (1)	0 (0)
Sexual identity (%)										
Heterosexual	341 (96)	240 (97)	385 (95)	328 (98)	336 (95)	441 (96)	319 (93)	412 (97)	161 (90)	197 (93)
Bisexual	11 (3)	3 (1)	6 (2)	2 (<1)	8 (2)	7 (2)	12 (4)	4 (1)	7 (4)	2 (1)
Gay/lesbian	5 (1)	3 (1)	9 (2)	1 (<1)	6 (2)	3 (1)	3 (1)	4 (1)	3 (2)	2 (1)
Unsure	0 (0)	0 (0)	2 (<1)	0 (0)	1 (<1)	2 (0)	4 (1)	2 (<1)	3 (2)	4 (2)
Not reported	0 (0)	1 (<1)	4 (<1)	3 (<1)	2 (1)	5 (1)	4 (1)	3 (1)	4 (2)	6 (3)
Region/Country of birth (%)										
Australia	310 (87)	182 (74)	354 (87)	263 (79)	314 (89)	372 (81)	318 (93)	348 (82)	168 (94)	190 (90)
Other Oceania	12 (3)	17 (7)	9 (2)	13 (4)	15 (4)	29 (6)	8 (2)	23 (5)	7 (4)	6 (3)
Asia	13 (4)	14 (6)	19 (5)	20 (6)	9 (3)	22 (5)	5 (1)	23 (5)	1 (1)	7 (3)
UK & Ireland	8 (2)	9 (4)	7 (2)	7 (2)	7 (2)	6 (1)	7 (2)	6 (1)	0 (0)	1 (<1)
Other	13 (4)	23 (9)	15 (4)	27 (8)	7 (2)	29 (6)	4 (1)	25 (6)	2 (1)	5 (2)
Not reported	1 (<1)	2 (<1)	2 (<1)	4 (1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)
Residential remoteness in 12 months before prison (%)										
Highly/accessible	325 (91)	215 (87)	362 (89)	286 (86)	313 (89)	329 (72)	286 (84)	295 (69)	149 (84)	126 (60)
Mod accessible	9 (3)	6 (2)	11 (3)	14 (4)	15 (4)	22 (5)	36 (11)	58 (14)	18 (10)	28 (13)
Very/remote	13 (4)	14 (6)	11 (3)	11 (3)	14 (4)	84 (18)	8 (2)	56 (13)	7 (4)	52 (25)
Not reported	10 (3)	12 (5)	22 (5)	23 (7)	11 (3)	23 (5)	12 (4)	16 (4)	4 (2)	5 (2)
First time in prison (%)										
No	302 (85)	149 (60)	336 (83)	161 (48)	290 (82)	262 (57)	274 (80)	230 (54)	151 (85)	124 (59)
Yes	55 (15)	98 (40)	69 (17)	171 (51)	61 (17)	190 (41)	67 (20)	191 (45)	27 (15)	87 (41)
Not reported	0 (0)	0 (0)	1 (<1)	2 (<1)	2 (1)	6 (1)	1 (<1)	4 (1)	0 (0)	0 (0)
Lifetime imprisonments (%)										
One	55 (15)	98 (40)	69 (17)	171 (51)	118 (33)	285 (62)	n/a	n/a	21 (14)	31 (25)
Two to four	178 (50)	117 (47)	163 (40)	119 (36)	115 (33)	109 (24)	n/a	n/a	53 (35)	47 (38)
Five to nine	87 (24)	17 (7)	95 (23)	23 (7)	72 (20)	43 (9)	n/a	n/a	41 (27)	18 (15)
Ten or more	32 (9)	3 (1)	60 (15)	10 (3)	46 (13)	15 (3)	n/a	n/a	24 (16)	10 (8)
Not reported	5 (1)	12 (5)	19 (5)	11 (3)	2 (1)	6 (1)	n/a	n/a	12 (8)	18 (15)
Imprisonment in last year (%)										
No	129 (36)	137 (55)	113 (34)	47 (29)	160 (45)	277 (60)	90 (33)	84 (37)	39 (26)	35 (28)
Yes	220 (62)	98 (40)	214 (64)	111 (68)	180 (51)	153 (33)	164 (60)	131 (57)	100 (66)	77 (62)
Not reported	8 (2)	12 (5)	10 (3)	5 (3)	13 (4)	28 (6)	20 (7)	15 (7)	12 (8)	12 (10)

Table 21 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Ever smoked a full cigarette (%)										
No	n/a	n/a	14 (3)	45 (14)	7 (2)	44 (10)	11 (3)	56 (13)	4 (2)	27 (13)
Yes	n/a	n/a	392 (97)	289 (87)	346 (98)	413 (90)	331 (97)	368 (87)	174 (98)	184 (87)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)	0 (0)	0 (0)
Age of smoking										
Med age 1 st smoked	n/a	n/a	14	14	13	15	13	15	13	15
Age range	n/a	n/a	5 – 36	4 – 31	3 – 37	6 – 50	5 – 35	5 – 40	4 – 31	5 – 32
Current smoker (%)*										
No	n/a	n/a	26 (6)	85 (25)	20 (6)	99 (22)	21 (6)	42 (11)	17 (10)	29 (16)
Yes	n/a	n/a	379 (93)	249 (75)	333 (94)	357 (78)	309 (93)	320 (87)	156 (90)	154 (84)
Not reported	n/a	n/a	1 (<1)	0 (0)	0 (0)	2 (<1)	1 (<1)	6 (2)	1 (1)	1 (1)
Smoking frequency (%)										
Weekly or less	n/a	n/a	13 (3)	22 (9)	11 (3)	12 (3)	7 (2)	16 (5)	8 (5)	10 (7)
5-10/day	n/a	n/a	98 (26)	60 (24)	106 (32)	152 (42)	102 (33)	115 (35)	53 (34)	42 (27)
11-20/day	n/a	n/a	154 (41)	85 (34)	144 (43)	104 (29)	127 (41)	115 (35)	47 (30)	61 (39)
> 20/day	n/a	n/a	113 (30)	81 (33)	70 (21)	88 (25)	70 (23)	69 (21)	43 (27)	41 (27)
Not reported	n/a	n/a	2 (<1)	1 (<1)	2 (1)	1 (<1)	4 (1)	10 (3)	6 (4)	1 (1)
Other drugs used last month (%)**										
None	n/a	n/a	n/a	n/a	63 (19)	222 (52)	37 (11)	211 (50)	19 (11)	96 (45)
Cannabis	n/a	n/a	n/a	n/a	205 (74)	167 (80)	197 (65)	145 (68)	90 (58)	74 (70)
Heroin	n/a	n/a	n/a	n/a	78 (28)	11 (5)	72 (24)	7 (3)	36 (23)	2 (2)
Cocaine	n/a	n/a	n/a	n/a	18 (6)	11 (5)	18 (6)	12 (6)	13 (8)	5 (5)
Methamphetamine	n/a	n/a	n/a	n/a	159 (57)	49 (23)	212 (70)	85 (40)	123 (79)	43 (41)
Methadone	n/a	n/a	n/a	n/a	23 (8)	0 (0)	16 (5)	1 (<1)	9 (6)	0 (0)
Other opiates	n/a	n/a	n/a	n/a	43 (16)	2 (1)	51 (17)	10 (5)	19 (12)	3 (3)
Buprenorphine	n/a	n/a	n/a	n/a	33 (12)	3 (1)	18 (6)	4 (2)	17 (11)	3 (3)
Anabolic steroids^	n/a	n/a	n/a	n/a	7 (3)	2 (1)	8 (3)	1 (<1)	6 (4)	0 (0)
Hallucinogens	n/a	n/a	n/a	n/a	7 (3)	5 (2)	13 (4)	8 (4)	5 (3)	2 (2)
Ecstasy/MDA	n/a	n/a	n/a	n/a	62 (22)	15 (7)	77 (25)	23 (11)	20 (13)	10 (9)
Inhalants	n/a	n/a	n/a	n/a	17 (6)	16 (8)	24 (8)	12 (6)	0 (0)	1 (1)
Other drug	n/a	n/a	n/a	n/a	1 (<1)	1 (<1)	0 (0)	3 (1)	6 (4)	8 (8)
Not reported	n/a	n/a	n/a	n/a	2 (1)	1 (<1)	13 (4)	11 (5)	3 (2)	9 (4)
Risk of alcohol-related harm (%)^^										
Non-drinker	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	51 (29)	47 (22)
Low risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	68 (38)	77 (36)
High risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	52 (29)	76 (36)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	6 (3)	11 (5)

*Prior to prison; **More than one drug option could be selected; ^Also includes hormones and peptides from 2016; ^^AUDIT-C

Table 22 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004 N = 357	2007 N = 406	2010 N = 353	2013 N = 342	2016 N = 178
Median age 1st IDU	18	18	18	18	18
Age range	9 – 41	8 – 44	7 – 42	10 – 47	10 – 42
Not reported	8	9	13	5	5
Median years since first drug injection	10	12	13	13	14
Range	<1 – 37	<1 – 36	<1 – 40	<1 – 44	<0 – 40
Not reported	0	0	0	11	8
Years since first drug injection (%)					
<3 years	36 (10)	24 (6)	33 (9)	43 (13)	23 (13)
3+ years	311 (87)	372 (92)	306 (87)	288 (86)	150 (84)
Not reported	10 (3)	10 (2)	14 (4)	5 (1)	5 (3)
Last drug injected (%)					
Methamphetamine	206 (58)	238 (59)	207 (59)	231 (68)	125 (70)
Anabolic steroids [^]	1 (1)	0 (0)	2 (1)	8 (2)	1 (<1)
Cocaine	7 (2)	7 (2)	3 (1)	2 (<1)	0 (0)
Heroin	115 (32)	126 (31)	88 (25)	68 (20)	32 (18)
Methadone	7 (2)	6 (1)	5 (1)	3 (1)	2 (1)
Morphine	9 (3)	12 (3)	20 (6)	13 (4)	5 (3)
Subutex/buprenorphine/Suboxone	n/a	n/a	n/a	0 (0)	2 (1)
Other	10 (2)	16 (4)	23 (6)	10 (3)	7 (4)
Not reported	0 (0)	1 (<1)	5 (1)	7 (2)	1 (<1)
Frequency of injection last month (%)					
Not last month	125 (35)	152 (37)	150 (42)	108 (32)	64 (36)
< Weekly	47 (13)	54 (13)	68 (19)	50 (15)	31 (17)
Weekly	28 (8)	52 (13)	23 (7)	43 (13)	17 (10)
Daily or more	154 (43)	142 (35)	108 (31)	138 (40)	64 (36)
Not reported	3 (<1)	6 (2)	4 (1)	3 (1)	2 (1)
N^o injected last month	N = 232	N = 248	N = 199	N = 231	N = 112
Places injected last month (%)*					
Prison	8 (3)	7 (3)	4 (2)	7 (3)	3 (3)
Own home	181 (78)	199 (80)	120 (61)	155 (67)	78 (70)
Friend's home	117 (50)	137 (55)	78 (40)	92 (40)	49 (44)
Dealer's home	51 (22)	74 (30)	27 (14)	44 (19)	25 (22)
Street, park, beach	73 (31)	95 (38)	30 (15)	37 (16)	24 (21)
Car	82 (35)	112 (45)	45 (23)	46 (20)	27 (24)
Public toilet	56 (24)	69 (28)	31 (16)	37 (16)	22 (20)
Commercial injecting room	8 (3)	7 (3)	1 (<1)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	9 (4)	10 (4)	3 (2)	1 (<1)	0 (0)
Squat	19 (8)	14 (6)	4 (2)	3 (1)	4 (4)
Other place	5 (2)	12 (5)	1 (<1)	5 (2)	2 (<1)
Use of sterile needles & syringes last month (%)					
All injections	160 (69)	162 (65)	137 (69)	161 (70)	85 (76)
Most of the time	38 (16)	52 (21)	42 (21)	45 (20)	17 (15)
Half of the time	14 (6)	11 (4)	7 (4)	7 (3)	4 (4)
Some of the time	17 (7)	18 (7)	3 (2)	15 (7)	3 (3)
Not last month	2 (<1)	0 (0)	3 (2)	2 (1)	3 (3)
Not reported	1 (<1)	5 (2)	7 (4)	0 (0)	0 (0)
Times injected by someone else after they injected themselves or others in past month (%)					
More than 5 times	7 (3)	10 (4)	9 (5)	11 (5)	4 (4)
3 to 5 times	7 (3)	10 (4)	1 (4)	9 (4)	2 (2)
Once or twice	19 (8)	26 (10)	20 (10)	19 (8)	6 (5)
None	196 (84)	197 (79)	157 (79)	190 (82)	100 (89)
Not reported	3 (1)	1 (<1)	0 (0)	2 (1)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	196 (84)	198 (80)	157 (79)	190 (82)	92 (82)
Once	6 (3)	10 (4)	11 (6)	13 (6)	6 (5)
Twice	14 (6)	10 (4)	9 (5)	6 (3)	8 (7)
3-5 times	7 (3)	7 (3)	7 (4)	9 (4)	1 (1)
>5 times	7 (3)	19 (8)	9 (5)	11 (5)	5 (4)
Not reported	2 (<1)	4 (2)	6 (3)	2 (1)	0 (0)

*More than one drug option could be selected; [^]Also includes hormones and peptides from 2016.

Table 23 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year (cont.)

Injecting behaviour	2004	2007	2010	2013	2016
	N = 357	N = 406	N = 353	N = 342	N = 178
Number of people needle & syringe was re-used after last month (%)*					
One	20 (9)	31 (12)	16 (8)	20 (49)	7 (35)
Two	7 (3)	3 (1)	6 (3)	5 (12)	3 (15)
Three to five	4 (2)	4 (2)	2 (1)	3 (7)	0 (0)
More than five	2 (<1)	0 (0)	4 (2)	7 (17)	3 (15)
Don't know how many	0 (0)	5 (2)	7 (4)	3 (7)	4 (27)
Not reported	2 (<1)	13 (5)	8 (4)	3 (7)	3 (15)
Relationship to people needle & syringe was re-used after last month (%)**					
Regular sex partner	18 (8)	25 (10)	20 (10)	10 (26)	4 (24)
Casual sex partner	2 (<1)	2 (<1)	3 (2)	3 (8)	2 (12)
Close friend	7 (3)	13 (5)	7 (4)	12 (31)	7 (41)
Acquaintance	5 (2)	5 (2)	6 (3)	12 (31)	4 (23)
Other	5 (2)	5 (2)	4 (2)	6 (15)	2 (12)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (12)
Last time re-used needle or syringe after someone (%)					
Last month	31 (9)	46 (12)	23 (7)	32 (9)	12 (7)
In the last 2-6 months	22 (6)	16 (4)	16 (5)	13 (4)	11 (6)
More than 6 months ago	83 (24)	92 (23)	76 (23)	87 (26)	38 (21)
Never	208 (59)	239 (61)	221 (66)	207 (61)	116 (65)
Not reported	7 (2)	0 (0)	0 (0)	0 (0)	1 (1)
Last place re-used needle or syringe after someone (%)					
Prison	18 (13)	25 (16)	25 (20)	35 (26)	11 (18)
Own home	49 (35)	58 (36)	41 (32)	45 (33)	26 (42)
Friend's home	29 (21)	34 (21)	29 (23)	29 (21)	12 (19)
Dealer's home	0 (0)	4 (3)	3 (2)	3 (2)	1 (2)
Street, park, bench	8 (6)	11 (7)	9 (7)	3 (2)	3 (5)
Car	7 (5)	4 (3)	5 (4)	1 (1)	2 (3)
Public toilet	1 (1)	2 (1)	2 (2)	1 (1)	1 (2)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Squat	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	29 (21)	21 (13)	14 (11)	17 (13)	5 (8)
Equipment used after someone else last month (%)**					
Spoon	49 (21)	76 (30)	50 (25)	36 (16)	24 (65)
Water	39 (17)	63 (25)	39 (20)	24 (11)	22 (60)
Filter	34 (15)	57 (23)	40 (20)	14 (6)	11 (30)
Tourniquet	18 (8)	31 (13)	26 (13)	17 (8)	18 (49)
Drug mix	33 (14)	49 (20)	36 (18)	22 (10)	9 (24)
Did not share equipment	0 (0)	0 (0)	0 (0)	0 (0)	73 (67)

*Of those reporting sharing needles & syringes in the past month

**More than one drug option could be selected.

Table 24 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition	2004	2007	2010	2013	2016
N° surveyed	N = 233	N = 248	N = 353	N = 342	N = 178
Location of needle & syringe acquisition in the past month (%)*					
Needle & Syringe Program (NSP/NCP)	n/a	n/a	n/a	n/a	74 (42)
Chemist/pharmacy	n/a	n/a	n/a	n/a	67 (38)
Vending machine	n/a	n/a	n/a	n/a	24 (14)
Personal source (e.g. friend)	n/a	n/a	n/a	n/a	20 (11)
Other	n/a	n/a	n/a	n/a	13 (7)
Not in the last month	n/a	n/a	n/a	n/a	46 (26)
From an NSP last month (%)					
Daily or almost daily	31 (13)	30 (12)	26 (7)	17 (5)	4 (3)
A couple of times each week	38 (16)	57 (22)	37 (10)	42 (12)	23 (17)
Less than weekly	33 (14)	38 (15)	40 (11)	42 (12)	19 (14)
Weekly	n/a	n/a	19 (5)	n/a	n/a
Once last month	39 (17)	29 (12)	12 (3)	53 (15)	29 (22)
Not in the last month	57 (24)	45 (18)	154 (44)	179 (52)	48 (37)
Not reported	35 (15)	52 (21)	65 (18)	9 (3)	9 (7)
From a chemist last month (%)					
Daily or almost daily	17 (7)	14 (6)	17 (5)	9 (3)	5 (4)
A couple of times each week	36 (16)	32 (13)	29 (8)	27 (8)	18 (14)
Less than weekly	51 (22)	35 (14)	38 (11)	41 (12)	12 (9)
Weekly	n/a	n/a	36 (10)	n/a	n/a
Once last month	38 (17)	32 (13)	0 (0)	45 (13)	34 (26)
Not in the last month	86 (37)	84 (34)	173 (49)	211 (62)	58 (44)
Not reported	2 (<1)	51 (21)	60 (17)	9 (3)	5 (4)
Ever participated in the annual NSP community survey (%)					
No	298 (83)	312 (79)	319 (90)	288 (84)	164 (92)
Yes	42 (12)	20 (5)	16 (5)	19 (5)	10 (6)
Don't remember	7 (2)	5 (1)	11 (3)	6 (2)	2 (1)
Not reported	13 (4)	59 (15)	7 (2)	29 (8)	2 (1)

* More than one drug option could be selected.

Table 25 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Any treatment/therapy for drug use (%)**										
No	195 (55)	228 (92)	125 (31)	182 (54)	157 (44)	397 (87)	170 (50)	356 (84)	98 (55)	154 (73)
Yes	161 (45)	17 (7)	250 (62)	42 (13)	194 (55)	56 (12)	170 (50)	61 (14)	77 (43)	50 (24)
Not reported	1 (<1)	2 (<1)	31 (8)	110 (33)	2 (1)	4 (1)	2 (1)	8 (2)	3 (2)	7 (3)
History of methadone maintenance treatment (%)										
Currently	53 (15)	3 (1)	50 (12)	0 (0)	48 (14)	1 (<1)	30 (9)	0 (0)	9 (5)	0 (0)
Previously	76 (21)	2 (<1)	92 (23)	0 (0)	51 (14)	4 (1)	48 (14)	3 (1)	31 (17)	1 (<1)
Never	226 (63)	240 (97)	225 (55)	0 (0)	250 (71)	449 (98)	262 (77)	416 (98)	138 (78)	206 (98)
Not reported	2 (<1)	2 (<1)	39 (10)	0 (0)	4 (1)	4 (1)	2 (1)	6 (1)	0 (0)	4 (2)
History of other pharmacotherapy treatment (%)										
Currently	19 (5)	3 (1)	28 (7)	0 (0)	32 (9)	4 (1)	6 (2)	2 (<1)	5 (3)	0 (0)
Previously	49 (14)	1 (<1)	95 (23)	0 (0)	44 (12)	4 (1)	49 (14)	1 (<1)	36 (20)	1 (<1)
Never	284 (80)	241 (98)	268 (66)	0 (0)	276 (78)	447 (98)	285 (83)	413 (97)	137 (77)	205 (97)
Not reported	5 (1)	2 (<1)	15 (4)	0 (0)	1 (<1)	3 (1)	2 (1)	9 (2)	0 (0)	5 (2)

**E.g. detox, rehab, counselling, NA

Table 26 Number (%) of respondents reporting body piercing and tattoos by injector status and survey year

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Body or ear piercings (%)										
No	184 (52)	161 (65)	179 (44)	198 (59)	205 (58)	297 (65)	197 (58)	256 (60)	101 (75)	153 (73)
Yes	172 (48)	85 (34)	224 (55)	133 (40)	147 (42)	161 (35)	144 (42)	168 (40)	75 (42)	56 (27)
Not reported	1 (<1)	1 (<1)	3 (1)	3 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	2 (1)	2 (1)
Piercings other than ears (%)										
No	118 (69)	61 (71)	137 (61)	83 (61)	86 (58)	115 (71)	64 (44)	91 (54)	26 (35)	39 (69)
Yes	51 (30)	22 (26)	80 (36)	48 (35)	62 (42)	46 (29)	79 (55)	73 (43)	49 (65)	15 (27)
Not reported	3 (2)	3 (4)	8 (4)	6 (4)	0 (0)	0 (0)	2 (1)	5 (3)	0 (0)	2 (4)
Pierced in past 12 months (%)										
No	121 (70)	49 (58)	170 (76)	95 (72)	103 (69)	108 (66)	115 (80)	136 (81)	48 (64)	33 (59)
Yes	22 (13)	9 (10)	25 (11)	15 (11)	18 (12)	22 (13)	14 (10)	17 (10)	18 (24)	16 (29)
Not reported	29 (17)	27 (32)	29 (13)	23 (17)	28 (19)	33 (20)	15 (10)	15 (9)	9 (12)	7 (13)
Who did piercing (%)*										
Professional	15 (69)	9 (99)	17 (68)	10 (63)	10 (56)	17 (77)	12 (85)	15 (88)	14 (78)	14 (88)
Non-professional^^	2 (9)	0 (0)	3 (12)	1 (6)	4 (23)	2 (9)	2 (14)	1 (6)	1 (6)	1 (6)
Prisoner	1 (5)	0 (0)	1 (6)	1 (4)	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Self	5 (23)	0 (0)	3 (12)	4 (25)	5 (28)	0 (0)	2 (14)	0 (0)	3 (17)	4 (25)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Needle used by other (%)										
No	21 (95)	9 (100)	3 (12)	1 (7)	9 (50)	11 (50)	4 (29)	0 (0)	n/a	n/a
Yes	1 (5)	0 (0)	0 (0)	2 (13)	0 (0)	0 (0)	0 (0)	1 (6)	n/a	n/a
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Not reported	0 (0)	0 (0)	22 (88)	12 (80)	9 (50)	11 (50)	10 (71)	16 (94)	n/a	n/a
Penile implants (%)**										
No	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	146 (98)	187 (98)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3 (2)	1 (<1)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	2 (1)
Penile implant in prison (%)**										
No	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (33)	1 (100)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (67)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Tattoos (%)										
No	96 (27)	137 (55)	111 (27)	170 (51)	72 (20)	238 (52)	55 (16)	177 (42)	28 (16)	105 (50)
Yes	261 (73)	109 (44)	294 (72)	164 (49)	275 (78)	209 (46)	285 (83)	246 (58)	150 (84)	106 (50)
Not reported	0 (0)	1 (<1)	1 (<1)	0 (0)	6 (2)	11 (2)	2 (1)	1 (<1)	0 (0)	0 (0)
Tattoos in past 12 months (%)										
No	205 (79)	91 (83)	220 (75)	100 (61)	197 (72)	132 (63)	199 (70)	161 (65)	81 (54)	53 (50)
Yes	53 (20)	17 (15)	74 (25)	62 (38)	75 (27)	73 (35)	82 (29)	86 (35)	61 (41)	43 (41)
Not reported	3 (1)	1 (2)	1 (<1)	2 (1)	3 (1)	4 (2)	4 (1)	0 (0)	8 (5)	10 (9)
Who did tattooing (%)*										
Professional^	32 (60)	10 (59)	41 (55)	47 (76)	40 (53)	47 (64)	37 (45)	51 (59)	32 (53)	33 (77)
Non-professional^^	12 (23)	3 (18)	21 (28)	11 (18)	31 (41)	21 (29)	30 (35)	34 (42)	23 (38)	6 (14)
Prisoner	11 (21)	2 (12)	16 (22)	2 (3)	7 (9)	2 (3)	8 (10)	1 (1)	9 (15)	3 (7)
Self	7 (13)	2 (12)	4 (5)	4 (7)	4 (5)	4 (5)	18 (22)	4 (5)	8 (13)	8 (19)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	1 (2)	0 (0)

*More than one drug option could be selected.

**Male only, new question in 2016.

^E.g. chemist, hairdresser, beauty salon, tattooist; ^^Non-professional outside prison e.g. friend family.

Table 27 Number (%) of respondents by sexual behaviour in the 3 months prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Sex last month/last 3 months (%)*										
No	93 (26)	75 (30)	107 (26)	84 (25)	41 (12)	80 (17)	38 (11)	70 (16)	30 (17)	42 (20)
Yes	263 (74)	168 (68)	298 (73)	248 (74)	307 (87)	368 (80)	300 (88)	349 (82)	147 (83)	165 (78)
Not reported	1 (<1)	4 (2)	1 (<1)	2 (<1)	5 (1)	10 (2)	4 (1)	6 (2)	1 (1)	4 (2)
Male sex partners in last 3 months*										
Median	n/a	n/a	n/a	n/a	1 (0–300)	1 (0–10)	0 (0–15)	0 (0–10)	0 (0–10)	0 (0–10)
Female sex partners in last 3 months*										
Median	n/a	n/a	n/a	n/a	1 (0–90)	1 (0–26)	1 (0–20)	1 (0–40)	0 (0–20)	1 (0–15)
Condom use at last sex (%)										
No	270 (76)	175 (71)	327 (81)	239 (72)	n/a	n/a	n/a	n/a	n/a	n/a
Yes	87 (24)	69 (28)	75 (18)	94 (28)	n/a	n/a	n/a	n/a	n/a	n/a
Not reported	0 (0)	3 (1)	4 (<1)	1 (<1)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)**										
No	160 (86)	112 (81)	189 (84)	149 (74)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	14 (7)	12 (9)	24 (11)	31 (15)	n/a	n/a	n/a	n/a	n/a	n/a
Always	13 (7)	14 (10)	12 (5)	22 (11)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)**										
No	27 (55)	9 (47)	44 (59)	11 (28)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	8 (16)	3 (16)	14 (19)	15 (38)	n/a	n/a	n/a	n/a	n/a	n/a
Always	14 (29)	7 (37)	16 (22)	14 (35)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)**										
No	41 (49)	18 (47)	66 (69)	19 (35)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	14 (17)	6 (16)	15 (16)	18 (33)	n/a	n/a	n/a	n/a	n/a	n/a
Always	28 (34)	14 (37)	15 (16)	17 (31)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)*										
Never	n/a	n/a	n/a	n/a	30 (79)	18 (64)	6 (14)	9 (35)	19 (86)	12 (75)
Sometimes	n/a	n/a	n/a	n/a	5 (13)	4 (14)	26 (62)	12 (46)	1 (5)	2 (13)
Always	n/a	n/a	n/a	n/a	3 (8)	6 (21)	10 (24)	5 (19)	2 (9)	2 (13)
Condom use last sex - casual male partners - last 3 months (%)*										
Never	n/a	n/a	n/a	n/a	8 (57)	4 (57)	4 (29)	3 (33)	12 (80)	5 (83)
Sometimes	n/a	n/a	n/a	n/a	2 (14)	2 (29)	6 (43)	1 (11)	0 (0)	0 (0)
Always	n/a	n/a	n/a	n/a	4 (29)	1 (14)	4 (29)	5 (56)	3 (20)	1 (17)
Condom use last sex - regular female partners - last 3 months (%)*										
Never	n/a	n/a	n/a	n/a	157 (79)	168 (62)	153 (77)	185 (70)	88 (76)	91 (66)
Sometimes	n/a	n/a	n/a	n/a	26 (13)	47 (17)	33 (17)	49 (18)	19 (16)	26 (19)
Always	n/a	n/a	n/a	n/a	16 (8)	57 (21)	13 (7)	32 (12)	9 (8)	20 (15)
Condom use last sex - casual female partners - last 3 months (%)*										
Never	n/a	n/a	n/a	n/a	55 (53)	41 (37)	64 (58)	47 (42)	40 (56)	39 (57)
Sometimes	n/a	n/a	n/a	n/a	28 (27)	25 (22)	27 (24)	40 (35)	17 (24)	15 (22)
Always	n/a	n/a	n/a	n/a	20 (19)	46 (41)	20 (18)	26 (23)	15 (21)	14 (21)
Sex work last month (%)										
No	349 (98)	240 (97)	392 (97)	323 (97)	340 (96)	442 (97)	322 (94)	413 (97)	170 (96)	205 (97)
Yes	6 (2)	2 (<1)	10 (2)	5 (1)	10 (3)	3 (1)	17 (5)	3 (1)	6 (3)	2 (1)
Not reported	2 (<1)	5 (2)	4 (<1)	6 (2)	3 (1)	13 (3)	3 (1)	9 (2)	2 (1)	4 (2)
Condom used at last sex work last month (%)										
No	3 (43)	1 (50)	4 (40)	1 (20)	2 (20)	1 (33)	4 (24)	1 (33)	4 (67)	0 (0)
Yes	4 (57)	1 (50)	5 (50)	2 (40)	5 (50)	2 (67)	6 (35)	1 (33)	2 (33)	0 (0)
Not reported	0 (0)	0 (0)	1 (10)	2 (40)	3 (30)	0 (0)	7 (41)	1 (33)	0 (0)	2 (100)

*In 2004 and 2007, sexual health questions reflect behaviour in the past month, from 2010, sexual health questions were changed to reflect the past 3 months and to differentiate between male and female partners.

**Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 28 Number (%) of respondents reporting previous testing for HIV, HBV infection, vaccinations for HBV and cervical cancer by injector status and survey year

Testing & treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Previous HIV test (%)										
Last year	168 (47)	46 (19)	182 (45)	80 (24)	160 (45)	125 (27)	149 (44)	120 (28)	87 (49)	82 (39)
>1 year ago	117 (33)	72 (29)	159 (39)	99 (30)	109 (31)	105 (23)	129 (38)	126 (30)	55 (31)	57 (27)
Never tested	71 (20)	126 (51)	61 (15)	155 (46)	82 (23)	225 (49)	60 (18)	172 (40)	35 (20)	66 (31)
Not reported	1 (<1)	3 (1)	4 (1)	0 (0)	2 (1)	3 (1)	4 (1)	7 (2)	1 (1)	6 (3)
Result of last HIV test (self-report) (%)										
No	264 (93)	106 (90)	313 (92)	160 (89)	249 (93)	212 (92)	242 (87)	205 (39)	135 (95)	115 (83)
Yes	0 (0)	1 (1)	5 (2)	3 (2)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Don't know	19 (7)	9 (8)	21 (6)	14 (8)	20 (7)	17 (7)	35 (13)	42 (17)	7 (5)	24 (17)
Not reported	2 (1)	2 (2)	2 (1)	3 (2)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
HBV infection (%)										
No	278 (78)	226 (91)	329 (81)	311 (93)	306 (87)	411 (90)	265 (77)	339 (80)	154 (87)	160 (76)
Yes	51 (14)	5 (2)	47 (12)	6 (2)	25 (7)	8 (2)	43 (13)	8 (2)	5 (3)	14 (7)
Don't know	28 (8)	16 (6)	29 (7)	12 (4)	21 (6)	36 (8)	26 (8)	73 (17)	17 (10)	28 (13)
Not reported	0 (0)	0 (0)	1 (<1)	5 (1)	1 (<1)	3 (1)	8 (2)	5 (1)	2 (1)	9 (4)
HBV vaccination (%)*										
No	82 (27)	116 (48)	125 (31)	162 (49)	96 (27)	186 (41)	59 (17)	112 (26)	38 (21)	33 (16)
Yes	188 (61)	78 (32)	239 (59)	124 (37)	203 (58)	164 (36)	203 (59)	141 (33)	100 (56)	82 (39)
Don't know	36 (12)	44 (18)	35 (9)	45 (13)	53 (15)	103 (22)	65 (19)	161 (38)	40 (22)	85 (40)
Not reported	0 (0)	4 (2)	7 (2)	3 (1)	1 (<1)	5 (1)	15 (4)	11 (3)	0 (0)	11 (5)
N^o of HBV vaccinations (%)										
One	29 (15)	8 (10)	24 (10)	16 (13)	15 (7)	24 (15)	12 (6)	4 (3)	3 (3)	2 (2)
Two	28 (14)	18 (23)	41 (17)	12 (10)	33 (16)	31 (19)	21 (10)	19 (13)	21 (21)	13 (16)
Three or more	138 (71)	51 (66)	165 (69)	90 (73)	151 (74)	98 (60)	138 (63)	93 (66)	50 (50)	46 (56)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	48 (22)	25 (18)	24 (24)	21 (26)
Not reported	0 (0)	0 (0)	9 (4)	6 (7)	4 (2)	11 (7)	0 (0)	0 (0)	2 (2)	0 (0)
Ever had cervical cancer vaccine (women only) (%)**										
No	n/a	n/a	n/a	n/a	11 (65)	7 (58)	15 (54)	11 (41)	11 (69)	5 (38)
Yes	n/a	n/a	n/a	n/a	6 (35)	4 (33)	9 (32)	10 (37)	3 (19)	3 (23)
Unsure	n/a	n/a	n/a	n/a	0 (0)	1 (8)	4 (14)	6 (22)	2 (13)	5 (38)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

*Number (%) among participants with no history of HBV infection.

**Proportion of women eligible for the National HPV Vaccination Program, i.e. those who were under 27 years of age in 2007 (or 35 years or under in 2016).

Table 29 Number (%) of respondents reporting previous testing for HCV infection and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425	N = 178	N = 211
Previous HCV test (%)										
Last year	155 (43)	42 (17)	178 (44)	75 (22)	164 (46)	111 (24)	160 (47)	120 (28)	89 (50)	83 (39)
>1 year ago	138 (39)	48 (20)	180 (44)	83 (25)	123 (35)	104 (23)	132 (39)	115 (27)	60 (34)	53 (25)
Never tested	61 (17)	154 (63)	48 (12)	174 (52)	61 (17)	241 (53)	47 (14)	186 (44)	27 (15)	69 (33)
Unsure	2 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (<1)	2 (<1)	0 (0)	1 (<1)	4 (1)	2 (<1)	2 (1)	4 (1)	2 (1)	6 (3)
Result of last HCV test (self-report) (%)										
Hepatitis C antibody positive	156 (53)	2 (2)	191 (53)	5 (3)	123 (43)	4 (2)	113 (48)	4 (1)	n/a	n/a
Never had hep C	114 (39)	81 (90)	142 (40)	141 (89)	137 (48)	194 (90)	133 (56)	188 (64)	75 (50)	114 (80)
Cleared hep C naturally	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	7 (5)	0 (0)
Cleared hep C with treatment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3 (2)	0 (0)
Chronic hep C	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	48 (32)	1 (1)
Don't know	22 (8)	7 (8)	22 (6)	10 (6)	26 (9)	14 (7)	45 (19)	44 (39)	13 (9)	18 (13)
Not reported	0 (0)	0 (0)	3 (1)	2 (1)	1 (<1)	3 (1)	1 (<1)	1 (<1)	5 (3)	9 (6)
Age 1st diagnosed with hep C										
Median age	27	24	25	34	24	30	25	27	25	49
Range	11 – 47	10 – 38	9 – 53	23 – 54	15 – 50	30 – 40	5 – 48	24 – 38	10 – 53	--
Ever had HCV treatment (%)*										
	N = 149	N = 7	N = 197	N = 11	N=137	N = 4	N=113	N = 4	N = 71	N = 1
No treatment	148 (99)	6 (86)	195 (99)	11 (100)	130 (99)	4 (100)	111 (90)	4 (100)	61 (86)	1 (100)
Interferon-based medication	1 (<1)	1 (14)	2 (1)	0 (0)	7 (5)	0 (0)	9 (8)	0 (0)	8 (11)	0 (0)
Direct-acting antiviral (DAA)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (1)	0 (0)
Interferon-based & DAA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (1)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Ever had PCR/RNA test to test for reinfections (%)										
<1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	6 (60)	--
>1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not tested	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4 (40)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Result of PCR/RNA test (%)										
Still cured of hep C	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (17)	--
Reinfected	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4 (67)	--
Don't know	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (17)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--

*Number (%) of those reporting positive HCV test results or specifying an age of hep C diagnosis.

Table 30 Number (%) of respondents reporting interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Ever sought out HCV treatment? (%)*										
No	n/a	n/a	n/a	n/a	n/a	n/a	50 (45)	1 (25)	37(61)	1 (100)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	31 (28)	1 (25)	24 (39)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	30 (27)	2 (50)	0 (0)	0 (0)
Willingness to receive treatment for HCV (%)										
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	14 (13)	0 (0)	0 (0)	0 (0)
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	5 (5)	0 (0)	5 (7)	1 (100)
Willing	n/a	n/a	n/a	n/a	n/a	n/a	41 (37)	2 (50)	62 (89)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	51 (46)	2 (50)	3 (4)	0 (0)
Treatment location preference (%)										
Prison	n/a	n/a	n/a	n/a	n/a	n/a	28 (25)	0 (0)	8 (11)	0 (0)
Community	n/a	n/a	n/a	n/a	n/a	n/a	25 (23)	1 (25)	18 (26)	1 (100)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	23 (21)	0 (0)	42 (60)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	35 (32)	3 (75)	2 (3)	0 (0)
Knowledge & awareness of DAA treatments for hepatitis C[^]									N = 178	N = 211
<i>New treatments for hep C are available (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	102 (57)	45 (21)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	7 (4)	8 (4)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	56 (32)	143 (68)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	13 (7)	15 (7)
<i>The new hep C treatments require injections (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	20 (11)	9 (4)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	45 (25)	14 (7)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	101 (57)	170 (81)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	12 (7)	18 (9)
<i>The new hep C treatments have few side-effects (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	55 (31)	9 (4)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	9 (5)	5 (2)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	102 (57)	179 (85)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	12 (7)	18 (9)
<i>The new hep C treatments take up to one year (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	24 (14)	7 (3)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	34 (19)	11 (5)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	108 (61)	175 (83)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	12 (7)	18 (9)

*Of those who have not had treatment

[^]Correct response is shaded

HIV antibody prevalence

Table 31 HIV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	240	2 (<1)	23	0 (0)	263	2 (<1)
Non-IDU	172	1 (<1)	12	0 (0)	184	1 (<1)
p value		0.8		--		0.8
2007						
IDU	287	2 (<1)	37	1 (3)	324	3 (<1)
Non-IDU	246	1 (<1)	16	0 (0)	262	1 (<1)
p value		0.7		0.5		0.4
2010						
IDU	246	0 (0)	28	0 (0)	274	0 (0)
Non-IDU	358	0 (0)	29	0 (0)	387	0 (0)
p value		--		--		--
2013						
IDU	173	0 (0)	40	0 (0)	213	0 (0)
Non-IDU	233	0 (0)	32	0 (0)	265	0 (0)
p value		--		--		--
2016						
IDU	94	0 (0)	21	0 (0)	115	0 (0)
Non-IDU	122	0 (0)	13	0 (0)	135	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 32 HIV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	407	1 (<1)	30	0 (0)	437	1 (<1)
Bisexual	2	1 (50)	5	0 (0)	7	1 (14)
Homosexual	3	1 (33)	0	0 (0)	3	1 (33)
Unsure	0	0 (0)	0	0 (0)	0	--
p value		<0.001		--		<0.001
2007						
Heterosexual	522	2 (<1)	44	1 (2)	566	3 (<1)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
Unsure	1	0 (0)	1	0 (0)	2	0 (0)
p value		<0.001		1.0		<0.001
2010						
Heterosexual	588	0 (0)	45	0 (0)	633	0 (0)
Bisexual	4	0 (0)	9	0 (0)	13	0 (0)
Homosexual	4	0 (0)	3	0 (0)	7	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
Heterosexual	398	0 (0)	57	0 (0)	455	0 (0)
Bisexual	2	0 (0)	10	0 (0)	12	0 (0)
Gay/lesbian	1	0 (0)	3	0 (0)	4	0 (0)
Unsure	1	0 (0)	3	0 (0)	4	0 (0)
p value		--		--		--
2016						
Heterosexual	208	0 (0)	26	0 (0)	234	0 (0)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Gay/lesbian	2	0 (0)	2	0 (0)	4	0 (0)
Unsure	3	0 (0)	2	0 (0)	5	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 33 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Non-Indigenous	340	1 (<1)	25	0 (0)	365	1 (<1)
Indigenous	68	2 (3)	10	0 (0)	78	2 (3)
p value		0.06		--		0.08
2007						
Non-Indigenous	433	3 (<1)	35	1 (3)	468	4 (<1)
Indigenous	93	0 (0)	17	0 (0)	110	0 (0)
p value		0.4		0.5		0.3
2010						
Non-Indigenous	398	0 (0)	39	0 (0)	437	0 (0)
Indigenous	206	0 (0)	18	0 (0)	224	0 (0)
p value		--		--		--
2013						
Non-Indigenous	286	0 (0)	55	0 (0)	341	0 (0)
Indigenous	132	0 (0)	22	0 (0)	154	0 (0)
p value		--		--		--
2016						
Non-Indigenous	162	0 (0)	21	0 (0)	183	0 (0)
Indigenous	85	0 (0)	17	0 (0)	102	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 34 HIV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Highly accessible/accessible	372	3 (1)	30	0 (0)	402	3 (1)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	18	0 (0)	2	0 (0)	20	0 (0)
p value		0.9		--		0.9
2007						
Highly accessible/accessible	470	3 (1)	45	1 (2)	515	4 (1)
Moderately accessible	16	0 (0)	1	0 (0)	17	0 (0)
Remote/very remote	20	0 (0)	1	0 (0)	21	0 (0)
p value		0.9		1.0		0.9
2010						
Highly accessible/accessible	471	0 (0)	46	0 (0)	517	0 (0)
Moderately accessible	27	0 (0)	4	0 (0)	31	0 (0)
Remote/very remote	80	0 (0)	5	0 (0)	85	0 (0)
p value		--		--		--
2013						
Highly accessible/accessible	322	0 (0)	62	0 (0)	384	0 (0)
Moderately accessible	40	0 (0)	4	0 (0)	44	0 (0)
Remote/very remote	30	0 (0)	1	0 (0)	31	0 (0)
p value	392	--	67	--	459	--
2016						
Highly accessible/accessible	149	0 (0)	28	0 (0)	177	0 (0)
Moderately accessible	23	0 (0)	5	0 (0)	28	0 (0)
Remote/very remote	40	0 (0)	1	0 (0)	41	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 35 Self-reported HIV status versus HIV serology by gender†

Self-report HIV	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Positive	1	1 (100)	0	0 (0)	1	1 (100)
Negative	240	2 (<1)	23	0 (0)	263	2 (<1)
Not sure	19	0 (0)	4	0 (0)	23	0 (0)
p value		<0.001		--		<0.001
2007						
Positive	6	0 (0)	0	0 (0)	6	0 (0)
Negative	334	2 (<1)	36	1 (3)	370	3 (<1)
Not sure	25	0 (0)	5	0 (0)	30	0 (0)
p value		0.9		0.7		0.9
2010						
Positive	0	0 (0)	0	0 (0)	0	0 (0)
Negative	324	0 (0)	36	0 (0)	360	0 (0)
Not sure	30	0 (0)	2	0 (0)	32	0 (0)
p value		--		--		--
2013						
Positive	0	0 (0)	0	0 (0)	0	0 (0)
Negative	235	0 (0)	45	0 (0)	280	0 (0)
Not sure	26	0 (0)	5	0 (0)	31	0 (0)
p value		--		--		--
2016						
Positive	0	0 (0)	0	0 (0)	0	0 (0)
Negative	142	0 (0)	22	0 (0)	164	0 (0)
Not sure	17	0 (0)	1	0 (0)	18	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 36 HCV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	242	130 (54)	23	19 (83)	265	149 (56)
Non-IDU	174	7 (4)	12	0 (0)	186	7 (4)
p value		<0.001		<0.001		<0.001
2007						
IDU	287	166 (58)	40	31 (78)	327	197 (60)
Non-IDU	247	9 (4)	15	2 (13)	262	11 (4)
p value		<0.001		<0.001		<0.001
2010						
IDU	239	118 (49)	28	19 (68)	267	137 (51)
Non-IDU	356	4 (1)	28	0 (0)	384	4 (1)
p value		<0.001		<0.001		<0.001
2013						
IDU	215	121 (56)	48	32 (67)	263	153 (58)
Non-IDU	239	10 (4)	34	2 (6)	273	12 (4)
p value		<0.001		<0.001		<0.001
2016						
IDU	97	50 (52)	20	9 (45)	117	59 (50)
Non-IDU	121	1 (1)	12	0 (0)	133	1 (1)
p value		<0.001		0.006		<0.001

† Excludes equivocal test results and missing values.

Table 37 HCV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	411	136 (33)	31	16 (52)	442	152 (34)
Bisexual	2	0 (0)	4	3 (75)	6	3 (50)
Homosexual	3	1 (33)	0	0 (0)	3	1 (33)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.6		0.4		0.7
2007						
Heterosexual	523	172 (33)	45	24 (53)	568	196 (35)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	6	2 (33)	2	2 (100)	8	4 (50)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.8		0.4		0.3
2010						
Heterosexual	579	120 (21)	44	12 (27)	623	132 (21)
Bisexual	4	0 (0)	9	5 (56)	13	5 (38)
Homosexual	4	2 (50)	3	2 (67)	7	4 (57)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.2		0.1		0.03
2013						
Heterosexual	446	130 (29)	68	22 (32)	514	152 (30)
Bisexual	2	0 (0)	9	7 (78)	11	7 (64)
Gay/lesbian	1	0 (0)	2	0 (0)	3	0 (0)
Unsure	1	0 (0)	4	4 (100)	5	4 (80)
p value		0.8		0.006		0.03
2016						
Heterosexual	210	48 (23)	24	4 (17)	234	52 (22)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Gay/lesbian	2	1 (50)	2	1 (50)	4	2 (50)
Unsure	3	0 (0)	2	1 (50)	5	1 (20)
p value		0.6		0.08		0.06

† Excludes equivocal test results and missing values.

Table 38 HCV antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	36	1 (3)	1	0 (0)	37	1 (3)
20 – 24	91	25 (27)	4	2 (50)	95	27 (28)
25 – 29	89	28 (31)	9	6 (67)	98	34 (35)
30 + years	205	84 (41)	20	9 (45)	225	93 (41)
p value		<0.001		0.5		<0.001
2007						
< 20 years	35	2 (6)	1	0 (0)	36	2 (6)
20 – 24	117	22 (19)	6	4 (67)	123	26 (21)
25 – 29	114	44 (39)	16	11 (69)	130	55 (42)
30 + years	267	107 (40)	32	18 (56)	299	125 (42)
p value		<0.001		0.5		<0.001
2010						
< 20 years	65	1 (2)	4	1 (25)	69	2 (3)
20 – 24	127	19 (15)	7	1 (14)	134	20 (15)
25 – 29	126	24 (19)	11	5 (45)	137	29 (21)
30 + years	277	78 (28)	34	12 (35)	311	90 (29)
p value		<0.001		0.6		<0.001
2013						
< 20 years	33	6 (18)	7	3 (43)	40	9 (23)
20 – 24	82	11 (13)	13	0 (0)	95	11 (12)
25 – 29	93	22 (24)	19	9 (47)	112	31 (28)
30 + years	264	94 (36)	49	23 (47)	313	117 (37)
p value		<0.001		0.02		<0.001
2016						
< 20 years	7	0 (0)	2	0 (0)	9	0 (0)
20 – 24	40	5 (13)	10	1 (10)	50	6 (12)
25 – 29	54	11 (20)	4	1 (25)	58	12 (21)
30 + years	147	37 (25)	20	8 (40)	167	45 (27)
p value		0.2		0.3		0.05

† Excludes equivocal test results and missing values.

Table 39 HCV antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	28	1 (4)	1	0 (0)	29	1 (3)
3 to 5 years	25	11 (44)	2	1 (50)	27	12 (44)
6 to 10 years	75	34 (45)	7	6 (86)	82	40 (49)
10 + years	111	84 (76)	12	11 (92)	123	95 (77)
p value		<0.001		0.1		<0.001
2007						
<3 years	19	4 (21)	1	1 (100)	20	5 (25)
3 to 5 years	29	12 (41)	3	2 (67)	32	14 (44)
6 to 10 years	69	28 (41)	17	12 (71)	86	40 (47)
10 + years	161	116 (72)	19	16 (84)	180	132 (73)
p value		<0.001		0.7		<0.001
2010						
<3 years	28	3 (11)	2	0 (0)	30	3 (10)
3 to 5 years	22	6 (27)	4	1 (25)	26	7 (27)
6 to 10 years	47	24 (51)	7	4 (57)	54	28 (52)
10 + years	133	81 (61)	14	13 (93)	147	94 (64)
p value		<0.001		<0.01		<0.001
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	20	4 (20)	4	3 (75)	24	7 (29)
6 to 10 years	34	14 (41)	9	5 (56)	43	19 (44)
10 + years	130	91 (70)	27	20 (74)	157	111 (71)
p value		<0.001		0.6		<0.001
2016						
<3 years	12	1 (8)	6	1 (17)	18	2 (11)
3 to 5 years	13	5 (38)	1	0 (0)	14	5 (36)
6 to 10 years	17	7 (41)	2	2 (100)	19	9 (47)
10 + years	51	33 (65)	11	6 (55)	62	39 (63)
p value		0.003		0.1		0.001

† Excludes equivocal test results and missing values.

Table 40 HCV antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Methamphetamine (Speed, Ice)	22	1 (5)	129	65 (50)	151	66 (44)
Heroin	1	0 (0)	75	63 (84)	76	63 (83)
More than one drug	5	0 (0)	23	15 (65)	28	15 (54)
Other/not reported	1	0 (0)	5	5(100)	6	5 (83)
p value		1.0		<0.001		<0.001
2007						
Methamphetamine (Speed, Ice)	17	3 (18)	178	83 (47)	195	86 (44)
Heroin	3	2 (67)	90	76 (84)	93	78 (84)
More than one drug	0	0 (0)	11	10 (91)	11	10 (91)
Other/not reported	0	0 (0)	19	17 (89)	19	17 (89)
p value		0.07		<0.001		<0.001
2010						
Methamphetamine (Speed, Ice)	19	1 (5)	136	67 (49)	155	68 (44)
Heroin	5	1 (20)	52	39 (75)	57	40 (70)
More than one drug	0	0 (0)	8	1 (13)	8	1 (13)
Other/not reported	6	1 (17)	31	22 (71)	37	23 (62)
p value		0.5		<0.001		<0.001
2013						
Methamphetamine (Speed, Ice)	25	7 (28)	150	82 (55)	175	89 (51)
Heroin	4	3 (75)	53	43 (81)	57	46 (81)
More than one drug	0	0 (0)	1	1 (100)	1	1 (100)
Other/not reported	2	0 (0)	24	15 (63)	26	26 (100)
p value		0.1		0.007		0.001
2016						
Methamphetamine (Speed, Ice)	15	2 (13)	64	29 (45)	79	31 (39)
Heroin	0	0 (0)	17	14 (82)	17	14 (82)
More than one drug	0	0 (0)	8	6 (75)	8	6 (75)
Other/not reported	3	0 (0)	5	4 (80)	8	4 (50)
p value		0.5		0.02		0.008

† Excludes equivocal test results and missing values.

Table 41 HCV antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	11	0 (0)	40	30 (75)	51	30 (59)
Daily or more	9	1 (11)	101	70 (69)	110	71 (65)
p value		0.3		0.2		0.1
2007						
Less than daily	3	1 (33)	77	45 (58)	80	46 (58)
Daily or more	5	2 (40)	110	86 (78)	115	88 (77)
p value		0.9		<0.01		<0.001
2010						
Less than daily	12	1 (8)	56	34 (61)	68	35 (51)
Daily or more	9	2 (22)	68	46 (68)	77	48 (62)
p value		0.4		0.4		0.2
2013						
Less than daily	10	2 (20)	59	33 (56)	69	35 (51)
Daily or more	13	5 (38)	96	72 (75)	109	77 (71)
p value		0.3		0.02		0.007
2016						
Less than daily	9	1 (11)	25	16 (64)	34	17 (50)
Daily or more	2	1 (50)	36	24 (67)	38	25 (66)
p value		0.2		0.8		0.2

† Excludes equivocal test results and missing values.

Table 42 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	19	1 (5)	103	76 (74)	122	77 (63)
Yes	2	0 (0)	38	25 (66)	40	25 (63)
p value		0.1		0.7		0.8
2007						
No	8	3 (38)	143	97 (68)	151	100 (66)
Yes	0	0 (0)	36	28 (78)	36	28 (78)
p value		--		0.3		0.2
2010						
No	16	1 (6)	95	59 (62)	111	60 (54)
Yes	4	2 (50)	18	12 (67)	22	14 (64)
p value		0.03		0.7		0.4
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	5	3 (60)	29	24 (83)	34	27 (79)
p value		--		--		--
2016						
No	11	2 (18)	48	32 (67)	59	34 (58)
Yes	0	0 (0)	13	8 (62)	13	8 (62)
p value		--		0.7		0.8

† Excludes equivocal test results and missing values.

Table 43 HCV antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	12	0 (0)	80	51 (64)	92	51 (55)
Yes	17	1 (6)	148	94 (64)	165	95 (58)
p value		0.4		1.0		0.7
2007						
No	5	1 (20)	86	53 (62)	91	54 (59)
Yes	6	3 (50)	156	114 (73)	162	117 (72)
p value		0.3		0.07		0.04
2010						
No	16	1 (6)	96	49 (51)	112	50 (45)
Yes	13	2 (15)	123	75 (61)	136	77 (57)
p value		0.4		0.1		0.06
2013						
No	6	1 (17)	65	39 (50)	71	40 (56)
Yes	12	5 (42)	118	82 (69)	130	87 (67)
p value		0.3		0.2		0.1
2016						
No	1	1 (100)	25	14 (56)	26	15 (58)
Yes	10	0 (0)	51	32 (63)	61	32 (52)
p value		0.001		0.6		0.07

† Excludes equivocal test results and missing values.

Table 44 HCV antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	104	14 (13)	11	1 (9)	115	15 (13)
2 to 4	211	68 (32)	17	11 (65)	228	79 (35)
5 to 9	68	38 (56)	4	4 (100)	72	42 (58)
10 +	23	16 (70)	3	3 (100)	26	19 (73)
p value		<0.001		0.001		<0.001
2007						
1	170	9 (5)	21	9 (43)	191	18 (9)
2 to 4	210	66 (31)	20	13 (65)	230	79 (34)
5 to 9	82	54 (66)	8	7 (88)	90	61 (68)
10 +	52	39 (75)	4	3 (75)	56	42 (75)
p value		<0.001		0.1		<0.001
2010						
1	301	26 (9)	33	8 (24)	334	34 (10)
2 to 4	169	41 (24)	14	8 (57)	183	49 (27)
5 to 9	78	31 (40)	6	1 (17)	84	32 (38)
10 +	42	23 (55)	3	2 (67)	45	25 (56)
p value		<0.001		0.07		<0.001
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	28	4 (14)	5	0 (0)	33	4 (12)
2 to 4	58	14 (24)	10	3 (30)	68	17 (25)
5 to 9	33	16 (48)	3	3 (100)	36	19 (53)
10 +	21	10 (48)	1	1 (100)	22	11 (50)
p value		0.007		0.02		<0.001

† Excludes equivocal test results and missing values.

Table 45 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	345	112 (32)	24	13 (54)	369	125 (34)
Indigenous	68	24 (35)	10	5 (50)	78	29 (37)
p value		0.7		0.8		0.5
2007						
Non-Indigenous	435	136 (31)	36	19 (53)	471	155 (33)
Indigenous	92	34 (37)	18	13 (72)	110	47 (43)
p value		0.3		0.2		0.05
2010						
Non-Indigenous	392	88 (22)	39	13 (33)	431	101 (23)
Indigenous	203	34 (17)	17	6 (35)	220	40 (18)
p value		0.1		0.9		0.1
2013						
Non-Indigenous	322	90 (28)	63	25 (40)	385	115 (30)
Indigenous	145	42 (29)	25	10 (40)	170	52 (31)
p value		0.8		1.0		0.9
2016						
Non-Indigenous	166	38 (23)	20	5 (25)	186	43 (23)
Indigenous	83	16 (19)	16	5 (31)	99	21 (21)
p value		0.5		0.7		0.7

† Excludes equivocal test results and missing values.

Table 46 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	156	5 (3)	210	119 (57)	366	124 (34)
Indigenous	28	1 (4)	49	28 (57)	77	29 (38)
p value		0.9		0.9		0.6
2007						
Non-Indigenous	221	9 (4)	250	146 (58)	471	155 (33)
Indigenous	40	2 (5)	70	45 (64)	110	47 (43)
p value		0.8		0.4		0.05
2010						
Non-Indigenous	237	2 (1)	194	99 (51)	431	101 (23)
Indigenous	147	2 (1)	73	38 (52)	220	40 (18)
p value		0.6		0.9		0.1
2013						
Non-Indigenous	203	9 (4)	174	105 (60)	377	114 (30)
Indigenous	70	3 (4)	89	48 (54)	159	51 (32)
p value		1.0		0.3		0.9
2016						
Non-Indigenous	78	0 (0)	88	40 (45)	166	40 (24)
Indigenous	55	1 (2)	29	19 (66)	84	20 (24)
p value		0.2		0.061		0.8

† Excludes equivocal test results and missing values.

Table 47 HCV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	375	128 (34)	31	18 (58)	406	146 (36)
Moderately accessible	10	2 (20)	1	0 (0)	11	2 (18)
Remote/very remote	18	2 (11)	2	0 (0)	20	2 (10)
p value		0.09		0.2		0.03
2007						
Highly accessible/accessible	471	161 (34)	47	28 (60)	518	189 (36)
Moderately accessible	16	2 (13)	1	0 (0)	17	2 (12)
Remote/very remote	20	3 (15)	1	0 (0)	21	3 (14)
p value		0.04		0.2		0.01
2010						
Highly accessible/accessible	466	107 (23)	46	18 (39)	512	125 (24)
Moderately accessible	25	6 (24)	4	1 (25)	29	7 (24)
Remote/very remote	78	5 (6)	4	0 (0)	82	5 (6)
p value		0.04		0.3		0.01
2013						
Highly accessible/accessible	366	113 (31)	74	32 (43)	440	145 (33)
Moderately accessible	41	10 (24)	4	0 (0)	45	10 (22)
Remote/very remote	33	5 (15)	1	0 (0)	34	5 (15)
p value		0.1		0.2		0.04
2016						
Highly accessible/accessible	155	41 (26)	26	9 (35)	181	50 (28)
Moderately accessible	22	8 (36)	5	0 (0)	27	8 (30)
Remote/very remote	37	0 (0)	1	0 (0)	38	0 (0)
p value		0.001		0.2		0.001

† Excludes equivocal test results and missing values.

Table 48 HCV antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	338	118 (35)	33	19 (58)	371	137 (37)
Other Oceania	23	2 (9)	0	0 (0)	23	2 (9)
Asia	18	10 (56)	2	0 (0)	20	10 (50)
UK & Ireland	9	2 (22)	0	0 (0)	9	2 (22)
Other	27	5 (19)	0	0 (0)	27	5 (19)
p value		<0.01		0.1		<0.01
2007						
Australia	450	149 (33)	47	28 (60)	497	177 (36)
Other Oceania	17	3 (18)	2	1 (50)	19	4 (21)
Asia	29	14 (48)	3	1 (33)	32	15 (47)
UK & Ireland	9	3 (33)	1	1 (100)	10	4 (40)
Other	27	5 (19)	2	2 (100)	29	7 (24)
p value		0.2		0.6		0.3
2010						
Australia	512	109 (21)	46	17 (37)	558	126 (23)
Other Oceania	33	8 (24)	2	0 (0)	35	8 (23)
Asia	20	2 (10)	4	0 (0)	24	2 (8)
UK & Ireland	6	0 (0)	1	1 (100)	7	1 (14)
Other	24	3 (13)	3	1 (33)	27	4 (15)
p value		0.4		0.3		0.4
2013						
Australia	383	121 (32)	68	31 (46)	451	152 (34)
Other Oceania	22	3 (14)	5	2 (40)	27	5 (19)
Asia	20	3 (15)	5	0 (0)	25	3 (12)
UK & Ireland	7	2 (29)	2	0 (0)	9	2 (22)
Other	23	2 (9)	5	1 (20)	28	3 (11)
p value		0.04		0.2		0.01
2016						
Australia	194	47 (24)	30	8 (27)	224	55 (25)
Other Oceania	11	2 (18)	1	1 (100)	12	3 (25)
Asia	6	1 (17)	1	0 (0)	7	1 (14)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.2		0.6		0.5

† Excludes equivocal test results and missing values.

Table 49 Self-reported HCV status versus HCV serology by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	88	87 (99)	16	16 (100)	104	103 (99)
Negative	138	25 (18)	7	1 (14)	145	26 (18)
Not sure	22	13 (59)	2	1 (50)	24	14 (58)
p value		<0.001		<0.001		<0.001
2007						
Positive	125	120 (96)	29	28 (97)	154	148 (96)
Negative	211	33 (16)	13	2 (15)	224	35 (16)
Not sure	25	10 (40)	4	2 (50)	29	12 (41)
p value		<0.001		<0.001		<0.001
2010						
Positive	79	78 (99)	19	19 (100)	98	97 (99)
Negative	231	17 (7)	21	0 (0)	252	17 (7)
Not sure	35	11 (31)	1	0 (0)	36	11 (31)
p value		<0.001		<0.001		<0.001
2013						
Positive	93	93 (100)	18	18 (100)	111	111 (100)
Negative	182	12 (7)	27	4 (15)	209	16 (8)
Not sure	31	18 (58)	15	11 (73)	46	29 (63)
p value		<0.001		<0.001		<0.001
2016						
Cleared hep C naturally	5	5 (100)	2	2 (100)	7	7 (100)
Cleared hep C with treatment	1	1 (100)	0	0 (0)	1	1 (100)
Chronic hep C	22	22 (100)	4	4 (100)	26	26 (100)
Negative	114	7 (6)	15	2 (13)	129	9 (7)
Not sure	18	9 (50)	1	1 (100)	19	10 (53)
p value		<0.001		0.002		0.001

† Excludes equivocal test results and missing values.

Table 50 Self-reported HCV status versus HCV serology (PCR/RNA) by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	Detected (%)	N° tested	Detected (%)	N° tested	Detected (%)
2016						
Cleared hep C naturally	2	0 (0)	2	0 (0)	4	0 (0)
Cleared hep C with treatment	1	0 (0)	0	0 (0)	1	0 (0)
Chronic hep C	6	6 (100)	4	4 (100)	10	10 (100)
Negative	39	3 (8)	6	2 (33)	45	5 (11)
Not sure	7	3 (43)	1	0 (0)	8	3 (38)
p value		<0.001		0.05		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 51 HBV surface-antigen prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	244	12 (5)	24	1 (4)	268	13 (5)
Non-IDU	172	0 (0)	12	0 (0)	184	0 (0)
p value		<0.01		0.5		<0.01
2007						
IDU	288	9 (3)	38	2 (5)	326	11 (3)
Non-IDU	247	3 (1)	14	0 (0)	261	3 (1)
p value		0.1		0.4		0.08
2010						
IDU	232	3 (1)	25	0 (0)	257	3 (1)
Non-IDU	324	8 (2)	28	2 (7)	352	10 (3)
p value		0.3		0.2		0.2
2013						
IDU	139	5 (4)	19	0 (0)	158	7 (3)
Non-IDU	203	7 (3)	18	0 (0)	221	5 (3)
p value		0.9		--		1.0
2016						
IDU	87	2 (2)	20	0 (0)	107	2 (2)
Non-IDU	106	4 (4)	12	0 (0)	118	4 (3)
p value		0.6		--		0.5

† Excludes equivocal test results and missing values.

Table 52 HBV core-antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	239	64 (27)	23	7 (30)	264	71 (27)
Non-IDU	172	14 (8)	10	3 (30)	182	17 (9)
p value		<0.001		1.0		<0.001
2007						
IDU	272	83 (31)	39	13 (33)	311	96 (31)
Non-IDU	239	22 (9)	16	2 (13)	255	24 (9)
p value		<0.001		0.1		<0.001
2010						
IDU	214	40 (19)	9	1 (11)	223	41 (18)
Non-IDU	291	57 (20)	13	3 (23)	304	60 (20)
p value		0.8		0.5		0.7
2013						
IDU	166	33 (20)	23	3 (13)	189	36 (19)
Non-IDU	224	39 (17)	19	2 (11)	243	41 (17)
p value		0.5		0.8		0.6
2016						
IDU	90	10 (11)	20	1 (5)	110	11 (10)
Non-IDU	115	25 (22)	12	0 (0)	127	25 (20)
p value		0.05		0.4		0.04

† Excludes equivocal test results and missing values.

Table 53 HBV core-antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	406	78 (19)	29	9 (31)	435	87 (20)
Bisexual	2	0 (0)	4	1 (25)	6	1 (17)
Homosexual	3	0 (0)	0	0 (0)	3	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.6		0.8		0.7
2007						
Heterosexual	501	104 (21)	45	12 (27)	546	116 (21)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	5	1 (20)	2	1 (50)	7	2 (29)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.2		0.5
2010						
Heterosexual	494	93 (19)	16	4 (25)	510	97 (19)
Bisexual	4	1 (25)	4	0 (0)	8	1 (13)
Homosexual	2	1 (50)	2	0 (0)	4	1 (25)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.5		0.4		0.9
2013						
Heterosexual	384	72 (19)	35	3 (9)	419	75 (18)
Bisexual	1	0 (0)	5	0 (0)	6	0 (0)
Gay/lesbian	1	0 (0)	1	0 (0)	2	0 (0)
Unsure	0	0 (0)	2	2 (100)	2	2 (100)
p value		0.7		0.002		0.01
2016						
Heterosexual	199	33 (17)	24	0 (0)	223	33 (15)
Bisexual	0	0 (0)	4	0 (0)	4	0 (0)
Gay/lesbian	2	0 (0)	2	1 (50)	4	1 (25)
Unsure	3	2 (67)	2	0 (0)	5	2 (40)
p value		0.06		0.001		0.3

† Excludes equivocal test results and missing values.

Table 54 HBV core-antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	37	1 (3)	1	0 (0)	38	1 (3)
20 – 24	89	11 (12)	5	2 (40)	94	13 (14)
25 – 29	89	17 (19)	8	2 (25)	97	19 (20)
30 + years	201	49 (24)	19	6 (32)	220	55 (25)
p value		<0.01		0.9		<0.01
2007						
< 20 years	32	2 (6)	1	0 (0)	33	2 (6)
20 – 24	115	11 (10)	6	0 (0)	121	11 (9)
25 – 29	110	24 (22)	15	2 (13)	125	26 (21)
30 + years	253	68 (27)	33	13 (39)	286	81 (28)
p value		<0.001		0.09		<0.001
2010						
< 20 years	54	3 (6)	1	0 (0)	55	3 (6)
20 – 24	107	6 (6)	4	0 (0)	111	6 (5)
25 – 29	106	19 (18)	3	1 (33)	109	20 (18)
30 + years	238	69 (29)	14	3 (21)	252	72 (29)
p value		<0.001		0.6		<0.001
2013						
< 20 years	30	1 (3)	5	0 (0)	35	1 (3)
20 – 24	71	4 (6)	10	0 (0)	81	4 (5)
25 – 29	79	14 (18)	9	2 (22)	88	16 (18)
30 + years	227	56 (25)	24	5 (21)	251	61 (24)
p value		<0.001		0.3		<0.001
2016						
< 20 years	6	0 (0)	2	0 (0)	8	0 (0)
20 – 24	38	3 (8)	10	0 (0)	48	3 (6)
25 – 29	48	5 (10)	4	0 (0)	52	5 (10)
30 + years	141	33 (23)	20	3 (15)	161	36 (22)
p value		0.03		0.5		0.011

† Excludes equivocal test results and missing values.

Table 55 HBV core-antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	29	2 (7)	1	0 (0)	30	2 (7)
3 to 5 years	23	2 (9)	3	1 (33)	26	3 (12)
6 to 10 years	76	18 (24)	7	3 (43)	83	21 (25)
10 + years	108	41 (38)	12	3 (25)	120	44 (37)
p value		<0.01		0.8		<0.01
2007						
<3 years	19	2 (11)	1	0 (0)	20	2 (10)
3 to 5 years	29	5 (17)	3	0 (0)	32	5 (16)
6 to 10 years	66	17 (26)	17	4 (24)	83	21 (25)
10 + years	149	55 (37)	18	9 (50)	167	64 (38)
p value		0.02		0.2		<0.01
2010						
<3 years	25	1 (4)	1	0 (0)	26	1 (4)
3 to 5 years	19	3 (16)	2	1 (50)	21	4 (19)
6 to 10 years	41	5 (12)	3	0 (0)	44	5 (11)
10 + years	123	29 (24)	3	0 (0)	126	29 (23)
p value		0.08		0.3		0.07
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	17	0 (0)	2	0 (0)	19	0 (0)
6 to 10 years	25	2 (8)	6	1 (17)	31	3 (10)
10 + years	99	30 (30)	11	2 (18)	110	32 (29)
p value		0.003		0.8		0.003
2016						
<3 years	11	0 (0)	6	0 (0)	17	0 (0)
3 to 5 years	12	0 (0)	1	0 (0)	13	0 (0)
6 to 10 years	16	0 (0)	2	0 (0)	18	0 (0)
10 + years	47	10 (21)	11	1 (9)	58	11 (19)
p value		0.03		0.8		0.017

† Excludes equivocal test results and missing values.

Table 56 HBV core-antibody prevalence by last drug injected, years since first drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Methamphetamine (Speed, Ice)	23	2 (9)	130	38 (22)	153	40 (26)
Heroin	1	0 (0)	70	22 (31)	71	22 (31)
More than one drug	5	0 (0)	23	7 (30)	28	7 (25)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.9		0.9		0.8
2007						
Methamphetamine (Speed, Ice)	17	2 (12)	165	41 (25)	182	43 (24)
Heroin	3	0 (0)	87	35 (40)	90	35 (39)
More than one drug	0	0 (0)	11	5 (45)	11	5 (45)
Other/not reported	0	0 (0)	19	9 (47)	19	9 (47)
p value		0.5		0.02		0.01
2010						
Methamphetamine (Speed, Ice)	16	0 (0)	119	22 (18)	135	22 (16)
Heroin	4	0 (0)	39	13 (33)	43	13 (30)
More than one drug	0	0 (0)	6	1 (17)	6	1 (17)
Other/not reported	6	1 (17)	27	2 (7)	33	3 (9)
p value		0.2		0.06		0.09
2013						
Methamphetamine (Speed, Ice)	21	1 (5)	105	18 (17)	126	19 (15)
Heroin	3	0 (0)	35	12 (34)	38	12 (32)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	2	0 (0)	19	5 (26)	21	5 (24)
p value		0.9		0.2		0.1
2016						
Methamphetamine (Speed, Ice)	14	0 (0)	61	7 (11)	75	7 (9)
Heroin	0	0 (0)	14	2 (14)	14	2 (14)
More than one drug	0	0 (0)	7	2 (29)	7	2 (29)
Other/not reported	3	0 (0)	6	0 (0)	9	0 (0)
p value		--		0.5		0.4

† Excludes equivocal test results and missing values.

Table 57 HBV core-antibody prevalence by frequency of injection last month, years since first drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	11	1 (19)	41	20 (49)	52	21 (40)
Daily or more	10	0 (0)	99	26 (26)	109	26 (24)
p value		0.3		0.01		0.02
2007						
Less than daily	3	0 (0)	73	24 (33)	76	24 (32)
Daily or more	6	0 (0)	102	39 (38)	108	39 (36)
p value		--		0.5		0.5
2010						
Less than daily	10	0 (0)	52	11 (21)	62	11 (18)
Daily or more	8	0 (0)	54	8 (15)	62	8 (13)
p value		--		0.4		0.5
2013						
Less than daily	10	0 (0)	45	9 (20)	55	9 (16)
Daily or more	10	0 (0)	62	15 (24)	72	15 (21)
p value		--		0.6		0.5
2016						
Less than daily	9	0 (0)	24	2 (8)	33	2 (6)
Daily or more	2	0 (0)	34	6 (18)	36	6 (17)
p value		--		0.3		0.2

† Excludes equivocal test results and missing values.

Table 58 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, years since first drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	20	1 (5)	101	33 (33)	121	34 (28)
Yes	2	0 (0)	39	13 (33)	41	13 (32)
p value		0.7		0.9		0.8
2007						
No	9	0 (0)	135	47 (35)	144	47 (33)
Yes	0	0 (0)	32	13 (41)	32	13 (41)
p value		--		0.5		0.4
2010						
No	15	0 (0)	81	15 (19)	96	15 (16)
Yes	2	0 (0)	15	1 (7)	17	1 (6)
p value		--		0.3		0.3
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	5	0 (0)	18	6 (33)	23	6 (26)
p value		--		--		--
2016						
No	11	0 (0)	46	5 (11)	57	5 (9)
Yes	0	0 (0)	12	3 (25)	12	3 (25)
p value		--		0.2		0.1

† Excludes equivocal test results and missing values.

Table 59 HBV core-antibody prevalence by imprisonment last year, years since first drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	12	0 (0)	79	29 (37)	91	29 (32)
Yes	18	2 (11)	145	37 (26)	163	39 (24)
p value		g0.2		0.2		0.6
2007						
No	5	2 (40)	81	25 (31)	86	27 (31)
Yes	6	0 (0)	148	49 (33)	154	49 (32)
p value		0.9		0.7		0.9
2010						
No	14	0 (0)	84	17 (20)	98	17 (17)
Yes	11	1 (9)	100	19 (19)	111	20 (18)
p value		0.3		0.8		0.9
2013						
No	3	0 (0)	51	11 (22)	54	11 (20)
Yes	12	1 (8)	77	20 (26)	89	21 (24)
p value		0.6		0.6		0.7
2016						
No	1	0 (0)	24	2 (8)	25	2 (8)
Yes	9	0 (0)	49	7 (15)	58	7 (12)
p value		--		0.5		0.6

† Excludes equivocal test results and missing values.

Table 60 HBV core-antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	103	9 (9)	9	3 (33)	112	12 (11)
2 to 4	211	40 (19)	17	4 (24)	228	44 (19)
5 to 9	67	22 (33)	4	1 (25)	71	23 (32)
10 +	22	6 (27)	3	2 (67)	25	8 (32)
p value		<0.01		0.5		<0.01
2007						
1	163	15 (9)	21	6 (29)	184	21 (11)
2 to 4	204	44 (22)	21	2 (10)	225	46 (20)
5 to 9	76	24 (32)	7	4 (57)	83	28 (34)
10 +	48	16 (33)	4	1 (25)	52	17 (33)
p value		<0.01		0.08		<0.01
2010						
1	250	31 (12)	12	3 (25)	262	34 (13)
2 to 4	145	33 (23)	7	0 (0)	152	33 (22)
5 to 9	67	21 (31)	3	1 (33)	70	22 (31)
10 +	38	12 (32)	0	0 (0)	38	12 (32)
p value		<0.001		0.3		<0.01
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	25	2 (8)	5	0 (0)	30	2 (7)
2 to 4	57	11 (19)	10	0 (0)	67	11 (16)
5 to 9	32	6 (19)	3	0 (0)	35	6 (17)
10 +	21	5 (24)	1	1 (100)	22	6 (27)
p value		0.5		<0.001		0.3

† Excludes equivocal test results and missing values.

Table 61 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	340	57 (17)	23	7 (30)	363	64 (18)
Indigenous	68	20 (29)	9	2 (22)	77	22 (29)
p value		0.02		0.6		0.03
2007						
Non-Indigenous	416	67 (16)	36	8 (22)	452	75 (17)
Indigenous	88	37 (42)	18	7 (39)	106	44 (42)
p value		<0.001		0.2		<0.001
2010						
Non-Indigenous	342	53 (15)	14	2 (14)	356	55 (15)
Indigenous	163	44 (27)	8	2 (25)	171	46 (27)
p value		<0.01		0.5		<0.01
2013						
Non-Indigenous	277	43 (16)	31	4 (13)	308	47 (15)
Indigenous	125	32 (26)	17	3 (18)	142	35 (25)
p value		0.02		0.7		0.02
2016						
Non-Indigenous	152	13 (9)	20	0 (0)	172	13 (8)
Indigenous	82	28 (34)	16	3 (19)	98	31 (32)
p value		<0.001		0.04		<0.001

† Excludes equivocal test results and missing values.

Table 62 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	154	14 (9)	206	50 (24)	360	64 (18)
Indigenous	26	3 (12)	50	19 (38)	76	22 (29)
p value		0.7		0.05		0.03
2007						
Non-Indigenous	215	12 (6)	237	63 (27)	452	75 (17)
Indigenous	39	12 (31)	67	32 (48)	106	44 (42)
p value		<0.001		0.01		<0.001
2010						
Non-Indigenous	194	25 (13)	162	30 (19)	356	55 (15)
Indigenous	110	35 (32)	61	11 (18)	171	46 (27)
p value		<0.001		0.9		<0.01
2013						
Non-Indigenous	180	22 (12)	121	24 (20)	301	46 (15)
Indigenous	63	19 (30)	68	12 (18)	131	31 (24)
p value		0.001		0.7		0.02
2016						
Non-Indigenous	73	6 (8)	81	6 (7)	154	12 (8)
Indigenous	54	19 (35)	28	5 (18)	82	24 (29)
p value		<0.001		0.1		<0.001

† Excludes equivocal test results and missing values.

Table 63 HBV core-antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	370	66 (18)	28	8 (29)	398	74 (19)
Moderately accessible	10	1 (10)	1	0 (0)	11	1 (9)
Remote/very remote	18	7 (39)	2	0 (0)	20	7 (35)
p value		0.06		0.6		0.1
2007						
Highly accessible/accessible	454	89 (20)	47	13 (28)	501	102 (20)
Moderately accessible	15	1 (7)	1	0 (0)	16	1 (6)
Remote/very remote	17	7 (41)	1	1 (100)	18	8 (44)
p value		0.04		0.2		0.02
2010						
Highly accessible/accessible	411	68 (17)	16	2 (13)	427	70 (16)
Moderately accessible	19	5 (26)	1	0 (0)	20	5 (25)
Remote/very remote	56	20 (36)	3	2 (67)	59	22 (37)
p value		<0.01		0.09		<0.01
2013						
Highly accessible/accessible	310	50 (16)	33	3 (9)	343	53 (15)
Moderately accessible	40	5 (13)	4	1 (25)	44	6 (14)
Remote/very remote	29	13 (45)	1	0 (0)	30	13 (43)
p value		<0.001		0.6		<0.001
2016						
Highly accessible/accessible	143	15 (10)	26	1 (4)	169	16 (9)
Moderately accessible	22	5 (23)	5	0 (0)	27	5 (19)
Remote/very remote	36	14 (39)	1	0 (0)	37	14 (38)
p value		<0.001		0.9		<0.001

† Excludes equivocal test results and missing values.

Table 64 HBV core-antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	337	63 (19)	31	8 (26)	368	71 (19)
Other Oceania	23	6 (26)	0	0 (0)	23	6 (26)
Asia	15	6 (40)	2	2 (100)	17	8 (47)
UK & Ireland	9	1 (11)	0	0 (0)	9	1 (11)
Other	26	2 (8)	0	0 (0)	26	2 (8)
p value		0.1		0.07		0.02
2007						
Australia	431	86 (20)	47	11 (23)	478	97 (20)
Other Oceania	17	5 (29)	2	1 (50)	19	6 (32)
Asia	29	7 (24)	3	1 (33)	32	8 (25)
UK & Ireland	8	3 (38)	1	0 (0)	9	3 (33)
Other	24	4 (17)	2	2 (100)	26	6 (23)
p value		0.6		0.2		0.7
2010						
Australia	431	74 (17)	18	2 (11)	449	76 (17)
Other Oceania	26	7 (27)	0	0 (0)	26	7 (27)
Asia	20	8 (40)	3	2 (67)	23	10 (43)
UK & Ireland	5	0 (0)	0	0 (0)	5	0 (0)
Other	23	8 (35)	1	0 (0)	24	8 (33)
p value		0.01		0.06		<0.01
2013						
Australia	324	51 (16)	37	5 (14)	361	56 (16)
Other Oceania	19	4 (21)	4	1 (25)	23	5 (22)
Asia	20	10 (50)	1	0 (0)	21	10 (48)
UK & Ireland	6	0 (0)	2	0 (0)	8	0 (0)
Other	21	7 (33)	1	0 (0)	22	7 (32)
p value		0.001		0.9		0.002
2016						
Australia	182	29 (16)	30	1 (3)	212	30 (14)
Other Oceania	10	2 (20)	1	0 (0)	11	2 (18)
Asia	6	3 (50)	1	0 (0)	7	2 (43)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.2		1.0		0.3

† Excludes equivocal test results and missing values.

Table 65 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	270	117 (43)	60 (22)	13 (5)	80 (30)
Non-IDU	185	134 (72)	17 (9)	0 (0)	34 (18)
p value					<0.001
2007					
IDU	308	111 (36)	90 (29)	10 (3)	97 (31)
Non-IDU	246	166 (67)	21 (9)	3 (1)	56 (23)
p value					<0.001
2010					
IDU	236	80 (34)	38 (16)	3 (1)	115 (49)
Non-IDU	319	145 (45)	52 (16)	10 (3)	112 (35)
p value					<0.01
2013					
IDU	182	65 (36)	32 (18)	5 (3)	80 (44)
Non-IDU	208	105 (51)	37 (18)	7 (3)	58 (28)
p value					0.006
2016					
IDU	87	36 (41)	10 (11)	3 (3)	38 (44)
Non-IDU	108	52 (48)	21 (19)	4 (4)	31 (29)
p value					0.1

† Excludes equivocal test results and missing values; * HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 66 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	445	245 (55)	76 (17)	13 (3)	111 (25)
Bisexual	7	4 (57)	1 (14)	0 (0)	2 (29)
Homosexual	3	2 (67)	0 (0)	0 (0)	1 (33)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2007					
Heterosexual	534	269 (50)	108 (20)	11 (2)	146 (27)
Homosexual	5	2 (40)	0 (0)	0 (0)	3 (60)
Bisexual	7	3 (43)	1 (14)	1 (14)	2 (29)
Unsure	2	1 (50)	1 (50)	0 (0)	146 (27)
p value					0.4
2010					
Heterosexual	534	218 (41)	86 (16)	13 (2)	217 (41)
Homosexual	4	2 (50)	1 (25)	0 (0)	1 (25)
Bisexual	11	2 (18)	1 (9)	0 (0)	8 (73)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.5
2013					
Heterosexual	376	167 (44)	67 (18)	12 (3)	130 (35)
Gay/lesbian	7	1 (14)	0 (0)	0 (0)	6 (86)
Bisexual	2	1 (50)	0 (0)	0 (0)	1 (50)
Unsure	4	1 (25)	2 (50)	0 (0)	1 (25)
p value					0.4
2016					
Heterosexual	184	85 (46)	29 (16)	6 (3)	64 (35)
Gay/lesbian	4	1 (50)	1 (50)	0 (0)	0 (0)
Bisexual	2	1 (25)	0 (0)	0 (0)	3 (75)
Unsure	5	1 (20)	1 (20)	1 (20)	2 (40)
p value					0.4

† Excludes equivocal test results and missing values; * HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 67 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	38	23 (61)	0 (0)	1 (3)	14 (37)
20 – 24	96	53 (55)	10 (10)	4 (4)	29 (30)
25 – 29	100	57 (57)	16 (16)	3 (3)	24 (24)
30 + years	226	123 (54)	51 (23)	5 (2)	47 (21)
p value					0.02
2007					
< 20 years	34	21 (62)	3 (9)	0 (0)	10 (29)
20 – 24	117	59 (50)	9 (8)	2 (2)	47 (40)
25 – 29	121	54 (45)	24 (20)	3 (2)	40 (33)
30 + years	281	142 (51)	75 (27)	8 (3)	56 (20)
p value					<0.001
2010					
< 20 years	59	23 (39)	3 (5)	0 (0)	33 (56)
20 – 24	110	49 (45)	6 (5)	0 (0)	55 (50)
25 – 29	120	53 (44)	16 (13)	5 (4)	46 (38)
30 + years	266	100 (38)	65 (24)	8 (3)	93 (35)
p value					<0.001
2013					
< 20 years	31	17 (55)	1 (3)	1 (3)	12 (39)
20 – 24	73	32 (44)	3 (4)	2 (3)	36 (49)
25 – 29	83	36 (43)	14 (17)	3 (4)	30 (36)
30 + years	224	95 (42)	56 (25)	7 (3)	66 (29)
p value					0.003
2016					
< 20 years	8	7 (88)	0 (0)	0 (0)	1 (13)
20 – 24	40	22 (55)	2 (5)	2 (5)	14 (35)
25 – 29	40	10 (25)	5 (13)	0 (0)	25 (63)
30 + years	137	64 (47)	30 (22)	6 (4)	32 (27)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 68 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2004					
1	115	85 (74)	10 (9)	2 (2)	18 (16)
2 to 4	232	124 (53)	39 (17)	8 (3)	61 (26)
5 to 9	74	25 (34)	21 (28)	1 (1)	27 (36)
10 +	25	11 (44)	6 (24)	2 (8)	6 (24)
p value					<0.001
2007					
1	182	130 (71)	19 (10)	3 (2)	30 (16)
2 to 4	215	109 (51)	42 (20)	5 (2)	59 (27)
5 to 9	83	16 (19)	27 (33)	3 (4)	37 (45)
10 +	52	13 (25)	15 (29)	2 (4)	22 (42)
p value					<0.001
2010					
1	277	143 (52)	28 (10)	6 (2)	100 (36)
2 to 4	154	51 (33)	31 (20)	3 (2)	69 (45)
5 to 9	75	22 (29)	20 (27)	2 (3)	31 (41)
10 +	44	6 (14)	11 (25)	2 (5)	25 (57)
p value					<0.001
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--
2016					
1	25	11 (44)	2 (8)	0 (0)	12 (48)
2 to 4	52	24 (46)	10 (19)	2 (4)	16 (31)
5 to 9	29	8 (28)	4 (14)	2 (7)	15 (52)
10 +	17	3 (18)	6 (35)	1 (6)	7 (41)
p value					0.2

† Excludes equivocal test results and missing values; * HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 69 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2004					
Non-Indigenous	372	223 (60)	57 (15)	9 (2)	83 (22)
Indigenous	78	26 (33)	18 (23)	4 (5)	30 (38)
p value					<0.001
2007					
Non-Indigenous	442	242 (55)	70 (16)	8 (2)	122 (28)
Indigenous	104	32 (31)	40 (38)	5 (5)	27 (26)
p value					<0.001
2010					
Non-Indigenous	370	174 (47)	48 (13)	7 (2)	141 (38)
Indigenous	185	51 (28)	42 (23)	6 (3)	86 (46)
p value					<0.001
2013					
Non-Indigenous	269	131 (49)	42 (16)	7 (3)	89 (33)
Indigenous	139	48 (35)	32 (23)	5 (3)	54 (39)
p value					0.04
2016					
Non-Indigenous	140	75 (54)	11 (8)	3 (2)	51 (36)
Indigenous	85	28 (33)	26 (31)	5 (6)	26 (31)
p value					<0.001

† Excludes equivocal test results and missing values; * HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 70 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	409	231 (56)	64 (16)	12 (3)	102 (25)
Moderately accessible	11	6 (55)	1 (9)	0 (0)	4 (36)
Remote/very remote	20	7 (35)	7 (35)	0 (0)	6 (30)
p value					0.2
2007					
Highly accessible/accessible	494	248 (50)	92 (19)	13 (3)	141 (29)
Moderately accessible	14	13 (93)	1 (7)	0 (0)	0 (0)
Remote/very remote	15	3 (20)	9 (60)	0 (0)	3 (20)
p value					<0.001
2010					
Highly accessible/accessible	447	191 (43)	64 (14)	6 (1)	186 (42)
Moderately accessible	25	9 (36)	4 (16)	2 (8)	10 (40)
Remote/very remote	64	17 (27)	18 (28)	5 (8)	24 (38)
p value					<0.001
2013					
Highly accessible/accessible	311	146 (47)	47 (15)	9 (3)	109 (35)
Moderately accessible	38	18 (47)	6 (16)	0 (0)	14 (37)
Remote/very remote	27	5 (19)	12 (44)	1 (4)	9 (33)
p value					0.006
2016					
Highly accessible/accessible	134	65 (49)	14 (10)	3 (2)	52 (39)
Moderately accessible	24	12 (50)	4 (17)	2 (8)	6 (25)
Remote/very remote	35	11 (31)	12 (34)	2 (6)	10 (29)
p value					0.012

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 71 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	128	14 (11)	8	3 (38)	136	17 (13)
Yes	163	81 (50)	12	5 (42)	175	86 (49)
Not sure	46	9 (20)	6	2 (33)	52	11 (21)
p value		<0.001		0.9		<0.001
2007						
No	144	17 (12)	21	4 (19)	165	21 (13)
Yes	196	111 (57)	18	11 (61)	214	122 (57)
Not sure	47	9 (19)	1	0 (0)	48	9 (19)
p value		<0.001		0.02		<0.001
2010						
No	135	34 (25)	7	1 (14)	142	35 (25)
Yes	207	149 (72)	21	15 (71)	228	164 (72)
Not sure	78	27 (35)	1	0 (0)	79	27 (34)
p value		<0.001		0.4		<0.001
2013						
No	53	14 (26)	13	6 (46)	66	20 (30)
Yes	126	70 (56)	23	17 (74)	149	87 (58)
Not sure	83	27 (33)	8	3 (38)	91	30 (33)
p value		<0.001		0.1		<0.001
2016						
No	28	5 (18)	6	0 (0)	34	5 (15)
Yes	57	35 (61)	13	7 (54)	70	42 (60)
Not sure	41	17 (41)	10	5 (50)	51	22 (43)
p value		0.001		0.07		<0.001

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 72 Genital chlamydia prevalence by gender and survey year†

Gender	N° tested	N° with chlamydia (%)
2010		
Male	559	27 (5)
Female	59	1 (2)
p value		0.3
2013		
Male	410	20 (5)
Female	83	3 (4)
p value		0.6
2016		
Male	227	8 (4)
Female	30	2 (7)
p value		0.4

† Excludes missing values.

Gonorrhoea

Table 73 Genital gonorrhoea prevalence by gender and survey year†

Gender	N° tested	N° with gonorrhoea (%)
2010		
Male	548	5 (1)
Female	59	0 (0)
p value		0.5
2013		
Male	408	1 (<1)
Female	83	0 (0)
p value		0.7
2016		
Male	233	4 (2)
Female	32	0 (0)
p value		0.5

† Excludes missing values.

Syphilis

Table 74 Syphilis markers by gender and survey year†

Gender	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	573	37 (6)	14 (2)	37 (6)
Female	50	3 (6)	1 (2)	3 (6)
p value		0.9	0.9	0.9
2013				
Male	429	6 (1)	4 (1)	2 (<1)
Female	83	1 (1)	1 (1)	1 (1)
p value		0.9	0.9	0.9
2016				
Male	233	10 (4)	4 (25)	10 (4)
Female	34	6 (18)	2 (25)	6 (17)
p value		0.002	1.0	0.003

† Excludes missing values.

**Northern Territory
2010, 2013, 2016**

Table 75 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 2		N = 1		N = 2	
N° surveyed	N = 9	N = 66	N = 3	N = 45	N = 4	N = 57
Gender (%)						
Male	8 (89)	64 (97)	3 (100)	43 (96)	4 (100)	52 (91)
Female	1 (11)	2 (3)	0 (0)	2 (4)	0 (0)	5 (9)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age (years)						
Median age	34	30	30	32	37	34
Age range	25 – 21	18 – 56	27 – 36	18 – 56	33 – 41	18 – 58
Age group (%)						
<25 years	0 (0)	19 (29)	0 (0)	14 (31)	0 (0)	8 (14)
25+ years	9 (100)	47 (71)	3 (100)	31 (69)	4 (100)	49 (86)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Aboriginal and/or Torres Strait Islander origin (%)						
No	4 (44)	5 (8)	1 (33)	8 (18)	4 (100)	3 (5)
Yes	5 (56)	61 (92)	2 (67)	37 (82)	0 (0)	54 (95)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)						
Heterosexual	9 (100)	62 (94)	3 (100)	45 (100)	4 (100)	56 (98)
Bisexual	0 (0)	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Gay/lesbian	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Region/Country of birth (%)						
Australia	7 (78)	64 (97)	3 (100)	43 (96)	4 (100)	57 (100)
Other Oceania	1 (11)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Asia	1 (11)	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Residential remoteness in 12 months before prison (%)						
Highly / accessible	5 (56)	11 (17)	0 (0)	2 (4)	0 (0)	3 (5)
Mod accessible	0 (0)	1 (2)	2 (67)	15 (33)	2 (50)	6 (11)
Very / remote	4 (44)	47 (71)	1 (33)	27 (60)	2 (50)	47 (82)
Not reported	0 (0)	7 (11)	0 (0)	1 (2)	0 (0)	1 (2)
First time in prison (%)						
No	7 (78)	52 (79)	2 (67)	30 (67)	3 (75)	49 (86)
Yes	2 (22)	14 (21)	1 (33)	13 (29)	1 (25)	8 (14)
Not reported	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)
Lifetime imprisonments (%)						
One	3 (33)	29 (44)	n/a	n/a	0 (0)	7 (14)
Two to four	3 (33)	20 (30)	n/a	n/a	2 (67)	15 (31)
Five to nine	3 (33)	14 (21)	n/a	n/a	0 (0)	9 (18)
Ten or more	0 (0)	3 (5)	n/a	n/a	1 (33)	9 (18)
Not reported	0 (0)	0 (0)	n/a	n/a	0 (0)	9 (18)
Imprisonment in the last year (%)						
No	4 (44)	27 (41)	2 (100)	7 (23)	2 (67)	11 (22)
Yes	5 (56)	29 (44)	0 (0)	23 (77)	1 (33)	35 (71)
Not reported	0 (0)	10 (15)	0 (0)	0 (0)	0 (0)	3 (6)

Table 76 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 9	N = 66	N = 3	N = 45	N = 4	N = 57
Ever smoked a full cigarette (%)						
No	0 (0)	6 (9)	0 (0)	3 (7)	0 (0)	8 (14)
Yes	9 (100)	60 (91)	3 (100)	42 (93)	4 (100)	49 (86)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age of smoking						
Med age 1 st smoked	15	17	13	16	16	15
Age range	5 – 17	10 – 27	13 – 15	8 – 31	8 – 20	5 – 22
Current smoker (%)*						
No	0 (0)	7 (11)	0 (0)	1 (2)	0 (0)	3 (6)
Yes	9 (100)	59 (89)	3 (100)	41 (98)	4 (100)	46 (94)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Smoking frequency (%)						
Weekly or less	0 (0)	3 (5)	0 (0)	2 (5)	0 (0)	3 (7)
5-10/day	4 (44)	19 (32)	0 (0)	16 (39)	2 (50)	15 (33)
11 to 20/day	1 (11)	7 (12)	2 (67)	16 (39)	0 (0)	19 (41)
≥21/day	4 (44)	30 (51)	1 (33)	7 (17)	2 (50)	9 (20)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other drugs used last month (%)**						
None	0 (0)	46 (71)	0 (0)	15 (33)	1 (25)	37 (65)
Cannabis	6 (67)	19 (100)	2 (67)	29 (97)	3 (100)	19 (95)
Heroin	1 (11)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cocaine	1 (11)	0 (0)	0 (0)	1 (3)	1 (33)	0 (0)
Methamphetamine	2 (22)	0 (0)	0 (0)	4 (13)	2 (67)	1 (5)
Methadone	3 (33)	0 (0)	1 (33)	0 (0)	0 (0)	0 (0)
Other opiates	3 (33)	0 (0)	2 (67)	0 (0)	0 (0)	0 (0)
Buprenorphine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Anabolic steroids [^]	1 (11)	0 (0)	0 (0)	0 (0)	1 (33)	0 (0)
Hallucinogens	0 (0)	0 (0)	0 (0)	2 (7)	0 (0)	0 (0)
Benzodiazepine	1 (11)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)
Ecstasy/MDA	1 (11)	0 (0)	0 (0)	0 (0)	1 (33)	0 (0)
Inhalants	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other drug	1 (11)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Risk of alcohol-related harm (%)^^						
Non-drinker	n/a	n/a	n/a	n/a	1 (25)	6 (10)
Low risk of harm	n/a	n/a	n/a	n/a	1 (25)	15 (26)
High risk of harm	n/a	n/a	n/a	n/a	2 (50)	35 (61)
Not reported	n/a	n/a	n/a	n/a	0 (0)	1 (2)

*Prior to prison; **More than one drug option could be selected; [^]Also includes hormones and peptides from 2016; ^{^^}AUDIT-C

Table 77 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010	2013	2016
	N = 9	N = 3	N = 4
Age of first injection (years)			
Median age 1 st IDU	25	18	21
Age range	14 – 42	12 – 21	16 – 24
Not reported	1	0 (0)	0 (0)
Median IDU (years)	11	10	15.5
Range	1 – 32	9 – 24	13 – 23
Years since first drug injection (%)			
<3 years	1 (11)	0 (0)	0 (0)
3+ years	7 (78)	3 (100)	4 (100)
Not reported	1 (11)	0 (0)	0 (0)
Frequency of injection last month (%)			
Not last month	4 (44)	1 (33)	4 (100)
< Weekly	1 (11)	1 (33)	0 (0)
Weekly	0 (0)	1 (33)	0 (0)
Daily or more	3 (33)	0 (0)	0 (0)
Not reported	1 (11)	0 (0)	0 (0)
Last drug injected (%)	N = 9	N = 3	N = 4
Methamphetamine	3 (33)	1 (33)	3 (75)
Anabolic steroids [^]	0 (0)	0 (0)	0 (0)
Cocaine	0 (0)	0 (0)	0 (0)
Heroin	0 (0)	0 (0)	0 (0)
Methadone	0 (0)	0 (0)	0 (0)
Morphine	2 (22)	1 (33)	1 (25)
Other	3 (33)	1 (33)	0 (0)
Not reported	1 (11)	0 (0)	0 (0)
N° Injected last month	N = 4	N = 2	N = 0
Places injected last month (%)*			
Prison	0 (0)	0 (0)	--
Own home	3 (75)	2 (100)	--
Friend's home	2 (50)	0 (0)	--
Dealer's home	0 (0)	0 (0)	--
Street, park, beach	1 (25)	0 (0)	--
Car	0 (0)	0 (0)	--
Public toilet	0 (0)	0 (0)	--
Commercial injecting room	0 (0)	0 (0)	--
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	--
Squat	0 (0)	0 (0)	--
Other place	0 (0)	1 (50)	--
Use of sterile needles & syringes last month (%)			
All injections	4 (100)	2 (100)	--
Most of the time	0 (0)	0 (0)	--
Half of the time	0 (0)	0 (0)	--
Some of the time	0 (0)	0 (0)	--
Not last month	0 (0)	0 (0)	--
Not reported	0 (0)	0 (0)	--
Times injected by someone else after they injected themselves or others in past month (%)			
More than 5 times	0 (0)	2 (100)	--
3 to 5 times	0 (0)	0 (0)	--
Once or twice	0 (0)	0 (0)	--
None	4 (100)	0 (0)	--
Re-used someone else's used needle & syringe last month (%)			
None	4 (100)	2 (100)	--
Once	0 (0)	0 (0)	--
Twice	0 (0)	0 (0)	--
3-5 times	0 (0)	0 (0)	--
>5 times	0 (0)	0 (0)	--
Not reported	0 (0)	0 (0)	--

* More than one drug option could be selected; [^]Also includes hormones and peptides from 2016.

Table 78 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year (cont.)

Injecting behaviour	2010 N = 9	2013 N = 3	2016 N = 4
Number of people needle & syringe was re-used after last month (%)*			
One	--	--	--
Two	--	--	--
Three to five	--	--	--
More than five	--	--	--
Don't know how many	--	--	--
Not reported	--	--	--
Relationship to people needle & syringe was re-used after last month (%)*			
Regular sex partner	--	--	--
Casual sex partner	--	--	--
Close friend	--	--	--
Acquaintance	--	--	--
Other	--	--	--
Last time re-used needle after someone (%)			
Last month	0 (0)	0 (0)	0 (0)
In last 2-6 months	0 (0)	0 (0)	0 (0)
More than 6 months ago	1 (11)	2 (67)	0 (0)
Never	5 (56)	1 (33)	4 (100)
Not reported	3 (33)	0 (0)	0 (0)
Last place re-used a needle or syringe after someone (%)**			
Prison	0 (0)	0 (0)	--
Own home	0 (0)	1 (33)	--
Friend's home	0 (0)	1 (33)	--
Dealer's home	0 (0)	0 (0)	--
Street, park, beach	0 (0)	0 (0)	--
Car	0 (0)	0 (0)	--
Public toilet	0 (0)	0 (0)	--
Commercial injecting room	0 (0)	0 (0)	--
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	--
Squat	0 (0)	0 (0)	--
Other place	0 (0)	0 (0)	--
Not reported	4 (100)	1 (33)	--
Equipment used after someone else last month (%)*			
Spoon	--	1 (50)	--
Water	--	0 (0)	--
Filter	--	1 (50)	--
Tourniquet	--	0 (0)	--
Drug mix	--	0 (0)	--

*Of those reporting sharing needles & syringes in the past month.

**More than one drug option could be selected.

Table 79 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition	2010	2013	2016
N° surveyed	N = 8	N = 3	N = 4
Location of needle & syringe acquisition in the past month (%)*			
Needle & Syringe Program (NSP/CNP)	n/a	n/a	0 (0)
Chemist/Pharmacy	n/a	n/a	0 (0)
Vending machine	n/a	n/a	0 (0)
Personal source (e.g. friend)	n/a	n/a	1 (25)
Other	n/a	n/a	0 (0)
Not in the last month	n/a	n/a	3 (75)
From an NSP last month (%)			
Daily or almost daily	0 (0)	0 (0)	0 (0)
A couple of times each week	1 (13)	0 (0)	0 (0)
Less than weekly	1 (13)	0 (0)	0 (0)
Weekly	0 (0)	0 (0)	0 (0)
Once last month	1 (13)	1 (33)	0 (0)
Not in the last month	4 (50)	2 (67)	4 (100)
Not reported	1 (13)	0 (0)	0 (0)
From a chemist last month (%)			
Daily or almost daily	0 (0)	0 (0)	0 (0)
A couple of times each week	1 (11)	0 (0)	0 (0)
Less than weekly	0 (0)	0 (0)	0 (0)
Weekly	0 (0)	0 (0)	0 (0)
Once last month	0 (0)	0 (0)	0 (0)
Not in the last month	6 (67)	3 (100)	4 (100)
Not reported	1 (11)	0 (0)	0 (0)
Ever participated in the annual NSP community survey (%)			
No	6 (75)	3 (100)	4 (100)
Yes	1 (13)	0 (0)	0 (0)
Don't remember	1 (13)	0 (0)	0 (0)
Not reported	1 (13)	0 (0)	0 (0)

* More than one drug option could be selected.

Table 80 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 9	N = 66	N = 3	N = 45	N = 4	N = 57
Any treatment/therapy for drug use (%)*						
No	3 (33)	64 (97)	2 (67)	45 (100)	3 (75)	42 (74)
Yes	6 (67)	2 (3)	1 (33)	0 (0)	1 (25)	15 (26)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)						
Currently	1 (11)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Previously	3 (33)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)
Never	5 (56)	66 (100)	3 (100)	45 (100)	3 (75)	57 (100)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of other pharmacotherapy treatment (%)						
Currently	0 (0)	0 (0)	1 (33)	0 (0)	0 (0)	0 (0)
Previously	2 (22)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Never	7 (78)	66 (100)	2 (67)	45 (100)	4 (100)	57 (100)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

*E.g. detox, rehab, counselling, NA

Table 81 Number (%) of respondents by body piercing and tattoos by injector status and survey year

Demographics	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 9	N = 66	N = 3	N = 45	N = 4	N = 57
Body or ear piercings (%)						
No	6 (67)	56 (85)	2 (67)	20 (44)	4 (100)	45 (79)
Yes	3 (33)	10 (15)	1 (33)	25 (56)	0 (0)	12 (21)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Piercings other than ears (%)						
No	9 (90)	3 (100)	0 (0)	18 (72)	--	11 (92)
Yes	1 (10)	0 (0)	1 (100)	6 (24)	--	1 (8)
Not reported	0 (0)	0 (0)	0 (0)	1 (4)	--	0 (0)
Pierced in past 12 months (%)						
No	1 (33)	7 (70)	1 (100)	23 (92)	--	9 (75)
Yes	0 (0)	2 (20)	0 (0)	1 (4)	--	3 (25)
Not reported	2 (67)	1 (10)	0 (0)	1 (4)	--	0 (0)
Who did piercing (%)*						
Professional [^]	--	1 (50)	0 (0)	0 (0)	--	2 (67)
Non-professional ^{^^}	--	0 (0)	0 (0)	1 (100)	--	1 (33)
Prisoner	--	0 (0)	0 (0)	0 (0)	--	0 (0)
Self	--	0 (0)	0 (0)	0 (0)	--	0 (0)
Other	--	0 (0)	0 (0)	0 (0)	--	0 (0)
Not reported	--	1 (50)	0 (0)	0 (0)	--	0 (0)
Needle used by others (%)						
No	--	0 (0)	--	0 (0)	n/a	n/a
Yes	--	0 (0)	--	1 (100)	n/a	n/a
Unsure	--	0 (0)	--	0 (0)	n/a	n/a
Not reported	--	2 (100)	--	0 (0)	n/a	n/a
Penile implants (%)**						
No	n/a	n/a	n/a	n/a	4 (100)	52 (100)
Yes	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Penile implant in prison (%)**						
No	n/a	n/a	n/a	n/a	--	--
Yes	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	--	--
Tattoos (%)						
No	2 (22)	55 (83)	1 (33)	32 (71)	1 (3)	47 (82)
Yes	7 (78)	10 (15)	2 (67)	13 (29)	3 (75)	10 (18)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Tattoos in past 12 months (%)						
No	6 (86)	5 (50)	2 (100)	10 (77)	1 (33)	10 (100)
Yes	1 (14)	4 (40)	0 (0)	3 (23)	1 (33)	0 (0)
Not reported	0 (0)	1 (10)	0 (0)	0 (0)	1 (33)	0 (0)
Who did tattooing (%)*						
Professional	1 (100)	3 (75)	--	1 (33)	1 (100)	--
Non-professional ^{^^}	0 (0)	0 (0)	--	2 (67)	0 (0)	--
Prisoner	0 (0)	1 (25)	--	0 (0)	0 (0)	--
Self	0 (0)	0 (0)	--	0 (0)	0 (0)	--
Other	0 (0)	0 (0)	--	0 (0)	0 (0)	--

* More than one drug option could be selected.

** Males only, new question in 2017

[^] E.g. chemist, hairdresser, beauty salon, tattooist; ^{^^} Non-professional outside prison e.g. friend, family

Table 82 Number (%) of respondents by sexual behaviour in the 3 months prior to survey by injector status and survey year

Sexual behaviour	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 9	N = 66	N = 3	N = 45	N = 4	N = 57
Sex last 3 months (%)						
No	1 (11)	8 (12)	0 (0)	4 (9)	0 (0)	13 (23)
Yes	8 (89)	57 (86)	3 (100)	41 (91)	4 (100)	44 (77)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Male sex partners in last 3 months						
Median (Range)	--	0 (0–1)	--	2 (0–5)	--	0 (0–1)
Female sex partners in last 3 months						
Median (Range)	1 (0–90)	1 (0–7)	--	1 (0–8)	1 (1–5)	1 (0–5)
Condom use last sex - regular male partners - last 3 months (%)**						
Never	1 (100)	2 (100)	--	0 (0)	--	2 (100)
Sometimes	0 (0)	0 (0)	--	2 (67)	--	0 (0)
Always	0 (0)	0 (0)	--	1 (33)	--	0 (0)
Not reported	0 (0)	0 (0)	--	0 (0)	--	0 (0)
Condom use last sex - casual male partners - last 3 months (%)**						
Never	0 (0)	1 (33)	--	--	--	1 (100)
Sometimes	0 (0)	1 (33)	--	--	--	0 (0)
Always	0 (0)	1 (33)	--	--	--	0 (0)
Not reported	0 (0)	0 (0)	--	--	--	0 (0)
Condom use last sex - regular female partners - last 3 months (%)**						
Never	4 (80)	25 (61)	3 (100)	25 (93)	1 (25)	29 (71)
Sometimes	0 (0)	4 (10)	0 (0)	1 (4)	1 (25)	8 (20)
Always	1 (20)	12 (29)	0 (0)	1 (4)	2 (50)	4 (10)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Condom use last sex - casual female partners - last 3 months (%)**						
Never	2 (100)	7 (37)	--	6 (55)	0 (0)	11 (69)
Sometimes	0 (0)	3 (16)	--	5 (45)	0 (0)	2 (13)
Always	0 (0)	9 (47)	--	0 (0)	0 (0)	3 (19)
Not reported	0 (0)	0 (0)	--	0 (0)	0 (0)	0 (0)
Sex work last month (%)						
No	8 (89)	63 (95)	3 (100)	45 (100)	4 (100)	55 (96)
Yes	1 (11)	2 (3)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)
Condom used at last sex work last month (%)						
No	1 (100)	1 (50)	--	--	--	0 (0)
Yes	0 (0)	1 (50)	--	--	--	0 (0)
Not reported	0 (0)	0 (0)	--	--	--	1 (100)

**Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month

Table 83 Number (%) of respondents reporting previous testing for HIV, HBV infection, vaccinations for HBV and cervical cancer by injector status and survey year

Testing & treatment	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 9	N = 66	N = 3	N = 45	N = 4	N = 57
Previous HIV test (%)						
Last year	4 (44)	10 (15)	2 (67)	24 (53)	2 (50)	51 (89)
>1 year ago	1 (11)	14 (21)	1 (33)	13 (29)	2 (50)	4 (7)
Never tested	4 (44)	42 (64)	0 (0)	8 (18)	0 (0)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
HIV infection (self-report) (%)						
No	5 (100)	24 (100)	3 (100)	36 (97)	3 (75)	36 (64)
Yes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	18 (32)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	2 (4)
HBV infection (%)						
No	8 (89)	61 (92)	0 (0)	2 (4)	4 (100)	29 (51)
Yes	0 (0)	0 (0)	1 (33)	0 (0)	0 (0)	11 (19)
Don't know	1 (11)	4 (6)	2 (67)	43 (96)	0 (0)	15 (26)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)
HBV vaccination (%)*						
No	4 (44)	48 (73)	0 (0)	0 (0)	1 (25)	5 (9)
Yes	5 (56)	12 (18)	1 (33)	3 (7)	2 (50)	20 (35)
Don't know	0 (0)	5 (8)	2 (67)	41 (91)	1 (25)	28 (49)
Not reported	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	4 (7)
N° HBV injections (%)						
One	0 (0)	5 (42)	0 (0)	0 (0)	1 (50)	0 (0)
Two	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (10)
Three or more	5 (100)	7 (58)	0 (0)	2 (66)	0 (0)	11 (55)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	7 (35)
Not reported	0 (0)	0 (0)	1 (100)	1 (33)	0 (0)	0 (0)
Ever had cervical cancer vaccine (women only)** (%)						
No	--	--	--	1 (50)	0 (0)	1 (100)
Yes	--	--	--	0 (0)	0 (0)	0 (0)
Unsure	--	--	--	1 (50)	0 (0)	0 (0)
Missing	--	--	--	0 (0)	0 (0)	0 (0)

* Number (%) among participants with no history of HBV infection.

**Proportion of women eligible for the National HPV Vaccination Program, i.e. those who were under 27 years of age in 2007 (or 35 years or under in 2016).

Table 84 Number (%) of respondents reporting previous testing for HCV infection and HCV treatment by injector status and survey year

Testing & treatment	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 9	N = 66	N = 3	N = 45	N = 9	N = 66
Previous HCV test (%)						
Last year	4 (44)	6 (9)	2 (67)	20 (44)	2 (50)	3 (5)
>1 year ago	1 (11)	18 (27)	1 (33)	11 (24)	2 (50)	49 (86)
Never tested	3 (33)	42 (64)	0 (0)	14 (31)	0 (0)	5 (9)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (11)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Result of last HCV test (%)						
Hepatitis C antibody positive	2 (40)	0 (0)	0 (0)	0 (0)	n/a	n/a
Never had hep C	2 (40)	24 (100)	1 (33)	29 (94)	3 (75)	36 (69)
Cleared hep C naturally	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Cleared hep C with treatment	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Chronic hep C	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Don't know	1 (20)	0 (0)	2 (67)	2 (7)	0 (0)	13 (25)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	3 (6)
Age first diagnosed with hep C						
Median age	--	--	25	24	--	--
Range	--	--	--	--	--	--
Ever had HCV treatment (%)*						
	N = 3	N = 0	N = 0	N = 0	N = 0	N = 0
No treatment	3 (100)	--	--	--	--	--
Interferon-based medication	0 (0)	--	--	--	--	--
Direct-acting antiviral (DAA)	n/a	n/a	n/a	n/a	--	--
Other	0 (0)	--	--	--	--	--
Not reported	0 (0)	--	--	--	--	--
Ever had PCR/RNA test to test for reinfection (%)						
< 1 year ago	n/a	n/a	n/a	n/a	--	--
>1 year ago	n/a	n/a	n/a	n/a	--	--
Not retested	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	--	--
Result of PCR/RNA test (%)^						
Still cured of hep C	n/a	n/a	n/a	n/a	--	--
Reinfected	n/a	n/a	n/a	n/a	--	--
Don't know	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	--	--

*Number (%) of those reporting positive HCV test results or specifying age of hep C diagnosis.

Table 85 Number (%) of respondents reporting interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Ever sought out HCV treatment (%)*						
No	n/a	n/a	--	--	--	--
Yes	n/a	n/a	--	--	--	--
Not reported	n/a	n/a	--	--	--	--
Willingness to receive treatment for HCV (%)						
Unwilling	n/a	n/a	--	--	--	--
Neutral	n/a	n/a	--	--	--	--
Willing	n/a	n/a	--	--	--	--
Not reported	n/a	n/a	--	--	--	--
More willing to receive HCV treatment in prison than community (%)						
Yes	n/a	n/a	--	--	--	--
No	n/a	n/a	--	--	--	--
Unsure	n/a	n/a	--	--	--	--
Not reported	n/a	n/a	--	--	--	--
Knowledge & awareness of DAA treatments for hepatitis C[^]					N = 4	N = 57
<i>New treatments for hep C are available (%)</i>						
True	n/a	n/a	n/a	n/a	1 (25)	5 (9)
False	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Unsure	n/a	n/a	n/a	n/a	1 (25)	48 (84)
Not reported	n/a	n/a	n/a	n/a	2 (50)	4 (7)
<i>The new hep C treatments require injections (%)</i>						
True	n/a	n/a	n/a	n/a	1 (25)	1 (2)
False	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Unsure	n/a	n/a	n/a	n/a	1 (25)	49 (86)
Not reported	n/a	n/a	n/a	n/a	2 (50)	7 (12)
<i>The new hep C treatments have few side-effects (%)</i>						
True	n/a	n/a	n/a	n/a	1 (25)	2 (4)
False	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Unsure	n/a	n/a	n/a	n/a	1 (25)	48 (84)
Not reported	n/a	n/a	n/a	n/a	2 (50)	7 (12)
<i>The new hep C treatments take up to one year (%)</i>						
True	n/a	n/a	n/a	n/a	1 (25)	1 (2)
False	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Unsure	n/a	n/a	n/a	n/a	1 (25)	49 (86)
Not reported	n/a	n/a	n/a	n/a	2 (50)	7 (12)

*Of those who have not had treatment

[^]Correct response is shaded.

HIV antibody prevalence

Table 86 HIV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2010						
IDU	7	0 (0)	1	0 (0)	59	0 (0)
Non-IDU	57	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--
2013						
IDU	3	0 (0)	0	0 (0)	3	0 (0)
Non-IDU	35	0 (0)	2	0 (0)	37	0 (0)
p value		--		--		--
2016						
IDU	2	0 (0)	0	0 (0)	2	0 (0)
Non-IDU	39	0 (0)	2	0 (0)	41	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 87 HCV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
IDU	7	3 (43)	1	0 (0)	8	3 (38)
Non-IDU	57	0 (0)	2	0 (0)	59	0 (0)
p value		<0.001		--		<0.001
2013						
IDU	2	2 (100)	0	0 (0)	2	2 (100)
Non-IDU	33	1 (3)	2	0 (0)	35	1 (3)
p value		<0.001		--		<0.001
2016						
IDU	2	0 (0)	0	0 (0)	2	0 (0)
Non-IDU	35	0 (0)	2	0 (0)	37	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 88 HCV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Heterosexual	61	3 (5)	3	0 (0)	64	3 (5)
Bisexual	1	0 (0)	0	0 (0)	1	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.1		--		0.9
2013						
Heterosexual	35	3 (9)	2	0 (0)	37	3 (8)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Heterosexual	36	0 (0)	2	0 (0)	38	0 (0)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 89 HCV antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
< 20 years	6	0 (0)	0	0 (0)	6	0 (0)
20 – 24	12	0 (0)	0	0 (0)	12	0 (0)
25 – 29	13	0 (0)	0	0 (0)	13	0 (0)
30 + years	33	3 (9)	0	0 (0)	36	3 (8)
p value		0.4		--		0.4
2013						
< 20 years	5	0 (0)	0	0 (0)	5	0 (0)
20 – 24	10	0 (0)	1	0 (0)	11	0 (0)
25 – 29	8	1 (13)	1	0 (0)	9	1 (11)
30 + years	23	2 (9)	1	0 (0)	24	2 (8)
p value		0.6		--		0.7
2016						
< 20 years	3	0 (0)	0	0 (0)	3	0 (0)
20 – 24	6	0 (0)	1	0 (0)	7	0 (0)
25 – 29	9	0 (0)	1	0 (0)	10	0 (0)
30 + years	30	0 (0)	3	0 (0)	33	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 90 HCV antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	0	0 (0)	1	0 (0)	1	0 (0)
6 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
10 + years	5	3 (60)	0	0 (0)	5	3 (60)
p value		0.3		--		0.4
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	1	1 (100)	0	0 (0)	1	1 (100)
10 + years	1	1 (100)	0	0 (0)	1	1 (100)
p value		--		--		--
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
10 + years	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 91 HCV antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Amphetamine (Speed, Ice)	0	0 (0)	3	2 (67)	3	2 (67)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	2	0 (0)	2	0 (0)
Other/not reported	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.2		0.3
2013						
Amphetamine (Speed, Ice)	0	0 (0)	1	1 (100)	1	1 (100)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		--		--
2016						
Amphetamine (Speed, Ice)	0	0 (0)	1	0 (0)	1	0 (0)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 92 HCV antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Less than daily	0	0 (0)	1	1 (100)	1	1 (100)
Daily or more	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.3		0.3
2013						
Less than daily	0	0 (0)	1	1 (100)	1	1 (100)
Daily or more	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Less than daily	0	0 (0)	0	0 (0)	0	0 (0)
Daily or more	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 93 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	0	0 (0)	4	2 (50)	4	2 (50)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 94 HCV antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	0	0 (0)	3	2 (67)	3	2 (67)
Yes	1	0 (0)	3	1 (33)	4	1 (25)
p value		--		0.4		0.3
2013						
No	0	0 (0)	2	2 (100)	2	2 (100)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
No	0	0 (0)	2	0 (0)	2	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 95 HCV antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
1	26	1 (4)	2	0 (0)	28	1 (4)
2 to 4	21	1 (5)	0	0 (0)	21	1 (5)
5 to 9	14	1 (7)	1	1 (100)	15	1 (7)
10 +	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.0		--		1.0
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	2	0 (0)	1	0 (0)	3	0 (0)
2 to 4	11	0 (0)	1	0 (0)	12	0 (0)
5 to 9	6	0 (0)	0	0 (0)	6	0 (0)
10 +	8	0 (0)	0	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 96 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	7	2 (29)	1	0 (0)	8	2 (25)
Indigenous	57	1 (2)	2	0 (0)	59	1 (2)
p value		0.002		--		0.003
2013						
Non-Indigenous	7	2 (29)	0	0 (0)	7	2 (29)
Indigenous	38	1 (3)	3	0 (0)	41	1 (2)
p value		0.01		--		0.008
2016						
Non-Indigenous	4	0 (0)	1	0 (0)	5	0 (0)
Indigenous	44	0 (0)	4	0 (0)	48	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 97 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
Indigenous	55	0 (0)	4	1 (25)	59	1 (2)
p value		--		0.5		0.003
2013						
Non-Indigenous	5	1 (20)	1	1 (100)	6	2 (33)
Indigenous	30	0 (0)	1	1 (100)	31	1 (3)
p value		0.01		--		0.008
2016						
Non-Indigenous	2	0 (0)	2	0 (0)	4	0 (0)
Indigenous	35	0 (0)	0	0 (0)	35	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 98 HCV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Highly accessible/accessible	14	1 (7)	1	0 (0)	15	1 (7)
Moderately accessible	0	0 (0)	0	0 (0)	0	0 (0)
Remote/very remote	43	2 (5)	2	0 (0)	45	2 (4)
p value		0.7		--		0.7
2013						
Highly accessible/accessible	1	0 (0)	0	0 (0)	1	0 (0)
Moderately accessible	11	1 (9)	1	0 (0)	12	1 (8)
Remote/very remote	22	2 (9)	1	0 (0)	23	2 (9)
p value		1.0		--		1.0
2016						
Highly accessible/accessible	1	0 (0)	0	0 (0)	1	0 (0)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	31	0 (0)	1	0 (0)	32	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 99 HCV antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Australia	61	2 (3)	2	0 (0)	63	2 (3)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		<0.001		--		<0.001
2013						
Australia	34	3 (9)	2	0 (0)	36	3 (8)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.8		--		0.8
2016						
Australia	37	0 (0)	2	0 (0)	37	0 (0)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 100 Self-reported HCV status versus HCV serology by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Positive	2	2 (100)	0	0 (0)	2	2 (100)
Negative	24	0 (0)	0	0 (0)	24	0 (0)
Not sure	0	0 (0)	1	0 (0)	1	0 (0)
p value		<0.001				<0.001
2013						
Positive	0	0 (0)	0	0 (0)	0	0 (0)
Negative	20	0 (0)	0	0 (0)	20	0 (0)
Not sure	3	3 (100)	0	0 (0)	3	3 (100)
p value		<0.001		--		<0.001
2016						
Positive	0	0 (0)	0	0 (0)	0	0 (0)
Negative	29	0 (0)	1	0 (0)	29	0 (0)
Not sure	4	0 (0)	0	0 (0)	4	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HBV prevalence

Table 101 HBV surface-antigen prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	72	2 (3)	3	0 (0)	75	2 (3)
Non-IDU	125	4 (3)	4	0 (0)	129	4 (3)
p value		0.9		--		0.9
2013						
IDU	3	0 (0)	0	0 (0)	3	0 (0)
Non-IDU	33	1 (3)	2	0 (0)	35	1 (3)
p value		0.8		--		0.8
2016						
IDU	2	0 (0)	0	0 (0)	2	0 (0)
Non-IDU	34	2 (6)	2	0 (0)	36	2 (6)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 102 HBV core-antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	7	0 (0)	1	0 (0)	8	0 (0)
Non-IDU	44	2 (5)	2	1 (50)	46	3 (7)
p value		0.6		0.4		0.5
2013						
IDU	3	1 (33)	0	0 (0)	3	1 (33)
Non-IDU	33	16 (48)	2	1 (50)	35	17 (49)
p value		0.6		--		0.6
2016						
IDU	2	0 (0)	0	0 (0)	2	0 (0)
Non-IDU	34	15 (44)	2	0 (0)	36	15 (42)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 103 HBV core-antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Heterosexual	49	17 (35)	3	0 (0)	52	20 (38)
Bisexual	1	0 (0)	0	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.5		--		0.4
2013						
Heterosexual	36	17 (47)	2	1 (50)	38	18 (47)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Heterosexual	35	14 (40)	2	0 (0)	37	14 (38)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 104 HBV core-antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010	6	1 (17)	0	0 (0)	6	1 (17)
< 20 years	10	1 (10)	0	0 (0)	10	1 (10)
20 – 24	9	3 (33)	0	0 (0)	9	3 (33)
25 – 29	26	13 (50)	3	3 (100)	29	16 (55)
30 + years		0.1		--		0.04
p value						
2013						
< 20 years	5	0 (0)	0	0 (0)	5	0 (0)
20 – 24	9	2 (22)	1	0 (0)	10	2 (20)
25 – 29	8	3 (38)	1	1 (100)	9	4 (44)
30 + years	25	15 (60)	1	1 (100)	26	16 (62)
p value		0.04		0.2		0.02
2016						
< 20 years	3	0 (0)	0	0 (0)	3	0 (0)
20 – 24	6	3 (50)	1	0 (0)	7	3 (43)
25 – 29	9	2 (22)	1	0 (0)	10	2 (20)
30 + years	29	15 (52)	3	2 (67)	32	17 (53)
p value		0.2		0.3		0.1

† Excludes equivocal test results and missing values.

Table 105 HBV core-antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 5 years	0	0 (0)	1	1 (100)	1	1 (100)
6 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
10 + years	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.2		--		0.2
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	2	0 (0)	0	0 (0)	2	0 (0)
10 + years	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.08		--		0.08
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
10 + years	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 106 HBV core-antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Amphetamine (Speed, Ice)	0	0 (0)	3	1 (33)	3	1 (33)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	2	1 (50)	2	1 (50)
Other/not reported	1	1 (100)	2	0 (0)	3	1 (33)
p value		--		0.5		0.9
2013						
Amphetamine (Speed, Ice)	0	0 (0)	1	1 (100)	1	1 (100)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.08		0.08
2016						
Amphetamine (Speed, Ice)	0	0 (0)	1	0 (0)	1	0 (0)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 107 HBV core-antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Less than daily	0	0 (0)	1	1 (100)	1	1 (100)
Daily or more	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.3		0.3
2013						
Less than daily	0	0 (0)	2	1 (50)	2	1 (50)
Daily or more	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Less than daily	0	0 (0)	0	0 (0)	0	0 (0)
Daily or more	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 108 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	0	0 (0)	4	2 (50)	4	2 (50)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 109 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	0	0 (0)	3	0 (0)	3	0 (0)
Yes	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.2		0.1
2013						
No	0	0 (0)	2	1 (50)	2	1 (50)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
No	0	0 (0)	2	0 (0)	2	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 110 HBV core-antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
1	21	5 (24)	2	2 (100)	23	7 (30)
2 to 4	15	5 (33)	0	0 (0)	15	5 (33)
5 to 9	12	6 (50)	1	1 (100)	13	7 (54)
10 +	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.3		--		0.4
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	2	1 (50)	1	0 (0)	3	1 (33)
2 to 4	10	6 (60)	1	0 (0)	11	6 (55)
5 to 9	6	3 (50)	0	0 (0)	6	3 (50)
10 +	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.5		--		0.6

† Excludes equivocal test results and missing values.

Table 111 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	7	1 (14)	1	1 (100)	8	2 (25)
Indigenous	44	17 (39)	2	2 (100)	46	19 (41)
p value		0.2		--		0.4
2013						
Non-Indigenous	8	3 (38)	--	--	8	3 (38)
Indigenous	38	17 (45)	3	2 (67)	41	19 (46)
p value		0.7		--		0.7
2016						
Non-Indigenous	4	0 (0)	1	0 (0)	5	0 (0)
Indigenous	43	20 (47)	4	2 (50)	47	22 (47)
p value		0.07		0.4		0.04

† Excludes equivocal test results and missing values.

Table 112 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
Indigenous	42	18 (43)	4	1 (25)	46	19 (41)
p value		0.09		0.5		0.4
2013						
Non-Indigenous	6	2 (33)	1	1 (100)	7	3 (43)
Indigenous	29	15 (52)	2	0 (0)	31	15 (48)
p value		0.4		0.08		0.7
2016						
Non-Indigenous	2	0 (0)	2	0 (0)	4	0 (0)
Indigenous	34	15 (44)	0	0 (0)	34	15 (44)
p value		0.2		--		0.04

† Excludes equivocal test results and missing values.

Table 113 HBV core-antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Highly accessible/accessible	15	6 (40)	1	1 (100)	16	7 (44)
Moderately accessible	0	0 (0)	0	0 (0)	0	0 (0)
Remote/very remote	32	12 (38)	2	2 (100)	34	14 (41)
p value		0.9		--		0.9
2013						
Highly accessible/accessible	1	0 (0)	--	--	1	0 (0)
Moderately accessible	13	4 (31)	1	1 (100)	14	5 (46)
Remote/very remote	22	13 (59)	1	0 (0)	23	13 (57)
p value		0.2		0.2		0.3
2016						
Highly accessible/accessible	1	0 (0)	0	0 (0)	1	0 (0)
Moderately accessible	4	1 (25)	1	0 (0)	5	1 (20)
Remote/very remote	30	13 (43)	1	0 (0)	31	13 (42)
p value		0.6		--		0.5

† Excludes equivocal test results and missing values.

Table 114 HBV core-antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Australia	48	17 (35)	2	2 (100)	50	19 (38)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	2	0 (0)	1	1 (100)	3	1 (33)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.2		--		0.4
2013						
Australia	35	16 (46)	2	1 (50)	37	17 (46)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.3		--		0.4
2016						
Australia	36	15 (42)	2	0 (0)	38	15 (39)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 115 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
IDU	8	1 (13)	3 (38)	0 (0)	4 (50)
Non-IDU	46	17 (37)	15 (33)	3 (7)	11 (24)
p value					0.3
2013					
IDU	3	1 (33)	1 (33)	0 (0)	1 (33)
Non-IDU	35	7 (20)	16 (46)	1 (3)	11 (31)
p value					0.9
2016					
IDU	2	1 (50)	0 (0)	0 (0)	1 (50)
Non-IDU	36	12 (33)	13 (36)	2 (6)	9 (25)
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 116 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2010					
Heterosexual	52	18 (35)	17 (33)	3 (6)	14 (27)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.5
2013					
Heterosexual	38	8 (21)	17 (45)	1 (3)	12 (32)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2016					
Heterosexual	37	13 (35)	12 (32)	2 (5)	10 (27)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 117 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2010					
< 20 years	6	4 (67)	1 (17)	0 (0)	1 (17)
20 – 24	10	3 (30)	1 (10)	0 (0)	6 (60)
25 – 29	9	3 (33)	1 (11)	2 (22)	3 (33)
30 + years	29	8 (28)	15 (52)	1 (3)	5 (17)
p value					0.02
2013					
< 20 years	5	3 (60)	0 (0)	0 (0)	2 (40)
20 – 24	11	3 (27)	1 (9)	1 (9)	6 (55)
25 – 29	9	5 (56)	4 (44)	0 (0)	0 (0)
30 + years	25	1 (4)	16 (64)	0 (0)	8 (32)
p value					0.002
2016					
< 20 years	3	3 (100)	0 (0)	0 (0)	0 (0)
20 – 24	7	4 (57)	2 (29)	1 (14)	0 (0)
25 – 29	10	4 (40)	2 (20)	0 (0)	4 (40)
30 + years	31	8 (26)	14 (45)	2 (6)	7 (23)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 118 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2010					
1	23	10 (43)	5 (22)	2 (9)	6 (26)
2 to 4	15	6 (40)	5 (33)	0 (0)	4 (27)
5 to 9	13	2 (15)	6 (46)	1 (8)	4 (31)
10 +	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.6
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--
2016					
1	3	2 (67)	1 (33)	0 (0)	0 (0)
2 to 4	11	2 (18)	6 (55)	0 (0)	3 (27)
5 to 9	6	1 (17)	1 (17)	2 (33)	2 (33)
10 +	8	2 (25)	2 (25)	0 (0)	4 (50)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 119 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2010					
Non-Indigenous	8	4 (50)	2 (25)	0 (0)	2 (25)
Indigenous	46	14 (33)	16 (35)	3 (7)	13 (28)
p value					0.7
2013					
Non-Indigenous	8	3 (38)	3 (38)	0 (0)	2 (25)
Indigenous	41	9 (22)	18 (44)	1 (2)	9 (22)
p value					0.8
2016					
Non-Indigenous	5	3 (60)	0 (0)	0 (0)	2 (40)
Indigenous	46	16 (35)	18 (39)	3 (7)	9 (20)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 120 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Highly accessible/accessible	16	3 (19)	7 (44)	0 (0)	6 (38)
Moderately accessible	0	0 (0)	0 (0)	0 (0)	0 (0)
Remote/very remote	34	11 (32)	11 (32)	3 (9)	9 (26)
p value					0.4
2013					
Highly accessible/accessible	1	1 (100)	0 (0)	0 (0)	0 (0)
Moderately accessible	14	4 (49)	5 (36)	0 (0)	5 (36)
Remote/very remote	22	3 (14)	12 (55)	1 (5)	6 (27)
p value					0.4
2016					
Highly accessible/accessible	1	1 (100)	0 (0)	0 (0)	0 (0)
Moderately accessible	5	2 (40)	1 (20)	0 (0)	2 (40)
Remote/very remote	31	10 (32)	11 (35)	2 (6)	8 (26)
p value					0.8

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 121 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2010						
No	23	9 (39)	0	0 (0)	23	9 (39)
Yes	8	5 (63)	0	0 (0)	8	5 (63)
Not sure	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.0		--		0.3
2013						
No	0	0	0	0 (0)	0	0 (0)
Yes	2	2 (100)	0	0 (0)	2	2 (100)
Not sure	16	10 (63)	1	0 (0)	17	10 (59)
p value		0.3		--		0.3
2016						
No	2	1 (50)	1	0 (0)	3	1 (33)
Yes	10	5 (50)	1	1 (100)	11	6 (55)
Not sure	7	3 (43)	0	0 (0)	7	3 (43)
p value		1.0		--		0.8

* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 122 Genital chlamydia prevalence by gender and survey year†

Gender	N° tested	N° with chlamydia (%)
2010		
Male	63	1 (2)
Female	3	0 (0)
p value		0.8
2013		
Male	49	4 (8)
Female	3	0 (0)
p value		0.6
2016		
Male	46	0 (0)
Female	2	0 (0)
p value		--

† Excludes missing values.

Gonorrhoea

Table 123 Genital gonorrhoea prevalence by gender and survey year†

Gender	N° tested	N° with gonorrhoea (%)
2010		
Male	63	2 (3)
Female	3	0 (0)
p value		0.8
2013		
Male	47	1 (2)
Female	3	0 (0)
p value		0.8
2016		
Male	47	4 (8)
Female	4	0 (0)
p value		0.6

† Excludes missing values.

Syphilis

Table 124 Syphilis markers by gender and survey year†

Gender	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	64	13 (20)	5 (8)	13 (20)
Female	3	1 (33)	0 (0)	1 (33)
p value		0.6	0.4	0.6
2013				
Male	47	6 (13)	4 (8)	2 (4)
Female	3	1 (33)	1 (33)	1 (33)
p value		0.3	0.4	0.2
2016				
Male	52	9 (17)	4 (44)	9 (17)
Female	5	4 (80)	1 (25)	4 (80)
p value		0.001	0.5	0.001

† Excludes missing values.

Queensland
2004, 2007, 2010, 2013, 2016

Table 125 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 1		N = 1		N = 5		N = 4		N = 4	
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140	N = 84	N = 68
Gender (%)										
Male	80 (100)	58 (100)	91 (100)	66 (100)	70 (82)	110 (87)	121 (87)	129 (92)	61 (73)	59 (87)
Female	0 (0)	0 (0)	0 (0)	0 (0)	15 (18)	16 (13)	18 (13)	11 (8)	22 (26)	9 (13)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Age (years)										
Median age	29	36	29	27	30	30	32	31	34	32
Age range	17 – 53	17 – 67	18 – 47	17 – 63	18 – 52	17 – 66	17 – 55	17 – 64	17 – 52	17 – 70
Age group (%)										
<25 years	28 (34)	12 (21)	21 (23)	29 (44)	26 (31)	43 (34)	28 (20)	41 (29)	20 (24)	17 (25)
25+ years	54 (64)	46 (79)	70 (77)	37 (56)	59 (69)	83 (66)	109 (78)	98 (70)	64 (76)	51 (75)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	1 (1)	0 (0)	0 (0)
Aboriginal and/or Torres Strait Islander origin (%)										
No	74 (90)	52 (90)	77 (85)	57 (86)	63 (74)	76 (60)	87 (63)	88 (63)	63 (75)	49 (72)
Yes	8 (10)	6 (10)	14 (15)	9 (14)	22 (26)	50 (40)	51 (37)	52 (37)	19 (23)	19 (28)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	2 (2)	0 (0)
Sexual identity (%)										
Heterosexual	81 (99)	56 (97)	90 (99)	66 (100)	76 (89)	123 (98)	135 (97)	135 (96)	71 (85)	60 (88)
Bisexual	1 (1)	2 (3)	0 (0)	0 (0)	5 (6)	1 (1)	3 (2)	2 (1)	6 (7)	1 (1)
Gay/lesbian	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	2 (1)	3 (4)	2 (3)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	3 (4)	5 (7)
Region/Country of birth (%)										
Australia	71 (87)	40 (69)	83 (91)	61 (92)	76 (89)	106 (84)	128 (92)	124 (89)	76 (90)	61 (90)
Other Oceania	8 (10)	8 (14)	1 (1)	1 (2)	4 (5)	11 (9)	5 (4)	8 (6)	6 (7)	2 (3)
Asia	2 (2)	2 (3)	6 (7)	1 (2)	1 (1)	0 (0)	1 (1)	2 (1)	1 (1)	2 (3)
UK & Ireland	1 (1)	3 (5)	0 (0)	0 (0)	3 (4)	2 (2)	4 (3)	2 (1)	0 (0)	0 (0)
Other	0 (0)	5 (9)	0 (0)	3 (5)	1 (1)	7 (6)	1 (1)	4 (3)	1 (1)	2 (3)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Residential remoteness in 12 months before prison (%)										
Highly/accessible	80 (98)	52 (90)	82 (90)	60 (91)	72 (85)	89 (71)	119 (86)	90 (64)	76 (90)	51 (75)
Mod accessible	0 (0)	1 (2)	1 (1)	2 (3)	4 (5)	9 (7)	14 (10)	24 (17)	4 (5)	11 (16)
Very / remote	2 (2)	2 (3)	2 (2)	1 (2)	3 (4)	22 (17)	5 (4)	22 (16)	2 (2)	3 (4)
Not reported	0 (0)	3 (5)	6 (7)	3 (5)	6 (7)	6 (5)	1 (1)	4 (3)	2 (2)	3 (4)
First time in prison (%)										
No	81 (99)	53 (91)	80 (88)	33 (50)	73 (86)	68 (54)	118 (85)	82 (59)	72 (86)	31 (46)
Yes	1 (1)	5 (9)	11 (12)	32 (48)	12 (14)	56 (44)	20 (14)	57 (41)	12 (14)	37 (54)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	2 (2)	1 (1)	1 (1)	0 (0)	0 (0)
Lifetime imprisonments (%)										
One	1 (1)	5 (9)	11 (12)	32 (48)	25 (29)	78 (62)	n/a	n/a	10 (14)	12 (39)
Two to four	57 (70)	47 (81)	48 (53)	25 (38)	28 (33)	30 (24)	n/a	n/a	24 (33)	11 (35)
Five to nine	19 (23)	4 (7)	20 (22)	3 (5)	21 (25)	8 (6)	n/a	n/a	22 (31)	2 (6)
Ten or more	5 (6)	1 (2)	10 (11)	4 (6)	11 (13)	8 (6)	n/a	n/a	7 (10)	1 (3)
Not reported	0 (0)	1 (2)	2 (2)	2 (3)	0 (0)	2 (2)	n/a	n/a	9 (13)	5 (16)
Imprisonment in last year (%)										
No	2 (2)	5 (9)	32 (40)	11 (32)	27 (32)	80 (63)	33 (28)	22 (57)	14 (19)	11 (35)
Yes	80 (98)	53 (91)	46 (58)	22 (65)	55 (65)	41 (33)	77 (65)	53 (65)	51 (71)	14 (45)
Not reported	0 (0)	0 (0)	2 (3)	1 (3)	3 (4)	5 (4)	8 (7)	7 (9)	7 (10)	6 (19)

Table 126 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140	N = 84	N = 68
Ever smoked a full cigarette (%)										
No	n/a	n/a	5 (5)	14 (21)	2 (2)	11 (9)	8 (6)	20 (14)	1 (1)	12 (18)
Yes	n/a	n/a	86 (95)	52 (79)	83 (98)	115 (91)	131 (94)	120 (86)	83 (99)	56 (82)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age of smoking										
Med age 1 st	n/a	n/a	14	14	14	14	13	15	13	14
Age range	n/a	n/a	6–25	6–22	7–37	6–50	6–35	6–40	7–24	8–27
Current smoker (%)*										
No	n/a	n/a	5 (6)	14 (21)	8 (9)	30 (24)	9 (7)	13 (11)	13 (16)	12 (21)
Yes	n/a	n/a	86 (95)	52 (79)	77 (91)	96 (76)	122 (93)	103 (86)	69 (83)	43 (77)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (3)	1 (1)	1 (2)
Smoking frequency (%)										
Weekly or less	n/a	n/a	5 (6)	4 (8)	1 (1)	6 (6)	0 (0)	0 (0)	4 (6)	3 (7)
5 - 10/day	n/a	n/a	19 (22)	11 (21)	18 (23)	46 (48)	46 (38)	41 (39)	24 (35)	9 (21)
11 - 20/day	n/a	n/a	28 (33)	15 (29)	40 (52)	24 (25)	48 (39)	40 (38)	23 (33)	17 (40)
>20/day	n/a	n/a	34 (40)	21 (40)	17 (22)	19 (20)	26 (21)	20 (19)	15 (22)	14 (33)
Not reported	n/a	n/a	0 (0)	1 (2)	1 (1)	1 (1)	2 (2)	5 (5)	3 (4)	0 (0)
Other drugs used last month (%)**										
None	n/a	n/a	n/a	n/a	17 (21)	53 (47)	16 (12)	64 (46)	12 (14)	27 (40)
Cannabis	n/a	n/a	n/a	n/a	45 (69)	48 (81)	84 (68)	57 (75)	39 (56)	23 (68)
Heroin	n/a	n/a	n/a	n/a	23 (35)	1 (2)	31 (25)	2 (3)	14 (20)	0 (0)
Cocaine	n/a	n/a	n/a	n/a	1 (2)	1 (2)	7 (6)	5 (7)	3 (4)	2 (6)
Methamphetamine	n/a	n/a	n/a	n/a	33 (51)	7 (12)	89 (72)	26 (34)	57 (81)	10 (29)
Methadone	n/a	n/a	n/a	n/a	4 (6)	0 (0)	7 (6)	1 (1)	3 (4)	0 (0)
Other opiates	n/a	n/a	n/a	n/a	6 (9)	1 (2)	28 (23)	3 (4)	9 (13)	1 (3)
Buprenorphine	n/a	n/a	n/a	n/a	10 (15)	1 (2)	6 (5)	0 (0)	6 (9)	0 (0)
Anabolic steroids [^]	n/a	n/a	n/a	n/a	0 (0)	1 (2)	6 (5)	0 (0)	0 (0)	0 (0)
Hallucinogens	n/a	n/a	n/a	n/a	1 (2)	0 (0)	4 (3)	4 (5)	1 (1)	1 (3)
Benzodiazepine	n/a	n/a	n/a	n/a	15 (23)	4 (7)	28 (23)	7 (9)	13 (19)	4 (12)
Ecstasy/MDA	n/a	n/a	n/a	n/a	2 (3)	2 (3)	11 (9)	6 (8)	8 (11)	3 (9)
Inhalants	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (3)
Other drug	n/a	n/a	n/a	n/a	0 (0)	1 (2)	2 (2)	0 (0)	3 (4)	2 (6)
Not reported	n/a	n/a	n/a	n/a	3 (4)	14 (11)	0 (0)	0 (0)	2 (2)	7 (10)
Risk of alcohol-related harm (%)^^										
Non-drinker	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	26 (27)	19 (28)
Low risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	36 (43)	23 (34)
High risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	18 (21)	18 (26)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4 (5)	8 (12)

*Prior to prison; **More than one drug option could be selected; ^Also includes hormones and peptides from 2016; ^^AUDIT-C

Table 127 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013	2016
	N = 82	N = 91	N = 85	N = 139	N = 84
Med age 1st IDU	17	17	17	18	17
Age range	11 – 38	11 – 34	8 – 35	10 – 47	10 – 42
Not reported	0	5	4	4	4
Med IDU (years)	9	10	13	14	15
Range	<1 – 28	<1 – 33	<1 – 34	<1 – 44	<1 – 35
Years since first drug injection (%)					
<3 years	9 (11)	6 (7)	5 (6)	18 (13)	15 (18)
3+ years	73 (89)	80 (88)	76 (89)	114 (84)	66 (78)
Not reported	0 (0)	5 (5)	4 (5)	4 (3)	3 (4)
Last drug injected (%)					
Methamphetamine	59 (72)	57 (63)	49 (58)	95 (68)	63 (75)
Anabolic steroids	0 (0)	0 (0)	0 (0)	4 (3)	0 (0)
Cocaine	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)
Heroin	20 (24)	20 (22)	21 (25)	24 (17)	10 (12)
Methadone	1 (1)	2 (2)	0 (0)	1 (1)	2 (2)
Morphine	2 (2)	4 (4)	5 (6)	7 (5)	0 (0)
Subutex/buprenorphine/Suboxone	n/a	n/a	n/a	0 (0)	2 (2)
Other	0 (0)	6 (6)	7 (8)	4 (3)	7 (8)
Not reported	0 (0)	1 (1)	2 (2)	3 (2)	0 (0)
Frequency of injection last month (%)					
Not last month	32 (39)	44 (48)	38 (45)	36 (26)	28 (33)
< Weekly	6 (7)	10 (11)	8 (9)	24 (17)	11 (13)
Weekly	7 (9)	6 (7)	5 (6)	14 (10)	10 (12)
Daily or more	37 (45)	28 (31)	33 (39)	63 (45)	35 (42)
Not reported	0 (0)	3 (3)	1 (1)	2 (1)	0 (0)
N° Injected last month	N = 50	N = 44	N = 46	N = 102	N = 56
Places injected last month (%)*					
Prison	3 (6)	1 (2)	2 (4)	2 (2)	2 (4)
Own home	45 (90)	39 (89)	28 (61)	61 (60)	39 (70)
Friend's home	37 (74)	27 (61)	20 (43)	34 (33)	24 (43)
Dealer's home	23 (46)	19 (43)	8 (17)	15 (15)	13 (23)
Street, park, beach	25 (50)	20 (45)	8 (17)	12 (12)	17 (30)
Car	31 (62)	21 (48)	12 (26)	16 (16)	14 (25)
Public toilet	21 (42)	16 (36)	11 (24)	9 (9)	11 (20)
Commercial injecting room	2 (4)	0 (0)	1 (2)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	4 (8)	0 (0)	1 (2)	0 (0)	0 (0)
Squat	9 (18)	1 (2)	1 (2)	0 (0)	1 (2)
Other place	0 (0)	1 (2)	1 (2)	1 (1)	0 (0)
Use of sterile needles & syringes last month (%)					
All injections	37 (74)	28 (64)	38 (83)	75 (74)	39 (70)
Most of the time	8 (16)	9 (20)	4 (9)	17 (17)	13 (23)
Half of the time	4 (8)	4 (9)	2 (4)	1 (1)	0 (0)
Some of the time	1 (2)	3 (7)	0 (0)	6 (6)	2 (4)
Not last month	0 (0)	0 (0)	1 (2)	1 (1)	2 (4)
Not reported	0 (0)	0 (0)	1 (2)	2 (2)	0 (0)
Times injected by someone else after they injected themselves or others in past month (%)					
More than 5 times	1 (2)	1 (2)	1 (2)	4 (4)	2 (4)
3 to 5 times	1 (2)	2 (2)	4 (9)	1 (1)	1 (2)
Once or twice	1 (2)	1 (2)	2 (4)	8 (8)	5 (9)
None	47 (94)	30 (68)	38 (83)	82 (80)	48 (86)
Not reported	0 (0)	10 (23)	0 (0)	6 (6)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	39 (78)	33 (75)	36 (78)	81 (79)	42 (75)
Once	1 (2)	2 (5)	2 (4)	4 (4)	3 (5)
Twice	4 (8)	3 (7)	3 (7)	3 (3)	6 (11)
3-5 times	2 (4)	3 (7)	2 (4)	5 (5)	1 (2)
>5 times	4 (8)	3 (7)	2 (4)	7 (7)	4 (7)
Not reported	0 (0)	0 (0)	1 (2)	2 (2)	0 (0)

* More than one drug option could be selected.

Table 128 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year (cont.)

Injecting behaviour	2004	2007	2010	2013	2016
	N = 82	N = 91	N = 85	N = 139	N = 84
Number of people needle & syringe was re-used after last month (%)*					
One	8 (16)	5 (11)	2 (4)	7 (33)	3 (21)
Two	2 (4)	1 (2)	2 (4)	4 (19)	3 (21)
Three to five	1 (2)	2 (5)	1 (2)	3 (14)	0 (0)
More than five	0 (0)	0 (0)	2 (4)	3 (14)	2 (14)
Don't know how many	0 (0)	3 (7)	1 (2)	1 (5)	4 (29)
Not reported	0 (0)	0 (0)	1 (2)	3 (14)	2 (14)
Relationship to people needle & syringe was re-used after last month (%)**					
Regular sex partner	8 (16)	6 (14)	3 (7)	3 (14)	2 (14)
Casual sex partner	1 (2)	1 (2)	2 (4)	2 (10)	1 (7)
Close friend	2 (4)	5 (11)	2 (4)	8 (38)	6 (43)
Acquaintance	1 (2)	1 (2)	3 (7)	7 (33)	3 (21)
Other	1 (2)	0 (0)	1 (2)	1 (5)	1 (7)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	4 (29)
Last time re-used needle or syringe after someone (%)					
Last month	11 (13)	12 (13)	7 (8)	14 (10)	9 (11)
In the last 2-6 months	1 (1)	3 (3)	2 (2)	8 (6)	5 (6)
More than 6 months ago	28 (34)	12 (13)	17 (20)	35 (25)	23 (27)
Never	39 (48)	61 (67)	56 (66)	80 (58)	47 (56)
Not reported	2 (2)	3 (3)	3 (4)	2 (1)	0 (0)
Last place re-used needle or syringe after someone (%)					
Prison	7 (18)	3 (11)	8 (31)	19 (33)	6 (16)
Own home	10 (25)	13 (48)	9 (35)	18 (32)	16 (43)
Friend's home	5 (13)	4 (15)	5 (19)	12 (21)	11 (30)
Dealer's home	0 (0)	0 (0)	0 (0)	2 (4)	1 (3)
Street, park, bench	0 (0)	1 (4)	2 (8)	0 (0)	2 (5)
Car	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)
Public toilet	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Squat	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	19 (48)	6 (22)	0 (0)	6 (11)	1 (3)
Equipment used after someone else last month (%)*					
Spoon	11 (22)	20 (46)	15 (33)	8 (38)	8 (53)
Water	42 (84)	18 (41)	12 (26)	8 (38)	8 (53)
Filter	42 (84)	19 (43)	12 (26)	4 (19)	6 (40)
Tourniquet	2 (4)	10 (23)	9 (20)	4 (19)	8 (53)
Drug mix	7 (14)	18 (41)	10 (22)	9 (43)	3 (20)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)

*Of those who reported sharing needles & syringes in the past month

**More than one drug option could be selected

Table 129 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013	2016
N° surveyed	N = 82	N = 91	N = 85	N = 139	N = 84
Location of needle & syringe acquisition in the past month (%)*					
Needle & Syringe Program (NSP/CNP)	n/a	n/a	n/a	n/a	41 (49)
Chemist/Pharmacy	n/a	n/a	n/a	n/a	38 (45)
Vending machine	n/a	n/a	n/a	n/a	13 (16)
Personal source (e.g. friend)	n/a	n/a	n/a	n/a	9 (11)
Other	n/a	n/a	n/a	n/a	8 (10)
Not in the last month	n/a	n/a	n/a	n/a	19 (23)
From an NSP last month (%)					
Daily or almost daily	11 (22)	4 (9)	6 (7)	5 (4)	4 (6)
A couple of times each week	10 (20)	7 (16)	17 (20)	15 (11)	16 (25)
Less than weekly	n/a	n/a	6 (7)	21 (15)	9 (14)
Weekly	8 (16)	8 (18)	12 (14)	0 (0)	0 (0)
Once last month	10 (20)	3 (7)	0 (0)	28 (20)	15 (23)
Not in the last month	11 (22)	6 (14)	37 (44)	65 (47)	19 (29)
Not reported	0 (0)	16 (36)	6 (7)	5 (4)	1 (2)
From a chemist last month (%)					
Daily or almost daily	4 (8)	5 (11)	1 (1)	2 (1)	3 (5)
A couple of times each week	12 (24)	2 (5)	10 (12)	6 (4)	13 (20)
Less than weekly	12 (24)	12 (27)	7 (8)	15 (11)	6 (9)
Weekly	n/a	n/a	7 (8)	0 (0)	n/a
Once last month	7 (14)	5 (11)	0 (0)	21 (15)	18 (28)
Not in the last month	15 (30)	4 (9)	54 (64)	90 (65)	25 (38)
Not reported	0 (0)	16 (36)	4 (5)	5 (4)	0 (0)
Ever participated in the annual NSP community survey (%)					
No	75 (91)	52 (57)	72 (85)	111 (80)	77 (92)
Yes	3 (4)	0 (0)	3 (4)	7 (5)	5 (6)
Don't remember	0 (0)	2 (2)	4 (5)	0 (0)	0 (0)
Not reported	3 (4)	37 (41)	6 (7)	21 (15)	2 (2)

* More than one drug option could be selected.

Table 130 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140	N = 84	N = 68
Any treatment/therapy for drug use (%)*										
No	50 (61)	55 (95)	48 (53)	9 (14)	48 (56)	115 (91)	81 (58)	121 (86)	49 (58)	52 (76)
Yes	32 (38)	2 (3)	24 (26)	0 (0)	37 (44)	8 (6)	58 (42)	17 (12)	34 (40)	11 (16)
Not reported	0 (0)	1 (2)	19 (21)	57 (86)	0 (0)	3 (2)	0 (0)	2 (1)	1 (1)	5 (7)
History of methadone maintenance treatment (%)										
Currently	3 (4)	2 (3)	2 (2)	0 (0)	4 (5)	0 (0)	3 (2)	0 (0)	2 (2)	0 (0)
Previously	17 (21)	0 (0)	9 (10)	0 (0)	12 (14)	0 (0)	16 (12)	0 (0)	6 (7)	0 (0)
Never	62 (76)	56 (97)	62 (68)	0 (0)	69 (81)	123 (98)	138 (99)	120 (86)	76 (90)	64 (94)
Not reported	0 (0)	0 (0)	18 (20)	0 (0)	0 (0)	3 (2)	0 (0)	2 (1)	0 (0)	4 (6)
History of other pharmacotherapy treatment (%)										
Currently	66	56 (97)	7 (8)	0 (0)	5 (6)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Previously	4 (5)	2 (3)	9 (10)	0 (0)	11 (13)	0 (0)	12 (9)	0 (0)	15 (18)	0 (0)
Never	12 (15)	0 (0)	64 (70)	0 (0)	69 (81)	123 (98)	126 (91)	137 (98)	68 (81)	63 (93)
Not reported	0 (0)	0 (0)	11 (12)	0 (0)	0 (0)	2 (2)	1 (1)	3 (2)	0 (0)	5 (7)

*E.g. detox, rehab, counselling, NA

Table 131 Number (%) of respondents by body piercing and tattoos by injector status and survey year

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140	N = 84	N = 68
Body or ear piercings (%)										
No	50 (61)	40 (69)	55 (60)	44 (67)	46 (54)	76 (60)	88 (63)	95 (68)	46 (55)	48 (71)
Yes	31 (38)	18 (31)	35 (38)	22 (33)	39 (46)	50 (40)	51 (37)	45 (32)	37 (44)	19 (28)
Not reported	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Piercings other than ears (%)										
No	19 (59)	13 (72)	25 (69)	14 (64)	19 (48)	38 (74)	25 (49)	25 (56)	12 (32)	10 (50)
Yes	13 (41)	5 (28)	9 (25)	8 (36)	21 (53)	13 (26)	25 (49)	18 (40)	26 (68)	7 (35)
Not reported	0 (0)	0 (0)	2 (6)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	3 (15)
Pierced in past 12 months (%)										
No	10 (32)	5 (28)	14 (40)	9 (40)	26 (65)	26 (50)	43 (84)	36 (80)	27 (73)	13 (65)
Yes	5 (16)	0 (0)	4 (11)	1 (5)	4 (10)	3 (6)	4 (8)	6 (13)	7 (19)	3 (15)
Not reported	16 (52)	13 (72)	17 (49)	12 (55)	10 (25)	23 (44)	4 (8)	3 (7)	3 (8)	4 (20)
Who did piercing (%)*										
Professional^	1 (20)	0 (0)	3 (75)	1 (100)	1 (25)	3 (100)	3 (75)	6 (100)	7 (70)	3 (43)
Non-professional^^	1 (20)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)	1 (25)	0 (0)	0 (0)	0 (0)
Prisoner	1 (20)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Self	3 (60)	0 (0)	1 (25)	0 (0)	2 (50)	0 (0)	1 (25)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (30)	4 (57)
Needle used by other (%)										
No	5 (100)	0 (0)	1 (25)	0 (0)	3 (75)	0 (0)	2 (100)	0 (0)	n/a	n/a
Yes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Not reported	0 (0)	0 (0)	3 (75)	1 (100)	1 (25)	3 (100)	0 (0)	0 (0)	n/a	n/a
Penile implants (%)**										
No	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	60 (98)	58 (98)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	1 (2)
Penile implant in prison (%)										
No	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (100)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Tattoos (%)										
No	23 (28)	30 (52)	25 (27)	36 (55)	9 (11)	53 (42)	15 (11)	50 (36)	11 (13)	25 (37)
Yes	59 (72)	28 (48)	66 (73)	30 (45)	71 (84)	64 (51)	124 (89)	90 (64)	73 (87)	43 (63)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	5 (6)	9 (7)	0 (0)	0 (0)	0 (0)	0 (0)
Tattoos in past 12 months (%)										
No	42 (71)	24 (86)	51 (77)	13 (43)	49 (69)	44 (69)	82 (66)	62 (69)	42 (58)	20 (47)
Yes	15 (25)	4 (14)	15 (23)	17 (57)	21 (30)	17 (27)	39 (31)	28 (31)	28 (38)	19 (44)
Not reported	2 (3)	0 (0)	0 (0)	0 (0)	1 (1)	3 (5)	3 (2)	0 (0)	3 (4)	4 (9)
Who did tattooing (%)*										
Professional^	9 (60)	2 (50)	3 (20)	12 (71)	10 (48)	6 (35)	13 (33)	13 (46)	11 (39)	14 (73)
Non-professional^^	2 (13)	1 (25)	7 (47)	4 (24)	10 (48)	9 (53)	17 (44)	13 (46)	11 (39)	5 (26)
Prisoner	3 (20)	0 (0)	3 (20)	1 (6)	3 (14)	1 (6)	5 (13)	0 (0)	5 (18)	2 (11)
Self	2 (13)	1 (25)	1 (7)	0 (0)	1 (5)	2 (12)	7 (18)	3 (11)	2 (7)	3 (16)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (7)	1 (4)	0 (0)

* More than one drug option could be selected.

**Males only, new question 2017

^ E.g. chemist, hairdresser, beauty salon, tattooist; ^^Non-professional outside prison e.g. friend, family

Table 132 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140	N = 84	N = 68
Sex last month / last 3 months (%)**										
No	13 (16)	15 (26)	26 (29)	20 (30)	9 (11)	26 (21)	21 (15)	21 (15)	14 (17)	13 (19)
Yes	69 (84)	43 (74)	64 (70)	46 (70)	73 (86)	97 (77)	117 (84)	117 (84)	69 (82)	51 (75)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	3 (4)	3 (2)	1 (1)	2 (1)	1 (1)	4 (6)
Male sex partners in last 3 months**										
Median (Range)	n/a	n/a	n/a	n/a	1 (0-300)	1 (0-2)	0 (0-10)	0 (0-15)	0 (0-10)	0 (0-3)
Female sex partners in last 3 months**										
Median (Range)	n/a	n/a	n/a	n/a	1 (0-12)	1 (0-26)	1 (0-20)	1 (0-40)	1 (0-15)	1 (0-10)
Condom use at last sex (%)										
No	66 (80)	44 (76)	69 (76)	45 (68)	n/a	n/a	n/a	n/a	n/a	n/a
Yes	16 (20)	14 (24)	21 (23)	21 (32)	n/a	n/a	n/a	n/a	n/a	n/a
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*										
No	47 (94)	29 (81)	33 (75)	29 (85)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	3 (6)	2 (6)	4 (9)	4 (12)	n/a	n/a	n/a	n/a	n/a	n/a
Always	0 (0)	5 (14)	7 (16)	1 (3)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*										
No	8 (100)	2 (100)	1 (100)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	0 (0)	0 (0)	0 (0)	1 (50)	n/a	n/a	n/a	n/a	n/a	n/a
Always	0 (0)	0 (0)	0 (0)	1 (50)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*										
No	17 (40)	8 (40)	17 (74)	6 (43)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	9 (21)	4 (20)	4 (17)	5 (36)	n/a	n/a	n/a	n/a	n/a	n/a
Always	17 (40)	8 (40)	2 (9)	3 (21)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	8 (73)	9 (64)	1 (7)	3 (38)	14 (82)	5 (63)
Sometimes	n/a	n/a	n/a	n/a	1 (9)	2 (14)	10 (71)	3 (38)	1 (6)	2 (25)
Always	n/a	n/a	n/a	n/a	2 (18)	3 (21)	3 (21)	2 (25)	2 (12)	1 (13)
Condom use last sex - casual male partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	3 (60)	1 (100)	1 (50)	1 (25)	11 (85)	3 (75)
Sometimes	n/a	n/a	n/a	n/a	0 (0)	0 (0)	1 (50)	1 (25)	0 (0)	0 (0)
Always	n/a	n/a	n/a	n/a	2 (40)	0 (0)	0 (0)	2 (50)	2 (15)	1 (25)
Condom use last sex - regular female partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	37 (84)	40 (62)	62 (82)	59 (66)	37 (71)	26 (60)
Sometimes	n/a	n/a	n/a	n/a	4 (9)	12 (18)	10 (13)	18 (20)	10 (19)	11 (26)
Always	n/a	n/a	n/a	n/a	3 (7)	13 (20)	4 (5)	13 (14)	5 (10)	6 (14)
Condom use last sex - casual female partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	16 (70)	8 (24)	25 (57)	14 (45)	26 (62)	16 (50)
Sometimes	n/a	n/a	n/a	n/a	4 (17)	9 (27)	12 (27)	9 (29)	10 (24)	10 (31)
Always	n/a	n/a	n/a	n/a	3 (13)	16 (48)	7 (16)	8 (26)	6 (14)	6 (19)
Sex work last month (%)										
No	81 (99)	57 (98)	90 (99)	66 (100)	82 (96)	122 (97)	134 (96)	138 (99)	80 (95)	64 (94)
Yes	0 (0)	1 (2)	0 (0)	0 (0)	3 (4)	0 (0)	5 (4)	2 (1)	3 (4)	1 (1)
Not reported	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	4 (3)	0 (0)	0 (0)	1 (1)	3 (4)
Condom used at last sex work last month (%)										
No	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (60)	1 (50)	2 (67)	0 (0)
Yes	0 (0)	1 (100)	0 (0)	0 (0)	2 (67)	0 (0)	1 (20)	1 (50)	1 (33)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (33)	0 (0)	1 (20)	0 (0)	0 (0)	0 (0)

*In 2004 and 2007, sexual health questions reflect behaviour in the past month, from 2010, sexual health questions were changed to reflect the past 3 months and to differentiate between male and female partners.

**Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 133 Number (%) of respondents reporting previous testing for HIV and HBV infection, vaccinations for HBV and cervical cancer by injector status and survey year

Testing & treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140	N = 84	N = 68
Previous HIV test (%)										
Last year	33 (40)	10 (17)	59 (65)	26 (39)	52 (61)	53 (42)	84 (60)	66 (47)	11 (13)	29 (43)
>1 year ago	33 (40)	26 (45)	24 (26)	25 (38)	23 (27)	33 (26)	39 (28)	34 (24)	46 (55)	15 (22)
Never tested	16 (20)	22 (38)	7 (8)	15 (23)	9 (11)	40 (32)	13 (9)	38 (27)	26 (31)	20 (29)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	3 (2)	2 (1)	1 (1)	4 (6)
HIV infection (self-report) (%)										
No	62 (94)	34 (94)	76 (91)	49 (96)	66 (87)	75 (88)	103 (83)	72 (72)	70 (96)	32 (91)
Yes	0 (0)	1 (3)	4 (5)	1 (2)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Don't know	4 (6)	1 (3)	3 (4)	1 (2)	10 (13)	10 (12)	21 (17)	27 (27)	3 (4)	3 (9)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
HBV infection (%)										
No	76 (93)	56 (97)	88 (97)	61 (92)	75 (88)	113 (90)	203 (73)	106 (76)	71 (85)	55 (82)
Yes	6 (7)	1 (2)	2 (2)	0 (0)	1 (1)	3 (2)	32 (11)	8 (6)	2 (2)	2 (3)
Don't know	0 (0)	1 (2)	1 (1)	1 (2)	9 (11)	10 (8)	34 (12)	23 (16)	10 (12)	5 (7)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (5)	3 (2)	1 (1)	5 (7)
HBV vaccination (%)*										
No	13 (16)	27 (47)	14 (15)	17 (26)	11 (13)	34 (27)	11 (8)	26 (19)	11 (13)	8 (12)
Yes	69 (84)	31 (53)	72 (79)	42 (64)	68 (80)	68 (54)	89 (64)	65 (46)	54 (64)	28 (41)
Don't know	0 (0)	0 (0)	5 (5)	7 (11)	6 (7)	24 (19)	26 (19)	43 (31)	19 (23)	27 (40)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	13 (9)	6 (4)	0 (0)	5 (7)
N° of HBV injections (%)										
One	6 (9)	3 (10)	2 (3)	3 (7)	5 (7)	7 (10)	2 (2)	0 (0)	2 (4)	2 (6)
Two	6 (9)	2 (6)	2 (3)	4 (10)	8 (12)	5 (9)	9 (10)	7 (11)	16 (30)	4 (12)
Three or more	57 (83)	26 (84)	68 (94)	35 (83)	55 (81)	53 (78)	68 (76)	43 (66)	24 (44)	19 (58)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	11 (20)	3 (9)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (4)	10 (11)	15 (23)	1 (2)	5 (15)
Ever had cervical cancer vaccine (women only)** (%)										
No	n/a	n/a	n/a	n/a	6 (75)	2 (50)	5 (71)	4 (50)	8 (67)	3 (50)
Yes	n/a	n/a	n/a	n/a	2 (25)	1 (25)	1 (14)	3 (38)	3 (25)	1 (17)
Unsure	n/a	n/a	n/a	n/a	0 (0)	1 (25)	1 (14)	1 (13)	1 (8)	2 (33)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* Number (%) among participants with no history of HBV infection.

**Proportion of women eligible for the National HPV Vaccination Program, i.e. those who were under 27 years of age in 2007 (or 35 years or under in 2016).

Table 134 Number (%) of respondents reporting previous testing for HCV infection and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N =	N = 139	N = 140	N = 84	N = 68
Previous HCV test (%)										
Last year	30 (37)	9 (16)	6 (7)	15 (23)	54 (64)	51 (40)	87 (63)	65 (46)	11 (13)	27 (40)
>1 year ago	43 (52)	21 (36)	60 (66)	28 (42)	24 (28)	34 (27)	39 (28)	33 (24)	44 (52)	16 (24)
Never tested	9 (11)	28 (48)	25 (27)	23 (35)	6 (7)	41 (33)	13 (9)	41 (29)	27 (32)	20 (29)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	5 (7)
Result of last HCV test (self-report) (%)										
Hepatitis C antibody positive	33 (45)	0 (0)	39 (59)	1 (2)	30 (39)	1 (1)	53 (42)	2 (2)	n/a	n/a
Never had hep C	36 (49)	30 (100)	27 (41)	42 (98)	36 (46)	74 (87)	49 (39)	65 (66)	32 (44)	33 (89)
Cleared hep C naturally	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4 (6)	0 (0)
Cleared hep C with treatment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (1)	0 (0)
Chronic hep C	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	30 (41)	1 (3)
Don't know	4 (6)	0 (0)	0 (0)	0 (0)	12 (15)	7 (8)	23 (18)	31 (32)	6 (8)	2 (5)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (4)	1 (1)	0 (0)	0 (0)	1 (3)
Age first diagnosed with hep C										
Median age (range)	26	23	24	--	26	40	25	32	24	49
Range	13 – 41	18 – 35	15 – 36	--	16 – 50	--	15 – 48	27 – 37	10 – 36	--
Ever had HCV treatment (%)*										
No treatment	N = 36	N = 2	N = 41	N = 2	N = 41	N = 0	N = 53	N = 2	N = 40	N = 0
Interferon-based medication	36 (100)	2 (100)	40 (98)	2 (100)	40 (98)	--	0 (0)	0 (0)	36 (90)	--
Direct-acting antiviral (DAA)	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	--	2 (4)	0 (0)	3 (8)	--
Interferon-based & DAA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--	2 (4)	0 (0)	0 (0)	--
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--	0 (0)	2 (100)	1 (3)	--
Ever had PCR/RNA test to test for reinfections (%)^										
< 1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (33)	--
> 1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not tested	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (67)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Result of PCR/RNA test (%)										
Still cured of hep C	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Reinfected	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (100)	--
Don't know	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--

*Number (%) of those reporting positive HCV test results or specifying age of hep C diagnosis.

Table 135 Number (%) of respondents reporting interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Ever sought out HCV treatment?										
No	n/a	n/a	n/a	n/a	n/a	n/a	25 (49)	1 (50)	19 (50)	1 (100)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	25 (49)	1 (50)	19 (50)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)	0 (0)	0 (0)
Willingness to receive treatment for HCV										
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	11 (22)	0 (0)	0 (0)	0 (0)
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)	2 (5)	1 (100)
Willing	n/a	n/a	n/a	n/a	n/a	n/a	22 (43)	2 (100)	36 (95)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	17 (33)	0 (0)	0 (0)	0 (0)
Treatment location preference (%)										
Prison	n/a	n/a	n/a	n/a	n/a	n/a	15 (29)	0 (0)	1 (3)	0 (0)
Community	n/a	n/a	n/a	n/a	n/a	n/a	15 (29)	1 (50)	9 (24)	1 (100)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	13 (25)	0 (0)	n/a	n/a
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	8 (16)	1 (50)	28 (74)	0 (0)
Knowledge & awareness of DAA treatments for hepatitis C^{***}										
<i>New treatments for hep C are available (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	44 (52)	12 (18)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	1 (2)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	35 (42)	49 (72)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	5 (6)	6 (9)
<i>The new hep C treatments require injections (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	9 (11)	4 (6)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	17 (20)	3 (4)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	51 (61)	53 (78)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	7 (8)	8 (12)
<i>The new hep C treatments have few side-effects (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	25 (30)	2 (3)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4 (5)	2 (3)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	47 (56)	56 (82)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	8 (10)	8 (12)
<i>The new hep C treatments take up to one year (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	13 (16)	4 (6)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	10 (12)	2 (3)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	53 (63)	54 (79)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	8 (10)	8 (12)

*Of those who have not had treatment.

^Correct response is shaded.

HIV antibody prevalence

Table 136 HIV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	77	0 (0)	0	0 (0)	77	0 (0)
Non-IDU	53	1 (2)	0	0 (0)	53	1 (2)
p value		0.2		--		0.2
2007						
IDU	77	1 (1)	0	0 (0)	77	1 (1)
Non-IDU	59	0 (0)	0	0 (0)	59	0 (0)
p value		0.4		--		0.4
2010						
IDU	59	0 (0)	14	0 (0)	73	0 (0)
Non-IDU	103	0 (0)	15	0 (0)	118	0 (0)
p value		--		--		--
2013						
IDU	43	0 (0)	11	0 (0)	54	0 (0)
Non-IDU	30	0 (0)	8	0 (0)	38	0 (0)
p value		--		--		--
2016						
IDU	35	0 (0)	17	0 (0)	52	0 (0)
Non-IDU	35	0 (0)	7	0 (0)	42	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 137 HCV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	75	36 (48)	0	0 (0)	75	36 (48)
Non-IDU	54	2 (4)	0	0 (0)	54	2 (4)
p value		<0.001		--		<0.001
2007						
IDU	77	41 (53)	0	0 (0)	77	41 (53)
Non-IDU	58	2 (3)	0	0 (0)	58	2 (3)
p value		<0.001		--		<0.001
2010						
IDU	58	29 (50)	14	12 (86)	72	41 (57)
Non-IDU	102	0 (0)	14	0 (0)	116	0 (0)
p value		<0.001		<0.001		<0.001
2013						
IDU	71	50 (70)	17	12 (71)	88	62 (70)
Non-IDU	32	3 (9)	8	1 (13)	40	4 (10)
p value		<0.001		0.006		<0.001
2016						
IDU	35	18 (51)	16	8 (50)	51	26 (51)
Non-IDU	34	0 (0)	6	0 (0)	40	0 (0)
p value		<0.001		0.03		<0.001

† Excludes equivocal test results and missing values.

Table 138 HCV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	127	38 (30)	0	0 (0)	127	38 (30)
Bisexual	2	0 (0)	0	0 (0)	2	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	--	0	--	0	0 (0)
p value		0.4				0.4
2007						
Heterosexual	134	42 (31)	0	0 (0)	134	42 (31)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2010						
Heterosexual	154	28 (18)	23	8 (35)	177	36 (20)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
Unsure	0	0 (0)	--	0 (0)	--	0 (0)
p value		0.1		0.2		<0.01
2013						
Heterosexual	103	53 (51)	20	9 (45)	123	62 (50)
Bisexual	0	0 (0)	3	3 (100)	3	2 (67)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.3		0.6
2016						
Heterosexual	66	17 (26)	15	3 (20)	81	20 (25)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Gay/lesbian	0	0 (0)	1	1 (100)	1	1 (100)
Unsure	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.7		0.1		0.1

† Excludes equivocal test results and missing values.

Table 139 HCV antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	0 (0)	0	0 (0)	11	0 (0)
20 – 24	27	6 (22)	0	0 (0)	27	6 (22)
25 – 29	24	11 (46)	0	0 (0)	24	11 (46)
30 + years	67	21 (31)	0	0 (0)	67	21 (31)
p value		0.04		--		0.04
2007						
< 20 years	13	1 (8)	0	0 (0)	13	1 (8)
20 – 24	32	10 (31)	0	0 (0)	32	10 (31)
25 – 29	36	13 (36)	0	0 (0)	36	13 (36)
30 + years	54	19 (35)	0	0 (0)	54	19 (35)
p value		0.3		--		0.3
2010						
< 20 years	23	0 (0)	3	1 (33)	26	1 (4)
20 – 24	36	8 (22)	3	1 (33)	39	9 (23)
25 – 29	28	5 (18)	6	4 (67)	34	9 (27)
30 + years	73	16 (22)	16	6 (38)	89	22 (25)
p value		0.1		0.6		0.1
2013						
< 20 years	9	3 (33)	2	0 (0)	11	3 (27)
20 – 24	18	5 (28)	2	0 (0)	20	5 (25)
25 – 29	19	9 (47)	5	3 (60)	24	12 (50)
30 + years	58	37 (64)	17	11 (65)	75	48 (64)
p value		0.031		0.1		0.005
2016						
< 20 years	4	0 (0)	2	0 (0)	6	0 (0)
20 – 24	12	2 (17)	6	1 (17)	18	3 (17)
25 – 29	11	4 (36)	2	1 (50)	13	5 (38)
30 + years	45	13 (29)	12	6 (50)	57	19 (33)
p value		0.4		0.3		0.2

† Excludes equivocal test results and missing values.

Table 140 HCV antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	8	0 (0)	0	0 (0)	8	0 (0)
3 to 5 years	9	1 (11)	0	0 (0)	9	1 (11)
6 to 10 years	22	10 (45)	0	0 (0)	22	10 (45)
10 + years	36	25 (69)	0	0 (0)	36	25 (69)
p value		<0.001		--		<0.001
2007						
<3 years	5	1 (20)	0	0 (0)	5	1 (20)
3 to 5 years	10	5 (50)	0	0 (0)	10	5 (50)
6 to 10 years	23	9 (39)	0	0 (0)	23	9 (39)
10 + years	34	22 (65)	0	0 (0)	34	22 (65)
p value		0.1		--		0.1
2010						
<3 years	4	1 (25)	0	0 (0)	4	1 (25)
3 to 5 years	5	1 (20)	2	1 (50)	7	2 (29)
6 to 10 years	13	6 (46)	3	3 (100)	16	9 (56)
10 + years	33	20 (61)	8	7 (88)	41	27 (66)
p value		0.2		0.3		0.2
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	6	1 (17)	0	0 (0)	6	1 (17)
6 to 10 years	10	8 (80)	3	2 (67)	13	10 (77)
10 + years	45	37 (82)	11	9 (82)	56	46 (82)
p value		0.002		0.6		0.002
2016						
<3 years	5	0 (0)	6	1 (17)	11	1 (9)
3 to 5 years	3	2 (67)	1	0 (0)	4	2 (50)
6 to 10 years	6	2 (33)	2	2 (100)	8	4 (50)
10 + years	19	12 (63)	7	5 (71)	26	17 (65)
p value		0.06		0.07		0.02

† Excludes equivocal test results and missing values.

Table 141 HCV antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Methamphetamine	8	0 (0)	46	20 (43)	54	20 (37)
Heroin	0	0 (0)	19	15 (79)	19	15 (79)
More than one drug	0	0 (0)	2	1 (50)	2	1 (50)
Other/not reported	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.03		0.007
2007						
Methamphetamine	4	0 (0)	46	19 (41)	50	19 (38)
Heroin	1	1 (100)	13	10 (77)	14	1 (79)
More than one drug	0	0 (0)	2	2 (100)	2	2 (100)
Other/not reported	0	0 (0)	6	5 (83)	6	5 (83)
p value		0.03		0.02		0.002
2010						
Methamphetamine	4	1 (25)	36	17 (47)	40	18 (45)
Heroin	0	0 (0)	18	15 (83)	18	15 (83)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	0	0 (0)	9	6 (67)	9	6 (67)
p value		--		0.04		0.03
2013						
Methamphetamine	7	1 (14)	54	39 (72)	61	40 (66)
Heroin	1	0 (0)	17	15 (88)	18	15 (83)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	1	0 (0)	7	6 (86)	8	6 (75)
p value		0.9		0.3		0.3
2016						
Methamphetamine	8	1 (13)	27	13 (48)	35	14 (40)
Heroin	0	0 (0)	4	4 (100)	4	4 (100)
More than one drug	0	0 (0)	7	6 (86)	7	6 (86)
Other/not reported	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.5		0.05		0.008

† Excludes equivocal test results and missing values.

Table 142 HCV antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	2	0 (0)	9	7 (78)	11	7 (64)
Daily or more	3	0 (0)	30	18 (60)	33	18 (55)
p value		--		0.09		0.6
2007						
Less than daily	1	0 (0)	13	6 (46)	14	6 (43)
Daily or more	1	1 (100)	21	15 (71)	22	16 (73)
p value		0.2		0.1		0.07
2010						
Less than daily	2	1 (50)	9	4 (44)	11	5 (45)
Daily or more	0	0 (0)	24	19 (79)	24	19 (79)
p value		--		0.05		0.05
2013						
Less than daily	4	0 (0)	18	12 (67)	22	1 (55)
Daily or more	4	1 (25)	44	40 (91)	48	41 (85)
p value		0.3		0.02		0.05
2016						
Less than daily	6	1 (17)	8	6 (75)	14	7 (50)
Daily or more	1	0 (0)	18	13 (72)	19	13 (68)
p value		0.2		0.02		0.3

† Excludes equivocal test results and missing values.

Table 143 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	5	0 (0)	28	16 (57)	33	16 (48)
Yes	0	0 (0)	11	9 (82)	11	9 (82)
p value		--		0.1		0.05
2007						
No	2	1 (50)	25	12 (48)	27	13 (48)
Yes	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.01		0.005
2010						
No	1	0 (0)	27	19 (70)	28	19 (68)
Yes	1	1 (100)	5	3 (60)	6	4 (67)
p value		0.2		0.7		1.0
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	3	1 (33)	12	12 (100)	15	13 (87)
p value		--		--		--
2016						
No	7	1 (14)	18	14 (78)	25	15 (60)
Yes	0	0 (0)	8	5 (63)	8	5 (63)
p value		--		0.4		0.9

† Excludes equivocal test results and missing values.

Table 144 HCV antibody prevalence by imprisonment last year, years since first drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	0	0 (0)	1	1 (100)	1	1 (100)
Yes	8	0 (0)	66	35 (53)	74	35 (47)
p value		--		0.4		0.3
2007						
No	2	0 (0)	24	9 (38)	26	9 (35)
Yes	2	1 (50)	33	26 (79)	35	27 (77)
p value		0.2		0.002		0.001
2010						
No	1	0 (0)	20	9 (45)	21	9 (43)
Yes	3	1 (33)	42	27 (64)	45	28 (62)
p value		0.5		0.2		0.1
2013						
No	2	0 (0)	17	12 (71)	19	12 (63)
Yes	3	0 (0)	51	42 (82)	54	42 (78)
p value		--		0.3		0.005
2016						
No	0	0 (0)	9	6 (67)	9	6 (67)
Yes	6	0 (0)	21	16 (76)	27	16 (59)
p value		--		0.6		0.6

† Excludes equivocal test results and missing values.

Table 145 HCV antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	5	1 (20)	0	0 (0)	5	1 (20)
2 to 4	97	24 (25)	0	0 (0)	97	24 (25)
5 to 9	20	10 (50)	0	0 (0)	20	10 (50)
10 +	6	3 (50)	0	0 (0)	6	3 (50)
p value		0.09		--		0.09
2007						
1	40	0 (0)	0	0 (0)	40	0 (0)
2 to 4	64	22 (34)	0	0 (0)	64	22 (34)
5 to 9	17	11 (65)	0	0 (0)	17	11 (65)
10 +	12	9 (75)	0	0 (0)	12	9 (75)
p value		<0.001		--		<0.001
2010						
1	78	4 (5)	17	5 (29)	95	9 (10)
2 to 4	50	11 (22)	6	5 (83)	56	16 (29)
5 to 9	17	9 (53)	3	1 (33)	20	10 (50)
10 +	14	5 (36)	2	1 (50)	16	6 (38)
p value		<0.001		0.1		<0.001
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	11	1 (9)	4	0 (0)	15	1 (7)
2 to 4	16	6 (38)	6	3 (50)	22	9 (41)
5 to 9	11	8 (73)	2	2 (100)	13	3 (23)
10 +	2	1 (50)	1	1 (100)	3	1 (33)
p value		0.02		0.07		0.002

† Excludes equivocal test results and missing values.

Table 146 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	115	34 (30)	0	0 (0)	115	34 (30)
Indigenous	14	4 (29)	0	0 (0)	14	4 (29)
p value		0.9		--		0.9
2007						
Non-Indigenous	116	36 (31)	0	0 (0)	116	36 (31)
Indigenous	19	7 (37)	0	0 (0)	19	7 (37)
p value		0.6		--		0.6
2010						
Non-Indigenous	99	19 (19)	21	8 (38)	120	27 (23)
Indigenous	61	10 (16)	7	4 (57)	68	14 (21)
p value		0.7		0.4		0.8
2013						
Non-Indigenous	76	34 (45)	17	9 (53)	93	43 (46)
Indigenous	28	20 (71)	9	5 (56)	37	25 (68)
p value		0.016		0.9		0.03
2016						
Non-Indigenous	59	14 (24)	15	5 (33)	74	19 (26)
Indigenous	13	5 (38)	7	3 (43)	20	8 (40)
p value		0.3		0.7		0.2

† Excludes equivocal test results and missing values.

Table 147 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	48	2 (4)	67	32 (48)	115	34 (30)
Indigenous	6	0 (0)	8	4 (50)	14	4 (29)
p value		0.6		0.9		0.9
2007						
Non-Indigenous	50	1 (2)	66	35 (53)	116	36 (31)
Indigenous	8	1 (13)	11	6 (55)	19	7 (37)
p value		0.1		0.9		0.6
2010						
Non-Indigenous	68	0 (0)	52	27 (52)	120	27 (23)
Indigenous	48	0 (0)	20	14 (70)	68	14 (21)
p value		--		0.2		0.8
2013						
Non-Indigenous	36	3 (8)	56	39 (70)	92	42 (46)
Indigenous	4	1 (25)	32	23 (72)	36	24 (67)
p value		0.3		0.8		0.03
2016						
Non-Indigenous	31	0 (0)	40	18 (45)	71	18 (25)
Indigenous	9	0 (0)	11	8 (73)	20	8 (40)
p value		--		0.1		0.1

† Excludes equivocal test results and missing values.

Table 148 HCV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	123	37 (30)	0	0 (0)	123	37 (30)
Moderately accessible	1	0 (0)	0	0 (0)	1	0 (0)
Remote/very remote	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.8		--		0.8
2007						
Highly accessible/accessible	123	40 (33)	0	0 (0)	123	40 (33)
Moderately accessible	2	0 (0)	0	0 (0)	2	0 (0)
Remote/very remote	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.6		--		0.6
2010						
Highly accessible/accessible	118	26 (22)	24	11 (46)	142	37 (26)
Moderately accessible	8	0 (0)	3	1 (33)	11	1 (9)
Remote/very remote	23	0 (0)	1	0 (0)	24	0 (0)
p value		0.02		0.6		0.01
2013						
Highly accessible/accessible	96	48 (50)	23	12 (52)	119	60 (50)
Moderately accessible	3	2 (67)	1	0 (0)	4	2 (50)
Remote/very remote	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.5		0.3		0.6
2016						
Highly accessible/accessible	59	15 (25)	22	8 (36)	81	23 (28)
Moderately accessible	7	2 (29)	0	0 (0)	7	2 (29)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.8		--		0.8

† Excludes equivocal test results and missing values.

Table 149 HCV antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	104	34 (33)	0	0 (0)	104	34 (33)
Other Oceania	15	2 (13)	0	0 (0)	15	2 (13)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	3	0 (0)	0	0 (0)	3	0 (0)
Other	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.1		--		0.1
2007						
Australia	124	38 (31)	0	0 (0)	124	38 (31)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	6	4 (67)	0	0 (0)	6	4 (67)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.2		--		0.2
2010						
Australia	143	26 (18)	23	10 (43)	166	36 (22)
Other Oceania	11	2 (18)	2	0 (0)	13	2 (15)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	1	0 (0)	1	1 (100)	2	1 (50)
Other	4	0 (0)	2	1 (50)	6	1 (17)
p value		0.2		0.4		0.3
2013						
Australia	86	49 (57)	20	12 (60)	106	61 (58)
Other Oceania	9	2 (22)	3	1 (33)	12	3 (25)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	3	1 (33)	1	0 (0)	4	1 (25)
Other	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.05		0.4		0.04
2016						
Australia	57	14 (25)	21	7 (33)	78	21 (28)
Other Oceania	6	2 (33)	1	1 (100)	7	3 (43)
Asia	3	1 (33)	0	0 (0)	3	1 (33)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.8		0.2		0.7

† Excludes equivocal test results and missing values.

Table 150 Self-reported HCV status versus HCV serology (HCVab) by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCVab (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	29	29 (100)	0	0 (0)	29	29 (100)
Negative	61	5 (8)	0	0 (0)	61	5 (8)
Not sure	4	2 (50)	0	0 (0)	4	2 (50)
p value		<0.001		0 (0)		<0.001
2007						
Positive	30	27 (90)	0	0 (0)	30	27 (90)
Negative	80	11 (14)	0	0 (0)	80	11 (14)
Not sure	7	4 (57)	0	0 (0)	7	4 (57)
p value		<0.001		--		<0.001
2010						
Positive	16	16 (100)	12	12 (100)	28	28 (100)
Negative	87	6 (7)	9	0 (0)	96	6 (6)
Not sure	18	6 (33)	0	0 (0)	18	6 (33)
p value		<0.001		<0.001		<0.001
2013						
Positive	47	47 (100)	6	6 (100)	53	53 (100)
Negative	37	2 (5)	6	0 (0)	43	2 (5)
Not sure	6	4 (67)	9	7 (78)	15	11 (73)
p value		<0.001		0.001		<0.001
2016						
Cleared hep C naturally	2	2 (100)	2	2 (100)	4	4 (100)
Cleared hep C with treatment	0	0 (0)	0	0 (0)	0	0 (0)
Chronic hep C	14	14 (100)	4	4 (100)	18	18 (100)
Negative	29	0 (0)	11	1 (9)	38	1 (3)
Not sure	5	2 (40)	1	1 (100)	6	3 (50)
p value		<0.001		0.003		<0.001

† Excludes equivocal test results and missing values.

Table 151 Self-reported HCV status versus HCV serology (PCR/RNA) by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	Detected (%)	N° tested	Detected (%)	N° tested	Detected (%)
2016						
Cleared hep C naturally	0	0 (0)	2	0 (0)	2	0 (0)
Cleared hep C with treatment	0	0 (0)	0	0 (0)	0	0 (0)
Chronic hep C	0	0 (0)	4	4 (100)	4	4 (100)
Negative	0	0 (0)	5	1 (20)	5	1 (5)
Not sure	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.033		0.03

† Excludes equivocal test results and missing values.

HBV prevalence

Table 152 HBV surface-antigen prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	77	3 (4)	0	0 (0)	77	3 (4)
Non-IDU	54	0 (0)	0	0 (0)	54	0 (0)
p value		0.1		--		0.1
2007						
IDU	78	1 (1)	0	0 (0)	78	1 (1)
Non-IDU	59	0 (0)	0	0 (0)	59	0 (0)
p value		0.4		--		0.4
2010						
IDU	58	0 (0)	14	0 (0)	72	0 (0)
Non-IDU	93	2 (2)	14	0 (0)	107	2 (2)
p value		0.3		--		0.2
2013						
IDU	8	2 (25)	2	0 (0)	10	2 (20)
Non-IDU	5	1 (20)	4	0 (0)	9	1 (11)
p value		0.8		--		0.6
2016						
IDU	34	0 (0)	16	0 (0)	50	0 (0)
Non-IDU	34	2 (6)	6	0 (0)	40	2 (5)
p value		0.2		--		0.1

† Excludes equivocal test results and missing values.

Table 153 HBV core-antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	74	12 (16)	0	0 (0)	74	12 (16)
Non-IDU	54	5 (9)	0	0 (0)	54	5 (9)
p value		0.3		--		0.3
2007						
IDU	78	8 (10)	0	0 (0)	78	8 (10)
Non-IDU	59	4 (7)	0	0 (0)	59	4 (7)
p value		0.5		--		0.5
2010						
IDU	32	6 (19)	1	0 (0)	33	6 (18)
Non-IDU	48	8 (17)	1		49	8 (16)
p value		0.8		--		0.8
2013						
IDU	44	4 (9)	9	1 (11)	53	4 (11)
Non-IDU	29	3 (10)	7	1 (14)	36	5 (9)
p value		0.9		0.9		0.8
2016						
IDU	29	4 (14)	16	1 (6)	45	5 (11)
Non-IDU	32	6 (19)	6	0 (0)	38	6 (16)
p value		0.6		0.5		0.5

† Excludes equivocal test results and missing values.

Table 154 HBV core-antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	126	17 (13)	0	0 (0)	126	17 (13)
Bisexual	2	0 (0)	0	0 (0)	2	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.6		--		0.6
2007						
Heterosexual	136	12 (9)	0	0 (0)	136	12 (9)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2010						
Heterosexual	78	14 (18)	2	0 (0)	80	14 (18)
Bisexual	1	0 (0)	0	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.6		--		0.7
2013						
Heterosexual	73	7 (10)	12	0 (0)	85	7 (8)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		<0.001		<0.001
2016						
Heterosexual	60	9 (15)	15	0 (0)	75	9 (12)
Bisexual	0	0 (0)	4	0 (0)	4	0 (0)
Gay/lesbian	0	0 (0)	1	1 (100)	1	1 (100)
Unsure	1	1 (100)	2	0 (0)	3	1 (33)
p value		0.02		<0.001		0.04

† Excludes equivocal test results and missing values.

Table 155 HBV core-antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	12	1 (8)	0	0 (0)	12	1 (8)
20 – 24	26	1 (4)	0	0 (0)	26	1 (4)
25 – 29	24	3 (13)	0	0 (0)	24	3 (13)
30 + years	66	12 (18)	0	0 (0)	66	12 (18)
p value		0.3		--		0.3
2007						
< 20 years	13	2 (15)	0	0 (0)	13	2 (15)
20 – 24	33	1 (3)	0	0 (0)	33	1 (3)
25 – 29	36	4 (11)	0	0 (0)	36	4 (11)
30 + years	55	5 (9)	0	0 (0)	55	5 (9)
p value		0.5		--		0.5
2010						
< 20 years	13	0 (0)	0	0 (0)	13	0 (0)
20 – 24	19	1 (5)	0	0 (0)	19	1 (5)
25 – 29	12	2 (17)	0	0 (0)	12	2 (17)
30 + years	36	11 (31)	2	0 (0)	38	11 (29)
p value		0.03		--		0.04
2013						
< 20 years	8	0 (0)	2	0 (0)	10	0 (0)
20 – 24	14	0 (0)	2	0 (0)	16	0 (0)
25 – 29	15	3 (20)	3	1 (33)	18	4 (22)
30 + years	37	4 (11)	10	1 (10)	47	5 (11)
p value		0.2		0.6		0.1
2016						
< 20 years	3	0 (0)	2	0 (0)	5	0 (0)
20 – 24	11	0 (0)	6	0 (0)	17	0 (0)
25 – 29	9	0 (0)	2	0 (0)	11	0 (0)
30 + years	41	11 (27)	12	1 (8)	53	12 (23)
p value		0.06		0.8		0.03

† Excludes equivocal test results and missing values.

Table 156 HBV core-antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	0	0 (0)	9	1 (11)
3 to 5 years	9	0 (0)	0	0 (0)	9	0 (0)
6 to 10 years	22	2 (9)	0	0 (0)	22	2 (9)
10 + years	34	9 (26)	0	0 (0)	34	9 (26)
p value		0.1		--		0.1
2007						
<3 years	5	1 (20)	0	0 (0)	5	1 (20)
3 to 5 years	10	0 (0)	0	0 (0)	10	0 (0)
6 to 10 years	23	2 (9)	0	0 (0)	23	2 (9)
10 + years	35	3 (9)	0	0 (0)	35	3 (9)
p value		0.6		--		0.6
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	4	0 (0)	0	0 (0)	4	0 (0)
6 to 10 years	7	1 (14)	0	0 (0)	7	1 (14)
10 + years	19	5 (26)	1	0 (0)	20	5 (25)
p value		0.6		--		0.6
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	5	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	4	0 (0)	0	0 (0)	5	0 (0)
10 + years	27	4 (15)	1	0 (0)	5	0 (0)
p value		0.5		0.7		0.4
2016						
<3 years	4	0 (0)	6	0 (0)	10	0 (0)
3 to 5 years	3	0 (0)	1	0 (0)	4	0 (0)
6 to 10 years	6	0 (0)	2	0 (0)	8	0 (0)
10 + years	14	4 (29)	7	1 (14)	21	5 (24)
p value		0.2		0.7		0.1

† Excludes equivocal test results and missing values.

Table 157 HBV core-antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	9	1 (11)	46	7 (15)	55	8 (15)
Heroin	0	0 (0)	17	4 (24)	17	4 (24)
More than one drug	0	0 (0)	2	0 (0)	2	0 (0)
Other/not reported	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.6		0.6
2007						
Amphetamine (Speed, Ice)	4	1 (25)	47	4 (9)	51	5 (10)
Heroin	1	0 (0)	13	0 (0)	14	0 (0)
More than one drug	0	0 (0)	2	0 (0)	2	0 (0)
Other/not reported	0	0 (0)	6	1 (17)	6	1 (17)
p value		0.6		0.6		0.5
2010						
Amphetamine (Speed, Ice)	1	0 (0)	19	2 (11)	20	2 (10)
Heroin	0	0 (0)	8	4 (50)	8	4 (50)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.04		0.03
2013						
Amphetamine (Speed, Ice)	7	0 (0)	30	3 (10)	37	3 (8)
Heroin	2	0 (0)	10	2 (20)	12	2 (17)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	1	0 (0)	3	0 (0)	4	0 (0)
p value		--		0.6		0.5
2016						
Amphetamine (Speed, Ice)	7	0 (0)	24	3 (13)	31	3 (10)
Heroin	0	0 (0)	2	0 (0)	2	0 (0)
More than one drug	0	0 (0)	6	2 (33)	6	2 (33)
Other/not reported	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		0.4		0.3

† Excludes equivocal test results and missing values.

Table 158 HBV core-antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	2	0 (0)	9	5 (56)	11	5 (45)
Daily or more	4	0 (0)	29	4 (14)	33	4 (12)
p value		--		0.01		0.01
2007						
Less than daily	1	0 (0)	13	2 (15)	14	2 (14)
Daily or more	1	0 (0)	21	1 (5)	22	1 (5)
p value		--		0.3		0.3
2010						
Less than daily	0	0 (0)	6	0 (0)	6	0 (0)
Daily or more	0	0 (0)	12	4 (33)	12	4 (33)
p value		--		0.1		0.1
2013						
Less than daily	5	0 (0)	11	0 (0)	16	0 (0)
Daily or more	4	0 (0)	19	4 (21)	23	4 (17)
p value		--		0.1		0.08
2016						
Less than daily	6	0 (0)	6	0 (0)	12	0 (0)
Daily or more	1	0 (0)	17	3 (18)	18	3 (17)
p value		--		0.3		0.1

† Excludes equivocal test results and missing values.

Table 159 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	27	6 (22)	33	6 (18)
Yes	0	0 (0)	11	3 (27)	11	3 (27)
p value		--		0.7		0.5
2007						
No	2	0 (0)	25	3 (12)	27	3 (11)
Yes	0	0 (0)	7	0 (0)	7	0 (0)
p value		0 (0)		0.3		0.4
2010						
No	0	0 (0)	15	3 (20)	15	3 (20)
Yes	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.5		0.5
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	3	0 (0)	5	2 (40)	8	2 (25)
p value		--		--		--
2016						
No	7	0 (0)	16	1 (7)	23	1 (4)
Yes	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.1		0.06

† Excludes equivocal test results and missing values.

Table 160 HBV core-antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	0	0 (0)	1	1 (100)	1	1 (100)
Yes	9	1 (11)	64	11 (17)	73	12 (16)
p value		--		0.7		0.4
2007						
No	2	1 (50)	25	3 (12)	27	4 (15)
Yes	2	0 (0)	33	2 (6)	35	2 (6)
p value		0.3		0.4		0.2
2010						
No	0	0 (0)	11	4 (36)	11	4 (36)
Yes	1	0 (0)	19	2 (11)	20	2 (10)
p value		--		0.1		0.1
2013						
No	2	0 (0)	11	0 (0)	13	0 (0)
Yes	4	0 (0)	27	5 (19)	31	5 (16)
p value		--		0.1		0.1
2016						
No	0	0 (0)	8	0 (0)	8	0 (0)
Yes	5	0 (0)	19	4 (21)	24	4 (17)
p value		--		0.2		0.2

† Excludes equivocal test results and missing values.

Table 161 HBV core-antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	5	0 (0)	0	0 (0)	5	0 (0)
2 to 4	96	12 (13)	0	0 (0)	96	12 (13)
5 to 9	20	4 (20)	0	0 (0)	20	4 (20)
10 +	6	1 (17)	0	0 (0)	6	1 (17)
p value		0.7		--		0.7
2007						
1	40	2 (5)	0	0 (0)	40	2 (5)
2 to 4	66	10 (15)	0	0 (0)	66	10 (15)
5 to 9	17	0 (0)	0	0 (0)	17	0 (0)
10 +	12	0 (0)	0	0 (0)	12	0 (0)
p value		0.08		--		0.08
2010						
1	32	2 (6)	1	0 (0)	33	2 (6)
2 to 4	31	6 (19)	1	0 (0)	32	6 (19)
5 to 9	8	4 (50)	0	0 (0)	8	4 (50)
10 +	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.03		--		0.03
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	9	0 (0)	4	0 (0)	13	0 (0)
2 to 4	15	2 (13)	6	0 (0)	21	2 (10)
5 to 9	10	1 (10)	2	0 (0)	12	1 (8)
10 +	2	2 (100)	1	1 (100)	3	3 (100)
p value		0.003		0.005		<0.001

† Excludes equivocal test results and missing values.

Table 162 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	114	15 (13)	0	0 (0)	114	15 (13)
Indigenous	14	2 (14)	0	0 (0)	14	2 (14)
p value		0.9		0 (0)		0.9
2007						
Non-Indigenous	117	7 (6)	0	0 (0)	117	7 (6)
Indigenous	20	5 (25)	0	0 (0)	20	5 (25)
p value		0.005		--		0.005
2010						
Non-Indigenous	47	4 (9)	1	0 (0)	48	4 (8)
Indigenous	33	10 (30)	1	0 (0)	34	10 (29)
p value		0.01		--		0.01
2013						
Non-Indigenous	55	5 (9)	11	1 (9)	66	6 (9)
Indigenous	19	2 (11)	6	1 (17)	25	3 (12)
p value		0.9		0.6		0.7
2016						
Non-Indigenous	51	7 (14)	15	0 (0)	66	7 (11)
Indigenous	13	4 (31)	7	1 (14)	20	5 (25)
p value		0.1		0.1		0.1

† Excludes equivocal test results and missing values.

Table 163 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	48	5 (10)	66	10 (15)	114	15 (13)
Indigenous	6	0 (0)	8	2 (25)	14	2 (14)
p value		0.7		0.5		0.9
2007						
Non-Indigenous	50	1 (2)	67	6 (9)	117	7 (6)
Indigenous	9	3 (33)	11	2 (18)	20	5 (25)
p value		0.001		0.4		0.005
2010						
Non-Indigenous	24	0 (0)	24	4 (17)	48	4 (8)
Indigenous	25	8 (32)	9	2 (22)	34	10 (29)
p value		0.002		0.7		0.01
2013						
Non-Indigenous	33	3 (9)	32	3 (9)	65	6 (9)
Indigenous	3	1 (33)	21	2 (10)	24	3 (13)
p value		0.2		1.0		0.7
2016						
Non-Indigenous	29	3 (10)	34	3 (9)	63	6 (10)
Indigenous	9	3 (33)	11	2 (18)	20	5 (25)
p value		0.1		0.4		0.1

† Excludes equivocal test results and missing values.

Table 164 HBV core-antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	122	15 (12)	0	0 (0)	122	15 (12)
Moderately accessible	1	0 (0)	0	0 (0)	1	0 (0)
Remote/very remote	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.02		--		0.02
2007						
Highly accessible/accessible	125	9 (7)	0	0 (0)	125	9 (7)
Moderately accessible	2	0 (0)	0	0 (0)	2	0 (0)
Remote/very remote	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.2		--		0.2
2010						
Highly accessible/accessible	60	7 (12)	2	0 (0)	62	7 (11)
Moderately accessible	2	0 (0)	0	0 (0)	2	0 (0)
Remote/very remote	11	5 (45)	0	0 (0)	11	5 (46)
p value		0.02		--		0.01
2013						
Highly accessible/accessible	71	7 (10)	14	1 (7)	85	8 (9)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.9		0.8		0.9
2016						
Highly accessible/accessible	51	8 (16)	22	1 (5)	73	9 (12)
Moderately accessible	7	2 (29)	0	0 (0)	7	2 (29)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.6		--		0.5

† Excludes equivocal test results and missing values.

Table 165 HBV core-antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	No tested	No with HBV (%)	No tested	No with HBV (%)	No tested	No with HBV (%)
2004						
Australia	103	12 (12)	0	0 (0)	103	12 (12)
Other Oceania	15	2 (13)	0	0 (0)	15	2 (13)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	3	0 (0)	0	0 (0)	3	0 (0)
Other	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.07		--		0.07
2007						
Australia	126	11 (9)	0	0 (0)	126	11 (9)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	6	0 (0)	0	0 (0)	6	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.2		--		0.2
2010						
Australia	72	13 (18)	2	0 (0)	74	13 (18)
Other Oceania	4	0 (0)	0	0 (0)	4	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.1		--		0.1
2013						
Australia	58	4 (7)	12	2 (17)	70	6 (9)
Other Oceania	8	1 (13)	2	0 (0)	10	1 (10)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	2	0 (0)	1	0 (0)	3	0 (0)
Other	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.02		0.9		0.4
2016						
Australia	50	6 (12)	21	1 (5)	71	7 (10)
Other Oceania	5	2 (40)	1	0 (0)	6	2 (33)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.04		0.8		0.03

† Excludes equivocal test results and missing values.

Table 166 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2004					
IDU	77	29 (38)	10 (13)	3 (4)	35 (45)
Non-IDU	54	35 (65)	5 (9)	0 (0)	14 (26)
p value					0.02
2007					
IDU	78	30 (38)	8 (10)	1 (1)	39 (50)
Non-IDU	59	38 (64)	4 (7)	0 (0)	17 (29)
p value					0.02
2010					
IDU	43	6 (14)	6 (14)	0 (0)	31 (72)
Non-IDU	64	10 (16)	8 (13)	2 (3)	44 (69)
p value					0.7
2013					
IDU	54	19 (35)	3 (6)	2 (4)	30 (56)
Non-IDU	35	22 (63)	3 (9)	1 (3)	9 (26)
p value					0.04
2016					
IDU	44	20 (54)	4 (11)	2 (5)	11 (30)
Non-IDU	37	16 (36)	5 (11)	0 (0)	23 (52)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 167 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N ^o tested	N ^o (%) with no evidence of HBV immunity	N ^o (%) immune through past exposure	N ^o (%) HBV carrier	N ^o (%) vaccine conferred immunity*
2004					
Heterosexual	129	62 (48)	15 (12)	3 (2)	49 (38)
Bisexual	2	2 (100)	0 (0)	0 (0)	0 (0)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2007					
Heterosexual	136	68 (50)	12 (9)	0 (0)	56 (41)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2010					
Heterosexual	102	13 (13)	14 (14)	2 (2)	73 (72)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	3	1 (33)	0 (0)	0 (0)	2 (67)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.7
2013					
Heterosexual	85	41 (48)	4 (5)	3 (4)	37 (44)
Gay/lesbian	2	0 (0)	0 (0)	0 (0)	2 (100)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	2	0 (0)	0 (0)	0 (0)	0 (0)
p value					<0.001
2016					
Heterosexual	73	34 (47)	8 (11)	1 (1)	30 (41)
Gay/lesbian	4	1 (25)	0 (0)	0 (0)	3 (75)
Bisexual	1	0 (0)	1 (100)	0 (0)	0 (0)
Unsure	3	1 (33)	0 (0)	1 (33)	1 (33)
p value					0.008

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 168 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	12	5 (42)	0 (0)	1 (8)	6 (50)
20 – 24	28	12 (43)	2 (7)	0 (0)	14 (50)
25 – 29	24	9 (38)	2 (8)	1 (4)	12 (50)
30 + years	67	38 (57)	11 (16)	1 (1)	17 (25)
p value					0.1
2007					
< 20 years	13	8 (62)	2 (15)	0 (0)	3 (23)
20 – 24	33	11 (33)	1 (3)	0 (0)	21 (64)
25 – 29	36	18 (50)	4 (11)	0 (0)	14 (39)
30 + years	55	31 (53)	5 (9)	1 (2)	18 (33)
p value					0.2
2010					
< 20 years	17	5 (29)	0 (0)	0 (0)	12 (71)
20 – 24	19	2 (11)	1 (5)	0 (0)	16 (84)
25 – 29	21	3 (14)	2 (10)	1 (5)	15 (71)
30 + years	50	6 (12)	11 (22)	1 (2)	32 (64)
p value					0.2
2013					
< 20 years	10	6 (60)	0 (0)	0 (0)	4 (40)
20 – 24	16	10 (63)	0 (0)	0 (0)	6 (38)
25 – 29	18	5 (28)	2 (11)	2 (11)	9 (50)
30 + years	47	21 (45)	4 (9)	1 (2)	21 (45)
p value					0.4
2016					
< 20 years	5	4 (80)	0 (0)	0 (0)	1 (20)
20 – 24	17	10 (59)	0 (0)	0 (0)	7 (41)
25 – 29	11	2 (18)	0 (0)	0 (0)	9 (82)
30 + years	51	21 (41)	10 (20)	2 (4)	18 (35)
p value					0.05

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 169 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	5	4 (80)	0 (0)	0 (0)	1 (20)
2 to 4	98	50 (51)	12 (12)	2 (2)	34 (35)
5 to 9	21	6 (29)	3 (14)	0 (0)	12 (57)
10 +	6	3 (50)	0 (0)	1 (17)	2 (33)
p value					0.2
2007					
1	40	31 (78)	2 (5)	0 (0)	7 (18)
2 to 4	66	26 (39)	10 (15)	1 (2)	29 (44)
5 to 9	17	7 (41)	0 (0)	0 (0)	10 (59)
10 +	12	3 (25)	0 (0)	0 (0)	9 (75)
p value					<0.01
2010					
1	46	10 (22)	2 (4)	0 (0)	34 (74)
2 to 4	35	4 (11)	6 (17)	1 (3)	24 (69)
5 to 9	12	2 (17)	4 (33)	0 (0)	6 (50)
10 +	13	0 (0)	2 (15)	1 (8)	10 (77)
p value					0.1
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--
2016					
1	12	5 (42)	0 (0)	0 (0)	7 (58)
2 to 4	21	10 (48)	2 (10)	0 (0)	9 (43)
5 to 9	11	2 (18)	1 (9)	0 (0)	8 (73)
10 +	3	0 (0)	3 (100)	0 (0)	0 (0)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 170 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	117	60 (51)	13 (11)	3 (3)	41 (35)
Indigenous	14	4 (29)	2 (14)	0 (0)	8 (57)
p value					0.3
2007					
Non-Indigenous	117	61 (52)	7 (6)	0 (0)	49 (42)
Indigenous	20	7 (35)	5 (25)	1 (5)	7 (35)
p value					<0.01
2010					
Non-Indigenous	59	11 (19)	4 (7)	0 (0)	44 (75)
Indigenous	48	5 (10)	10 (21)	2 (4)	31 (65)
p value					<0.01
2013					
Non-Indigenous	65	33 (51)	4 (6)	2 (3)	26 (40)
Indigenous	26	9 (35)	2 (8)	1 (4)	14 (54)
p value					0.6
2016					
Non-Indigenous	64	32 (50)	5 (8)	2 (3)	25 (39)
Indigenous	20	5 (25)	5 (25)	0 (0)	10 (50)
p value					0.07

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 171 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	125	62 (50)	13 (10)	3 (2)	47 (38)
Moderately accessible	1	1 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.1
2007					
Highly accessible/accessible	125	61 (49)	9 (7)	1 (1)	54 (43)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	1 (33)	1 (33)	0 (0)	1 (33)
p value					0.6
2010					
Highly accessible/accessible	78	12 (15)	7 (9)	0 (0)	59 (76)
Moderately accessible	7	2 (29)	0 (0)	1 (14)	4 (57)
Remote/very remote	22	8 (36)	1 (5)	1 (5)	12 (55)
p value					<0.01
2013					
Highly accessible/accessible	85	40 (47)	5 (6)	3 (4)	37 (44)
Moderately accessible	2	1 (50)	0 (0)	0 (0)	1 (50)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					1.0
2016					
Highly accessible/accessible	72	33 (46)	7 (10)	2 (3)	30 (42)
Moderately accessible	7	3 (43)	2 (29)	0 (0)	2 (29)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 172 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	32	4 (13)	0	0 (0)	32	4 (13)
Yes	81	45 (56)	0	0 (0)	81	45 (56)
Not sure	0	0 (0)	0	0 (0)	0	0 (0)
p value		<0.001		--		<0.001
2007						
No	26	3 (12)	0	0 (0)	26	3 (12)
Yes	88	52 (59)	0	0 (0)	88	52 (59)
Not sure	10	1 (10)	0	0 (0)	10	1 (10)
p value		<0.001		--		<0.001
2010						
No	6	1 (17)	1	0 (0)	7	1 (14)
Yes	69	65 (94)	11	6 (55)	80	71 (89)
Not sure	4	3 (75)	0	--	4	3 (75)
p value		<0.001		0.3		<0.001
2013						
No	5	0 (0)	6	3 (50)	11	3 (27)
Yes	48	28 (58)	7	4 (57)	55	32 (58)
Not sure	11	2 (27)	3	1 (33)	14	4 (29)
p value		0.01		0.8		0.04
2016						
No	7	1 (14)	3	0 (0)	10	1 (10)
Yes	24	16 (67)	10	6 (60)	34	22 (65)
Not sure	18	7 (39)	8	4 (50)	26	11 (42)
p value		0.03		0.2		0.007

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 173 Genital chlamydia prevalence by gender and survey year†

Gender	N° tested	N° with chlamydia (%)
2010		
Male	158	10 (6)
Female	31	0 (0)
p value		0.2
2013		
Male	77	5 (6)
Female	21	0 (0)
p value		0.2
2016		
Male	59	4 (7)
Female	17	1 (6)
p value		0.9

† Excludes missing values.

Gonorrhoea

Table 174 Genital gonorrhoea prevalence by gender and survey year†

Gender	N ^o tested	N ^o with gonorrhoea (%)
2010		
Male	158	2 (1)
Female	31	0 (0)
p value		0.5
2013		
Male	77	0 (0)
Female	21	0 (0)
p value		--
2016		
Male	59	0 (0)
Female	17	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 175 Syphilis markers by gender and survey year†

Gender	N ^o tested	N ^o with syphilis antibodies (%)	N ^o with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	161	15 (9)	7 (4)	15 (9)
Female	29	2 (7)	1 (3)	2 (7)
p value		0.7	0.9	0.7
2013				
Male	72	0 (0)	0 (0)	0 (0)
Female	20	0 (0)	0 (0)	0 (0)
p value		--	--	--
2016				
Male	71	1 (1)	0 (0)	1 (1)
Female	24	2 (8)	1 (50)	2 (8)
p value		0.09	0.4	0.09

† Excludes missing values.

**South Australia
2010, 2013, 2016**

Table 176 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 4		N = 3		N = 5	
N° surveyed	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Gender (%)						
Male	19 (70)	24 (83)	22 (96)	25 (100)	20 (91)	13 (87)
Female	8 (30)	5 (17)	1 (4)	0 (0)	2 (9)	2 (13)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age (years)						
Median (Med) age	32	37	35	33	34	29
Age range	20 – 45	19 – 80	20 – 59	19 – 70	22 – 55	20 – 51
Age group (%)						
<25 years	5 (19)	10 (34)	4 (17)	7 (28)	2 (9)	2 (13)
25+ years	22 (81)	19 (66)	19 (83)	18 (72)	19 (86)	13 (87)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
Aboriginal and/or Torres Strait Islander origin (%)						
No	19 (70)	17 (59)	13 (57)	15 (60)	14 (64)	11 (73)
Yes	8 (30)	12 (41)	10 (43)	10 (40)	8 (36)	4 (27)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)						
Heterosexual	24 (89)	27 (93)	21 (91)	23 (92)	20 (91)	15 (100)
Bisexual	2 (7)	1 (3)	1 (4)	0 (0)	0 (0)	0 (0)
Gay/lesbian	1 (4)	0 (0)	0 (0)	1 (4)	1 (5)	0 (0)
Unsure	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (3)	0 (0)	1 (4)	1 (5)	0 (0)
Region/Country of birth (%)						
Australia	25 (93)	28 (97)	22 (96)	23 (92)	22 (100)	15 (100)
Other Oceania	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Asia	2 (7)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
UK & Ireland	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Residential remoteness in 12 months before prison (%)						
Highly /accessible	24 (89)	22 (76)	19 (83)	16 (64)	16 (73)	9 (60)
Mod accessible	0 (0)	2 (7)	1 (4)	0 (0)	3 (14)	4 (27)
Very / remote	1 (4)	4 (14)	0 (0)	3 (12)	2 (9)	2 (13)
Not reported	2 (7)	1 (3)	3 (13)	6 (24)	1 (5)	0 (0)
First time in prison (%)						
No	24 (89)	21 (72)	21 (91)	12 (48)	20 (91)	10 (67)
Yes	3 (11)	8 (28)	2 (9)	12 (48)	2 (9)	5 (33)
Not reported	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
Lifetime imprisonments (%)*						
One	7 (26)	19 (66)	n/a	n/a	2 (10)	3 (30)
Two to four	11 (41)	5 (17)	n/a	n/a	7 (35)	5 (50)
Five to nine	5 (19)	4 (14)	n/a	n/a	3 (15)	0 (0)
Ten or more	4 (15)	1 (3)	n/a	n/a	7 (35)	0 (0)
Not reported	0 (0)	0 (0)	n/a	n/a	1 (5)	2 (20)
Imprisonment in last year (%)						
No	13 (48)	12 (41)	8 (38)	4 (33)	4 (20)	1 (10)
Yes	12 (44)	11 (38)	9 (43)	6 (50)	14 (70)	8 (80)
Not reported	2 (7)	6 (21)	4 (19)	2 (17)	2 (10)	1 (10)

Table 177 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Ever smoked a full cigarette (%)						
No	1 (4)	1 (3)	1 (4)	2 (8)	1 (5)	1 (7)
Yes	26 (96)	28 (97)	22 (96)	23 (92)	21 (95)	14 (93)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age of smoking						
Med age 1 st smoked	13	14	12	14	12	13
Age range	8 – 20	6 – 20	9 – 23	8 – 18	5 – 28	8 – 21
Current smoker (%)*						
No	1 (4)	4 (14)	3 (14)	2 (9)	1 (5)	1 (7)
Yes	26 (96)	24 (83)	18 (82)	19 (83)	20 (95)	13 (93)
Not reported	0 (0)	1 (3)	1 (5)	2 (9)	0 (0)	0 (0)
Smoking frequency (%)						
Weekly or less	1 (4)	2 (8)	0 (0)	0 (0)	0 (0)	2 (15)
5-10/day	7 (27)	8 (33)	3 (16)	4 (19)	9 (45)	4 (31)
11 to 20/day	10 (38)	11 (46)	8 (42)	6 (29)	6 (30)	3 (23)
>20/day	8 (31)	3 (13)	6 (32)	7 (33)	4 (20)	4 (31)
Not reported	0 (0)	0 (0)	2 (11)	4 (19)	1 (5)	0 (0)
Other drugs used last month (%)**						
None	5 (19)	7 (29)	3 (13)	2 (8)	2 (9)	3 (20)
Cannabis	18 (82)	14 (78)	10 (50)	15 (65)	11 (55)	7 (64)
Heroin	4 (18)	1 (6)	5 (25)	1 (4)	3 (15)	0 (0)
Cocaine	3 (14)	0 (0)	3 (15)	1 (4)	0 (0)	0 (0)
Methamphetamine	14 (64)	5 (28)	10 (50)	10 (43)	17 (85)	7 (64)
Methadone	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other opiates	2 (9)	0 (0)	3 (15)	4 (17)	0 (0)	0 (0)
Buprenorphine	4 (18)	0 (0)	2 (10)	0 (0)	3 (15)	0 (0)
Anabolic steroids [^]	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Hallucinogens	1 (5)	2 (11)	1 (5)	0 (0)	1 (5)	0 (0)
Benzodiazepine	4 (18)	3 (17)	4 (20)	3 (13)	2 (10)	0 (0)
Ecstasy/MDA	3 (14)	2 (11)	2 (10)	1 (4)	1 (5)	0 (0)
Inhalants	1 (5)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
Other drug	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
Not reported	0 (0)	5 (17)	0 (0)	0 (0)	0 (0)	1 (7)
Risk of alcohol-related harm (%)^^						
Non-drinker	n/a	n/a	n/a	n/a	8 (36)	6 (40)
Low risk of harm	n/a	n/a	n/a	n/a	5 (23)	6 (40)
High risk of harm	n/a	n/a	n/a	n/a	7 (32)	2 (13)
Not reported	n/a	n/a	n/a	n/a	2 (9)	1 (7)

*Prior to prison; **More than one drug option could be selected; [^]Also includes hormones and peptides from 2016; ^{^^}AUDIT-C

Table 178 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010	2013	2016
	N = 27	N = 23	N = 22
Median age 1st IDU	16	19	16
Age range	10 – 35	12 – 36	12 – 32
Not reported	2	0	0
Median years since first injection (%)	13	12	16
Range	<1 – 30	2 – 40	2 – 40
Not reported	0	0	1
Years since first drug injection (%)			
<3 years	1 (4)	3 (13)	1 (5)
3+ years	24 (89)	20 (87)	20 (95)
Not reported	2 (7)	0 (0)	0 (0)
Last drug injected (%)			
Methamphetamine	19 (70)	16 (70)	19 (86)
Anabolic steroids [^]	1 (4)	0 (0)	0 (0)
Cocaine	0 (0)	0 (0)	0 (0)
Heroin	6 (22)	6 (26)	2 (9)
Methadone	1 (4)	0 (0)	0 (0)
Morphine	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	1 (5)
Not reported	0 (0)	1 (4)	0 (0)
Frequency of injection last month (%)			
Not last month	16 (59)	11 (48)	5 (23)
< Weekly	4 (15)	0 (0)	10 (46)
Weekly	2 (7)	2 (9)	2 (9)
Daily or more	5 (19)	9 (39)	5 (23)
Not reported	0 (0)	1 (4)	0 (0)
N° Injected last month	N = 11	N = 11	N = 17
Places injected last month (%)*			
Prison	0 (0)	2 (18)	0 (0)
Own home	7 (64)	8 (73)	10 (59)
Friend's home	3 (27)	8 (73)	7 (41)
Dealer's home	1 (9)	6 (55)	3 (18)
Street, park, beach	1 (9)	5 (46)	1 (6)
Car	3 (27)	5 (46)	3 (18)
Public toilet	1 (9)	5 (46)	1 (6)
Commercial injecting room	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	0 (0)
Squat	0 (0)	1 (9)	1 (6)
Other place	0 (0)	0 (0)	0 (0)
Use of sterile needles & syringes last month (%)			
All injections	10 (91)	6 (55)	12 (71)
Most of the time	1 (9)	3 (27)	3 (18)
Half of the time	0 (0)	2 (18)	1 (6)
Some of the time	0 (0)	0 (0)	1 (6)
Not last month	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)
Times injected by someone else after they injected themselves or others in past month (%)			
More than 5 times	0 (0)	2 (18)	16 (73)
3 to 5 times	0 (0)	0 (0)	0 (0)
Once or twice	1 (9)	0 (0)	1 (5)
None	10 (91)	9 (82)	0 (0)
Not reported	0 (0)	0 (0)	5 (23)
Re-used someone else's used needle & syringe last month (%)			
None	10 (91)	9 (82)	14 (82)
Once	1 (9)	1 (9)	1 (6)
Twice	0 (0)	0 (0)	2 (12)
3-5 times	0 (0)	0 (0)	0 (0)
>5 times	0 (0)	1 (9)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)

* More than one drug option could be selected.

Table 179 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010	2013	2016
Number of people needle & syringe was re-used after last month (%)*			
One	0 (0)	1 (50)	2 (67)
Two	1 (9)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)
More than five	0 (0)	1 (50)	0 (0)
Don't know how many	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (33)
Relationship to people needle & syringe was re-used after last month (%)**			
Regular sex partner	0 (0)	0 (0)	1 (33)
Casual sex partner	0 (0)	0 (0)	1 (33)
Close friend	1 (9)	1 (50)	0 (0)
Acquaintance	0 (0)	1 (50)	0 (0)
Other	0 (0)	0 (0)	0 (0)
Last time re-used needle or syringe after someone (%)			
Last month	0 (0)	1 (5)	1 (5)
In the last 2-6 months	0 (0)	0 (0)	1 (5)
More than 6 months ago	5 (19)	1 (5)	2 (9)
Never	21 (81)	20 (91)	18 (82)
Not reported	0 (0)	0 (0)	0 (0)
Last place re-used needle or syringe after someone (%)			
Prison	1 (20)	1 (50)	0 (0)
Own home	2 (40)	0 (0)	1 (25)
Friend's home	1 (20)	0 (0)	0 (0)
Dealer's home	0 (0)	0 (0)	0 (0)
Street, park, bench	1 (20)	0 (0)	0 (0)
Car	0 (0)	0 (0)	2 (50)
Public toilet	0 (0)	0 (0)	1 (25)
Commercial injecting room	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	0 (0)
Squat	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (50)	0 (0)
Equipment used after someone else last month (%)*			
Spoon	1 (9)	4 (9)	3 (8)
Water	0 (0)	2 (4)	2 (5)
Filter	0 (0)	0 (0)	0 (0)
Tourniquet	1 (9)	1 (2)	0 (0)
Drug mix	0 (0)	1 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)
Did not share equipment	0 (0)	0 (0)	13 (76)

*Of those reporting shearing needles & syringes in the past month.

**More than one drug option could be selected.

Table 180 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2010	2013	2016
N° surveyed	N = 27	N = 23	N = 22
Location of needle & syringe acquisition in the past month (%)*			
Needle & Syringe Program (NSP/CNP)	n/a	n/a	7 (32)
Chemist/pharmacy	n/a	n/a	7 (32)
Vending machine	n/a	n/a	7 (32)
Personal source (e.g. friend)	n/a	n/a	1 (5)
Other	n/a	n/a	0 (0)
Not in the last month	n/a	n/a	3 (14)
From an NSP last month (%)			
Daily or almost daily	2 (7)	2 (9)	0 (0)
A couple of times each week	1 (4)	3 (13)	3 (16)
Less than weekly	2 (7)	2 (9)	1 (5)
Weekly	3 (11)	0 (0)	n/a
Once last month	0 (0)	3 (13)	3 (16)
Not in the last month	18 (67)	13 (57)	9 (47)
Not reported	1 (4)	0 (0)	3 (16)
From a chemist last month (%)			
Daily or almost daily	1 (4)	0 (0)	0 (0)
A couple of times each week	1 (4)	3 (13)	1 (5)
Less than weekly	3 (11)	1 (4)	0 (0)
Weekly	1 (4)	0 (0)	n/a
Once last month	0 (0)	3 (13)	7 (37)
Not in the last month	20 (74)	16 (70)	10 (53)
Not reported	1 (4)	0 (0)	1 (5)
Ever participated in the annual NSP community survey (%)			
No	27 (100)	18 (78)	20 (91)
Yes	0 (0)	2 (9)	1 (5)
Don't remember	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	3 (13)	1 (5)

* More than one drug option could be selected.

Table 181 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Any treatment/therapy for drug use (%)						
No	14 (52)	24 (83)	13 (57)	19 (76)	14 (64)	11 (73)
Yes	13 (48)	4 (14)	9 (39)	5 (20)	8 (36)	3 (20)
Not reported	0 (0)	1 (3)	1 (4)	1 (4)	0 (0)	1 (7)
History of methadone maintenance treatment (%)						
Currently	4 (15)	0 (0)	1 (4)	0 (0)	3 (14)	0 (0)
Previously	7 (26)	1 (3)	4 (17)	0 (0)	4 (18)	0 (0)
Never	16 (59)	27 (93)	16 (70)	24 (96)	15 (68)	15 (100)
Not reported	0 (0)	1 (3)	2 (9)	1 (4)	0 (0)	0 (0)
History of other pharmacotherapy treatment (%)						
Currently	2 (7)	0 (0)	1 (4)	0 (0)	1 (5)	0 (0)
Previously	5 (19)	0 (0)	3 (13)	0 (0)	6 (27)	0 (0)
Never	20 (74)	28 (97)	19 (83)	24 (96)	15 (68)	15 (100)
Not reported	0 (0)	1 (3)	0 (0)	1 (4)	0 (0)	0 (0)

*E.g. detox, rehab, counselling, NA

Table 182 Number (%) of respondents by body piercing and tattoos by injector status and survey year

Demographics	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Body or ear piercings (%)						
No	13 (48)	18 (62)	15 (65)	18 (72)	11 (50)	13 (87)
Yes	13 (48)	11 (38)	8 (35)	7 (28)	11 (50)	2 (13)
Not reported	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Piercings other than ears (%)						
No	8 (62)	8 (73)	0 (0)	0 (0)	5 (45)	1 (50)
Yes	5 (39)	3 (27)	8 (100)	7 (100)	5 (45)	1 (50)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (9)	0 (0)
Pierced in past 12 months (%)						
No	8 (57)	10 (91)	6 (75)	3 (43)	6 (55)	1 (50)
Yes	2 (14)	0 (0)	2 (25)	0 (0)	2 (18)	1 (50)
Not reported	4 (29)	1 (9)	0 (0)	4 (57)	3 (27)	0 (0)
Who did piercing (%)*						
Professional^	2 (100)	0 (0)	2 (100)	0 (0)	0 (0)	1 (100)
Non-professional^^	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)
Prisoner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Self	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Needle used by other (%)						
No	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Yes	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Not reported	0 (0)	2 (100)	0 (0)	0 (0)	n/a	n/a
Penile implants (%)**						
No	n/a	n/a	n/a	n/a	19 (95)	12 (92)
Yes	n/a	n/a	n/a	n/a	1 (5)	1 (8)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Penile implant in prison (%)						
No	n/a	n/a	n/a	n/a	0 (0)	1 (100)
Yes	n/a	n/a	n/a	n/a	1 (100)	0 (0)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Tattoos (%)						
No	8 (30)	17 (59)	1 (4)	10 (40)	2 (9)	8 (53)
Yes	18 (67)	12 (41)	22 (96)	15 (60)	20 (91)	7 (47)
Not reported	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Tattoos in past 12 months (%)						
No	14 (78)	10 (83)	12 (55)	7 (47)	15 (75)	5 (71)
Yes	3 (17)	2 (17)	10 (45)	8 (53)	4 (20)	2 (29)
Not reported	1 (5)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
Who did tattooing (%)*						
Professional^	3 (100)	2 (100)	7 (70)	5 (63)	1 (25)	2 (100)
Non-professional^^	0 (0)	0 (0)	2 (20)	3 (38)	3 (75)	0 (0)
Prisoner	0 (0)	0 (0)	2 (20)	0 (0)	1 (25)	0 (0)
Self	0 (0)	0 (0)	1 (10)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* More than one drug option could be selected.

**Males only, new question in 2017

^E.g. chemist, hairdresser, beauty salon, tattooist; ^^Non-professional outside of prison e.g. friend, family

Table 183 Number (%) of respondents by sexual behaviour in the 3 months prior to survey by injector status and survey year

Sexual behaviour	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Sex last 3 months (%)						
No	3 (11)	3 (10)	3 (13)	2 (8)	3 (14)	0 (0)
Yes	24 (89)	24 (83)	20 (87)	22 (88)	19 (86)	15 (100)
Not reported	0 (0)	2 (7)	0 (0)	0 (0)	0 (0)	0 (0)
Male sex partners in last 3 months*						
Median (Range)	1 (0–2)	0 (0–1)	0 (0–1)	--	0 (0–1)	0 (0–1)
Female sex partners in last 3 months*						
Median (Range)	1 (0–11)	1 (0–6)	1 (0–6)	1 (0–3)	1 (0–12)	2 (0–6)
Condom use at last sex - regular male partners – last 3 months (%)						
Never	5 (83)	2 (67)	0 (0)	0 (0)	1 (100)	1 (50)
Sometimes	0 (0)	0 (0)	2 (67)	0 (0)	0 (0)	0 (0)
Always	1 (17)	1 (33)	1 (33)	0 (0)	0 (0)	1 (50)
Condom use last sex - casual male partners - last 3 months (%)						
Never	2 (100)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)
Sometimes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Always	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Condom use last sex - regular female partners - last 3 months (%)						
Never	12 (75)	16 (84)	12 (71)	15 (75)	15 (83)	8 (73)
Sometimes	4 (25)	3 (16)	3 (18)	3 (15)	2 (11)	1 (9)
Always	0 (0)	0 (0)	2 (12)	2 (10)	1 (6)	2 (18)
Condom use last sex - casual female partners - last 3 months (%)						
Never	2 (67)	6 (100)	6 (67)	5 (50)	5 (63)	3 (75)
Sometimes	0 (0)	0 (0)	1 (11)	4 (40)	1 (13)	0 (0)
Always	1 (33)	0 (0)	2 (22)	1 (10)	2 (25)	1 (25)
Sex work last month (%)						
No	26 (96)	26 (90)	20 (87)	23 (92)	22 (100)	15 (100)
Yes	1 (4)	0 (0)	3 (13)	1 (4)	0 (0)	0 (0)
Not reported	0 (0)	3 (10)	0 (0)	1 (4)	0 (0)	0 (0)
Condom used at last sex work last month (%)						
No	0 (0)	0 (0)	0 (0)	0 (0)	--	--
Yes	1 (100)	0 (0)	0 (0)	0 (0)	--	--
Not reported	0 (0)	0 (0)	3 (100)	1 (100)	--	--

*In 2004 and 2007, sexual health questions reflect behaviour in the past month, from 2010, sexual health questions were changed to reflect the past 3 months and to differentiate between male and female partners.

**Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 184 Number (%) of respondents reporting previous testing for HIV and HBV infection, vaccinations for HBV and cervical cancer by injector status and survey year

Testing & treatment	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Previous HIV test (%)						
Last year	14 (52)	6 (21)	6 (26)	2 (8)	8 (36)	3 (20)
>1 year ago	5 (19)	7 (24)	12 (52)	5 (20)	7 (32)	3 (20)
Never tested	8 (30)	14 (48)	5 (22)	15 (60)	7 (32)	9 (60)
Not reported	0 (0)	0 (0)	0 (0)	3 (12)	0 (0)	0 (0)
Result of last HIV test (self-report) (%)						
Negative	18 (100)	11 (92)	17 (100)	9 (90)	12 (80)	6 (86)
Positive	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	1 (8)	0 (0)	1 (10)	3 (20)	1 (14)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HBV infection (%)						
No	25 (93)	23 (79)	18 (78)	21 (84)	20 (91)	12 (80)
Yes	2 (7)	0 (0)	2 (9)	0 (0)	1 (5)	1 (7)
Don't know	0 (0)	5 (17)	2 (9)	3 (12)	1 (5)	1 (7)
Not reported	0 (0)	1 (3)	1 (4)	1 (4)	0 (0)	1 (7)
HBV vaccination (%)*						
No	8 (30)	11 (38)	4 (17)	11 (44)	7 (32)	3 (20)
Yes	17 (63)	11 (38)	17 (74)	6 (24)	11 (50)	6 (40)
Don't know	2 (7)	6 (21)	2 (9)	6 (24)	4 (18)	5 (33)
Not reported	0 (0)	1 (3)	0 (0)	2 (8)	0 (0)	1 (7)
N° of HBV vaccine injections (%)						
One	0 (0)	1 (9)	1 (6)	1 (17)	0 (0)	0 (0)
Two	4 (24)	0 (0)	2 (12)	2 (33)	2 (18)	1 (14)
Three or more	12 (71)	8 (73)	11 (65)	2 (33)	6 (55)	2 (29)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	3 (27)	4 (57)
Not reported	1 (6)	2 (18)	3 (18)	1 (17)	0 (0)	0 (0)
Ever had cervical cancer vaccine (women only)** (%)						
No	2 (25)	1 (20)	0 (0)	0 (0)	1 (100)	0 (0)
Yes	3 (38)	2 (40)	0 (0)	0 (0)	0 (0)	1 (50)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)
Not reported	3 (38)	2 (40)	0 (0)	0 (0)	0 (0)	0 (0)

* Number (%) among participants with no history of HBV infection.

**Proportion of women eligible for the National HPV Vaccination Program, i.e. those who were under 27 years of age in 2007 (or 35 years or under in 2016).

Table 185 Number (%) of respondents reporting previous testing for HCV infection and HCV treatment by injector status and survey year

Testing & treatment	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
	N = 27	N = 29	N = 23	N = 25	N = 22	N = 15
Previous HCV test (%)						
Last year	13 (48)	7 (24)	11 (48)	4 (16)	8 (36)	2 (13)
>1 year ago	7 (26)	4 (14)	9 (39)	6 (24)	8 (36)	5 (33)
Never tested	6 (22)	16 (55)	3 (13)	14 (56)	6 (27)	8 (53)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (4)	2 (7)	0 (0)	1 (4)	0 (0)	0 (0)
Report of last HCV test (self-report) (%)						
Hepatitis C antibody positive	8 (40)	1 (9)	1 (5)	0 (0)	n/a	n/a
Never had hep C	12 (60)	9 (82)	17 (85)	9 (90)	9 (56)	7 (100)
Cleared hep C naturally	n/a	n/a	n/a	n/a	1 (6)	0 (0)
Cleared hep C with treatment	n/a	n/a	n/a	n/a	1 (6)	0 (0)
Chronic hep C	n/a	n/a	n/a	n/a	2 (13)	0 (0)
Don't know	0 (0)	1 (9)	2 (10)	1 (10)	3 (19)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age first diagnosed with hep C						
Median age	20	--	30	--	24	--
Range	17 – 37	--	27 – 31	--	21 – 53	--
Ever had HCV treatment (%)*						
	N = 6	N = 1	N = 4	N = 0	N = 7	N = 0
No treatment	6 (100)	1 (100)	0 (0)	--	4 (57)	--
Interferon based medication	0 (0)	0 (0)	2 (50)	--	3 (43)	--
Direct-acting antiviral (DAA)	0 (0)	0 (0)	0 (0)	--	0 (0)	--
Interferon-based and DAA	0 (0)	0 (0)	0 (0)	--	0 (0)	--
Other	0 (0)	0 (0)	0 (0)	--	0 (0)	--
Not reported	0 (0)	0 (0)	2 (50)	--	0 (0)	--
Ever had PCR/RNA test to test for reinfections (%)						
<1 year ago	n/a	n/a	n/a	n/a	3 (100)	--
>1 year ago	n/a	n/a	n/a	n/a	0 (0)	--
Not tested	n/a	n/a	n/a	n/a	0 (0)	--
Not reported	n/a	n/a	n/a	n/a	0 (0)	--
Result of PCR/RNA test (%)						
Still cured of hep C	n/a	n/a	n/a	n/a	1 (33)	--
Reinfected	n/a	n/a	n/a	n/a	2 (66)	--
Don't know	n/a	n/a	n/a	n/a	0 (0)	--
Not reported	n/a	n/a	n/a	n/a	0 (0)	--

*Number (%) of those reporting positive HCV test results or specifying age of hep C diagnosis.

Table 186 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness	2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Ever sought out HCV treatment? (%)*						
No	n/a	n/a	0 (0)	--	3 (75)	--
Yes	n/a	n/a	1 (50)	--	1 (25)	--
Not reported	n/a	n/a	1 (50)	--	0 (0)	--
Willingness to receive treatment for HCV (%)**						
Unwilling	n/a	n/a	--	--	0 (0)	--
Neutral	n/a	n/a	--	--	0 (0)	--
Willing	n/a	n/a	--	--	5 (83)	--
Not reported	n/a	n/a	2 (100)	--	1 (17)	--
Treatment location preference (%)						
Prison	n/a	n/a	1 (50)	--	3 (50)	--
Community	n/a	n/a	0 (0)	--	0 (0)	--
Unsure	n/a	n/a	0 (0)	--	3 (50)	--
Not reported	n/a	n/a	1 (50)	--	0 (0)	--
Knowledge & awareness of DAA treatments for hepatitis C[^]					N = 22	N = 15
<i>New treatments for hep C are available (%)</i>						
True	n/a	n/a	n/a	n/a	9 (41)	0 (0)
False	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Unsure	n/a	n/a	n/a	n/a	10 (46)	13 (87)
Not reported	n/a	n/a	n/a	n/a	3 (14)	2 (13)
<i>The new hep C treatments require injections (%)</i>						
True	n/a	n/a	n/a	n/a	4 (18)	0 (0)
False	n/a	n/a	n/a	n/a	4 (18)	0 (0)
Unsure	n/a	n/a	n/a	n/a	14 (64)	14 (93)
Not reported	n/a	n/a	n/a	n/a	0 (0)	1 (7)
<i>The new hep C treatments have few side-effects (%)</i>						
True	n/a	n/a	n/a	n/a	5 (23)	0 (0)
False	n/a	n/a	n/a	n/a	1 (5)	0 (0)
Unsure	n/a	n/a	n/a	n/a	16 (73)	14 (93)
Not reported	n/a	n/a	n/a	n/a	0 (0)	1 (7)
<i>The new hep C treatments take up to one year (%)</i>						
True	n/a	n/a	n/a	n/a	3 (14)	1 (7)
False	n/a	n/a	n/a	n/a	6 (27)	0 (0)
Unsure	n/a	n/a	n/a	n/a	13 (59)	13 (87)
Not reported	n/a	n/a	n/a	n/a	0 (0)	1 (7)

*Of those who have not had treatment.

[^]Correct response is shaded.

HIV antibody prevalence

Table 187 HIV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2010						
IDU	11	0 (0)	4	0 (0)	15	0 (0)
Non-IDU	18	0 (0)	3	0 (0)	21	0 (0)
p value		--		--		--
2013						
IDU	15	0 (0)	0	0 (0)	15	0 (0)
Non-IDU	16	0 (0)	0	0 (0)	16	0 (0)
p value		--		--		--
2016						
IDU	15	0 (0)	1	0 (0)	16	0 (0)
Non-IDU	8	0 (0)	0	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 188 HCV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
IDU	10	4 (40)	4	2 (50)	14	6 (43)
Non-IDU	16	1 (6)	3	0 (0)	19	1 (5)
p value		0.03		0.2		<0.01
2013						
IDU	18	5 (28)	1	1 (100)	19	6 (32)
Non-IDU	15	0 (0)	0	0 (0)	15	0 (0)
p value		0.03		--		0.02
2016						
IDU	16	10 (63)	1	0 (0)	17	10 (59)
Non-IDU	8	1 (13)	0	0 (0)	8	1 (13)
p value		0.02		--		0.03

† Excludes equivocal test results and missing values.

Table 189 HCV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Heterosexual	25	5 (20)	3	0 (0)	28	5 (18)
Bisexual	0	0 (0)	3	1 (33)	3	1 (33)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.2		0.1
2013						
Heterosexual	30	5 (17)	1	1 (100)	31	6 (19)
Bisexual	1	0 (0)	0	0 (0)	1	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.9		--		0.6
2016						
Heterosexual	22	9 (41)	1	0 (0)	23	9 (39)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	1	1 (100)	0	0 (0)	1	1 (100)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 190 HCV antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	6	0 (0)	1	0 (0)	7	0 (0)
25 – 29	5	1 (20)	2	0 (0)	7	1 (14)
30 + years	14	4 (29)	4	2 (50)	18	6 (33)
p value		0.5		0.4		0.3
2013						
< 20 years	2	0 (0)	0	0 (0)	2	0 (0)
20 – 24	8	1 (13)	0	0 (0)	8	1 (13)
25 – 29	6	0 (0)	0	0 (0)	6	0 (0)
30 + years	19	4 (21)	1	1 (100)	20	5 (25)
p value		0.6		--		0.4
2016						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	3	0 (0)	0	0 (0)	3	0 (0)
25 – 29	6	2 (33)	0	0 (0)	6	2 (33)
30 + years	14	8 (57)	1	0 (0)	15	8 (53)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 191 HCV antibody prevalence by years since first drug injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	1	0 (0)	2	0 (0)
6 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
10 + years	6	3 (50)	2	2 (100)	8	5 (63)
p value		0.5		0.1		0.2
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	2	0 (0)	0	0 (0)	2	0 (0)
6 to 10 years	6	1 (17)	0	0 (0)	6	1 (17)
10 + years	8	4 (50)	1	1 (100)	9	5 (56)
p value		0.3		--		0.2
2016						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	0	0 (0)	1	0 (0)
6 to 10 years	1	1 (100)	0	0 (0)	1	1 (100)
10 + years	12	8 (67)	1	0 (0)	13	8 (62)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 192 HCV antibody prevalence by last drug injected, years since first drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Amphetamine (Speed, Ice)	0	0 (0)	8	4 (50)	8	4 (50)
Heroin	0	0 (0)	3	0 (0)	3	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.2		0.3
2013						
Amphetamine (Speed, Ice)	2	0 (0)	11	2 (18)	13	2 (15)
Heroin	0	0 (0)	5	4 (80)	5	4 (80)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.04		0.02
2016						
Amphetamine (Speed, Ice)	1	0 (0)	13	7 (54)	14	7 (50)
Heroin	0	0 (0)	2	2 (100)	2	2 (100)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.2		0.2

† Excludes equivocal test results and missing values.

Table 193 HCV antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Less than daily	0	0 (0)	3	1 (33)	3	1 (33)
Daily or more	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.4		0.4
2013						
Less than daily	0	0 (0)	2	1 (50)	2	1 (50)
Daily or more	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		0.8		0.2
2016						
Less than daily	1	0 (0)	7	4 (57)	8	4 (50)
Daily or more	0	0 (0)	5	3 (60)	5	3 (60)
p value		--		0.9		0.7

† Excludes equivocal test results and missing values.

Table 194 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	0	0 (0)	4	1 (25)	4	1 (25)
Yes	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.6		0.6
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		--		--
2016						
No	1	0 (0)	9	4 (44)	10	4 (40)
Yes	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.09		0.07

† Excludes equivocal test results and missing values.

Table 195 HCV antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	0	0 (0)	5	2 (40)	5	2 (40)
Yes	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		1.0		0.8
2013						
No	2	0 (0)	5	1 (20)	7	1 (14)
Yes	0	0 (0)	7	3 (43)	7	3 (43)
p value		--		0.4		0.7
2016						
No	0	0 (0)	2	1 (50)	2	1 (50)
Yes	1	0 (0)	10	6 (60)	11	6 (55)
p value		--		0.8		0.9

† Excludes equivocal test results and missing values.

Table 196 HCV antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
1	16	2 (13)	3	1 (33)	19	3 (16)
2 to 4	4	1 (25)	2	1 (50)	6	2 (33)
5 to 9	4	1 (25)	2	0 (0)	6	1 (17)
10 +	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.6		0.5		0.6
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	3	1 (33)	0	0 (0)	3	1 (33)
2 to 4	8	3 (38)	0	0 (0)	8	3 (38)
5 to 9	2	1 (50)	0	0 (0)	2	1 (50)
10 +	7	5 (71)	0	0 (0)	7	5 (71)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 197 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	18	3 (17)	7	2 (29)	25	5 (20)
Indigenous	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.6		--		0.8
2013						
Non-Indigenous	18	2 (11)	0	0 (0)	18	2 (11)
Indigenous	15	3 (20)	1	1 (100)	16	4 (25)
p value		0.5		--		0.3
2016						
Non-Indigenous	16	8 (50)	0	0 (0)	16	8 (50)
Indigenous	8	3 (38)	1	0 (0)	9	3 (33)
p value		0.6		--		0.4

† Excludes equivocal test results and missing values.

Table 198 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	14	0 (0)	11	5 (45)	25	5 (20)
Indigenous	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.1		0.7		0.8
2013						
Non-Indigenous	8	0 (0)	10	2 (20)	18	2 (11)
Indigenous	7	0 (0)	9	4 (44)	16	4 (25)
p value		--		0.3		0.3
2016						
Non-Indigenous	5	0 (0)	11	8 (73)	16	8 (50)
Indigenous	3	1 (33)	6	2 (33)	9	3 (33)
p value		0.2		0.1		0.4

† Excludes equivocal test results and missing values.

Table 199 HCV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Highly accessible/accessible	23	4 (17)	6	2 (33)	29	6 (21)
Moderately accessible	1	0 (0)	0	0 (0)	1	0 (0)
Remote/very remote	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.1		--		0.2
2013						
Highly accessible/accessible	25	4 (16)	1	1 (100)	26	5 (19)
Moderately accessible	0	0 (0)	0	0 (0)	0	0 (0)
Remote/very remote	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.5		--		0.5
2016						
Highly accessible/accessible	17	8 (47)	1	0 (0)	18	8 (44)
Moderately accessible	2	2 (100)	0	0 (0)	2	2 (100)
Remote/very remote	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.06		--		0.06

† Excludes equivocal test results and missing values.

Table 200 HCV antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Australia	25	5 (20)	7	2 (29)	32	7 (22)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.6		--		0.6
2013						
Australia	32	5 (16)	1	1 (100)	33	6 (18)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.7		--		0.6
2016						
Australia	24	11 (46)	1	0 (0)	25	11 (44)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 201 Self-reported HCV status versus HCV serology by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Positive	3	3 (100)	2	2 (100)	5	5 (100)
Negative	7	1 (14)	3	0 (0)	10	1 (10)
Not sure	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.03		0.03		0.002
2013						
Positive	17	2 (12)	1	1 (100)	18	3 (17)
Negative	1	1 (100)	0	0 (0)	1	1 (100)
Not sure	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.005		--		0.13
2016						
Cleared hep C naturally	1	1 (100)	0	0 (0)	1	1 (100)
Cleared hep C with treatment	1	1 (100)	0	0 (0)	1	1 (100)
Chronic hep C	2	2 (100)	0	0 (0)	2	2 (100)
Negative	10	2 (20)	0	0 (0)	10	2 (20)
Not sure	3	3 (100)	0	0 (0)	3	3 (100)
p value		0.03		--		0.03

† Excludes equivocal test results and missing values.

HBV prevalence

Table 202 HBV surface-antigen prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	2	1 (50)	1	0 (0)	3	1 (33)
Non-IDU	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.2				0.1
2013						
IDU	13	1 (8)	0	0 (0)	13	1 (8)
Non-IDU	10	3 (30)	0	0 (0)	10	3 (30)
p value		0.2		--		0.2
2016						
IDU	14	0 (0)	1	0 (0)	15	0 (0)
Non-IDU	6	0 (0)	0	0 (0)	6	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 203 HBV core-antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	11	2 (18)	4	0 (0)	15	2 (13)
Non-IDU	16	1 (6)	3	0 (0)	19	1 (5)
p value		0.3		--		0.4
2013						
IDU	6	2 (33)	0	0 (0)	6	2 (33)
Non-IDU	10	0 (0)	0	0 (0)	10	0 (0)
p value		0.05		--		0.05
2016						
IDU	16	2 (13)	1	0 (0)	17	2 (12)
Non-IDU	8	1 (13)	0	0 (0)	8	1 (13)
p value		1.0		--		1.0

† Excludes equivocal test results and missing values.

Table 204 HBV core-antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Heterosexual	26	3 (12)	3	0 (0)	29	3 (10)
Bisexual	0	0 (0)	3	0 (0)	3	0 (0)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		0.8
2013						
Heterosexual	15	2 (13)	0	0 (0)	15	2 (13)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Heterosexual	22	3 (14)	1	0 (0)	23	3 (13)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 205 HBV core-antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
< 20 years	6	0 (0)	1	0 (0)	7	0 (0)
20 – 24	5	0 (0)	2	0 (0)	7	0 (0)
25 – 29	15	3 (20)	4	0 (0)	19	3 (16)
30 + years		0.4		--		0.5
p value						
2013						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	5	0 (0)	0	0 (0)	5	0 (0)
25 – 29	2	0 (0)	0	0 (0)	2	0 (0)
30 + years	10	2 (20)	0	0 (0)	10	0 (0)
p value		0.6		--		0.6
2016						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	3	0 (0)	0	0 (0)	3	0 (0)
25 – 29	6	0 (0)	0	0 (0)	6	0 (0)
30 + years	14	3 (21)	1	0 (0)	15	3 (20)
p value		0.3		--		0.4

† Excludes equivocal test results and missing values.

Table 206 HBV core-antibody prevalence by duration of years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
<3 years	6	0 (0)	0	0 (0)	6	0 (0)
3 to 5 years	5	2 (40)	0	0 (0)	5	2 (40)
6 to 10 years	11	2 (18)	0	0 (0)	11	2 (18)
10 + years	48	12 (25)	0	0 (0)	48	12 (25)
p value		0.4		--		0.4
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	3	0 (0)	0	0 (0)	3	0 (0)
10 + years	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.08		--		0.08
2016						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	0	0 (0)	1	0 (0)
6 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
10 + years	12	2 (17)	1	0 (0)	13	2 (15)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 207 HBV core-antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Methamphetamine	0	0 (0)	9	2 (22)	9	2 (22)
Heroin	0	0 (0)	3	0 (0)	3	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		0.6		0.5
2013						
Amphetamine (Speed, Ice)	0	0 (0)	4	1 (25)	4	1 (25)
Heroin	0	0 (0)	1	0 (0)	1	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.3		0.3
2016						
Amphetamine (Speed, Ice)	1	0 (0)	13	1 (8)	14	1 (7)
Heroin	0	0 (0)	2	1 (50)	2	1 (50)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.1		0.09

† Excludes equivocal test results and missing values.

Table 208 HBV core-antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Less than daily	0	0 (0)	3	1 (33)	3	1 (33)
Daily or more	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.4		0.4
2013						
Less than daily	0	0 (0)	0	0 (0)	0	0 (0)
Daily or more	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		--		--
2016						
Less than daily	1	0 (0)	7	1 (14)	8	1 (13)
Daily or more	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.8		0.7

† Excludes equivocal test results and missing values.

Table 209 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	3	0 (0)	21	4 (19)	24	4 (17)
Yes	1	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.9		0.9
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		--
2016						
No	1	0 (0)	9	1 (11)	10	1 (10)
Yes	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.4		0.3

† Excludes equivocal test results and missing values.

Table 210 HBV core-antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	0	0 (0)	6	0 (0)	6	0 (0)
Yes	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.3		0.3
2013						
No	0	0 (0)	3	1 (33)	3	1 (33)
Yes	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.7		0.7
2016						
No	0	0 (0)	2	0 (0)	2	0 (0)
Yes	1	0 (0)	10	1 (10)	11	1 (9)
p value		--		0.6		0.7

† Excludes equivocal test results and missing values.

Table 211 HBV core-antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
1	16	1 (6)	3	0 (0)	19	1 (5)
2 to 4	5	0 (0)	2	0 (0)	7	0 (0)
5 to 9	4	1 (25)	2	0 (0)	6	1 (17)
10 +	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.2		--		0.1
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	3	0 (0)	0	0 (0)	3	0 (0)
2 to 4	8	1 (13)	0	0 (0)	8	1 (13)
5 to 9	2	0 (0)	0	0 (0)	2	0 (0)
10 +	7	1 (14)	0	0 (0)	7	1 (14)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 212 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	19	1 (5)	7	0 (0)	26	1 (4)
Indigenous	8	2 (25)	--	0 (0)	8	2 (25)
p value		0.1		--		0.07
2013						
Non-Indigenous	7	1 (14)	0	0 (0)	7	1 (14)
Indigenous	9	1 (11)	0	0 (0)	9	1 (11)
p value		0.9		--		0.9
2016						
Non-Indigenous	16	2 (13)	0	0 (0)	16	2 (13)
Indigenous	8	1 (13)	1	0 (0)	9	1 (11)
p value		1.0		--		0.9

† Excludes equivocal test results and missing values.

Table 213 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	14	0 (0)	12	1 (8)	26	1 (4)
Indigenous	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.09		0.3		0.07
2013						
Non-Indigenous	5	0 (0)	2	1 (50)	7	1 (14)
Indigenous	5	0 (0)	4	1 (25)	9	1 (11)
p value		--		0.5		0.9
2016						
Non-Indigenous	5	0 (0)	11	2 (18)	16	2 (13)
Indigenous	3	1 (33)	6	0 (0)	9	1 (11)
p value		0.2		0.3		0.9

† Excludes equivocal test results and missing values.

Table 214 HBV core-antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Highly accessible/accessible	24	2 (8)	6	0 (0)	30	2 (7)
Moderately accessible	1	0 (0)	0	0 (0)	1	0 (0)
Remote/very remote	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.02		--		0.01
2013						
Highly accessible/accessible	11	2 (18)	0	0 (0)	11	2 (18)
Moderately accessible	0	0 (0)	0	0 (0)	0	0 (0)
Remote/very remote	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.6		--		0.6
2016						
Highly accessible/accessible	17	1 (6)	1	0 (0)	18	1 (6)
Moderately accessible	2	1 (50)	0	0 (0)	2	1 (50)
Remote/very remote	4	1 (25)	0	0 (0)	4	3 (13)
p value		0.2		--		0.1

† Excludes equivocal test results and missing values.

Table 215 HBV core-antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Australia	26	3 (12)	7	0 (0)	33	3 (9)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.7		--		0.8
2013						
Australia	15	2 (13)	0	0 (0)	15	2 (13)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.7		--		0.8
2016						
Australia	24	3 (13)	1	0 (0)	25	3 (12)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 216 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
IDU	15	1 (7)	1 (7)	1 (7)	12 (80)
Non-IDU	18	7 (39)	1 (6)	0 (0)	10 (56)
p value					0.1
2013					
IDU	9	5 (56)	2 (22)	0 (0)	2 (22)
Non-IDU	9	3 (33)	0 (0)	0 (0)	6 (67)
p value					0.1
2016					
IDU	5	2 (40)	2 (40)	0 (0)	1 (20)
Non-IDU	4	1 (25)	1 (25)	0 (0)	2 (50)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 217 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Heterosexual	28	7 (25)	2 (7)	1 (4)	18 (64)
Homosexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Bisexual	3	0 (0)	0 (0)	0 (0)	3 (100)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.9
2013					
Heterosexual	17	8 (47)	2 (12)	0 (0)	7 (41)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.5
2016					
Heterosexual	9	3 (33)	3 (33)	0 (0)	3 (33)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 218 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	7	0 (0)	0 (0)	0 (0)	7 (100)
25 – 29	7	1 (14)	0 (0)	0 (0)	6 (86)
30 + years	18	6 (33)	2 (11)	1 (6)	9 (50)
p value					0.3
2013					
< 20 years	2	1 (50)	0 (0)	0 (0)	1 (50)
20 – 24	6	3 (50)	0 (0)	0 (0)	3 (50)
25 – 29	4	1 (25)	0 (0)	0 (0)	3 (75)
30 + years	7	3 (43)	2 (29)	--	2 (29)
p value					0.5
2016					
< 20 years	0	0 (0)	0 (0)	0 (0)	0 (0)
20 – 24	2	0 (0)	0 (0)	0 (0)	2 (100)
25 – 29	1	1 (100)	0 (0)	0 (0)	0 (0)
30 + years	6	2 (33)	3 (50)	0 (0)	1 (17)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 219 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
1	18	6 (33)	1 (6)	0 (0)	11 (61)
2 to 4	7	1 (14)	0 (0)	0 (0)	6 (86)
5 to 9	6	1 (17)	0 (0)	1 (17)	4 (67)
10 +	2	0 (0)	1 (50)	0 (0)	1 (50)
p value					0.1
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--
2016					
1	1	0 (0)	0 (0)	0 (0)	1 (100)
2 to 4	1	0 (0)	1 (100)	0 (0)	0 (0)
5 to 9	0	0 (0)	0 (0)	0 (0)	0 (0)
10 +	3	1 (33)	1 (33)	0 (0)	1 (33)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 220 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Non-Indigenous	25	5 (20)	0 (0)	1 (4)	19 (76)
Indigenous	8	3 (38)	2 (25)	0 (0)	3 (38)
p value					0.03
2013					
Non-Indigenous	10	6 (60)	1 (10)	0 (0)	3 (30)
Indigenous	8	2 (25)	1 (13)	0 (0)	5 (63)
p value					0.3
2016					
Non-Indigenous	5	1 (20)	2 (40)	0 (0)	2 (40)
Indigenous	4	2 (50)	1 (25)	0 (0)	1 (25)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 221 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Highly accessible/accessible	29	7 (24)	2 (7)	0 (0)	20 (69)
Moderately accessible	1	0 (0)	0 (0)	0 (0)	1 (100)
Remote/very remote	1	0 (0)	0 (0)	1 (100)	0 (0)
p value					<0.001
2013					
Highly accessible/accessible	13	6 (46)	2 (15)	0 (0)	5 (38)
Moderately accessible	0	0 (0)	0 (0)	0 (0)	0 (0)
Remote/very remote	2	1 (50)	0 (0)	0 (0)	1 (50)
p value					0.8
2016					
Highly accessible/accessible	6	2 (33)	1 (17)	0 (0)	3 (50)
Moderately accessible	1	0 (0)	1 (100)	0 (0)	0 (0)
Remote/very remote	2	1 (50)	1 (50)	0 (0)	0 (0)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 222 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2010						
No	8	4 (50)	1	0 (0)	9	4 (44)
Yes	11	10 (91)	5	5 (100)	16	15 (94)
Not sure	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.1		0.01		0.02
2013						
No	7	3 (43)	0	0 (0)	7	3 (43)
Yes	4	2 (50)	0	0 (0)	4	2 (50)
Not sure	4	2 (50)	0	0 (0)	4	2 (50)
p value		1.0		--		1.0
2016						
No	2	0 (0)	0	0 (0)	2	0 (0)
Yes	2	2 (100)	0	0 (0)	2	2 (100)
Not sure	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.08		--		0.1

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 223 Genital chlamydia prevalence by gender and survey year†

Gender	N° tested	N° with chlamydia (%)
2010		
Male	29	0 (0)
Female	8	0 (0)
p value		--
2013		
Male	31	4 (13)
Female	--	0 (0)
p value		--
2016		
Male	24	1 (4)
Female	1	0 (0)
p value		0.8

† Excludes missing values.

Gonorrhoea

Table 224 Genital gonorrhoea prevalence by gender and survey year†

Gender	N° tested	N° with gonorrhoea (%)
2010		
Male	29	0 (0)
Female	8	0 (0)
p value		--
2013		
Male	31	0 (0)
Female	0	0 (0)
p value		--
2016		
Male	24	0 (0)
Female	1	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 225 Syphilis markers by gender and survey year†

Gender	N° tested	No with syphilis antibodies (%)	No with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	25	2 (8)	0 (0)	2 (8)
Female	0	0 (0)	0 (0)	0 (0)
p value		--	--	--
2013				
Male	31	0 (0)	0 (0)	0 (0)
Female	0	0 (0)	0 (0)	0 (0)
p value		--	--	--
2016				
Male	23	0 (0)	0 (0)	0 (0)
Female	1	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

Tasmania
2004, 2007, 2010, 2013, 2016

Table 226 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 2		N = 3		N = 4		N = 3		N = 3	
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Gender (%)										
Male	22 (85)	14 (93)	19 (86)	21 (88)	18 (95)	13 (100)	16 (94)	13 (81)	12 (80)	12 (86)
Female	4 (15)	1 (7)	3 (14)	3 (13)	1 (5)	0 (0)	1 (6)	3 (19)	3 (20)	2 (14)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age (years)										
Median age	25	42	32	26	27	26	31	34	34	32
Age range	21–48	17–64	21–45	19–58	19–50	19–59	18–43	19–60	20–48	20–48
Age group (%)										
<25 years	2 (8)	3 (20)	1 (5)	11 (46)	6 (32)	5 (38)	3 (18)	4 (25)	5 (33)	4 (29)
25+ years	24 (92)	12 (80)	21 (95)	13 (54)	13 (68)	8 (62)	14 (82)	12 (75)	10 (67)	10 (71)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Aboriginal and/or Torres Strait Islander origin (%)										
No	16 (62)	9 (60)	18 (82)	20 (83)	17 (89)	10 (77)	11 (65)	15 (94)	10 (67)	9 (64)
Yes	2 (8)	4 (27)	4 (18)	4 (17)	2 (11)	3 (23)	6 (35)	1 (6)	5 (33)	5 (36)
Not reported	8 (31)	2 (13)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	25 (96)	15 (100)	21 (95)	23 (96)	19 (100)	12 (92)	14 (82)	1 (94)	14 (93)	13 (93)
Bisexual	1 (4)	0 (0)	0 (0)	1 (4)	0 (0)	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)
Gay/lesbian	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (18)	1 (6)	0 (0)	1 (7)
Region/Country of birth (%)										
Australia	26 (100)	13 (87)	22 (100)	23 (96)	19 (100)	13 (100)	17 (100)	15 (94)	15 (100)	14 (100)
Other Oceania	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	2 (13)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Residential remoteness in 12 months before prison (%)										
Highly/accessible	20 (77)	11 (73)	13 (59)	18 (75)	16 (84)	8 (62)	7 (41)	8 (50)	8 (53)	10 (71)
Mod accessible	2 (8)	1 (7)	6 (27)	4 (17)	1 (5)	4 (31)	8 (47)	7 (44)	6 (40)	4 (29)
Very/remote	0 (0)	2 (13)	3 (14)	2 (8)	1 (5)	0 (0)	1 (6)	1 (6)	0 (0)	0 (0)
Not reported	4 (15)	1 (7)	0 (0)	0 (0)	1 (5)	1 (8)	1 (6)	0 (0)	1 (7)	0 (0)
First time in prison (%)										
No	17 (65)	10 (67)	19 (86)	12 (50)	15 (79)	10 (77)	12 (71)	4 (25)	13 (87)	10 (71)
Yes	9 (35)	5 (33)	3 (14)	12 (50)	4 (21)	3 (23)	5 (29)	12 (75)	2 (13)	4 (29)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Lifetime imprisonments (%)*										
One	9 (35)	5 (33)	3 (14)	12 (50)	5 (26)	6 (46)	n/a	n/a	1 (8)	1 (10)
Two to four	8 (31)	5 (33)	10 (45)	9 (38)	8 (42)	6 (46)	n/a	n/a	4 (31)	4 (40)
Five to nine	6 (23)	1 (7)	6 (27)	3 (13)	4 (21)	0 (0)	n/a	n/a	4 (31)	4 (40)
Ten or more	2 (8)	0 (0)	2 (9)	0 (0)	2 (11)	1 (8)	n/a	n/a	2 (15)	0 (0)
Not reported	1 (4)	4 (27)	1 (5)	0 (0)	0 (0)	0 (0)	n/a	n/a	2 (15)	1 (10)
Imprisonment in last year (%)										
No	12 (46)	7 (47)	5 (26)	5 (42)	11 (58)	8 (62)	5 (42)	2 (50)	2 (15)	5 (50)
Yes	11 (42)	4 (27)	13 (68)	7 (58)	8 (42)	5 (38)	4 (33)	2 (50)	8 (62)	5 (50)
Not reported	3 (12)	4 (27)	1 (5)	0 (0)	0 (0)	0 (0)	3 (25)	0 (0)	3 (23)	0 (0)

Table 227 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Ever smoked a full cigarette (%)										
No	n/a	n/a	0 (0)	1 (4)	0 (0)	1 (8)	0 (0)	3 (19)	0 (0)	1 (7)
Yes	n/a	n/a	22 (100)	23 (96)	19 (100)	12 (92)	17 (100)	13 (81)	15 (100)	13 (93)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age of smoking (%)										
Med age 1 st smoked	n/a	n/a	14	14	13	13	12	12	12	14
Age range	n/a	n/a	7–36	6–17	8–15	10–20	5–21	7–28	5–15	7–16
Current smoker (%)*										
No	n/a	n/a	1 (5)	4 (17)	1 (5)	4 (31)	2 (12)	2 (15)	1 (7)	0 (0)
Yes	n/a	n/a	21 (95)	20 (83)	18 (85)	9 (69)	15 (88)	11 (85)	14 (93)	13 (100)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Smoking frequency (%)										
Weekly or less	n/a	n/a	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	1 (8)
5 - 10/day	n/a	n/a	4 (19)	3 (15)	12 (67)	6 (67)	0 (0)	0 (0)	5 (36)	1 (8)
11 - 20/day	n/a	n/a	8 (38)	9 (45)	3 (17)	3 (33)	9 (60)	4 (40)	2 (14)	6 (46)
>20/day	n/a	n/a	9 (43)	7 (35)	3 (17)	0 (0)	6 (40)	6 (60)	5 (36)	5 (38)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
Other drugs used last month (%)**										
None	n/a	n/a	n/a	n/a	5 (26)	4 (31)	1 (6)	7 (44)	1 (7)	5 (36)
Cannabis	n/a	n/a	n/a	n/a	10 (71)	8 (89)	13 (81)	5 (56)	12 (86)	6 (67)
Heroin	n/a	n/a	n/a	n/a	1 (7)	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
Cocaine	n/a	n/a	n/a	n/a	2 (14)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	n/a	n/a	n/a	n/a	7 (50)	0 (0)	9 (56)	0 (0)	11 (79)	5 (56)
Methadone	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	3 (21)	0 (0)
Other opiates	n/a	n/a	n/a	n/a	2 (14)	0 (0)	2 (13)	2 (22)	1 (7)	0 (0)
Buprenorphine	n/a	n/a	n/a	n/a	2 (14)	1 (11)	0 (0)	0 (0)	3 (21)	2 (22)
Steroids	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
Hallucinogens	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Benzodiazepine	n/a	n/a	n/a	n/a	6 (43)	0 (0)	4 (25)	0 (0)	5 (36)	1 (11)
Ecstasy/MDA	n/a	n/a	n/a	n/a	1 (7)	0 (0)	3 (19)	0 (0)	3 (21)	1 (11)
Inhalants	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other drug	n/a	n/a	n/a	n/a	0 (0)	0 (0)	2 (13)	3 (33)	1 (7)	3 (33)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Risk of alcohol-related harm (%)^^										
Non-drinker	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (13)	2 (14)
Low risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	7 (47)	6 (43)
High risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	6 (40)	6 (43)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	0 (0)

*Prior to prison; **More than one drug option could be selected; ^Also includes hormones and peptides from 2016; ^^AUDIT-C

Table 228 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013	2016
	N = 26	N = 22	N = 19	N = 17	N = 15
Med age 1 st IDU	20	19	18	19	16
Age range	14 – 30	12 – 40	12 – 35	14 – 32	13 – 26
Not reported	0	0	0	0	1
Med IDU (years)	10	10	9	14	17
Range	1 – 32	<1 – 27	<1 – 25	<1 – 22	3 – 27
Years since first injection (%)					
<3 years	1 (4)	1 (5)	4 (21)	2 (12)	0 (0)
3+ years	23 (88)	21 (95)	15 (79)	13 (76)	15 (100)
Not reported	2 (8)	0 (0)	0 (0)	2 (12)	0 (0)
Last drug injected (%)					
Methamphetamine	20 (77)	16 (73)	12 (63)	14 (82)	11 (79)
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	2 (8)	1 (5)	0 (0)	0 (0)	0 (0)
Methadone	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Morphine	3 (12)	4 (18)	5 (26)	3 (18)	2 (14)
Subutex/buprenorphine/Suboxone	n/a	n/a	n/a	n/a	0 (0)
Other	1 (4)	1 (5)	2 (11)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)
Frequency of injection last month (%)					
Not last month	12 (46)	6 (27)	10 (53)	9 (53)	6 (40)
< Weekly	2 (8)	4 (18)	5 (26)	2 (12)	2 (13)
Weekly	6 (23)	4 (18)	2 (11)	2 (12)	0 (0)
Daily or more	5 (19)	8 (36)	2 (11)	4 (24)	5 (33)
Not reported	1 (4)	0 (0)	0 (0)	0 (0)	2 (13)
N° Injected last month					
	N = 14	N = 16	N = 9	N = 8	N = 9
Places injected last month (%)*					
Prison	1 (8)	1 (6)	0 (0)	0 (0)	0 (0)
Own home	11 (79)	15 (94)	4 (44)	6 (75)	4 (57)
Friend's home	7 (50)	13 (81)	4 (44)	5 (63)	1 (14)
Dealer's home	2 (14)	4 (25)	1 (11)	0 (0)	2 (29)
Street, park, beach	2 (14)	3 (19)	2 (22)	1 (13)	1 (14)
Car	7 (50)	10 (63)	5 (56)	1 (13)	2 (29)
Public toilet	4 (29)	4 (25)	2 (22)	0 (0)	3 (43)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre,	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Squat	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other place	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of sterile needles & syringes last month (%)					
All injections	12 (86)	13 (81)	7 (78)	6 (75)	7 (100)
Most of the time	1 (7)	2 (13)	2 (22)	2 (25)	0 (0)
Half of the time	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
Times injected by someone else after they injected themselves or others in past month (%)					
More than 5 times	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
3 to 5 times	1 (8)	1 (6)	0 (0)	0 (0)	0 (0)
Once or twice	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)
None	11 (85)	14 (88)	9 (100)	8 (100)	7 (100)
Re-used someone else's used needle & syringe last month (%)					
None	12 (86)	14 (88)	8 (89)	7 (88)	7 (100)
Once	1 (7)	1 (6)	0 (0)	1 (13)	0 (0)
Twice	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)
3-5 times	0 (0)	1 (6)	1 (11)	0 (0)	0 (0)
>5 times	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* More than one drug option could be selected.

Table 229 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year (cont.)

Injecting behaviour	2004	2007	2010	2013	2016
	N = 26	N = 22	N = 19	N = 17	N = 15
Number of people needle & syringe was re-used after last month (%)*					
One	1 (7)	1 (6)	0 (0)	1 (13)	--
Two	0 (0)	0 (0)	0 (0)	0 (0)	--
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	--
More than five	0 (0)	0 (0)	0 (0)	0 (0)	--
Don't know how many	0 (0)	1 (6)	1 (11)	0 (0)	--
Not reported	1 (7)	0 (0)	0 (0)	0 (0)	--
Relationship to people needle & syringe was re-used after last month (%)**					
Regular sex partner	1 (7)	2 (13)	1 (11)	1 (13)	--
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	--
Close friend	0 (0)	0 (0)	1 (11)	0 (0)	--
Acquaintance	1 (7)	0 (0)	0 (0)	0 (0)	--
Other	0 (0)	0 (0)	0 (0)	0 (0)	--
Last time re-used needle or syringe after someone (%)					
Last month	1 (4)	1 (5)	1 (5)	1 (6)	0 (0)
In the last 2-6 months	3 (12)	1 (5)	0 (0)	0 (0)	1 (7)
More than 6 months ago	2 (8)	5 (24)	4 (21)	5 (29)	4 (27)
Never	18 (69)	14 (64)	14 (74)	11 (65)	9 (60)
Not reported	2 (8)	1 (5)	0 (0)	0 (0)	1 (7)
Last place re-used needle or syringe after someone (%)					
Prison	0 (0)	1 (14)	2 (40)	2 (33)	2 (33)
Own home	3 (50)	3 (43)	2 (40)	2 (50)	2 (33)
Friend's home	1 (17)	2 (29)	0 (0)	1 (17)	0 (0)
Dealer's home	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Street, park, bench	0 (0)	1 (14)	1 (20)	0 (0)	0 (0)
Car	2 (33)	0 (0)	0 (0)	0 (0)	0 (0)
Public toilet	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre,	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Squat	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (17)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%)**					
Spoon	1 (7)	3 (19)	1 (11)	0 (0)	2 (22)
Water	4 (29)	2 (13)	1 (11)	0 (0)	1 (11)
Filter	2 (14)	1 (6)	1 (11)	0 (0)	0 (0)
Tourniquet	1 (7)	0 (0)	1 (11)	0 (0)	0 (0)
Drug mix	1 (7)	2 (13)	1 (11)	0 (0)	3 (33)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	3 (33)

*Of those reporting sharing needles & syringes in the past month.

**More than one drug option could be selected.

Table 230 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013	2016
N° surveyed	N = 26	N = 22	N = 19	N = 17	N = 15
Location of needle & syringe acquisition in the past month (%)*					
Needle & Syringe Program (NSP/CNP)	n/a	n/a	n/a	n/a	2 (13)
Chemist/Pharmacy	n/a	n/a	n/a	n/a	5 (33)
Vending machine	n/a	n/a	n/a	n/a	1 (7)
Personal source (e.g. friend)	n/a	n/a	n/a	n/a	1 (7)
Other	n/a	n/a	n/a	n/a	2 (13)
Not in the last month	n/a	n/a	n/a	n/a	4 (27)
From an NSP last month (%)**					
Daily or almost daily	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
A couple of times each week	2 (14)	5 (31)	3 (16)	1 (6)	1 (9)
Less than weekly	4 (29)	1 (6)	1 (5)	2 (12)	0 (0)
Weekly	n/a	n/a	4 (21)	n/a	n/a
Once last month	0 (0)	1 (6)	0 (0)	3 (18)	1 (9)
Not in the last month	0 (0)	1 (6)	11 (58)	11 (65)	6 (55)
Not reported	8 (57)	7 (44)	0 (0)	0 (0)	3 (27)
From a chemist last month (%)**					
Daily or almost daily	2 (14)	0 (0)	0 (0)	0 (0)	1 (9)
A couple of times each week	1 (7)	3 (19)	0 (0)	0 (0)	1 (9)
Less than weekly	1 (7)	3 (19)	1 (5)	2 (12)	0 (0)
Weekly	n/a	n/a	3 (16)	n/a	n/a
Once last month	6 (43)	0 (0)	0 (0)	1 (6)	3 (27)
Not in the last month	4 (29)	2 (13)	15 (79)	14 (82)	4 (36)
Not reported	0 (0)	8 (50)	0 (0)	0 (0)	2 (18)
Ever participated in the annual NSP community survey (%)					
No	19 (73)	17 (77)	17 (90)	14 (82)	13 (87)
Yes	4 (15)	4 (18)	2 (11)	3 (18)	1 (7)
Don't remember	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (4)	1 (5)	0 (0)	0 (0)	1 (7)

* More than one drug option could be selected.

Table 231 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Any treatment/therapy for drug use (%)										
No	10 (38)	14 (93)	9 (41)	16 (67)	7 (37)	12 (92)	12 (71)	14 (88)	7 (47)	13 (93)
Yes	16 (62)	0 (0)	13 (59)	4 (17)	12 (63)	1 (8)	5 (29)	1 (6)	6 (40)	1 (7)
Not reported	0 (0)	1 (7)	0 (0)	4 (17)	0 (0)	0 (0)	0 (0)	1 (6)	2 (13)	0 (0)
History of methadone maintenance treatment (%)										
Currently	3 (12)	0 (0)	3 (14)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Previously	6 (23)	0 (0)	2 (9)	0 (0)	2 (11)	0 (0)	2 (12)	0 (0)	2 (13)	0 (0)
Never	16 (62)	14 (93)	17 (77)	0 (0)	16 (84)	13 (100)	15 (88)	16 (100)	13 (87)	14 (100)
Not reported	1 (4)	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of other pharmacotherapy treatment (%)										
Currently	2 (8)	0 (0)	0 (0)	0 (0)	2 (11)	1 (8)	0 (0)	0 (0)	1 (7)	0 (0)
Previously	2 (8)	0 (0)	5 (23)	0 (0)	3 (16)	0 (0)	2 (12)	0 (0)	2 (13)	0 (0)
Never	21 (81)	14 (93)	17 (77)	0 (0)	14 (74)	12 (92)	15 (88)	15 (94)	12 (80)	14 (100)
Not reported	1 (4)	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)

Table 232 Number (%) of respondents by body piercing and tattoos by injector status and survey year

Demographics	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Body or ear piercings (%)										
No	11 (42)	8 (53)	8 (36)	15 (63)	12 (63)	10 (77)	9 (53)	8 (50)	9 (60)	9 (64)
Yes	15 (58)	7 (47)	14 (64)	9 (38)	7 (37)	3 (23)	7 (41)	8 (50)	6 (40)	5 (36)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
Piercings other than ears (%)										
Yes	5 (10)	1 (14)	4 (29)	3 (33)	4 (80)	1 (33)	3 (38)	2 (25)	2 (33)	3 (60)
No	9 (60)	4 (57)	10 (71)	6 (67)	3 (43)	2 (67)	4 (50)	5 (63)	4 (67)	2 (40)
Not reported	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (13)	1 (13)	0 (0)	0 (0)
Pierced in past 12 months (%)										
No	12 (80)	5 (71)	13 (93)	9 (100)	3 (43)	2 (67)	5 (71)	6 (75)	4 (67)	3 (60)
Yes	1 (7)	1 (14)	0 (0)	0 (0)	4 (57)	1 (33)	1 (14)	2 (25)	1 (17)	0 (0)
Not reported	2 (13)	1 (14)	1 (7)	0 (0)	0 (0)	0 (0)	1 (14)	0 (0)	1 (17)	2 (40)
Who did piercing (%)*										
Professional^	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	2 (100)	1 (100)	--
Non-professional^^	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)	0 (0)	0 (0)	0 (0)	--
Prisoner	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)	0 (0)	0 (0)	0 (0)	--
Self	0 (0)	0 (0)	0 (0)	0 (0)	2 (50)	0 (0)	0 (0)	0 (0)	0 (0)	--
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--
Penile implants (%)**										
No	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	12 (100)	10 (100)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Penile implant in prison (%)										
No	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Tattoos (%)										
No	48 (26)	67 (53)	25 (19)	44 (39)	20 (20)	64 (42)	1 (6)	3 (19)	2 (13)	2 (14)
Yes	19 (74)	59 (46)	17 (81)	69 (61)	80 (80)	90 (58)	16 (94)	13 (81)	13 (87)	12 (86)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Tattoos in past 12 months (%)										
No	2 (8)	9 (60)	6 (27)	11 (46)	1 (5)	7 (54)	10 (63)	11 (85)	6 (46)	6 (50)
Yes	24 (92)	6 (40)	16 (73)	13 (54)	18 (95)	5 (38)	6 (38)	2 (15)	5 (38)	3 (25)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	0 (0)	0 (0)	2 (15)	3 (25)
Who did tattooing (%)*										
Professional^	3 (43)	1 (100)	1 (33)	2 (67)	6 (67)	3 (100)	3 (50)	2 (100)	2 (40)	2 (67)
Non-professional^^	1 (14)	0 (0)	2 (67)	1 (33)	3 (33)	0 (0)	2 (33)	0 (0)	2 (40)	0 (0)
Prisoner	1 (14)	0 (0)	2 (67)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (20)	1 (33)
Self	1 (14)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (33)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* More than one drug option could be selected.

**Males only, new question in 2016

^E.g. chemist, hairdresser, beauty salon, tattooist; ^^ Non-professional outside prison e.g. friend, family

Table 233 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Sex last month / last 3 months (%)*										
No	9 (35)	8 (53)	6 (27)	3 (13)	4 (13)	2 (15)	0 (0)	3 (19)	2 (13)	3 (21)
Yes	17 (65)	7 (47)	16 (73)	21 (88)	28 (88)	11 (85)	14 (82)	12 (75)	13 (87)	11 (79)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (18)	1 (6)	0 (0)	0 (0)
Male sex partners in last 3 months*										
Median	n/a	n/a	n/a	n/a	1 (0–1)	--	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)
Female sex partners in last 3 months*										
Median	n/a	n/a	n/a	n/a	1 (0–4)	1 (0–2)	1 (1-10)	1 (0–3)	1 (0–16)	1 (0–10)
Condom use at last sex (%)										
No	22 (85)	10 (67)	19 (86)	23 (96)	n/a	n/a	n/a	n/a	n/a	n/a
Yes	4 (15)	5 (33)	3 (14)	1 (4)	n/a	n/a	n/a	n/a	n/a	n/a
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)**										
No	9 (90)	4 (57)	10 (91)	13 (76)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	1 (10)	1 (14)	1 (9)	4 (24)	n/a	n/a	n/a	n/a	n/a	n/a
Always	0 (0)	2 (29)	0 (0)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)**										
No	1 (50)	0 (0)	2 (100)	1 (100)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	1 (50)	0 (0)	0 (0)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Always	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)**										
No	5 (71)	0 (0)	4 (100)	3 (60)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	2 (29)	0 (0)	0 (0)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Always	0 (0)	0 (0)	0 (0)	2 (40)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	1 (100)
Sometimes	n/a	n/a	n/a	n/a	1 (100)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)
Always	n/a	n/a	n/a	n/a	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Condom use last sex - casual male partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	0 (0)	3 (60)	0 (0)	0 (0)	0 (0)	0 (0)
Sometimes	n/a	n/a	n/a	n/a	1 (100)	1 (20)	0 (0)	0 (0)	0 (0)	0 (0)
Always	n/a	n/a	n/a	n/a	0 (0)	1 (20)	0 (0)	0 (0)	0 (0)	0 (0)
Condom use last sex - regular female partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	7 (70)	7 (70)	6 (100)	7 (78)	8 (100)	8 (89)
Sometimes	n/a	n/a	n/a	n/a	2 (20)	2 (20)	0 (0)	0 (0)	0 (0)	0 (0)
Always	n/a	n/a	n/a	n/a	1 (10)	1 (10)	0 (0)	2 (22)	0 (0)	1 (11)
Condom use last sex - casual female partners - last 3 months (%)**										
Never	n/a	n/a	n/a	n/a	5 (71)	0 (0)	6 (86)	1 (50)	3 (50)	2 (50)
Sometimes	n/a	n/a	n/a	n/a	2 (29)	0 (0)	1 (14)	0 (0)	1 (17)	1 (25)
Always	n/a	n/a	n/a	n/a	0 (0)	1 (100)	0 (0)	1 (50)	2 (33)	1 (25)
Sex work last month (%)										
No	25 (96)	15 (100)	21 (95)	24 (100)	19 (100)	13 (100)	14 (82)	15 (94)	14 (93)	14 (100)
Yes	1 (4)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (18)	1 (6)	0 (0)	0 (0)
Condom used at last sex work last month (%)										
No	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	--
Yes	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--

*In 2004 and 2007, sexual health questions reflect behaviour in the past month, from 2010, sexual health questions were changed to reflect the past 3 months and to differentiate between males and female partners.

**Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 234 Number (%) of respondents reporting previous testing for HIV, HBV infection, vaccinations and cervical cancer by injector status and survey year

Testing & treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Previous HIV test (%)										
Last year	13 (50)	5 (22)	3 (14)	11 (46)	7 (37)	5 (38)	6 (35)	2 (13)	6 (40)	1 (7)
>1 year ago	8 (31)	4 (27)	7 (32)	5 (21)	6 (32)	1 (8)	6 (35)	4 (25)	5 (33)	7 (50)
Never tested	5 (19)	5 (33)	12 (55)	8 (33)	6 (32)	7 (54)	4 (24)	10 (63)	4 (27)	5 (36)
Not reported	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	1 (7)
HIV infection (self-report) (%)										
No	20 (100)	8 (89)	14 (74)	9 (56)	13 (100)	7 (54)	11 (92)	6 (100)	10 (91)	8 (100)
Yes	0 (0)	1 (11)	0 (0)	0 (0)	0 (0)	6 (46)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	5 (16)	4 (25)	0 (0)	0 (0)	1 (8)	0 (0)	1 (9)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	3 (19)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HBV infection (%)										
No	19 (73)	14 (93)	20 (91)	23 (96)	17 (89)	12 (92)	15 (88)	16 (100)	10 (67)	14 (100)
Yes	6 (23)	0 (0)	0 (0)	1 (4)	2 (11)	1 (8)	1 (6)	0 (0)	1 (7)	0 (0)
Don't know	1 (4)	1 (7)	2 (9)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	3 (20)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
HBV vaccination (%)*										
No	12 (46)	11 (73)	9 (41)	10 (42)	5 (26)	5 (38)	3 (18)	4 (25)	6 (40)	5 (36)
Yes	11 (42)	4 (27)	12 (55)	10 (42)	10 (53)	5 (38)	13 (76)	5 (31)	8 (53)	6 (43)
Don't know	6 (23)	0 (0)	1 (5)	4 (17)	3 (16)	3 (23)	1 (6)	7 (44)	1 (7)	3 (21)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
N° of HBV vaccinations (%)										
One	1 (9)	0 (0)	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Two	1 (9)	2 (50)	2 (17)	1 (10)	0 (0)	0 (0)	0 (0)	1 (11)	0 (0)	0 (0)
Three or more	8 (73)	2 (50)	9 (75)	9 (90)	10 (100)	5 (100)	9 (69)	5 (56)	6 (75)	5 (83)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (13)	0 (0)
Not reported	11 (9)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (31)	3 (33)	1 (13)	1 (17)
Ever had cervical cancer vaccine (women only)** (%)										
No	n/a	n/a	n/a	n/a	1 (100)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)
Yes	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	n/a	n/a	n/a	n/a	0 (0)	0 (0)	1 (100)	0 (0)	1 (50)	0 (0)
Not reported	n/a	n/a	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* Number (%) among participants with no history of HBV infection.

**Proportion of women eligible for the National HPV Vaccination Program, i.e. those who were under 27 years of age in 2007 (or 35 years or under in 2016).

Table 235 Number (%) of respondents reporting previous testing for HCV infection and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16	N = 15	N = 14
Previous HCV test (%)										
Last year	9 (35)	4 (27)	5 (23)	11 (46)	5 (26)	5 (38)	5 (31)	2 (13)	7 (47)	3 (21)
>1 year ago	11 (42)	3 (20)	7 (32)	7 (29)	7 (37)	1 (8)	8 (50)	4 (25)	4 (27)	6 (43)
Never tested	6 (23)	8 (53)	10 (45)	6 (25)	6 (32)	7 (54)	2 (13)	10 (63)	4 (27)	5 (36)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
Result of last HCV test (self-report) (%)										
Hepatitis C antibody positive	12 (63)	1 (14)	7 (41)	0 (0)	7 (54)	1 (17)	8 (62)	0 (0)	n/a	n/a
Never had hep C	7 (36)	5 (71)	7 (41)	10 (77)	6 (46)	5 (83)	3 (33)	6 (100)	2 (18)	8 (89)
Cleared hep C naturally	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (9)	0 (0)
Cleared hep C with treatment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (9)	0 (0)
Chronic hep C	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3 (27)	0 (0)
Don't know	0 (0)	1 (14)	3 (18)	3 (23)	0 (0)	0 (0)	2 (15)	0 (0)	1 (9)	1 (11)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (27)	0 (0)
Age first diagnosed with hep C										
Median age (years)	26	25	26	--	20	30	27	--	32	--
Range	11 – 47	17 – 34	19 – 45	--	19 – 29	--	16 – 30	--	19 – 38	--
Ever had HCV treatment (%)*										
	N = 12	N = 1	N = 7	N = 1	N = 8	N = 0	N = 8	N = 0	N = 9	N = 0
No treatment	12 (100)	0 (0)	7 (100)	1 (100)	7 (88)	--	8 (100)	--	6 (67)	--
Interferon-based medication	0 (0)	1 (100)	0 (0)	0 (0)	1 (13)	--	0 (0)	--	2 (22)	--
Direct-acting antiviral (DAA)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (11)	--
Interferon-based & DAA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--	0 (0)	--	0 (0)	--
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--	0 (0)	--	0 (0)	--
Ever had PCR/RNA test to test for reinfections (%)										
< 1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (33)	--
> 1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not tested	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (67)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Result of PCR/RNA test (%)										
Still cured of hep C	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Reinfected	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Don't know	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (100)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--

*Number (%) of those reporting positive HCV test results or specifying age of hep C diagnosis.

Table 236 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness	2004		2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Ever sought out HCV treatment?*										
No	n/a	n/a	n/a	n/a	n/a	n/a	8 (100)	--	3 (50)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--	3 (50)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--	0 (0)	--
Willingness to receive treatment for HCV										
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--	0 (0)	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--	1 (11)	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	8 (100)	--	6 (67)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--	2 (22)	--
Treatment location preference (%)										
Prison	n/a	n/a	n/a	n/a	n/a	n/a	3 (38)	--	4 (44)	--
Community	n/a	n/a	n/a	n/a	n/a	n/a	4 (50)	--	1 (11)	--
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	1 (13)	--	2 (22)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--	2 (22)	--
Knowledge & awareness of DAA treatments for hepatitis C[^]									N = 15	N = 14
<i>New treatments for hep C are available (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	8 (53)	3 (21)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (7)	2 (14)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4 (27)	6 (43)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (13)	3 (21)
<i>The new hep C treatments require injections (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3 (20)	1 (7)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3 (20)	3 (21)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	7 (47)	8 (57)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (13)	2 (14)
<i>The new hep C treatments have few side-effects (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3 (20)	2 (14)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2 (13)	1 (7)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	9 (60)	9 (64)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (7)	2 (14)
<i>The new hep C treatments take up to one year (%)</i>										
True	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (7)	0 (0)
False	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	5 (33)	3 (21)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	8 (53)	9 (64)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1 (7)	2 (14)

*Of those who have not had treatment.

[^]Correct response is shaded.

HIV antibody prevalence

Table 237 HIV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	15	0 (0)	2	0 (0)	17	0 (0)
Non-IDU	8	0 (0)	0	0 (0)	8	0 (0)
p value		--		--		--
2007						
IDU	16	0 (0)	0	0 (0)	16	0 (0)
Non-IDU	17	0 (0)	0	0 (0)	17	0 (0)
p value		--		--		--
2010						
IDU	18	0 (0)	1	0 (0)	19	0 (0)
Non-IDU	12	0 (0)	0	0 (0)	12	0 (0)
p value		--		--		--
2013						
IDU	10	0 (0)	0	0 (0)	10	0 (0)
Non-IDU	10	0 (0)	2	0 (0)	12	0 (0)
p value		--		--		--
2016						
IDU	8	0 (0)	2	0 (0)	10	0 (0)
Non-IDU	6	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 238 HCV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	No with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	16	10 (63)	2	2 (100)	18	12 (67)
Non-IDU	9	1 (11)	0	0 (0)	9	1 (11)
p value		0.01		--		<0.01
2007						
IDU	15	7 (47)	0	0 (0)	15	7 (47)
Non-IDU	17	1 (6)	0	0 (0)	17	1 (6)
p value		0.008		--		0.008
2010						
IDU	17	8 (47)	1	0 (0)	18	8 (44)
Non-IDU	12	0 (0)	0	0 (0)	12	0 (0)
p value		<0.01		--		<0.01
2013						
IDU	12	0 (0)	1	0 (0)	13	10 (77)
Non-IDU	10	9 (75)	2	1 (100)	12	0 (0)
p value		<0.001		0.08		<0.001
2016						
IDU	8	5 (63)	2	0 (0)	10	5 (50)
Non-IDU	6	0 (0)	2	0 (0)	8	0 (0)
p value		0.02		--		0.02

† Excludes equivocal test results and missing values.

Table 239 HCV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
Heterosexual	25	11 (44)	1	1 (100)	26	12 (46)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		0.3
2007						
Heterosexual	32	8 (25)	0	0 (0)	32	8 (25)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2010						
Heterosexual	28	8 (29)	1	0 (0)	29	8 (28)
Bisexual	1	0 (0)	0	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.5		--		0.5
2013						
Heterosexual	19	8 (42)	3	1 (33)	22	9 (41)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Heterosexual	14	5 (36)	3	0 (0)	17	5 (29)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	1	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 240 HCV antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N ^o tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	2	1 (50)	0	0 (0)	2	1 (50)
25 – 29	8	2 (25)	3	2 (67)	11	4 (36)
30 + years	16	9 (56)	0	0 (0)	16	9 (56)
p value		0.4		--		0.6
2007						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	8	1 (13)	0	0 (0)	8	1 (13)
25 – 29	6	1 (17)	0	0 (0)	6	1 (17)
30 + years	17	6 (35)	0	0 (0)	17	6 (35)
p value		0.5		--		0.5
2010						
< 20 years	3	1 (33)	0	0 (0)	3	1 (33)
20 – 24	7	1 (14)	1	0 (0)	8	1 (13)
25 – 29	6	2 (33)	0	0 (0)	6	2 (33)
30 + years	13	4 (31)	0	0 (0)	13	4 (31)
p value		0.8		--		0.8
2013						
< 20 years	4	0 (0)	1	1 (100)	5	1 (20)
20 – 24	0	0 (0)	0	0 (0)	0	0 (0)
25 – 29	5	2 (40)	0	0 (0)	5	2 (40)
30 + years	14	7 (50)	3	0 (0)	17	7 (41)
p value		0.2		0.05		0.7
2016						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	5	2 (40)	2	0 (0)	7	2 (29)
25 – 29	2	0 (0)	0	0 (0)	2	0 (0)
30 + years	9	3 (33)	2	0 (0)	11	3 (27)
p value		0.6		--		0.7

† Excludes equivocal test results and missing values.

Table 241 HCV antibody prevalence by duration of drug injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	6	2 (33)	1	1 (100)	7	3 (43)
10 + years	9	8 (89)	1	1 (100)	10	9 (90)
p value		0.03		--		0.04
2007						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	4	1 (25)	0	0 (0)	0	1 (25)
10 + years	10	6 (60)	0	0 (0)	10	6 (60)
p value		0.3		--		0.3
2010						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3 to 5 years	3	1 (33)	0	0 (0)	3	1 (33)
6 to 10 years	2	2 (100)	1	0 (0)	3	2 (67)
10 + years	8	5 (63)	0	0 (0)	8	5 (63)
p value		0.08		--		0.2
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
10 + years	8	7 (88)	0	0 (0)	8	7 (88)
p value		0.05		--		0.05
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	2	0 (0)	0	0 (0)	2	0 (0)
6 to 10 years	2	2 (100)	0	0 (0)	2	2 (100)
10 + years	4	3 (75)	2	0 (0)	6	3 (50)
p value		0.09		--		0.1

† Excludes equivocal test results and missing values.

Table 242 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	0	0 (0)	9	6 (67)	9	6 (67)
Heroin	0	0 (0)	1	1 (100)	1	1 (100)
More than one drug	0	0 (0)	7	5 (71)	7	5 (71)
Other/not reported	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.7		0.7
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	3 (30)	11	3 (27)
Heroin	0	0 (0)	1	1 (100)	1	1 (100)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.06		0.04
2010						
Amphetamine (Speed, Ice)	3	0 (0)	8	3 (38)	11	3 (27)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	5	5 (100)	6	5 (83)
p value		--		0.04		0.06
2013						
Amphetamine (Speed, Ice)	1	1 (100)	7	6 (86)	8	7 (88)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.5		0.4
2016						
Amphetamine (Speed, Ice)	0	0 (0)	6	3 (50)	6	3 (50)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 243 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	0	0 (0)	5	3 (60)	5	3 (60)
Daily or more	0	0 (0)	4	4 (100)	4	4 (100)
p value		--		0.3		0.3
2007						
Less than daily	0	0 (0)	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	3 (60)	6	3 (50)
p value		--		0.2		0.3
2010						
Less than daily	2	0 (0)	5	3 (60)	7	3 (43)
Daily or more	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.3		0.2
2013						
Less than daily	0	0 (0)	2	2 (100)	2	2 (100)
Daily or more	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		--		--
2016						
Less than daily	0	0 (0)	1	1 (100)	1	1 (100)
Daily or more	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 244 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	0	0 (0)	8	6 (75)	8	6 (75)
Yes	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.4		0.4
2007						
No	1	0 (0)	10	4 (40)	11	4 (36)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2010						
No	2	0 (0)	6	4 (67)	8	4 (50)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		--		--
2016						
No	0	0 (0)	4	3 (75)	4	3 (75)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 245 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	0	0 (0)	8	6 (75)	8	6 (75)
Yes	0	0 (0)	2	2 (100)	6	2 (100)
p value		--		0.7		0.7
2007						
No	0	0 (0)	4	3 (75)	4	3 (75)
Yes	0	0 (0)	10	4 (40)	10	4 (40)
p value		--		0.2		0.2
2010						
No	3	0 (0)	7	3 (43)	10	3 (30)
Yes	1	0 (0)	7	5 (71)	8	5 (63)
p value		--		0.3		0.2
2013						
No	0	0 (0)	4	4 (100)	4	4 (100)
Yes	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.2		0.2
2016						
No	0	0 (0)	1	1 (100)	1	1 (100)
Yes	0	0 (0)	6	3 (50)	6	3 (50)
p value		--		0.4		0.4

† Excludes equivocal test results and missing values.

Table 246 HCV antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	10	4 (40)	0	0 (0)	10	4 (40)
2 to 4	9	4 (44)	0	0 (0)	9	4 (44)
5 to 9	4	3 (75)	1	1 (100)	5	4 (80)
10 +	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.5		--		0.4
2007						
1	7	0 (0)	0	0 (0)	7	0 (0)
2 to 4	15	3 (20)	0	0 (0)	15	3 (20)
5 to 9	9	4 (44)	0	0 (0)	9	4 (44)
10 +	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.06		--		0.06
2010						
1	9	0 (0)	0	0 (0)	9	0 (0)
2 to 4	13	2 (15)	1	0 (0)	14	2 (14)
5 to 9	4	4 (100)	0	0 (0)	4	4 (100)
10 +	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.001		--		<0.001
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	0	0 (0)	0	0 (0)	0	0 (0)
2 to 4	3	1 (33)	2	0 (0)	5	1 (20)
5 to 9	4	1 (25)	0	0 (0)	4	1 (25)
10 +	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.2		--		0.1

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 247 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	16	9 (56)	1	1 (100)	17	10 (59)
Indigenous	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.5		--		0.4
2007						
Non-Indigenous	28	6 (21)	0	0 (0)	28	6 (21)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.2		--		0.2
2010						
Non-Indigenous	24	6 (25)	1	0 (0)	25	6 (24)
Indigenous	5	2 (40)	0	0 (0)	5	2 (40)
p value		0.5		--		0.5
2013						
Non-Indigenous	17	7 (41)	3	0 (0)	20	7 (35)
Indigenous	5	2 (40)	1	1 (100)	6	3 (50)
p value		1.0		0.05		0.5
2016						
Non-Indigenous	10	3 (30)	2	0 (0)	12	3 (25)
Indigenous	6	2 (33)	2	0 (0)	8	2 (25)
p value		0.9		--		1.0

† Excludes equivocal test results and missing values.

Table 248 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	5	0 (0)	11	9 (82)	16	9 (56)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.6		0.6
2007						
Non-Indigenous	16	1 (6)	12	5 (42)	28	6 (21)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		0.8		0.4		0.2
2010						
Non-Indigenous	9	0 (0)	16	6 (38)	25	6 (24)
Indigenous	3	0 (0)	2	2 (100)	5	2 (40)
p value		--		0.1		0.5
2013						
Non-Indigenous	11	0 (0)	8	7 (88)	19	7 (37)
Indigenous	1	0 (0)	5	3 (60)	6	3 (50)
p value		--		0.3		0.5
2016						
Non-Indigenous	4	0 (0)	6	3 (50)	10	3 (30)
Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
p value		--		1.0		1.0

† Excludes equivocal test results and missing values.

Table 249 HCV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	19	8 (42)	2	2 (100)	21	10 (48)
Moderately accessible	2	1 (50)	0	0 (0)	2	1 (50)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	24	7 (29)	0	0 (0)	24	7 (29)
Moderately accessible	4	1 (25)	0	0 (0)	4	1 (25)
Remote/very remote	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.5		--		0.5
2010						
Highly accessible/accessible	21	7 (33)	1	0 (0)	22	7 (32)
Moderately accessible	5	0 (0)	0	0 (0)	5	0 (0)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.3		--		0.3
2013						
Highly accessible/accessible	11	4 (36)	2	1 (50)	13	5 (38)
Moderately accessible	8	4 (50)	1	0 (0)	9	4 (44)
Remote/very remote	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.4		0.4		0.5
2016						
Highly accessible/accessible	9	2 (22)	1	0 (0)	10	2 (20)
Moderately accessible	5	3 (60)	3	0 (0)	8	3 (38)
Remote/very remote	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.2		--		0.4

† Excludes equivocal test results and missing values.

Table 250 HCV antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	25	11 (44)	2	2 (100)	27	13 (48)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2007						
Australia	31	8 (26)	0	0 (0)	31	8 (26)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.6		--		0.6
2010						
Australia	29	8 (28)	1	0 (0)	30	8 (27)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
Australia	21	9 (43)	3	1 (33)	24	10 (42)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.4		--		0.4
2016						
Australia	14	5 (36)	4	0 (0)	18	5 (28)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 251 Self-reported HCV status versus HCV serology by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	7	2 (29)	0	0 (0)	7	2 (29)
Not sure	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.01		--		0.006
2007						
Positive	4	4 (100)	0	0 (0)	4	4 (100)
Negative	11	1 (9)	0	0 (0)	11	1 (9)
Not sure	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.003		--		0.003
2010						
Positive	7	6 (86)	0	0 (0)	7	6 (86)
Negative	11	1 (9)	1	0 (0)	12	1 (8)
Not sure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.001		--		0.001
2013						
Positive	7	7 (100)	1	1 (100)	8	8 (100)
Negative	8	0 (0)	0	0 (0)	8	0 (0)
Not sure	2	2 (100)	0	0 (0)	2	2 (100)
p value		<0.001		--		<0.001
2016						
Cleared hep C naturally	1	1 (100)	0	0 (0)	1	1 (100)
Cleared hep C with treatment	0	0 (0)	0	0 (0)	0	0 (0)
Chronic hep C	0	0 (0)	0	0 (0)	0	0 (0)
Negative	5	0 (0)	2	0 (0)	7	0 (0)
Not sure	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.03		--		0.01

† Excludes equivocal test results and missing values.

Table 252 Self-reported HCV status versus HCV serology (PCR/RNA) by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	Detected (%)	N° tested	Detected (%)	N° tested	Detected (%)
2016						
Cleared hep C naturally	1	0 (0)	0	0 (0)	1	0 (0)
Cleared hep C with treatment	0	0 (0)	0	0 (0)	0	0 (0)
Chronic hep C	0	0 (0)	0	0 (0)	0	0 (0)
Never had hep C	0	0 (0)	0	0 (0)	0	0 (0)
Not sure	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HBV prevalence

Table 253 HBV surface-antigen prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	15	0 (0)	3	1 (33)	18	1 (6)
Non-IDU	8	0 (0)	0	0 (0)	8	0 (0)
p value		--		--		0.5
2007						
IDU	14	1 (7)	0	0 (0)	14	1 (7)
Non-IDU	16	0 (0)	0	0 (0)	16	0 (0)
p value		0.3		--		0.3
2010						
IDU	17	0 (0)	1	0 (0)	18	0 (0)
Non-IDU	12	0 (0)	0	0 (0)	12	0 (0)
p value		--		--		--
2013						
IDU	11	0 (0)	0	0 (0)	11	0 (0)
Non-IDU	10	0 (0)	2	0 (0)	12	0 (0)
p value		--		--		--
2016						
IDU	8	0 (0)	2	0 (0)	10	0 (0)
Non-IDU	6	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 254 HBV core-antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	16	6 (38)	3	2 (67)	19	8 (42)
Non-IDU	9	0 (0)	0	0 (0)	9	0 (0)
p value		0.04		--		0.02
2007						
IDU	15	3 (20)	0	0 (0)	15	3 (20)
Non-IDU	17	0 (0)	0	0 (0)	17	0 (0)
p value		0.05		--		0.05
2010						
IDU	17	2 (12)	1	0 (0)	18	2 (11)
Non-IDU	12	3 (25)	0	0 (0)	12	3 (25)
p value		0.4		--		0.3
2013						
IDU	11	1 (9)	0	0 (0)	11	1 (9)
Non-IDU	10	0 (0)	2	0 (0)	12	0 (0)
p value		0.3		--		0.3
2016						
IDU	8	0 (0)	2	0 (0)	10	0 (0)
Non-IDU	6	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 255 HBV core-antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	25	6 (24)	2	2 (100)	27	8 (30)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.08		0.5
2007						
Heterosexual	32	3 (9)	0	0 (0)	32	3 (9)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2010						
Heterosexual	28	4 (14)	1	0 (0)	29	4 (14)
Bisexual	1	1 (100)	0	0 (0)	1	1 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.03		--		0.02
2013						
Heterosexual	18	1 (6)	2	0 (0)	20	1 (5)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	0	0 (0)	0	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Heterosexual	14	0 (0)	3	0 (0)	17	0 (0)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	0	0 (0)	1	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 256 HBV core-antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	8	3 (38)	3	1 (33)	11	4 (36)
30 + years	16	3 (19)	0	0 (0)	16	3 (19)
p value		0.6		0.3		0.7
2007						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	8	0 (0)	0	0 (0)	8	0 (0)
25 – 29	6	0 (0)	0	0 (0)	6	0 (0)
30 + years	17	3 (18)	0	0 (0)	17	3 (18)
p value		0.4		--		0.4
2010						
< 20 years	3	0 (0)	0	0 (0)	3	0 (0)
20 – 24	7	0 (0)	1	0 (0)	8	0 (0)
25 – 29	6	1 (17)	0	0 (0)	6	1 (17)
30 + years	13	4 (31)	0	0 (0)	13	4 (31)
p value		0.3		--		0.3
2013						
< 20 years	4	0 (0)	0	0 (0)	4	0 (0)
20 – 24	0	0 (0)	0	0 (0)	0	0 (0)
25 – 29	5	1 (20)	0	0 (0)	5	1 (20)
30 + years	13	0 (0)	3	0 (0)	16	0 (0)
p value		0.2		--		0.1
2016						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	5	0 (0)	2	0 (0)	7	0 (0)
25 – 29	2	0 (0)	0	0 (0)	2	0 (0)
30 + years	9	0 (0)	2	0 (0)	11	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 257 HBV core-antibody prevalence by duration of drug injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	1	1 (100)	1	1 (100)
6 to 10 years	6	1 (17)	1	1 (100)	7	2 (29)
10 + years	9	4 (44)	1	0 (0)	10	4 (40)
p value		0.3		0.2		0.4
2007						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	4	0 (0)	0	0 (0)	4	0 (0)
10 + years	10	3 (30)	0	0 (0)	10	3 (30)
p value		0.4		--		0.4
2010						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3 to 5 years	3	0 (0)	0	0 (0)	3	0 (0)
6 to 10 years	2	0 (0)	1	0 (0)	3	0 (0)
10 + years	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.5		--		0.4
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
10 + years	8	1 (13)	0	0 (0)	8	1 (13)
p value		0.7		--		0.7
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	2	0 (0)	0	0 (0)	2	0 (0)
6 to 10 years	2	0 (0)	0	0 (0)	2	0 (0)
10 + years	4	0 (0)	2	0 (0)	6	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 258 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	0	0 (0)	10	5 (50)	10	5 (50)
Heroin	0	0 (0)	1	0 (0)	1	0 (0)
More than one drug	0	0 (0)	7	2 (29)	7	2 (29)
Other/not reported	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.4		0.4
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	1 (10)	11	1 (9)
Heroin	0	0 (0)	1	1 (100)	1	1 (100)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.1		0.08
2010						
Amphetamine (Speed, Ice)	3	0 (0)	8	1 (13)	11	1 (9)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.9		0.8
2013						
Amphetamine (Speed, Ice)	0	0 (0)	6	0 (0)	6	0 (0)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.1		0.1
2016						
Amphetamine (Speed, Ice)	0	0 (0)	6	0 (0)	6	0 (0)
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 259 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	0	0 (0)	6	1 (17)	6	1 (17)
Daily or more	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.07		0.07
2007						
Less than daily	0	0 (0)	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		1.0		0.9
2010						
Less than daily	2	0 (0)	5	1 (20)	7	1 (14)
Daily or more	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.5		0.6
2013						
Less than daily	0	0 (0)	1	0 (0)	1	0 (0)
Daily or more	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.5		0.5
2016						
Less than daily	0	0 (0)	1	0 (0)	1	0 (0)
Daily or more	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 260 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	0	0 (0)	8	3 (38)	8	3 (38)
Yes	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.9		0.9
2007						
No	1	0 (0)	10	2 (20)	11	2 (18)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2010						
No	2	0 (0)	6	1 (17)	8	1 (13)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		--
2016						
No	0	0 (0)	4	0 (0)	4	0 (0)
Yes	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 261 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	0	0 (0)	8	3 (38)	8	3 (38)
Yes	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.5		0.5
2007						
No	0	0 (0)	4	1 (25)	4	1 (25)
Yes	0	0 (0)	10	2 (20)	10	2 (20)
p value		--		0.8		0.8
2010						
No	3	0 (0)	7	0 (0)	10	0 (0)
Yes	1	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.1		0.1
2013						
No	0	0 (0)	4	0 (0)	4	0 (0)
Yes	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.2		0.2
2016						
No	0	0 (0)	1	0 (0)	1	0 (0)
Yes	0	0 (0)	6	0 (0)	6	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 262 HBV core-antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	10	3 (30)	0	0 (0)	10	3 (30)
2 to 4	9	1 (11)	1	1 (100)	10	2 (20)
5 to 9	4	1 (25)	1	0 (0)	5	1 (20)
10 +	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.6		0.2		0.4
2007						
1	7	0 (0)	0	0 (0)	7	0 (0)
2 to 4	15	1 (7)	0	0 (0)	15	1 (7)
5 to 9	9	2 (22)	0	0 (0)	9	2 (22)
10 +	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.4		--		0.4
2010						
1	9	2 (22)	0	0 (0)	9	2 (22)
2 to 4	13	1 (8)	1	0 (0)	14	1 (7)
5 to 9	4	2 (50)	0	0 (0)	4	2 (50)
10 +	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.2		--		0.2
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	0	0 (0)	0	0 (0)	0	0 (0)
2 to 4	3	0 (0)	2	0 (0)	5	0 (0)
5 to 9	4	0 (0)	0	0 (0)	4	0 (0)
10 +	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 263 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	16	4 (25)	2	1 (50)	18	5 (28)
Indigenous	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.8		--		0.8
2007						
Non-Indigenous	28	1 (4)	0	0 (0)	28	1 (4)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.003		--		0.003
2010						
Non-Indigenous	24	5 (21)	1	0 (0)	25	5 (20)
Indigenous	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.3		--		0.3
2013						
Non-Indigenous	16	1 (6)	3	0 (0)	19	1 (5)
Indigenous	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.6		--		0.6
2016						
Non-Indigenous	10	0 (0)	2	0 (0)	12	0 (0)
Indigenous	6	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 264 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	5	0 (0)	12	5 (42)	17	5 (29)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.3		0.9
2007						
Non-Indigenous	16	0 (0)	12	1 (8)	28	1 (4)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		--		0.02		0.003
2010						
Non-Indigenous	9	3 (33)	16	2 (13)	25	5 (20)
Indigenous	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.3		0.6		0.3
2013						
Non-Indigenous	11	0 (0)	7	1 (14)	18	1 (6)
Indigenous	1	0 (0)	4	0 (0)	5	0 (0)
p value		--		0.4		0.6
2016						
Non-Indigenous	4	0 (0)	6	0 (0)	10	0 (0)
Indigenous	4	0 (0)	4	0 (0)	8	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 265 HBV core-antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	19	3 (16)	2	1 (50)	21	4 (19)
Moderately accessible	2	1 (50)	0	0 (0)	2	1 (50)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.4		--		0.5
2007						
Highly accessible/accessible	24	2 (8)	0	0 (0)	24	2 (8)
Moderately accessible	4	1 (25)	0	0 (0)	4	1 (25)
Remote/very remote	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.5		--		0.5
2010						
Highly accessible/accessible	21	3 (14)	1	0 (0)	22	3 (14)
Moderately accessible	5	2 (40)	0	0 (0)	5	2 (40)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.4		--		0.3
2013						
Highly accessible/accessible	11	0 (0)	1	0 (0)	12	0 (0)
Moderately accessible	7	0 (0)	1	0 (0)	8	0 (0)
Remote/very remote	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--
2016						
Highly accessible/accessible	9	0 (0)	1	0 (0)	10	0 (0)
Moderately accessible	5	0 (0)	3	0 (0)	8	0 (0)
Remote/very remote	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 266 HBV core-antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	25	6 (24)	3	2 (67)	28	8 (29)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2007						
Australia	31	3 (10)	0	0 (0)	31	3 (10)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.7		--		0.7
2010						
Australia	29	5 (17)	1	0 (0)	30	5 (17)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2013						
Australia	20	1 (5)	2	0 (0)	22	1 (5)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.8		--		0.9
2016						
Australia	14	0 (0)	4	0 (0)	18	0 (0)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 267 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	No (%) vaccine conferred immunity*
2004					
IDU	20	7 (35)	7 (35)	1 (5)	5 (25)
Non-IDU	9	8 (89)	0 (0)	0 (0)	1 (11)
p value					0.05
2007					
IDU	7	2 (29)	3 (43)	0 (0)	2 (29)
Non-IDU	7	0 (0)	0 (0)	0 (0)	7 (100)
p value					0.02
2010					
IDU	17	10 (59)	2 (12)	0 (0)	5 (29)
Non-IDU	11	6 (55)	3 (27)	0 (0)	2 (18)
p value					0.5
2013					
IDU	7	6 (86)	1 (14)	0 (0)	0 (0)
Non-IDU	7	7 (100)	0 (0)	0 (0)	0 (0)
p value					0.3
2016					
IDU	5	4 (80)	0 (0)	1 (20)	0 (0)
Non-IDU	5	5 (100)	0 (0)	0 (0)	0 (0)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 268 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	No (%) vaccine conferred immunity*
2004					
Heterosexual	28	14 (50)	7 (25)	1 (4)	6 (21)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.8
2007					
Heterosexual	14	2 (14)	3 (21)	0 (0)	9 (64)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2010					
Heterosexual	27	16 (59)	4 (15)	0 (0)	7 (26)
Homosexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	1	0 (0)	1 (100)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.09
2013					
Heterosexual	12	11 (92)	1 (8)	0 (0)	0 (0)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2016					
Heterosexual	9	8 (89)	0 (0)	1 (11)	0 (0)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.7

† Excludes equivocal test results and missing values; * HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 269 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	3	1 (33)	0 (0)	1 (33)	1 (33)
25 – 29	12	7 (58)	4 (33)	0 (0)	1 (8)
30 + years	16	9 (56)	3 (19)	0 (0)	4 (25)
p value					0.1
2007					
< 20 years	1	0 (0)	0 (0)	0 (0)	1 (100)
20 – 24	4	0 (0)	0 (0)	0 (0)	4 (100)
25 – 29	1	0 (0)	0 (0)	0 (0)	1 (100)
30 + years	8	2 (25)	3 (38)	0 (0)	3 (38)
p value					0.4
2010					
< 20 years	2	1 (50)	0 (0)	0 (0)	1 (50)
20 – 24	7	4 (57)	0 (0)	0 (0)	3 (43)
25 – 29	6	5 (83)	1 (17)	0 (0)	0 (0)
30 + years	13	6 (46)	4 (31)	0 (0)	3 (23)
p value					0.4
2013					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	0	0 (0)	0 (0)	0 (0)	0 (0)
25 – 29	5	4 (80)	1 (20)	0 (0)	0 (0)
30 + years	9	9 (100)	0 (0)	0 (0)	0 (0)
p value					--
2016					
< 20 years	0	0 (0)	0 (0)	0 (0)	0 (0)
20 – 24	3	2 (67)	0 (0)	1 (33)	0 (0)
25 – 29	0	0 (0)	0 (0)	0 (0)	0 (0)
30 + years	9	9 (100)	0 (0)	0 (0)	0 (0)
p value					0.07

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 270 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	10	5 (50)	3 (30)	0 (0)	2 (20)
2 to 4	10	8 (80)	1 (10)	1 (10)	0 (0)
5 to 9	6	1 (17)	1 (17)	0 (0)	4 (67)
10 +	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.05
2007					
1	4	0 (0)	0 (0)	0 (0)	4 (100)
2 to 4	4	1 (25)	1 (25)	0 (0)	2 (50)
5 to 9	5	0 (0)	2 (40)	0 (0)	3 (60)
10 +	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.1
2010					
1	9	4 (44)	2 (22)	0 (0)	3 (33)
2 to 4	12	9 (75)	1 (8)	0 (0)	2 (17)
5 to 9	4	2 (50)	2 (50)	0 (0)	0 (0)
10 +	3	1 (33)	0 (0)	0 (0)	2 (67)
p value					0.2
2013					
1	0	0 (0)	0 (0)	0 (0)	0 (0)
2 to 4	0	0 (0)	0 (0)	0 (0)	0 (0)
5 to 9	0	0 (0)	0 (0)	0 (0)	0 (0)
10 +	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--
2016					
1	0	0 (0)	0 (0)	0 (0)	0 (0)
2 to 4	3	3 (100)	0 (0)	0 (0)	0 (0)
5 to 9	1	1 (100)	0 (0)	0 (0)	0 (0)
10 +	1	0 (0)	0 (0)	1 (100)	0 (0)
p value					0.08

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 271 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	18	9 (50)	4 (22)	1 (6)	4 (22)
Indigenous	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.8
2007					
Non-Indigenous	12	2 (17)	1 (8)	0 (0)	9 (75)
Indigenous	2	0 (0)	2 (100)	0 (0)	0 (0)
p value					0.01
2010					
Non-Indigenous	24	12 (50)	5 (21)	0 (0)	7 (29)
Indigenous	4	4 (100)	0 (0)	0 (0)	0 (0)
p value					0.2
2013					
Non-Indigenous	11	10 (91)	0 (0)	0 (0)	0 (0)
Indigenous	4	4 (100)	1 (9)	0 (0)	0 (0)
p value					--
2016					
Non-Indigenous	9	9 (100)	0 (0)	0 (0)	0 (0)
Indigenous	3	2 (67)	0 (0)	1 (33)	0 (0)
p value					

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 272 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	No (%) immune through past exposure	No (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	22	12 (55)	4 (18)	0 (0)	6 (27)
Moderately accessible	2	1 (50)	1 (50)	0 (0)	0 (0)
Remote/very remote	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.7
2007					
Highly accessible/accessible	13	2 (15)	2 (15)	0 (0)	9 (69)
Moderately accessible	1	0 (0)	1 (100)	0 (0)	0 (0)
Remote/very remote	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.1
2010					
Highly accessible/accessible	21	12 (57)	3 (14)	0 (0)	6 (29)
Moderately accessible	5	3 (60)	2 (40)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.2
2013					
Highly accessible/accessible	8	8 (100)	0 (0)	0 (0)	0 (0)
Moderately accessible	4	4 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					--
2016					
Highly accessible/accessible	4	4 (100)	0 (0)	0 (0)	0 (0)
Moderately accessible	6	5 (83)	0 (0)	1 (17)	0 (0)
Remote/very remote	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 273 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	9	0 (0)	0	0 (0)	9	0 (0)
Yes	10	6 (60)	0	0 (0)	11	6 (55)
Not sure	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.01		--		0.02
2007						
No	1	0 (0)	0	0 (0)	1	0 (0)
Yes	9	8 (89)	0	0 (0)	9	8 (89)
Not sure	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.08		--		0.08
2010						
No	5	0 (0)	1	1 (100)	6	1 (17)
Yes	14	6 (43)	0	0 (0)	14	6 (43)
Not sure	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.1		--		0.2
2013						
No	3	0 (0)	1	0 (0)	4	0 (0)
Yes	5	0 (0)	1	0 (0)	6	0 (0)
Not sure	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		--
2016						
No	5	0 (0)	2	0 (0)	7	0 (0)
Yes	1	0 (0)	0	0 (0)	1	0 (0)
Not sure	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 274 Genital chlamydia prevalence by gender and survey year†

Gender	N° tested	N° with chlamydia (%)
2010		
Male	10	0 (0)
Female	0	0 (0)
p value		--
2013		
Male	23	0 (0)
Female	4	0 (0)
p value		--
2016		
Male	12	0 (0)
Female	4	0 (0)
p value		--

† Excludes missing values.

Gonorrhoea

Table 275 Genital gonorrhoea prevalence by gender and survey year†

Gender	N° tested	N° with gonorrhoea (%)
2010		
Male	0	0 (0)
Female	0	0 (0)
p value		--
2013		
Male	23	0 (0)
Female	4	0 (0)
p value		--
2016		
Male	12	0
Female	4	0
p value		--

† Excludes missing values.

Syphilis

Table 276 Syphilis markers by gender and survey year†

Gender	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	5	0 (0)	0 (0)	0 (0)
Female	0	0 (0)	0 (0)	0 (0)
p value		--	--	--
2013				
Male	23	0 (0)	0 (0)	0 (0)
Female	4	0 (0)	0 (0)	0 (0)
p value		--	--	--
2016				
Male	6	0 (0)	0 (0)	0 (0)
Female	2	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

Victoria
2007, 2010, 2013, 2016

Table 277 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 3		N = 2		N = 2		N = 3	
N° surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Sex (%)								
Male	78 (90)	71 (95)	27 (87)	15 (88)	46 (77)	97 (87)	47 (96)	49 (94)
Female	9 (10)	4 (5)	4 (13)	2 (12)	14 (23)	15 (13)	2 (4)	3 (6)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age (years)								
Median (Med) age	32	32	30	32	31	31	32	31
Age range	18 – 54	18 – 77	21 – 55	20 – 75	18 – 68	18 – 64	20 – 52	20 – 62
Age group (%)								
<25 years	12 (14)	22 (29)	6 (19)	3 (18)	12 (20)	24 (21)	6 (12)	8 (15)
25+ years	75 (86)	53 (71)	25 (81)	14 (82)	48 (80)	88 (79)	43 (88)	44 (85)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Aboriginal and/or Torres Strait Islander origin (%)								
No	80 (92)	73 (97)	27 (87)	16 (94)	51 (85)	103 (92)	40 (82)	45 (87)
Yes	7 (8)	2 (3)	4 (13)	1 (6)	9 (15)	9 (8)	9 (18)	7 (13)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)								
Heterosexual	84 (97)	73 (97)	29 (94)	15 (88)	53 (88)	109 (97)	48 (98)	49 (94)
Bisexual	1 (1)	1 (1)	1 (3)	0 (0)	5 (8)	2 (2)	1 (2)	1 (2)
Gay/lesbian	0 (0)	1 (1)	1 (3)	1 (6)	1 (2)	1 (1)	0 (0)	2 (4)
Unsure	2 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Region/Country of birth (%)								
Australia	67 (77)	62 (83)	28 (90)	12 (71)	53 (88)	78 (70)	48 (98)	39 (75)
Other Oceania	3 (3)	2 (3)	0 (0)	1 (6)	0 (0)	5 (4)	1 (2)	4 (8)
Asia	6 (7)	4 (5)	0 (0)	3 (18)	3 (5)	16 (14)	0 (0)	5 (10)
UK & Ireland	4 (5)	1 (1)	1 (3)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)
Other	7 (8)	5 (7)	1 (3)	1 (6)	3 (5)	13 (12)	0 (0)	2 (4)
Not reported	0 (0)	1 (1)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Residential remoteness in 12 months before prison (%)								
Highly/accessible	83 (95)	66 (88)	31 (100)	12 (71)	55 (92)	107 (96)	45 (92)	49 (94)
Mod accessible	2 (2)	5 (7)	0 (0)	0 (0)	5 (8)	5 (4)	3 (6)	2 (4)
Very/remote	1 (1)	0 (0)	0 (0)	3 (18)	0 (0)	0 (0)	1 (2)	0 (0)
Not reported	1 (1)	4 (5)	0 (0)	2 (12)	0 (0)	0 (0)	0 (0)	1 (2)
First time in prison (%)								
No	69 (79)	25 (33)	25 (81)	8 (47)	45 (75)	50 (45)	40 (82)	23 (44)
Yes	18 (21)	50 (67)	6 (19)	9 (53)	15 (25)	62 (55)	9 (18)	29 (56)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Lifetime imprisonments (%)*								
One	18 (21)	50 (67)	11 (35)	13 (76)	n/a	n/a	7 (18)	8 (35)
Two to four	33 (38)	17 (23)	11 (35)	3 (18)	n/a	n/a	15 (38)	11 (48)
Five to nine	24 (28)	6 (8)	5 (16)	1 (6)	n/a	n/a	12 (30)	3 (13)
Ten or more	12 (14)	2 (3)	4 (13)	0 (0)	n/a	n/a	6 (15)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a	0 (0)	1 (4)
Imprisonment in last year (%)								
No	22 (32)	6 (24)	16 (52)	13 (76)	13 (29)	28 (56)	16 (40)	7 (30)
Yes	47 (68)	19 (76)	13 (42)	2 (12)	32 (71)	21 (42)	24 (60)	14 (61)
Not reported	0 (0)	0 (0)	2 (6)	2 (12)	0 (0)	1 (2)	0 (0)	2 (9)

Table 278 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Ever smoked a full cigarette (%)								
No	1 (1)	12 (16)	0 (0)	2 (12)	1 (2)	16 (14)	2 (4)	5 (10)
Yes	86 (99)	63 (84)	31 (100)	14 (82)	59 (98)	96 (86)	47 (96)	47 (90)
Not reported	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Med age 1st smoked	13	15	13	14	13	15	14	15
Age range	5 – 25	9 – 30	7 – 35	10 – 21	5 – 18	8 – 30	4 – 31	8 – 32
Current smoker (%)								
No	4 (5)	24 (32)	1 (3)	4 (24)	2 (3)	10 (10)	2 (4)	11 (23)
Yes	83 (95)	51 (68)	30 (97)	12 (71)	57 (97)	86 (90)	45 (96)	36 (77)
Not reported	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Smoking frequency (%)*								
Weekly or less	1 (1)	2 (4)	0 (0)	0 (0)	2 (4)	8 (9)	2 (4)	0 (0)
5 - 10/day	30 (36)	19 (37)	9 (30)	6 (50)	20 (35)	35 (41)	12 (27)	13 (36)
11 - 20/day	32 (39)	16 (31)	14 (47)	3 (25)	23 (40)	26 (30)	15 (33)	15 (42)
>20/day	20 (24)	14 (27)	7 (23)	3 (25)	12 (21)	17 (20)	16 (36)	8 (22)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other drugs used last month (%)**								
None	n/a	n/a	3 (14)	5 (42)	11 (18)	74 (66)	3 (6)	20 (38)
Cannabis	n/a	n/a	14 (74)	6 (86)	24 (49)	18 (47)	24 (53)	18 (58)
Heroin	n/a	n/a	9 (47)	1 (14)	19 (39)	3 (8)	18 (40)	2 (6)
Cocaine	n/a	n/a	1 (5)	1 (14)	2 (4)	2 (5)	8 (18)	3 (10)
Methamphetamine	n/a	n/a	11 (58)	3 (43)	32 (65)	23 (61)	33 (73)	20 (65)
Methadone	n/a	n/a	3 (16)	0 (0)	6 (12)	0 (0)	3 (7)	0 (0)
Other opiates	n/a	n/a	6 (32)	1 (14)	7 (14)	0 (0)	7 (16)	2 (6)
Buprenorphine	n/a	n/a	5 (26)	0 (0)	5 (10)	2 (5)	4 (9)	1 (3)
Anabolic steroids	n/a	n/a	2 (11)	0 (0)	0 (0)	1 (3)	4 (9)	0 (0)
Hallucinogens	n/a	n/a	3 (16)	0 (0)	2 (4)	1 (3)	3 (7)	1 (3)
Benzodiazepine	n/a	n/a	10 (53)	0 (0)	23 (47)	10 (26)	20 (44)	6 (19)
Ecstasy/MDA	n/a	n/a	2 (11)	0 (0)	1 (2)	3 (8)	7 (16)	6 (19)
Inhalants	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other drug	n/a	n/a	0 (0)	0 (0)	5 (10)	4 (11)	1 (2)	3 (10)
Not reported	n/a	n/a	9 (29)	5 (29)	0 (0)	0 (0)	1 (2)	1 (2)
Risk of alcohol-related harm (%)^^								
Non-drinker	n/a	n/a	n/a	n/a	n/a	n/a	13 (27)	14 (27)
Low risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	16 (33)	25 (48)
High risk of harm	n/a	n/a	n/a	n/a	n/a	n/a	19 (39)	12 (23)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	1 (2)

*Prior to prison; **More than one drug option could be selected; ^Also includes hormones and peptides from 2016; ^^AUDIT-C

Table 279 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2007	2010	2013	2016
	N = 87	N = 31	N = 60	N = 49
Median age 1st IDU	18	17	18	20
Age range	10 – 35	13 – 39	10 – 37	13 – 41
Not reported	0	0	0	1
Median years since first drug injection	12	11	13	12
Range	<1 – 29	2 – 35	<1 – 39	1 – 36
Not reported	0	0	0	1
Years since first drug injection (%)				
<3 years	4 (5)	2 (6)	7 (12)	4 (8)
3+ years	83 (95)	29 (94)	53 (88)	44 (90)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)
Last drug injected (%)				
Methamphetamine	37 (43)	12 (39)	31 (52)	26 (53)
Anabolic steroids	0 (0)	0 (0)	1 (2)	1 (2)
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)
Heroin	43 (49)	14 (45)	22 (37)	19 (39)
Methadone	0 (0)	0 (0)	0 (0)	0 (0)
Morphine	2 (2)	2 (6)	1 (2)	2 (4)
Subutex/buprenorphine/Suboxone	0 (0)	0 (0)	0 (0)	0 (0)
Other	4 (5)	3 (9)	5 (9)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)				
Not last month	27 (31)	8 (26)	20 (33)	19 (39)
< Weekly	7 (8)	9 (29)	6 (10)	4 (8)
Weekly	17 (20)	1 (3)	5 (8)	8 (16)
Daily or more	36 (41)	13 (42)	29 (48)	18 (37)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)
N° Injected last month	N = 60	N = 23	N = 40	N = 30
Places injected last month (%)*				
Prison	1 (2)	1 (4)	2 (5)	1 (3)
Own home	47 (78)	15 (65)	26 (65)	23 (77)
Friend's home	32 (53)	8 (35)	18 (45)	17 (57)
Dealer's home	15 (25)	3 (13)	6 (15)	7 (23)
Street, park, beach	21 (35)	7 (30)	5 (13)	4 (13)
Car	34 (57)	9 (39)	10 (25)	8 (27)
Public toilet	16 (27)	6 (26)	6 (15)	7 (23)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre, Sydney	0 (0)	0 (0)	0 (0)	0 (0)
Squat	3 (5)	2 (9)	1 (1)	1 (3)
Other place	6 (10)	0 (0)	2 (5)	1 (3)
Use of sterile needles & syringes last month (%)				
All injections	44 (73)	11 (48)	26 (65)	25 (83)
Most of the time	13 (22)	9 (39)	8 (20)	1 (3)
Half of the time	0 (0)	2 (9)	2 (5)	3 (10)
Some of the time	2 (3)	1 (4)	3 (8)	0 (0)
Not last month	0 (0)	0 (0)	1 (3)	1 (3)
Not reported	1 (2)	0 (0)	0 (0)	0 (0)
Times injected by someone else after they injected themselves or others in past month (%)				
More than 5 times	2 (3)	0 (0)	5 (13)	2 (7)
3 to 5 times	1 (2)	0 (0)	2 (5)	1 (3)
Once or twice	1 (2)	2 (9)	1 (3)	0 (0)
None	55 (92)	21 (91)	32 (80)	27 (90)
Not reported	1 (2)	0 (0)	0 (0)	0 (0)
Re-used someone else's used needle & syringe last month (%)				
None	50 (83)	18 (78)	33 (83)	27 (90)
Once	3 (5)	3 (13)	2 (5)	2 (7)
Twice	2 (3)	0 (0)	0 (0)	0 (0)
3-5 times	1 (2)	0 (0)	3 (8)	0 (0)
>5 times	1 (2)	2 (9)	2 (5)	1 (3)
Not reported	3 (5)	0 (0)	0 (0)	0 (0)

* More than one drug option could be selected.

Table 280 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year (cont.)

Injecting behaviour	2007	2010	2013	2016
	N = 87	N = 31	N = 60	N = 49
Number of people needle & syringe was re-used after last month (%)*				
One	3 (5)	2 (9)	5 (71)	2 (67)
Two	2 (3)	0 (0)	0 (0)	0 (0)
Three to five	1 (2)	1 (4)	0 (0)	0 (0)
More than five	1 (2)	0 (0)	1 (14)	1 (33)
Don't know how many	0 (0)	2 (9)	1 (14)	0 (0)
Not reported	3 (5)	0 (0)	0 (0)	0 (0)
Relationship to people needle & syringe was re-used after last month (%)**				
Regular sex partner	6 (10)	4 (17)	2 (29)	1 (33)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	3 (5)	0 (0)	1 (14)	1 (33)
Acquaintance	0 (0)	2 (9)	3 (43)	1 (33)
Other	1 (2)	1 (4)	1 (14)	1 (33)
Last time re-used needle or syringe after someone (%)				
Last month	6 (7)	4 (13)	6 (10)	2 (4)
In the last 2-6 months	5 (6)	4 (13)	2 (3)	4 (8)
More than 6 months ago	30 (34)	10 (32)	23 (38)	8 (16)
Never	46 (53)	13 (42)	29 (48)	35 (71)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)
Last placed re-used needle or syringe after someone (%)				
Prison	9 (22)	4 (22)	8 (26)	3 (21)
Own home	14 (34)	3 (17)	14 (45)	6 (43)
Friend's home	8 (20)	5 (6)	3 (10)	1 (7)
Dealer's home	1 (2)	0 (0)	1 (3)	0 (0)
Street, park, bench	0 (0)	2 (11)	1 (3)	1 (7)
Car	1 (2)	1 (6)	0 (0)	0 (0)
Public toilet	1 (2)	1 (6)	0 (0)	0 (0)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)
Medically Supervised Injecting Centre	0 (0)	0 (0)	0 (0)	0 (0)
Squat	0 (0)	0 (0)	1 (3)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	7 (17)	2 (11)	3 (10)	3 (21)
Equipment used after someone else last month (%)**				
Spoon	22 (37)	10 (43)	14 (35)	13 (43)
Water	10 (17)	7 (30)	10 (25)	11 (37)
Filter	11 (18)	6 (26)	7 (18)	5 (17)
Tourniquet	4 (7)	3 (13)	6 (15)	7 (23)
Drug mix	6 (10)	5 (22)	8 (20)	5 (17)
Did not share equipment	0 (0)	0 (0)	0 (0)	15 (13)

*Of those reporting sharing needles & syringes in the past month.

**More than one drug option could be selected.

Table 281 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition	2007	2010	2013	2016
N° surveyed	N = 87	N = 31	N = 60	N = 49
Location of needle & syringe acquisition in the past month (%)*				
Needle & Syringe Program (NSP/NCP)	n/a	n/a	n/a	23 (47)
Chemist/pharmacy	n/a	n/a	n/a	15 (31)
Vending machine	n/a	n/a	n/a	3 (6)
Personal source (e.g. friend)	n/a	n/a	n/a	8 (16)
Other	n/a	n/a	n/a	3 (6)
Not in the last month	n/a	n/a	n/a	16 (33)
From an NSP last month (%)				
Daily or almost daily	13 (22)	7 (23)	6 (10)	0 (0)
A couple of times each week	23 (38)	2 (6)	9 (15)	3 (9)
Less than weekly	8 (13)	6 (19)	6 (10)	9 (27)
Weekly	n/a	2 (6)	0 (0)	n/a
Once last month	7 (12)	1 (3)	10 (17)	9 (27)
Not in the last month	9 (15)	12 (39)	29 (48)	10 (30)
Not reported	0 (0)	1 (3)	0 (0)	1 (3)
From a chemist last month (%)				
Daily or almost daily	1 (2)	2 (6)	1 (2)	0 (0)
A couple of times each week	11 (18)	4 (13)	3 (5)	3 (9)
Less than weekly	5 (8)	2 (6)	7 (12)	5 (15)
Weekly	n/a	5 (16)	0 (0)	n/a
Once last month	10 (17)	0 (0)	7 (12)	6 (18)
Not in the last month	33 (55)	17 (55)	42 (70)	18 (55)
Not reported	0 (0)	1 (3)	0 (0)	0 (0)
Ever participated in the annual NSP community survey (%)				
No	80 (92)	28 (90)	53 (88)	47 (96)
Yes	4 (5)	2 (6)	3 (5)	2 (4)
Don't remember	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	2 (2)	1 (3)	4 (7)	0 (0)

* More than one drug option could be selected.

Table 282 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Any treatment/therapy for drug use (%)*								
No	14 (16)	42 (56)	6 (19)	14 (82)	15 (25)	89 (79)	23 (47)	33 (63)
Yes	71 (82)	13 (17)	24 (77)	3 (18)	45 (75)	23 (21)	26 (53)	18 (35)
Not reported	2 (2)	20 (27)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
History of methadone maintenance treatment (%)								
Currently	37 (43)	0 (0)	9 (29)	0 (0)	14 (23)	0 (0)	0 (0)	4 (8)
Previously	16 (18)	0 (0)	4 (13)	0 (0)	14 (23)	2 (2)	1 (2)	17 (35)
Never	32 (37)	0 (0)	17 (55)	17 (100)	32 (53)	110 (98)	51 (98)	28 (57)
Not reported	2 (2)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of other pharmacotherapy treatment (%)								
Currently	40 (46)	0 (0)	4 (13)	0 (0)	4 (7)	2 (2)	2 (4)	0 (0)
Previously	12 (14)	0 (0)	7 (23)	0 (0)	20 (33)	1 (1)	12 (24)	1 (2)
Never	35 (40)	0 (0)	19 (61)	17 (100)	36 (60)	109 (97)	35 (71)	51 (98)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

E.g. detox, rehab, counselling, NA

Table 283 Number (%) of respondents by body piercing and tattoos, injector status and survey year

Demographics	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Body or ear piercings (%)								
No	35 (40)	53 (71)	14 (45)	12 (71)	33 (55)	62 (55)	30 (61)	35 (67)
Yes	52 (60)	22 (29)	17 (55)	5 (59)	27 (45)	50 (45)	19 (39)	17 (33)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Piercings other than ears (%)								
No	28 (54)	15 (68)	9 (53)	5 (100)	12 (44)	25 (50)	6 (32)	12 (71)
Yes	22 (43)	7 (32)	8 (47)	0 (0)	15 (56)	25 (50)	12 (63)	4 (24)
Not reported	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	1 (6)
Pierced in past 12 months (%)								
No	42 (81)	16 (73)	8 (47)	1 (20)	25 (93)	45 (90)	7 (37)	6 (35)
Yes	6 (12)	4 (18)	2 (12)	0 (0)	2 (7)	5 (10)	8 (42)	9 (53)
Not reported	4 (8)	2 (9)	7 (41)	4 (80)	0 (0)	0 (0)	4 (21)	2 (12)
Who did piercing (%)*								
Professional piercer [^]	3 (50)	4 (100)	1 (50)	0 (0)	2 (100)	5 (100)	6 (75)	8 (89)
Non-professional ^{^^}	1 (17)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Prisoner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Self	1 (17)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	2 (25)	4 (44)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Needle used by other (%)								
No	1 (20)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	n/a	n/a
Yes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	n/a	n/a
Not reported	4 (80)	4 (100)	0 (0)	0 (0)	2 (100)	5 (100)	n/a	n/a
Penile implants (%)**								
No	n/a	n/a	n/a	n/a	n/a	n/a	46 (98)	49 (100)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Penile implants in prison (%)								
No	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	1 (100)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Tattoos (%)								
No	26 (30)	45 (60)	8 (26)	10 (59)	12 (20)	48 (43)	11 (22)	20 (38)
Yes	61 (70)	30 (40)	23 (74)	7 (41)	47 (78)	64 (57)	38 (78)	32 (62)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Tattoos in past 12 months (%)								
No	41 (67)	17 (57)	16 (65)	3 (43)	38 (81)	40 (63)	15 (39)	12 (38)
Yes	20 (33)	13 (43)	7 (30)	4 (57)	9 (19)	24 (38)	22 (58)	19 (59)
Not reported	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (3)	1 (3)
Who did tattooing (%)*								
Professional	15 (75)	10 (77)	4 (57)	3 (75)	6 (67)	14 (58)	16 (73)	15 (79)
Non-professional ^{^^}	4 (20)	1 (8)	1 (14)	3 (75)	2 (22)	11 (46)	7 (32)	1 (5)
Prisoner	4 (20)	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)	2 (9)	0 (0)
Self	1 (5)	2 (15)	0 (0)	0 (0)	3 (33)	1 (4)	6 (27)	5 (26)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* More than one drug option could be selected.

**Males only, new question in 2017

[^]E.g. chemist, hairdresser, beauty salon, tattooist^{^^}Non-professional outside prison, e.g. friend, family

Table 284 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sexual behaviour	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Sex last month / last 3 months (**)								
No	19 (22)	20 (27)	1 (11)	8 (12)	6 (10)	21 (19)	10 (20)	9 (17)
Yes	68 (78)	55 (73)	8 (89)	57 (86)	54 (90)	91 (81)	39 (80)	43 (83)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Male sex partners in last 3 months (**)								
Median (Range)	n/a	n/a	1 (1–4)	1 (0–2)	0 (0-15)	0 (0–2)	0 (0–2)	1 (0–10)
Female sex partners in last 3 months (**)								
Median (Range)	n/a	n/a	1 (0–20)	1 (0–5)	1 (0–7)	1 (0-20)	1 (0–20)	1 (0–15)
Condom use at last sex (%)								
No	69 (79)	48 (64)	n/a	n/a	n/a	n/a	n/a	n/a
Yes	18 (21)	27 (36)	n/a	n/a	n/a	n/a	n/a	n/a
Not reported	0 (0)	0 (0)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	41 (85)	33 (70)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	7 (15)	7 (15)	n/a	n/a	n/a	n/a	n/a	n/a
Always	0 (0)	7 (15)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	10 (56)	1 (13)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	3 (17)	3 (38)	n/a	n/a	n/a	n/a	n/a	n/a
Always	5 (28)	4 (50)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	15 (58)	3 (33)	n/a	n/a	n/a	n/a	n/a	n/a
Sometimes	4 (15)	3 (33)	n/a	n/a	n/a	n/a	n/a	n/a
Always	7 (27)	3 (33)	n/a	n/a	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (**)								
Never	n/a	n/a	5 (83)	0 (0)	1 (11)	2 (22)	2 (100)	3 (100)
Sometimes	n/a	n/a	1 (17)	1 (100)	5 (56)	6 (67)	0 (0)	0 (0)
Always	n/a	n/a	0 (0)	0 (0)	3 (33)	1 (11)	0 (0)	0 (0)
Condom use last sex - casual male partners - last 3 months (**)								
Never	n/a	n/a	2 (50)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)
Sometimes	n/a	n/a	1 (25)	1 (100)	2 (50)	0 (0)	0 (0)	0 (0)
Always	n/a	n/a	1 (25)	0 (0)	2 (50)	1 (100)	1 (100)	0 (0)
Condom use last sex - regular female partners - last 3 months (**)								
Never	n/a	n/a	14 (78)	6 (46)	17 (57)	44 (62)	27 (82)	20 (61)
Sometimes	n/a	n/a	4 (22)	4 (31)	11 (37)	21 (30)	5 (15)	6 (18)
Always	n/a	n/a	0 (0)	3 (23)	2 (7)	6 (8)	1 (3)	7 (21)
Condom use last sex - casual female partners - last 3 months (**)								
Never	n/a	n/a	5 (42)	1 (100)	12 (40)	15 (41)	6 (43)	6 (55)
Sometimes	n/a	n/a	4 (33)	0 (0)	12 (40)	15 (41)	5 (36)	2 (18)
Always	n/a	n/a	3 (25)	0 (0)	6 (20)	7 (19)	3 (21)	3 (27)
Sex work last month (%)								
No	85 (98)	74 (99)	27 (87)	15 (88)	56 (93)	111 (99)	46 (94)	52 (100)
Yes	2 (2)	0 (0)	2 (6)	1 (6)	4 (7)	0 (0)	2 (4)	0 (0)
Not reported	0 (0)	1 (1)	2 (6)	1 (6)	0 (0)	1 (1)	1 (2)	0 (0)
Condom used at last sex work last month (%)								
No	0 (0)	0 (0)	1 (50)	0 (0)	1 (25)	0 (0)	1 (50)	--
Yes	2 (100)	0 (0)	1 (50)	1 (100)	2 (50)	0 (0)	1 (50)	--
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)	0 (0)	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 285 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Previous HIV test (%)								
Last year	43 (49)	13 (17)	13 (42)	5 (29)	19 (32)	15 (13)	24 (49)	11 (21)
>1 year ago	28 (32)	19 (25)	13 (42)	5 (29)	26 (43)	36 (32)	13 (27)	20 (39)
Never tested	16 (18)	43 (57)	4 (13)	6 (35)	15 (25)	61 (54)	12 (25)	21 (40)
Not reported	0 (0)	0 (0)	1 (3)	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Result of last HIV test (self-report) (%)								
No	69 (97)	30 (94)	24 (92)	9 (82)	37 (82)	40 (78)	37 (100)	29 (94)
Yes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	2 (3)	2 (6)	2 (8)	2 (20)	8 (18)	11 (22)	0 (0)	2 (7)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HBV infection (%)								
No	67 (77)	72 (96)	25 (81)	13 (76)	51 (85)	111 (99)	46 (94)	46 (88)
Yes	9 (10)	0 (0)	4 (13)	2 (12)	3 (5)	0 (0)	1 (2)	0 (0)
Don't know	11 (13)	2 (3)	2 (6)	2 (12)	6 (10)	1 (1)	2 (4)	6 (12)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HBV vaccination (%)*								
No	25 (29)	43 (57)	5 (16)	6 (35)	16 (27)	41 (37)	12 (24)	11 (21)
Yes	51 (59)	20 (27)	15 (48)	6 (35)	33 (55)	40 (36)	23 (47)	19 (37)
Don't know	10 (11)	11 (15)	11 (35)	5 (29)	10 (17)	31 (28)	14 (29)	21 (40)
Not reported	1 (1)	1 (1)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)
N° of HBV vaccine injections (%)								
One	8 (16)	4 (20)	2 (13)	2 (33)	4 (14)	3 (8)	0 (0)	0 (0)
Two	16 (31)	1 (5)	2 (13)	4 (67)	3 (11)	6 (15)	3 (13)	5 (26)
Three or more	27 (53)	15 (75)	11 (73)	0 (0)	21 (75)	23 (58)	13 (57)	7 (37)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (30)	7 (37)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	5 (15)	8 (20)	0 (0)	0 (0)
Ever had cervical cancer vaccine (women only)** (%)								
No	n/a	n/a	2 (100)	1 (50)	3 (33)	4 (40)	1 (100)	1 (33)
Yes	n/a	n/a	0 (0)	1 (50)	5 (56)	2 (20)	0 (0)	0 (0)
Unsure	n/a	n/a	0 (0)	0 (0)	1 (11)	4 (40)	0 (0)	2 (67)
Not reported	n/a	n/a	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

* Number (%) among participants with no history of HBV infection.

**Proportion of women eligible for the National HPV Vaccination Program, i.e. those who were under 27 years of age in 2007 (or 35 years or under in 2016).

*** Number (%) of those reporting positive HCV test results.

Table 286 Number (%) of respondents reporting previous testing for HCV infection and HCV treatment by injector status and survey year

Testing & treatment	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112	N = 49	N = 52
Previous HCV test (%)								
Last year	11 (13)	53 (71)	18 (58)	5 (29)	22 (37)	14 (13)	26 (53)	12 (23)
>1 year ago	41 (47)	10 (13)	12 (39)	6 (35)	29 (48)	35 (31)	17 (35)	18 (35)
Never tested	35 (40)	12 (16)	1 (3)	6 (35)	9 (15)	63 (56)	6 (12)	21 (40)
Unsure	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Result of last HCV test (self-report) (%)								
Hepatitis C antibody positive	57 (76)	2 (3)	14 (47)	0 (0)	24 (47)	2 (4)	n/a	n/a
Never had hep C	16 (21)	20 (32)	14 (47)	8 (73)	20 (39)	38 (78)	27 (63)	28 (90)
Cleared hep C naturally	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)
Cleared hep C with treatment	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	0 (0)
Chronic hep C	n/a	n/a	n/a	n/a	n/a	n/a	13 (30)	0 (0)
Don't know	2 (3)	0 (0)	2 (7)	3 (27)	7 (14)	9 (18)	1 (2)	2 (7)
Not reported	23 (31)	41 (65)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)
Age first diagnosed with hep C								
Median age	24	44	22	--	25	31	25	--
Range	9 – 41	34 – 54	18 – 45	--	15 – 46	24 – 38	16 – 46	--
Ever had HCV treatment (%)*								
	N = 46	N = 3	N = 9	N = 1	N = 24	N = 2	N = 15	N = 0
No treatment	45 (98)	3 (100)	9 (100)	1 (100)	23 (96)	0 (0)	14 (93)	--
Interferon-based medication	0 (0)	1 (2)	0 (0)	0 (0)	1 (4)	1 (50)	1 (7)	--
Direct-acting antiviral (DAA)	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Interferon-based & DAA	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Other	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--
None	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	--
Ever had PCR/RNA test to test for reinfections (%)^								
<1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	1 (100)	--
>1 year ago	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not tested	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Result of PCR/RNA test (%)^								
Still cured of hep C	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Reinfected	n/a	n/a	n/a	n/a	n/a	n/a	1 (100)	--
Don't know	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--

*Number (%) of those reporting positive HCV test results or specifying age of hep C diagnosis.

Table 287 Number (%) of respondents reporting interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness	2007		2010		2013		2016	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
Ever sought out HCV treatment?***								
No	n/a	n/a	n/a	n/a	n/a	n/a	12 (86)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	2 (14)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Willingness to receive treatment for HCV (%)								
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	2 (13)	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	13 (87)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Treatment location preference (%)								
Prison	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Community	n/a	n/a	n/a	n/a	n/a	n/a	8 (53)	--
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	7 (47)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	0 (0)	--
Knowledge & awareness of DAA treatments for hepatitis C[^]							N = 49	N = 52
<i>New treatments for hep C are available (%)</i>								
True	n/a	n/a	n/a	n/a	n/a	n/a	36 (74)	24 (46)
False	n/a	n/a	n/a	n/a	n/a	n/a	6 (12)	5 (10)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	6 (12)	23 (44)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)
<i>The new hep C treatments require injections (%)</i>								
True	n/a	n/a	n/a	n/a	n/a	n/a	3 (6)	2 (4)
False	n/a	n/a	n/a	n/a	n/a	n/a	20 (41)	8 (15)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	25 (51)	42 (81)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)
<i>The new hep C treatments have few side-effects (%)</i>								
True	n/a	n/a	n/a	n/a	n/a	n/a	18 (37)	3 (6)
False	n/a	n/a	n/a	n/a	n/a	n/a	2 (4)	2 (4)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	28 (57)	47 (90)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)
<i>The new hep C treatments take up to one year (%)</i>								
True	n/a	n/a	n/a	n/a	n/a	n/a	5 (10)	1 (2)
False	n/a	n/a	n/a	n/a	n/a	n/a	11 (22)	6 (12)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	32 (65)	45 (87)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	0 (0)

*Of those who have not had treatment

[^]Correct response is shaded

HIV antibody prevalence

Table 288 HIV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	No with HIV (%)
2007						
IDU	59	0 (0)	5	0 (0)	64	0 (0)
Non-IDU	49	0 (0)	4	0 (0)	53	0 (0)
p value		--		--		--
2010						
IDU	17	0 (0)	3	0 (0)	20	0 (0)
Non-IDU	9	0 (0)	2	0 (0)	11	0 (0)
p value		--		--		--
2013						
IDU	43	0 (0)	13	0 (0)	56	0 (0)
Non-IDU	94	0 (0)	13	0 (0)	107	0 (0)
p value		--		--		--
2016						
IDU	30	0 (0)	1	0 (0)	31	0 (0)
Non-IDU	29	0 (0)	2	0 (0)	31	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 289 HCV antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
IDU	59	40 (68)	7	6 (86)	66	46 (70)
Non-IDU	49	2 (4)	4	1 (25)	53	3 (6)
p value		<0.001		0.04		<0.001
2010						
IDU	15	6 (40)	3	3 (100)	18	9 (50)
Non-IDU	10	1 (10)	2	0 (0)	12	1 (8)
p value		0.1		0.03		0.02
2013						
IDU	46	28 (61)	13	9 (69)	59	37 (63)
Non-IDU	94	4 (4)	13	1 (8)	107	5 (5)
p value		<0.001		0.001		<0.001
2016						
IDU	32	15 (47)	1	1 (100)	33	16 (48)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		<0.001		0.08		<0.001

† Excludes equivocal test results and missing values.

Table 290 HCV antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	106	42 (40)	9	6 (67)	115	48 (42)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.5		0.3		0.5
2010						
Heterosexual	23	6 (26)	4	2 (50)	27	8 (30)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.1		0.4		0.1
2013						
Heterosexual	138	32 (23)	19	5 (26)	157	37 (24)
Bisexual	1	0 (0)	5	4 (80)	6	4 (67)
Gay/lesbian	1	0 (0)	1	0 (0)	2	0 (0)
Unsure	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.7		0.07		0.04
2016						
Heterosexual	64	15 (23)	3	1 (33)	67	16 (24)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 291 HCV antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 20 years	6	0 (0)	0	0 (0)	6	0 (0)
20 – 24	21	4 (19)	0	0 (0)	21	4 (19)
25 – 29	25	17 (68)	3	2 (67)	28	19 (68)
30 + years	56	21 (38)	8	5 (63)	64	26 (41)
p value		0.001		0.9		0.001
2010						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	8	3 (38)	0	0 (0)	8	3 (38)
25 – 29	5	1 (20)	3	1 (33)	8	2 (25)
30 + years	12	3 (25)	2	2 (100)	14	5 (36)
p value		0.8		0.1		0.8
2013						
< 20 years	2	0 (0)	2	2 (100)	4	2 (50)
20 – 24	24	2 (8)	6	0 (0)	30	2 (7)
25 – 29	29	6 (21)	7	4 (57)	36	10 (28)
30 + years	86	24 (28)	11	4 (36)	97	28 (29)
p value		0.2		0.05		0.06
2016						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	13	1 (8)	1	0 (0)	14	1 (7)
25 – 29	24	4 (17)	1	0 (0)	25	4 (16)
30 + years	43	12 (28)	2	2 (100)	45	14 (31)
p value		0.2		0.1		0.1

† Excludes equivocal test results and missing values.

Table 292 HCV antibody prevalence by years since first injection, gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	3	0 (0)	0	0 (0)	3	0 (0)
3 to 5 years	7	4 (57)	1	1 (100)	8	5 (63)
6 to 10 years	17	9 (53)	2	1 (50)	19	10 (53)
10 + years	32	27 (84)	4	4 (100)	36	31 (86)
p value		0.006		0.2		0.003
2010						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 5 years	4	2 (50)	0	0 (0)	4	2 (50)
6 to 10 years	3	1 (33)	1	1 (100)	4	2 (50)
10 + years	6	3 (50)	2	2 (100)	8	5 (63)
p value		0.6		--		0.5
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	5	2 (40)	2	2 (100)	7	4 (57)
6 to 10 years	7	2 (29)	3	2 (67)	10	4 (40)
10 + years	29	22 (76)	6	4 (67)	35	26 (74)
p value		0.03		0.6		0.1
2016						
<3 years	3	0 (0)	0	0 (0)	3	0 (0)
3 to 5 years	7	3 (43)	0	0 (0)	7	3 (43)
6 to 10 years	7	1 (14)	0	0 (0)	7	1 (14)
10 + years	14	10 (71)	1	1 (100)	15	11 (73)
p value		0.03		--		0.02

† Excludes equivocal test results and missing values.

Table 293 HCV antibody prevalence by years since first injection, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Amphetamine (Speed, Ice)	3	0 (0)	27	15 (56)	30	15 (50)
Heroin	0	0 (0)	30	26 (87)	30	26 (87)
More than one drug	0	0 (0)	4	3 (75)	4	3 (75)
Other/not reported	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.05		0.02
2010						
Amphetamine (Speed, Ice)	1	0 (0)	5	3 (60)	6	3 (50)
Heroin	1	0 (0)	7	5 (71)	8	5 (63)
More than one drug	0	0 (0)	2	0 (0)	2	0 (0)
Other/not reported	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.4		0.5
2013						
Amphetamine (Speed, Ice)	6	2 (33)	25	13 (52)	31	15 (48)
Heroin	1	1 (100)	20	17 (85)	21	18 (86)
More than one drug	0	0 (0)	1	1 (100)	1	1 (100)
Other/not reported	0	0 (0)	6	3 (50)	6	3 (50)
p value		0.2		0.09		0.04
2016						
Amphetamine (Speed, Ice)	3	0 (0)	17	6 (35)	20	6 (30)
Heroin	0	0 (0)	10	7 (70)	10	7 (70)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.08		0.04

† Excludes equivocal test results and missing values.

Table 294 HCV antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	0	0 (0)	20	16 (80)	20	16 (80)
Daily or more	0	0 (0)	26	23 (88)	26	23 (88)
p value		--		0.4		0.4
2010						
Less than daily	0	0 (0)	5	2 (40)	5	2 (40)
Daily or more	2	0 (0)	8	6 (75)	10	6 (60)
p value		--		0.2		0.5
2013						
Less than daily	1	0 (0)	10	5 (50)	11	5 (45)
Daily or more	4	2 (50)	24	17 (71)	28	19 (68)
p value		0.4		0.3		0.8
2016						
Less than daily	1	0 (0)	9	5 (56)	10	5 (50)
Daily or more	0	0 (0)	10	6 (60)	10	6 (60)
p value		--		0.8		0.7

† Excludes equivocal test results and missing values.

Table 295 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No	0	0 (0)	36	30 (83)	36	30 (83)
Yes	0	0 (0)	9	8 (89)	9	8 (89)
p value		--		0.7		0.7
2010						
No	2	0 (0)	9	5 (56)	11	5 (45)
Yes	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.2		0.2
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	7	6 (86)	7	6 (86)
p value		--		--		--
2016						
No	1	0 (0)	17	11 (65)	18	11 (61)
Yes	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.08		0.1

† Excludes equivocal test results and missing values.

Table 296 HCV antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No	0	0 (0)	13	10 (77)	13	10 (77)
Yes	1	0 (0)	35	32 (91)	36	32 (89)
p value		--		0.2		0.3
2010						
No	1	0 (0)	8	5 (63)	9	5 (56)
Yes	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.6		0.8
2013						
No	0	0 (0)	13	10 (77)	13	10 (77)
Yes	5	2 (40)	26	18 (69)	31	20 (65)
p value		--		0.6		0.2
2016						
No	0	0 (0)	11	6 (55)	11	6 (55)
Yes	2	0 (0)	13	6 (46)	15	6 (40)
p value		--		0.7		0.5

† Excludes equivocal test results and missing values.

Table 297 HCV antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
1	48	2 (4)	6	3 (50)	54	5 (9)
2 to 4	33	17 (52)	3	2 (67)	36	19 (53)
5 to 9	17	15 (88)	2	2 (100)	19	17 (89)
10 +	10	8 (80)	0	0 (0)	10	8 (80)
p value		<0.001		0.4		<0.001
2010						
1	13	4 (31)	2	0 (0)	15	4 (27)
2 to 4	8	2 (25)	2	2 (100)	10	4 (40)
5 to 9	3	1 (33)	0	0 (0)	3	1 (33)
10 +	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.08		0.9
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	11	1 (9)	0	0 (0)	11	1 (9)
2 to 4	18	4 (22)	1	0 (0)	19	4 (21)
5 to 9	10	6 (60)	1	1 (100)	11	7 (64)
10 +	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.02		0.2		0.01

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 298 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non-Indigenous	100	37 (37)	10	6 (60)	110	43 (39)
Indigenous	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.2		0.4		0.1
2010						
Non-Indigenous	22	6 (27)	5	3 (60)	27	9 (33)
Indigenous	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.8		--		1.0
2013						
Non-Indigenous	128	27 (21)	22	8 (36)	150	35 (23)
Indigenous	13	5 (38)	4	2 (50)	17	7 (41)
p value		0.2		0.6		0.1
2016						
Non-Indigenous	70	12 (17)	2	0 (0)	72	12 (17)
Indigenous	10	5 (50)	2	2 (100)	12	7 (58)
p value		0.02		0.05		0.001

† Excludes equivocal test results and missing values.

Table 299 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non-Indigenous	51	3 (6)	59	40 (68)	110	43 (39)
Indigenous	2	0 (0)	7	6 (86)	9	6 (67)
p value		0.7		0.3		0.1
2010						
Non-Indigenous	11	1 (9)	16	8 (50)	27	9 (33)
Indigenous	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.8		1.0		1.0
2013						
Non-Indigenous	99	4 (4)	50	31 (62)	149	35 (23)
Indigenous	8	1 (13)	9	6 (67)	17	7 (41)
p value		0.3		0.8		0.1
2016						
Non-Indigenous	32	0 (0)	26	10 (38)	58	10 (17)
Indigenous	3	0 (0)	7	6 (86)	10	6 (60)
p value		--		0.03		0.03

† Excludes equivocal test results and missing values.

Table 300 HCV antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Highly accessible/accessible	98	42 (43)	11	7 (64)	109	49 (45)
Moderately accessible	6	0 (0)	0	0 (0)	6	0 (0)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.08		--		0.07
2010						
Highly accessible/accessible	21	7 (33)	5	3 (60)	26	10 (39)
Moderately accessible	0	0 (0)	0	0 (0)	0	0 (0)
Remote/very remote	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.3		--		0.3
2013						
Highly accessible/accessible	131	32 (24)	25	10 (40)	156	42 (27)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.09		0.4		0.06
2016						
Highly accessible/accessible	61	14 (23)	2	1 (50)	63	15 (24)
Moderately accessible	3	1 (33)	1	0 (0)	4	1 (25)
Remote/very remote	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.8		0.4		0.9

† Excludes equivocal test results and missing values.

Table 301 HCV antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	88	31 (35)	8	5 (63)	96	36 (38)
Other Oceania	3	1 (33)	1	0 (0)	4	1 (25)
Asia	8	5 (63)	1	1 (100)	9	6 (67)
UK & Ireland	3	3 (100)	1	1 (100)	4	4 (100)
Other	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.1		0.4		0.6
2010						
Australia	22	6 (27)	3	3 (100)	25	9 (36)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	2	0 (0)	3	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.7		0.03		0.4
2013						
Australia	108	27 (25)	19	9 (47)	127	36 (28)
Other Oceania	4	0 (0)	0	0 (0)	4	0 (0)
Asia	15	2 (13)	4	0 (0)	19	2 (11)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	12	2 (17)	3	1 (33)	15	3 (20)
p value		0.2		0.2		0.1
2016						
Australia	55	15 (27)	2	1 (50)	57	16 (28)
Other Oceania	5	0 (0)	0	0 (0)	5	0 (0)
Asia	3	0 (0)	1	0 (0)	4	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.4		0.4		0.3

† Excludes equivocal test results and missing values.

Table 302 Self-reported HCV status versus HCV serology by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Positive	35	35 (100)	7	7 (100)	42	42 (100)
Negative	24	4 (17)	2	0 (0)	26	4 (15)
Not sure	2	0 (0)	0	0 (0)	2	0 (0)
p value		<0.001		0.003		<0.001
2010						
Positive	4	4 (100)	3	3 (100)	7	7 (100)
Negative	14	1 (7)	1	0 (0)	15	1 (7)
Not sure	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.001		0.05		<0.001
2013						
Positive	48	3 (6)	7	2 (29)	55	5 (9)
Negative	21	21 (100)	5	5 (100)	26	26 (100)
Not sure	13	6 (46)	3	2 (67)	16	8 (50)
p value		<0.001		0.05		<0.001
2016						
Cleared hep C naturally	1	1 (100)	0	0 (0)	1	1 (100)
Cleared hep C with treatment	0	0 (0)	0	0 (0)	0	0 (0)
Chronic hep C	6	6 (100)	0	0 (0)	6	6 (100)
Never had hep C	38	5 (13)	1	1 (100)	39	6 (15)
Not sure	3	1 (33)	0	0 (0)	3	1 (33)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 303 Self-reported HCV status versus HCV serology (PCR/RNA) by gender and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	Detected (%)	N° tested	Detected (%)	N° tested	Detected (%)
2016						
Cleared hep C naturally	1	0 (0)	0	0 (0)	1	0 (0)
Cleared hep C with treatment	0	0 (0)	0	0 (0)	0	0 (0)
Chronic hep C	6	6 (100)	0	0 (0)	6	6 (100)
Never had hep C	35	3 (9)	1	1 (100)	36	4 (11)
Not sure	3	1 (33)	0	0 (0)	3	1 (33)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 304 HBV surface-antigen prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
IDU	59	4 (7)	6	0 (0)	65	4 (6)
Non-IDU	49	0 (0)	2	0 (0)	51	0 (0)
p value		0.06		--		0.07
2010						
IDU	15	0 (0)	3	0 (0)	18	0 (0)
Non-IDU	12	0 (0)	2	1 (50)	14	1 (7)
p value		--		0.2		0.3
2013						
IDU	43	1 (2)	2	0 (0)	45	1 (2)
Non-IDU	93	1 (1)	1	0 (0)	94	1 (1)
p value		0.6		--		0.6
2016						
IDU	25	2 (8)	1	0 (0)	26	2 (8)
Non-IDU	21	0 (0)	2	0 (0)	23	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 305 HBV core-antibody prevalence by gender, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
IDU	56	23 (41)	6	2 (33)	62	25 (40)
Non-IDU	49	2 (4)	4	0 (0)	53	2 (4)
p value		<0.001		0.2		<0.001
2010						
IDU	15	2 (13)	0	0 (0)	15	2 (13)
Non-IDU	12	1 (8)	1	1 (100)	13	2 (15)
p value		0.7		--		0.9
2013						
IDU	42	10 (24)	2	0 (0)	44	10 (23)
Non-IDU	94	11 (12)	1	0 (0)	95	11 (12)
p value		0.07		--		0.09
2016						
IDU	31	4 (13)	1	0 (0)	32	4 (13)
Non-IDU	30	3 (10)	2	0 (0)	32	3 (9)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 306 HBV core-antibody prevalence by sexual identity, gender and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Heterosexual	103	25 (24)	8	1 (13)	111	26 (23)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.7		0.1		0.7
2010						
Heterosexual	25	2 (8)	1	1 (100)	26	3 (12)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.8		--		0.7
2013						
Heterosexual	134	21 (16)	1	0 (0)	135	21 (16)
Bisexual	1	0 (0)	2	0 (0)	3	0 (0)
Gay/lesbian	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.8		--		0.7
2016						
Heterosexual	60	7 (12)	3	0 (0)	63	7 (11)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Gay/lesbian	1	0 (0)	0	0 (0)	1	0 (0)
Unsure	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 307 HBV core-antibody prevalence by age group, gender and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
< 20 years	5	0 (0)	0	0 (0)	5	0 (0)
20 – 24	21	3 (14)	0	0 (0)	21	3 (14)
25 – 29	25	9 (36)	2	0 (0)	27	9 (33)
30 + years	54	13 (24)	8	2 (25)	62	15 (24)
p value		0.2		0.4		0.3
2010						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	9	0 (0)	0	0 (0)	9	0 (0)
25 – 29	4	0 (0)	1	1 (100)	5	1 (20)
30 + years	14	3 (21)	0	0 (0)	14	3 (21)
p value		0.2		--		0.3
2013						
< 20 years	2	0 (0)	1	0 (0)	3	0 (0)
20 – 24	24	2 (8)	2	0 (0)	26	2 (8)
25 – 29	28	3 (11)	0	0 (0)	28	3 (11)
30 + years	83	16 (19)	0	0 (0)	83	16 (19)
p value		0.4		--		0.4
2016						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	12	0 (0)	1	0 (0)	13	0 (0)
25 – 29	20	3 (15)	1	0 (0)	21	3 (14)
30 + years	42	4 (10)	2	0 (0)	44	4 (9)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 308 HBV core-antibody prevalence by years since first injection gender and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3 to 5 years	7	3 (43)	1	0 (0)	8	3 (38)
6 to 10 years	16	7 (44)	2	1 (50)	18	8 (44)
10 + years	29	13 (45)	3	1 (33)	32	14 (44)
p value		0.4		0.7		0.4
2010						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 5 years	2	0 (0)	0	0 (0)	2	0 (0)
6 to 10 years	3	0 (0)	0	0 (0)	3	0 (0)
10 + years	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.6		--		0.6
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	5	0 (0)	0	0 (0)	5	0 (0)
6 to 10 years	7	2 (29)	1	0 (0)	8	2 (25)
10 + years	25	7 (28)	0	0 (0)	25	7 (28)
p value		0.4		--		0.4
2016						
<3 years	3	0 (0)	0	0 (0)	3	0 (0)
3 to 5 years	6	0 (0)	0	0 (0)	6	0 (0)
6 to 10 years	6	0 (0)	0	0 (0)	6	0 (0)
10 + years	15	4 (27)	1	0 (0)	16	4 (25)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 309 HBV core-antibody prevalence by last drug injected, years since first injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Amphetamine (Speed, Ice)	4	0 (0)	24	6 (25)	28	6 (21)
Heroin	0	0 (0)	28	15 (54)	28	15 (54)
More than one drug	0	0 (0)	4	2 (50)	4	2 (50)
Other/not reported	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.07		0.03
2010						
Amphetamine (Speed, Ice)	1	0 (0)	4	1 (25)	5	1 (20)
Heroin	1	0 (0)	5	1 (20)	6	1 (17)
More than one drug	0	0 (0)	2	0 (0)	2	0 (0)
Other/not reported	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.8		0.8
2013						
Amphetamine (Speed, Ice)	5	1 (20)	19	3 (16)	24	4 (17)
Heroin	1	0 (0)	13	4 (31)	14	4 (29)
More than one drug	0	0 (0)	1	0 (0)	1	0 (0)
Other/not reported	0	0 (0)	5	2 (40)	5	2 (40)
p value		0.6		0.6		0.6
2016						
Amphetamine (Speed, Ice)	3	0 (0)	17	3 (18)	20	3 (15)
Heroin	0	0 (0)	8	1 (13)	8	1 (13)
More than one drug	0	0 (0)	0	0 (0)	0	0 (0)
Other/not reported	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.7		0.8

† Excludes equivocal test results and missing values.

Table 310 HBV core-antibody prevalence by frequency of injection last month, years since first injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Less than daily	0	0 (0)	19	11 (58)	19	11 (58)
Daily or more	1	0 (0)	23	12 (52)	24	12 (50)
p value		--		0.7		0.6
2010						
Less than daily	0	0 (0)	4	0 (0)	4	0 (0)
Daily or more	2	0 (0)	7	1 (14)	9	1 (11)
p value		--		0.4		0.5
2013						
Less than daily	1	0 (0)	8	2 (25)	9	2 (22)
Daily or more	3	0 (0)	17	4 (24)	20	4 (20)
p value		--		0.9		0.9
2016						
Less than daily	1	0 (0)	10	1 (10)	11	1 (9)
Daily or more	0	0 (0)	9	2 (22)	9	2 (22)
p value		--		0.5		0.4

† Excludes equivocal test results and missing values.

Table 311 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
No	1	0 (0)	35	18 (51)	36	18 (50)
Yes	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.5		0.5
2010						
No	2	0 (0)	7	1 (14)	9	1 (11)
Yes	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.6		0.6
2013						
No	0	0 (0)	0	0 (0)	0	0 (0)
Yes	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		--		--
2016						
No	1	0 (0)	17	3 (18)	18	3 (17)
Yes	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 312 HBV core-antibody prevalence by imprisonment last year, years since first injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
No	0	0 (0)	11	4 (36)	11	4 (36)
Yes	1	0 (0)	33	16 (48)	34	16 (47)
p value		--		0.5		0.5
2010						
No	1	0 (0)	5	2 (40)	6	2 (33)
Yes	0	0 (0)	8	0 (0)	8	0 (0)
p value		--		0.05		0.08
2013						
No	0	0 (0)	10	3 (30)	10	3 (30)
Yes	5	1 (20)	18	5 (28)	23	6 (26)
p value		--		0.9		0.8
2016						
No	0	0 (0)	11	2 (18)	11	2 (18)
Yes	2	0 (0)	13	2 (15)	15	2 (13)
p value		--		0.9		0.7

† Excludes equivocal test results and missing values.

Table 313 HBV core-antibody by number of previous imprisonments, gender and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
1	48	5 (10)	6	1 (17)	54	6 (11)
2 to 4	33	9 (27)	3	0 (0)	36	9 (25)
5 to 9	14	7 (50)	1	1 (100)	15	8 (53)
10 +	10	4 (40)	0	0 (0)	10	4 (40)
p value		0.008		0.09		0.003
2010						
1	14	1 (7)	1	0 (0)	15	2 (13)
2 to 4	7	1 (14)	0	0 (0)	7	1 (14)
5 to 9	3	0 (0)	0	0 (0)	3	0 (0)
10 +	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.5		--		0.7
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--
2016						
1	10	1 (10)	0	0 (0)	10	1 (10)
2 to 4	19	2 (11)	1	0 (0)	20	2 (10)
5 to 9	10	2 (20)	1	0 (0)	11	2 (18)
10 +	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 314 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Non-Indigenous	97	20 (21)	9	2 (22)	106	22 (21)
Indigenous	8	5 (63)	1	0 (0)	9	5 (56)
p value		0.008		0.6		0.02
2010						
Non-Indigenous	23	2 (9)	1	1 (100)	24	3 (13)
Indigenous	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.3		--		0.5
2013						
Non-Indigenous	124	19 (15)	2	0 (0)	126	19 (15)
Indigenous	13	2 (15)	1	0 (0)	14	2 (14)
p value		1.0		--		0.9
2016						
Non-Indigenous	64	4 (6)	2	0 (0)	66	4 (6)
Indigenous	10	3 (30)	2	0 (0)	12	3 (25)
p value		0.02		--		0.04

† Excludes equivocal test results and missing values.

Table 315 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Non-Indigenous	51	2 (4)	55	20 (36)	106	22 (21)
Indigenous	2	0 (0)	7	5 (71)	9	5 (56)
p value		0.8		0.08		0.02
2010						
Non-Indigenous	12	2 (17)	12	1 (8)	24	3 (13)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.7		0.3		0.5
2013						
Non-Indigenous	88	11 (13)	37	8 (22)	125	19 (15)
Indigenous	7	0 (0)	7	2 (29)	14	2 (14)
p value		0.3		0.7		0.9
2016						
Non-Indigenous	29	3 (10)	25	1 (4)	54	4 (7)
Indigenous	3	0 (0)	7	3 (43)	10	3 (30)
p value		0.6		0.006		0.04

† Excludes equivocal test results and missing values.

Table 316 HBV core-antibody prevalence by gender, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Highly accessible/accessible	96	25 (26)	10	2 (20)	106	27 (25)
Moderately accessible	6	0 (0)	0	0 (0)	6	0 (0)
Remote/very remote	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.2		--		0.2
2010						
Highly accessible/accessible	23	2 (9)	1	1 (100)	24	3 (13)
Moderately accessible	0	0 (0)	0	0 (0)	0	0 (0)
Remote/very remote	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.7		--		0.6
2013						
Highly accessible/accessible	127	21 (17)	2	0 (0)	129	21 (16)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.2		--		0.2
2016						
Highly accessible/accessible	57	6 (11)	2	0 (0)	59	6 (10)
Moderately accessible	3	1 (33)	1	0 (0)	4	3 (75)
Remote/very remote	1	0 (0)	0	0 (0)	1	1 (100)
p value		0.5		--		0.6

† Excludes equivocal test results and missing values.

Table 317 HBV core-antibody prevalence by region/country of birth, gender and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2007						
Australia	85	17 (20)	7	2 (29)	92	19 (21)
Other Oceania	3	0 (0)	1	0 (0)	4	0 (0)
Asia	8	4 (50)	1	0 (0)	9	4 (44)
UK & Ireland	3	3 (100)	1	0 (0)	4	3 (75)
Other	6	1 (17)	0	0 (0)	6	1 (17)
p value		0.006		0.8		0.04
2010						
Australia	24	2 (8)	0	0 (0)	24	2 (8)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.2		--		0.09
2013						
Australia	105	9 (9)	3	0 (0)	108	9 (8)
Other Oceania	4	2 (50)	0	0 (0)	4	2 (50)
Asia	15	7 (47)	0	0 (0)	15	7 (47)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	11	3 (27)	0	0 (0)	11	3 (27)
p value		<0.001		0 (0)		0.001
2016						
Australia	51	5 (10)	2	0 (0)	53	5 (9)
Other Oceania	5	0 (0)	0	0 (0)	5	0 (0)
Asia	3	1 (33)	1	0 (0)	4	1 (25)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.02		--		0.04

† Excludes equivocal test results and missing values.

Table 318 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2007					
IDU	67	26 (39)	24 (36)	4 (6)	13 (9)
Non-IDU	53	45 (85)	2 (4)	0 (0)	6 (11)
p value					<0.001
2010					
IDU	19	7 (37)	2 (11)	0 (0)	10 (53)
Non-IDU	14	8 (57)	1 (7)	1 (7)	4 (29)
p value					0.3
2013					
IDU	32	36 (56)	9 (28)	1 (3)	9 (28)
Non-IDU	64	7 (22)	10 (16)	1 (2)	10 (16)
p value					0.02
2016					
IDU	27	12 (44)	3 (11)	2 (7)	10 (37)
Non-IDU	21	11 (52)	3 (14)	0 (0)	7 (33)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 319 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2007					
Heterosexual	116	68 (59)	25 (22)	4 (3)	19 (16)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Unsure	2	1 (50)	1 (50)	0 (0)	0 (0)
p value					1.0
2010					
Heterosexual	30	14 (47)	2 (7)	1 (3)	13 (43)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.8
2013					
Heterosexual	92	42 (46)	19 (21)	2 (2)	29 (32)
Gay/lesbian	3	0 (0)	0 (0)	0 (0)	1 (100)
Bisexual	1	1 (33)	0 (0)	0 (0)	2 (67)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.7
2016					
Heterosexual	48	23 (48)	6 (13)	2 (4)	17 (35)
Gay/lesbian	0	0 (0)	0 (0)	0 (0)	0 (0)
Bisexual	0	0 (0)	0 (0)	0 (0)	0 (0)
Unsure	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 320 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2007					
< 20 years	6	3 (50)	1 (17)	0 (0)	2 (33)
20 – 24	21	11 (52)	2 (10)	1 (5)	7 (33)
25 – 29	29	14 (48)	9 (31)	1 (3)	5 (17)
30 + years	64	43 (67)	14 (22)	2 (3)	5 (8)
p value					0.2
2010					
< 20 years	0	0 (0)	0 (0)	0 (0)	0 (0)
20 – 24	9	4 (44)	0 (0)	0 (0)	5 (56)
25 – 29	7	3 (43)	0 (0)	1 (14)	3 (43)
30 + years	17	8 (47)	3 (18)	0 (0)	6 (35)
p value					0.3
2013					
< 20 years	1	0 (0)	0 (0)	0 (0)	1 (100)
20 – 24	17	5 (29)	2 (12)	0 (0)	10 (59)
25 – 29	20	8 (40)	3 (15)	0 (0)	9 (45)
30 + years	58	30 (52)	14 (24)	0 (0)	12 (21)
p value					0.2
2016					
< 20 years	0	0 (0)	0 (0)	0 (0)	0 (0)
20 – 24	10	5 (50)	0 (0)	0 (0)	5 (50)
25 – 29	16	3 (19)	3 (19)	0 (0)	10 (63)
30 + years	34	21 (62)	3 (9)	2 (6)	8 (24)
p value					0.05

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 321 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2007					
1	55	42 (76)	6 (11)	1 (2)	6 (11)
2 to 4	36	24 (67)	8 (22)	1 (3)	3 (8)
5 to 9	19	3 (16)	10 (53)	0 (0)	6 (32)
10 +	10	2 (20)	2 (20)	2 (20)	4 (40)
p value					<0.001
2010					
1	17	10 (59)	1 (6)	1 (6)	5 (29)
2 to 4	8	3 (38)	1 (13)	0 (0)	4 (50)
5 to 9	4	1 (25)	0 (0)	0 (0)	3 (75)
10 +	4	1 (25)	1 (25)	0 (0)	2 (50)
p value					0.7
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--
2016					
1	8	4 (50)	1 (13)	0 (0)	3 (38)
2 to 4	14	8 (57)	1 (7)	2 (14)	3 (21)
5 to 9	11	4 (36)	2 (18)	0 (0)	5 (45)
10 +	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 322 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2007					
Non-Indigenous	111	69 (62)	21 (19)	4 (4)	17 (15)
Indigenous	9	2 (22)	5 (56)	0 (0)	2 (22)
p value					0.05
2010					
Non-Indigenous	28	15 (54)	2 (7)	1 (4)	10 (36)
Indigenous	5	0 (0)	1 (20)	0 (0)	4 (80)
p value					0.1
2013					
Non-Indigenous	86	39 (45)	17 (20)	2 (2)	28 (33)
Indigenous	10	4 (40)	2 (20)	0 (0)	4 (40)
p value					0.9
2016					
Non-Indigenous	50	26 (52)	4 (8)	1 (2)	19 (38)
Indigenous	10	3 (30)	2 (20)	1 (10)	4 (40)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 323 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	No (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2007					
Highly accessible/accessible	110	62 (56)	25 (23)	4 (4)	19 (17)
Moderately accessible	6	6 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.2
2010					
Highly accessible/accessible	29	14 (48)	2 (7)	1 (3)	12 (41)
Moderately accessible	0	0 (0)	0 (0)	0 (0)	0 (0)
Remote/very remote	2	1 (50)	0 (0)	0 (0)	1 (50)
p value					0.9
2013					
Highly accessible/accessible	88	40 (45)	19 (22)	2 (2)	27 (31)
Moderately accessible	8	3 (38)	0 (0)	0 (0)	5 (63)
Remote/very remote	0	0 (0)	0 (0)	0 (0)	0 (0)
p value					0.2
2016					
Highly accessible/accessible	43	22 (51)	6 (14)	1 (2)	14 (33)
Moderately accessible	4	1 (25)	0 (0)	1 (25)	2 (50)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 324 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2007						
No	38	3 (8)	4	0 (0)	42	3 (7)
Yes	26	12 (46)	5	2 (40)	31	14 (45)
Not sure	16	2 (13)	1	0 (0)	17	2 (12)
p value		0.001		0.3		<0.001
2010						
No	5	1 (20)	0	0 (0)	5	1 (20)
Yes	12	8 (67)	2	2 (100)	14	10 (71)
Not sure	10	3 (30)	0	0 (0)	10	3 (30)
p value		0.4		--		0.05
2013						
No	20	6 (30)	1	1 (100)	21	7 (33)
Yes	34	21 (62)	2	2 (100)	26	23 (64)
Not sure	18	2 (11)	0	0 (0)	18	2 (11)
p value		0.001		--		0.001
2016						
No	10	2 (20)	0	0 (0)	10	2 (20)
Yes	15	9 (60)	2	0 (0)	17	9 (53)
Not sure	12	5 (42)	1	1 (100)	13	6 (46)
p value		0.1		0.08		0.2

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 325 Genital chlamydia prevalence by gender and survey year†

Gender	N° tested	N° with chlamydia (%)
2010		
Male	19	1 (5)
Female	6	0 (0)
p value		0.6
2013		
Male	137	3 (2)
Female	27	2 (7)
p value		0.2
2016		
Male	81	3 (4)
Female	6	1 (17)
p value		0.1

† Excludes missing values.

Gonorrhoea

Table 326 Genital gonorrhoea prevalence by gender and survey year†

Gender	N° tested	N° with gonorrhoea (%)
2010		
Male	19	0 (0)
Female	6	0 (0)
p value		--
2013		
Male	137	0 (0)
Female	27	0 (0)
p value		--
2016		
Male	82	0 (0)
Female	6	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 327 Syphilis markers by gender and survey year†

Gender	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	27	1 (4)	0 (0)	1 (4)
Female	6	0 (0)	0 (0)	0 (0)
p value		0.6	--	0.6
2013				
Male	138	0 (0)	0 (0)	0 (0)
Female	26	0 (0)	0 (0)	0 (0)
p value		--	--	--
2016				
Male	78	0 (0)	0 (0)	0 (0)
Female	4	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

Methodological Notes

- Percentages over 1 have been rounded up to the nearest whole number while those less than 1 are indicated as '<1'.
- The label 'n/a' ('not asked') indicates survey items that were added or removed from previous years.
- The Accessibility/Remoteness Index of Australia (ARIA)² classification was developed in 1997 and revised in 2011 as a continuous measure of remoteness developed by the National Key Centre for Social Applications of Geographical Information Systems (GISCA). In the version of this index used in this report (known as ARTIA+), geographic accessibility is indexed on a range from 0 (high accessibility) to 15 (high remoteness) as determined by road distance measurements. The index of accessibility can be organised into five primary classifications:
 1. Highly Accessible - relatively unrestricted accessibility to a wide range of goods and services and opportunities for social interaction.
 2. Accessible - some restrictions to accessibility of some goods, services and opportunities for social interaction.
 3. Moderately Accessible - significantly restricted accessibility of goods, services and opportunities for social interaction.
 4. Remote - very restricted accessibility of goods, services and opportunities for social interaction.
 5. Very Remote - very little accessibility of goods, services and opportunities for social interaction.

For the purpose of this report, 3 ARIA groupings were created: highly accessible + accessible, moderately accessible, and remote + very remote. Categories were allocated by using the postcode the individual had spent most time in during the 12 months before coming into prison and is based in self-report.

- Hepatitis B immune status was determined in accordance with CDC guidelines - <http://www.cdc.gov/hepatitis/hbv/PDFs/SerologicChartv8.pdf> Participants with surface antibody levels above 10mIU/mL were considered to be immune to hepatitis B infection. In a limited number of cases hepatitis B surface antibody levels were not reported, vaccination conferred immunity to hepatitis B was established through a combination of self-report of having received three doses of the hepatitis B vaccine and hepatitis B surface-antigen and hepatitis B core-antibody results. Analysis of self-reported hepatitis B vaccination and surface-antibody levels of above 10mIU/mL correlate reasonably well and so justified this approach.
- Risk of alcohol-related harm was measured using the shortened version of the Alcohol Use Disorders Identification Test, the AUDIT-C. Out of a possible score of 12, those who scored more than 6 were considered at high risk of alcohol-related harm. This scoring is consistent with that used in the Australian Institute of Health and Welfare *Prisoners in Australia* report (AIHW, 2015).

Appendix 1 – Blood Tests, Test Kits and Testing Laboratories**Human Immunodeficiency Virus (HIV) Antibody & Antigen**

HIV Ag/Ab Combo Architect. ABBOTT (USA)

HIV Combi. ROCHE (USA)

ADVIA Centaur HIV Combo Assay. ROBION AG (Switzerland)

Hepatitis B Surface-Antibody

Anti-HBs Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B Surface-Antigen

HBsAg Qualitative Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B (IgG & IgM) Core-Antibody

Anti-HBc II Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis C Antibody

Anti-HCV Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Murex THCV. ABBOTT (USA)

Chiron Riba HCV 3.0 Immunoblot. NOVARITIS (USA)

***Treponema pallidum* Antibody**

TPLA test 2.0. SEKISUI (Japan)

Syphilis TP Architect. ABBOTT (USA)

Serodia T. pallidum Hemagglutination Assay. FUJIREBIO (Japan)

Macrovue Rapid Plasma Reagin Assay. BECTON-DICKISON (USA)

TrepoSpot Immunofluorescent. BIOMÉRIEUX (France)

***Chlamydia trachomatis* DNA**

COBAS TaqMan CT test 2.0. ROCHE (USA)

COBAS 4800. ROCHE (USA)

***Neisseria gonorrhoea* DNA**

COBAS Amplicore NG test. ROCHE (USA)



COBAS 4800. ROCHE (USA)

Appendix 2 – Questionnaire

- 16g. How many different people (including your sex partner) have used a needle before you in the last month (even if cleaned)?
- More than 5 people
 - 3 to 5 people
 - 2 people
 - 1 person
 - Don't know how many
- 16h. Who were these people?
- Select all that apply*
- Regular sex partner
 - Other sex partners
 - Close friend
 - Acquaintance
 - Other (specify) _____
17. When was the last time you re-used a needle after someone else?
- Last month
 - In the last 2 to 6 months
 - More than 6 months ago
 - Never **GO TO Q19a**
18. Where was the last place you re-used a needle or syringe after someone else?
- Select one only*
- Prison
 - Own home
 - Friend's home
 - Dealer's home
 - Street, park or beach
 - Car
 - Public toilet
 - Commercial "shooting" room
 - MSIC (KX injecting centre in Sydney)
 - Squat
 - Other (specify) _____
- 19a. Where did you get your needles & syringes from in the past month? *Select all that apply*
- Needle Syringe Program (NSP/CNP)
 - Chemist/Pharmacy
 - Vending machine
 - Personal source (friend etc)
 - Other (specify) _____
 - Did not get syringes in the last month **GO TO Q20**
- 19b. How many times last month did you get needles & syringes from a NSP?
- Daily or almost daily
 - A couple of times each week
 - Less than weekly (2-5 times)
 - Once last month
 - Not in the last month
- 19c. How many times last month did you get needles & syringes from a pharmacy?
- Daily or almost daily
 - A couple of times each week
 - Less than weekly (2 to 5 times)
 - Once last month
 - Not in the last month
20. Have you ever participated in the yearly finger-prick survey at a NSP in the community?
- Yes
 - No
 - Don't remember
21. Have you ever been prescribed methadone?
- Yes, on it now
 - Yes, in the past
 - No, never
22. Have you ever been prescribed Naltrexone, Buprenorphine, Suboxone or Subutex?
- Yes, am on it now
 - Yes, in the past
 - No, never
23. Have you ever had any other therapies for any drug use (e.g. detox, rehab, counselling, NA)?
- Yes No
24. Have you ever had hepatitis B infection?
- Yes No Unsure
- 25a. Have you ever had hepatitis B vaccination?
- Yes
 - No **GO TO Q26a**
 - Unsure **GO TO Q26a**
- 25b. If yes, how many injections have you had?
- One Two
 - 3 or more Unsure
- 26a. Have you ever been tested for HIV?
- Yes, in the last year
 - Yes, more than a year ago
 - Never tested **GO TO Q27a**
- 26b. If yes, what was the result of your last HIV test?
- Did not have HIV infection
 - I have HIV infection
 - Don't know the result
 - Declined to answer
- 27a. Have you ever been tested for hepatitis C?
- Yes, in the last year
 - Yes, more than a year ago
 - Never tested **GO TO Q27k**
- 27b. If yes, what was the result of your last hepatitis C test?
- Never had hep C (Ab and PCR negative) **GO TO Q27k**
 - Cleared hep C naturally (Ab positive but PCR negative, never had treatment)
 - Cleared hep C with treatment (Ab positive but PCR negative)
 - Chronic hep C (Ab positive and PCR positive)
 - Don't know
- 27c. How old were you when you first found out you had hepatitis C?
- 27d. Have you ever had treatment for hepatitis C?
- No treatment **GO TO Q27g**
 - Yes, Interferon-based medication
 - Yes, direct-acting antiviral (DAA) medication (no interferon)
 - Other (specify) _____
- 27e. Have you had a PCR/RNA test to see if you have been re-infected with hep C?
- Yes, re-tested in the last year
 - Yes, re-tested more than a year ago
 - No, I haven't been re-tested **GO TO Q27g**
- 27f. If yes, what was the the result?
- I am still cured of hep C **GO TO Q27k**
 - I have been re-infected with hep C
 - Don't know
- 27g. If you have not had treatment, have you ever sought treatment for hepatitis C?
- Yes **GO TO Q27i**
 - No
- 27h. If no, what was the main reason?
- _____
- 27i. Given that you have chronic hep C, how willing would you be to have treatment?
- Unwilling
 - Neither unwilling or willing
 - Willing
- 27j. Where would you prefer to be treated for HCV?
- Prison
 - Community
 - No preference
- | | True | False | Unsure |
|--|-----------------------|-----------------------|-----------------------|
| 27k. New treatments for hep C are available (direct-acting antivirals) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| The new hep C treatments: | | | |
| 27l. require injections | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| 27m. have few side-effects | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| 27n. takes up to one year | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
28. Have you had the cervical cancer vaccine?
- Yes No
 - Unsure Not applicable
29. Do you identify as:
- Heterosexual
 - Bisexual
 - Gay/lesbian
 - Unsure/Prefer not to say
- 30a. How many female partners have you had sex with, in the last 3 months?
- 30b. Did you use condoms with these partners?
- | | Never | Sometimes | Always |
|---------|-----------------------|-----------------------|-----------------------|
| Regular | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Casual | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
- 30c. How many male partners have you had sex with, in the last 3 months?
- 30d. Did you use condoms with these partners?
- | | Never | Sometimes | Always |
|---------|-----------------------|-----------------------|-----------------------|
| Regular | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Casual | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
- 30e. Have you been paid for sex in the last 3 months? (include non-cash payments)
- Yes
 - No **END OF QUESTIONNAIRE**
- 30f. If yes to Q30e, did you use condoms (or dams) the last time you were paid for sex?
- Yes **END OF QUESTIONNAIRE**
 - No **END OF QUESTIONNAIRE**

References

1. Australian Bureau of Statistics. *Prisoners in Australia, 2016*. 2016. Canberra, ACT: ABS. Available from: <http://www.abs.gov.au>
2. Australian Population and Migration Research Centre. *Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA+)*. 2011. Adelaide, SA: University of Adelaide.
3. Butler T, Levy M, Dolan K, Kaldor J. Drug use and its correlates in an Australian prisoner population. *Addiction Research Theory*. 2003;11:89-101.
4. Gore S, Bird AG. Drugs in British prisons. *British Medical Journal*. 2000;316:1256-1257.
5. Butler T, Lim D, Callander D. *National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007 and 2010*. 2011. Sydney, NSW: National Drug Research Institute (Curtin University) & National Centre in HIV Epidemiology and Clinical Research (University of New South Wales). ISBN: 1 74067 582 7. 2008.
6. Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners - NSW, 1996. *Australia & New Zealand Journal of Public Health*. 1999;23:377-384.
7. Butler T, Dolan K, Ferson M, McGuinness L, Brown P, Robertson P. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. *Medical Journal of Australia*. 1997;166:127-130.
8. Crofts N, Stewart T, Hearne P. Spread of Blood borne viruses among Australian prison entrants. *British Medical Journal*. 1996;310:285-288.
9. Christensen P, Krarup H, Niesters H, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. *European Journal of Epidemiology*. 2000;16:1043-1049.
10. Vescio M, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *Journal of Epidemiology and Community Health*. 2008;62:305-313.
11. Malliori M, Sypsa V, Psychogiou M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. *Addiction*. 1998;92:243-251.
12. Haber P, Parsons S, Harper S, White P, Rawlinson W, Lloyd A. Transmission of hepatitis C within Australian prisons. *Medical Journal of Australia*. 1999;171:31-33.
13. Post J, Dolan K, Whybin R, Carter I, Haber P, Lloyd A. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. *Medical Journal of Australia*. 2001;174:183-184.
14. Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons - not such a pretty picture. *American Journal of Infection Control*. 2007;35:477-480.
15. Miller ER, Bi P, Ryan P. The prevalence of HCV antibody in South Australian prisoners. *Journal of Infection*. 2006;53:125-130.
16. National Centre in HIV Epidemiology and Clinical Research. *Annual Surveillance Report, 2010: HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia*. 2010. Sydney, NSW: University of New South Wales. ISSN 1838-5559.
17. The Kirby Institute. *Australian NSP Survey. National Data Report 1995-2011*. Kirby Institute, University of New South Wales. ISSN 1448-5915. 2011.
18. Iversen J, Maher L. *Australian Needle and Syringe Program National Data Report 2009-2012*. 2013. Sydney, NSW: The Kirby Institute, UNSW Australia.



www.kirby.unsw.edu.au